<SEC-DOCUMENT>0001641172-25-020885.txt : 20250724
<SEC-HEADER>0001641172-25-020885.hdr.sgml : 20250724
<ACCEPTANCE-DATETIME>20250724173019
ACCESSION NUMBER:		0001641172-25-020885
CONFORMED SUBMISSION TYPE:	N-2/A
PUBLIC DOCUMENT COUNT:		15
FILED AS OF DATE:		20250724
DATE AS OF CHANGE:		20250724

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DAXOR CORP
		CENTRAL INDEX KEY:			0000027367
		ORGANIZATION NAME:           	
		EIN:				132682108
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		N-2/A
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-22684
		FILM NUMBER:		251147999

	BUSINESS ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 4740
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118
		BUSINESS PHONE:		212-330-8500

	MAIL ADDRESS:	
		STREET 1:		350 5TH AVENUE
		STREET 2:		SUITE 4740
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDANT CORP
		DATE OF NAME CHANGE:	19730823

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DAXOR CORP
		CENTRAL INDEX KEY:			0000027367
		ORGANIZATION NAME:           	
		EIN:				132682108
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		N-2/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281622
		FILM NUMBER:		251147998

	BUSINESS ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 4740
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118
		BUSINESS PHONE:		212-330-8500

	MAIL ADDRESS:	
		STREET 1:		350 5TH AVENUE
		STREET 2:		SUITE 4740
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDANT CORP
		DATE OF NAME CHANGE:	19730823
<IS-FILER-A-NEW-REGISTRANT>N
<IS-FILER-A-WELL-KNOWN-SEASONED-ISSUER>N
<FILED-PURSUANT-TO-GENERAL-INSTRUCTION-A2>N
<IS-FUND-24F2-ELIGIBLE>N
</SEC-HEADER>
<DOCUMENT>
<TYPE>N-2/A
<SEQUENCE>1
<FILENAME>formn-2a.htm
<DESCRIPTION>N-2/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:DXR="http://daxor.com/20250723">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_CEF%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_DXR_daxor.com_20250723 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20250723_20250723 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000027367 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000003" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000004" name="dei:EntityCentralIndexKey">0000027367</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-07-23" id="xdx2ixbrl0049" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric>
  <ix:nonFraction name="cef:SalesLoadPercent" contextRef="AsOf2025-07-23" id="xdx2ixbrl0055" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:OtherTransactionExpensesPercent" contextRef="AsOf2025-07-23" id="xdx2ixbrl0058" unitRef="Ratio" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyFourMember" id="xdx2ixbrl0093" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyThreeMember" id="xdx2ixbrl0096" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyTwoMember" id="xdx2ixbrl0099" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyOneMember" id="xdx2ixbrl0102" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyMember" id="xdx2ixbrl0105" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandNineteenMember" id="xdx2ixbrl0108" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandEighteenMember" id="xdx2ixbrl0111" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandSeventeenMember" id="xdx2ixbrl0114" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandSixteenMember" id="xdx2ixbrl0117" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandFifteenMember" id="xdx2ixbrl0120" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cef:SeniorSecuritiesAverageMarketValuePerUnit" contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandFourteenMember" id="xdx2ixbrl0123" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="dxr-20250723.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-07-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-23_custom_MarginLoansTwoThousandNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-23_custom_MarginLoansTwoThousandEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-23_custom_MarginLoansTwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-23_custom_MarginLoansTwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-23_custom_MarginLoansTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-23_custom_MarginLoansTwoThousandFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarketRisksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:MarketRisksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-192025-05-19_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-19</xbrli:startDate>
        <xbrli:endDate>2025-05-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_EquityInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:EquityInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_IndustryConcentrationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:IndustryConcentrationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_ShortSaleRisksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:ShortSaleRisksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_PutAndCallOptionsRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:PutAndCallOptionsRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-232025-07-23_custom_OperatingCompanyRisksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:OperatingCompanyRisksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-23</xbrli:startDate>
        <xbrli:endDate>2025-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000027367</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="xdx2ixbrl0055" toRefs="Footnote000074"/>
  <ix:relationship fromRefs="xdx2ixbrl0058" toRefs="Footnote000075"/>
  <ix:relationship fromRefs="Fact000063" toRefs="Footnote000076 Footnote000077"/>
  <ix:relationship fromRefs="Fact000065" toRefs="Footnote000076"/>
  <ix:relationship fromRefs="Fact000067" toRefs="Footnote000076 Footnote000078"/>
  <ix:relationship fromRefs="Fact000069" toRefs="Footnote000076"/>
  <ix:relationship fromRefs="Fact000071" toRefs="Footnote000076"/>
  <ix:relationship fromRefs="Fact000073" toRefs="Footnote000076 Footnote000080"/>
  <ix:relationship fromRefs="Fact000092" toRefs="Footnote000124"/>
  <ix:relationship fromRefs="Fact000095" toRefs="Footnote000124"/>
  <ix:relationship fromRefs="Fact000098" toRefs="Footnote000124"/>
  <ix:relationship fromRefs="Fact000101" toRefs="Footnote000124"/>
  <ix:relationship fromRefs="Fact000104" toRefs="Footnote000124"/>
  <ix:relationship fromRefs="Fact000107" toRefs="Footnote000124"/>
  <ix:relationship fromRefs="Fact000110" toRefs="Footnote000124"/>
  <ix:relationship fromRefs="Fact000113" toRefs="Footnote000124"/>
  <ix:relationship fromRefs="Fact000116" toRefs="Footnote000124"/>
  <ix:relationship fromRefs="Fact000119" toRefs="Footnote000124"/>
  <ix:relationship fromRefs="Fact000122" toRefs="Footnote000124"/>
  <ix:relationship fromRefs="xdx2ixbrl0093" toRefs="Footnote000125"/>
  <ix:relationship fromRefs="xdx2ixbrl0096" toRefs="Footnote000125"/>
  <ix:relationship fromRefs="xdx2ixbrl0099" toRefs="Footnote000125"/>
  <ix:relationship fromRefs="xdx2ixbrl0102" toRefs="Footnote000125"/>
  <ix:relationship fromRefs="xdx2ixbrl0105" toRefs="Footnote000125"/>
  <ix:relationship fromRefs="xdx2ixbrl0108" toRefs="Footnote000125"/>
  <ix:relationship fromRefs="xdx2ixbrl0111" toRefs="Footnote000125"/>
  <ix:relationship fromRefs="xdx2ixbrl0114" toRefs="Footnote000125"/>
  <ix:relationship fromRefs="xdx2ixbrl0117" toRefs="Footnote000125"/>
  <ix:relationship fromRefs="xdx2ixbrl0120" toRefs="Footnote000125"/>
  <ix:relationship fromRefs="xdx2ixbrl0123" toRefs="Footnote000125"/>
  <ix:relationship fromRefs="Fact000159" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000160" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000161" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000164" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000165" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000166" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000169" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000170" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000171" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000174" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000175" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000176" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000179" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000180" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000181" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000184" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000185" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000186" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000189" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000190" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000191" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000194" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000195" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000196" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000199" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000200" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000201" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000204" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000205" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000206" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000209" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000210" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000211" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000214" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000215" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000216" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000219" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000220" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000221" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000224" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000225" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000226" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000229" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000230" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000231" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000234" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000235" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000236" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000239" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000240" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000241" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000244" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000245" toRefs="Footnote000247"/>
  <ix:relationship fromRefs="Fact000246" toRefs="Footnote000247"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
Nos. <span id="xdx_90D_edei--EntityFileNumber_c20250723__20250723_zusYVIzFHbTd"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000010" name="dei:EntityFileNumber">333-281622</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--InvestmentCompanyActFileNumber_c20250723__20250723_zaHABYZ9FxRg"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000011" name="dei:InvestmentCompanyActFileNumber">811-22684</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span><span><span id="xdx_902_edei--DocumentType_c20250723__20250723_ztYD0wADOYd6"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000012" name="dei:DocumentType"><span id="xdx_90D_edei--EntityInvCompanyType_c20250723__20250723_z4igpVhuTAo1"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000013" name="dei:EntityInvCompanyType">N-2</ix:nonNumeric></span>/A</ix:nonNumeric></span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGISTRATION
    STATEMENT UNDER THE SECURITIES ACT OF 1933</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--DocumentRegistrationStatement_dbT_c20250723__20250723_zAsZQuFn9NYf"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentRegistrationStatement">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Effective
    Amendment No. <span id="xdx_90D_edei--PreEffectiveAmendmentNumber_c20250723__20250723_zdcjSLgl2VC3"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000015" name="dei:PreEffectiveAmendmentNumber">1</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreEffectiveAmendment_dbT_c20250723__20250723_zHfO68IDY41h"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleantrue" id="Fact000016" name="dei:PreEffectiveAmendment">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-Effective
    Amendment No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PostEffectiveAmendment_dbF_c20250723__20250723_zg8ZUx2jdYna"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000017" name="dei:PostEffectiveAmendment">&#9744;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and/or</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGISTRATION
    STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--InvestmentCompanyActRegistration_dbT_c20250723__20250723_zWxxW0dXjKA7"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleantrue" id="Fact000018" name="dei:InvestmentCompanyActRegistration">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--AmendmentDescription_c20250723__20250723_zaLFRDTAxs28"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000019" name="dei:AmendmentDescription">Amendment
    No. <span id="xdx_901_edei--InvestmentCompanyRegistrationAmendmentNumber_c20250723__20250723_zBWfSXzSUSPj"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000020" name="dei:InvestmentCompanyRegistrationAmendmentNumber">1</ix:nonNumeric></span></ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--InvestmentCompanyRegistrationAmendment_dbT_c20250723__20250723_zQlmunR83SSi"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleantrue" id="Fact000021" name="dei:InvestmentCompanyRegistrationAmendment">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityRegistrantName_c20250723__20250723_zTPUPBVnYjgl"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000022" name="dei:EntityRegistrantName">DAXOR
CORPORATION</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityAddressAddressLine1_c20250723__20250723_zocOfkRQxFK1"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000023" name="dei:EntityAddressAddressLine1">107
    Meco Lane</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityAddressCityOrTown_c20250723__20250723_zVnpLy6bw474"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000024" name="dei:EntityAddressCityOrTown">Oak
    Ridge</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20250723__20250723_zIVsgdhj0wOb"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000025" name="dei:EntityAddressStateOrProvince">TN</ix:nonNumeric></span></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20250723__20250723_zgRtAHt0ZSR6"><span id="xdx_909_edei--EntityAddressPostalZipCode_c20250723__20250723__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z1IQgJy6X41c"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000026" name="dei:EntityAddressPostalZipCode"><ix:nonNumeric contextRef="From2025-07-232025-07-23_dei_BusinessContactMember" id="Fact000027" name="dei:EntityAddressPostalZipCode">37830</ix:nonNumeric></ix:nonNumeric></span></span></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of Principal Executive Offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--CityAreaCode_c20250723__20250723_z0UJMHTm2lj3"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000028" name="dei:CityAreaCode">(212)</ix:nonNumeric></span>
<span id="xdx_900_edei--LocalPhoneNumber_c20250723__20250723_zS9YGCcXzaW9"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000029" name="dei:LocalPhoneNumber">330-8500</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
Telephone Number, including Area Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copy
    to:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--ContactPersonnelName_c20250723__20250723__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zZdTPUhanADi"><ix:nonNumeric contextRef="From2025-07-232025-07-23_dei_BusinessContactMember" id="Fact000030" name="dei:ContactPersonnelName">Michael
    Feldschuh</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    D. Fetzer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
    Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foley
    &amp; Lardner LLP</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20250723__20250723__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z3ic0YONu312"><ix:nonNumeric contextRef="From2025-07-232025-07-23_dei_BusinessContactMember" id="Fact000031" name="dei:EntityAddressAddressLine1">107
    Meco Lane</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">777
    East Wisconsin Avenue</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityAddressCityOrTown_c20250723__20250723__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zDIpxdWGJv8"><ix:nonNumeric contextRef="From2025-07-232025-07-23_dei_BusinessContactMember" id="Fact000032" name="dei:EntityAddressCityOrTown">Oak
    Ridge</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressStateOrProvince_c20250723__20250723__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zPmoQdyXB0lg"><ix:nonNumeric contextRef="From2025-07-232025-07-23_dei_BusinessContactMember" id="Fact000033" name="dei:EntityAddressStateOrProvince">TN</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milwaukee,
    Wisconsin 53202</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
    and Address of Agent for Service)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
Date of Proposed Public Offering: <span id="xdx_906_edei--ApproximateDateOfCommencementOfProposedSaleToThePublic_c20250723__20250723_zSjIiFV8yvLa"><ix:nonNumeric contextRef="AsOf2025-07-23" id="Fact000034" name="dei:ApproximateDateOfCommencementOfProposedSaleToThePublic">From time to time after the effective date of this Registration Statement.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--DividendOrInterestReinvestmentPlanOnly_c20250723__20250723_zJOpojyyifXj"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000035" name="dei:DividendOrInterestReinvestmentPlanOnly">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
    box if the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--DelayedOrContinuousOffering_c20250723__20250723_zKr6vEnzWDy7"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleantrue" id="Fact000036" name="dei:DelayedOrContinuousOffering">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
    box if any securities being registered on this Form will be offered on a delayed or continuous basis in reliance on Rule 415 under
    the Securities Act of 1933 (&#8220;Securities Act&#8221;), other than securities offered in connection with a dividend reinvestment
    plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecef--PrimaryShelfFlag_c20250723__20250723_zs6TT8eRS6Qg"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000037" name="cef:PrimaryShelfFlag">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
    box if this Form is a registration statement pursuant to General Instruction A.2 or a post-effective amendment thereto.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EffectiveUponFiling462e_c20250723__20250723_zxsF8xqq4Oj2"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000038" name="dei:EffectiveUponFiling462e">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
    box if this Form is a registration statement pursuant to General Instruction B or a post-effective amendment thereto that will become
    effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--AdditionalSecuritiesEffective413b_c20250723__20250723_zTpGca0RaVbd"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000039" name="dei:AdditionalSecuritiesEffective413b">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
    box if this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction B to register additional
    securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is proposed that this filing will become effective (check appropriate box):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EffectiveWhenDeclaredSection8c_c20250723__20250723_zxWM1G4pzDc1"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000040" name="dei:EffectiveWhenDeclaredSection8c">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">when
    declared effective pursuant to Section 8(c) of the Securities Act.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
appropriate, check the following box:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left"><span id="xdx_903_edei--NewEffectiveDateForPreviousFiling_c20250723__20250723_zZLmU5ESH9Sk"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000041" name="dei:NewEffectiveDateForPreviousFiling">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    post-effective amendment designates a new effective date for a previously filed post-effective amendment registration statement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span id="xdx_907_edei--AdditionalSecurities462b_c20250723__20250723_zBv527HpoOvl"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000042" name="dei:AdditionalSecurities462b">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, and the Securities
    Act registration statement number of the earlier effective registration statement for the same offering is: ____.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span id="xdx_903_edei--NoSubstantiveChanges462c_c20250723__20250723_z9p298x8SZ5g"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000043" name="dei:NoSubstantiveChanges462c">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, and the Securities Act registration statement
    number of the earlier effective registration statement for the same offering is: ____.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span id="xdx_90F_edei--ExhibitsOnly462d_c20250723__20250723_z519jBW9frq4"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000044" name="dei:ExhibitsOnly462d">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, and the Securities Act registration statement
    number of the earlier effective registration statement for the same offering is: ____.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
each box that appropriately characterizes the Registrant:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecef--RegisteredClosedEndFundFlag_c20250723__20250723_z3VISaAaJEFi"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleantrue" id="Fact000045" name="cef:RegisteredClosedEndFundFlag">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered
    Closed-End Fund (closed-end company that is registered under the Investment Company Act of 1940 (&#8220;Investment Company Act&#8221;)).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecef--BusinessDevelopmentCompanyFlag_c20250723__20250723_z75R0fr77Xpb"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000046" name="cef:BusinessDevelopmentCompanyFlag">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
    Development Company (closed-end company that intends or has elected to be regulated as a business development company under the Investment
    Company Act).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecef--IntervalFundFlag_c20250723__20250723_z2ntZPXLpHfh"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000047" name="cef:IntervalFundFlag">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interval
    Fund (Registered Closed-End Fund or a Business Development Company that makes periodic repurchase offers under Rule 23c-3 under the
    Investment Company Act).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecef--PrimaryShelfQualifiedFlag_c20250723__20250723_zWsrAxTXvkhc"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000048" name="cef:PrimaryShelfQualifiedFlag">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.2
    Qualified (qualified to register securities pursuant to General Instruction A.2 of this Form).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityWellKnownSeasonedIssuer_dxL_c20250723__20250723_zvPMBWnvD0hd" title="::XDX::No"><span style="-sec-ix-hidden: xdx2ixbrl0049">&#9744;</span></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well-Known
    Seasoned Issuer (as defined by Rule 405 under the Securities Act).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20250723__20250723_ztR0rkxSFVHi"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000050" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    Growth Company (as defined by Rule 12b-2 under the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    an Emerging Growth Company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
    with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecef--NewCefOrBdcRegistrantFlag_c20250723__20250723_zLoC1EFBmie8"><ix:nonNumeric contextRef="AsOf2025-07-23" format="ixt:booleanfalse" id="Fact000051" name="cef:NewCefOrBdcRegistrantFlag">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Registrant (registered or regulated under the Investment Company Act for less than 12 calendar months preceding this filing).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CALCULATION
OF REGISTRATION FEE UNDER THE SECURITIES ACT OF 1933</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Title of Securities<br/> Being Registered</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount Being<br/> Registered</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Proposed Maximum Offering Price Per Unit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Proposed Maximum Aggregate Offering Price (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount of <br/> Registration Fee</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; padding-bottom: 2.5pt">Common Stock, par value $0.001 per share</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">(1)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">(2)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">[&#9679;]</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">(3)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">[&#9679;]</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">(4)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.5in">(1)</td><td style="text-align: justify">There are being registered hereunder a
                                            presently indeterminate number of shares of common stock to be offered on an immediate, continuous
                                            or delayed basis. Pursuant to General Instruction I.B.6. of Form S-3, if the aggregate market
                                            value of the Registrant&#8217;s outstanding voting and non-voting common equity held by non-affiliates
                                            of the Registrant does not equal or exceed $75 million subsequent to the effective date of
                                            this registration statement, then the aggregate offering price of all of securities that
                                            the Registrant may issue pursuant to this registration statement in any 12-month period may
                                            not exceed one-third of the aggregate market value of the voting and non-voting common equity
                                            held by non-affiliates of the Registrant.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.5in">(2)</td><td style="text-align: justify">The proposed maximum offering price per
                                            share will be determined, from time to time, by the Registrant in connection with the sale
                                            by the Registrant of the securities registered under this registration statement.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.5in">(3)</td><td style="text-align: justify">Estimated solely for the purpose of calculating
                                            the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.5in">(4)</td><td style="text-align: justify">Paid herewith.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>EXPLANATORY NOTE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Pre-Effective Amendment No. 1 to Form
N-2 Registration Statement is being filed to respond to comments of the Staff of the Securities and Exchange Commission.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>SUBJECT
TO COMPLETION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>PRELIMINARY
PROSPECTUS DATED JuLY 23, 2025</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
information in this Prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This Prospectus is not an offer to sell these securities, and it is not
soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DAXOR
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BASE
PROSPECTUS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><b>$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Daxor
Corporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation is an investment company with medical instrumentation and biotechnology operations. While the company is not primarily engaged
in the business of investing, reinvesting, owning, holding or trading in securities, the company is dependent upon earnings from its
investment portfolio to fund operations and has registered as a closed-end investment company under the Investment Company Act of 1940,
as amended<i>.</i> While Daxor Corporation is registered as a closed-end investment company, it has always conducted its business as
an operating company and has never been in, or held itself out to be in, the business of investing, reinvesting, owning, holding or trading
in securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
major focus is the development of the BVA-100 &#174; Blood Volume Analyzer, an instrument that rapidly and accurately measures human blood
volume. This instrument is used in conjunction with Volumex &#174;, a single-use radiopharmaceutical diagnostic injection and collection
kit. We also own the Daxor Oak Ridge Operations (DORO) facility in Oak Ridge, Tennessee, which manufactures, tests, and develops next-generation
models of the BVA-100 &#174;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer shares of our common stock, par value $0.01 per share, from time to time under this prospectus, together with any applicable
prospectus supplement, at prices and on terms to be determined by market conditions at the time of offering. This prospectus provides
you with a description of the common stock we may offer. Each time we offer securities, we will provide a prospectus supplement that
will describe the specific amounts, prices and other important terms of the offering. During any 12-month period, the aggregate market
value of securities we may offer may not exceed one third of the aggregate market value of voting and non-voting common equity held by
persons who are not affiliates of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are registering shares of our common stock for resale by the selling shareholder named in this prospectus, or its transferees,
pledges, donees or successors. We will not receive any proceeds from the sale of these shares, although we have paid the expenses of
preparing this prospectus and the related registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to dividends as our board of directors may declare from time to time out of legally available funds.
Each holder of our common stock is entitled to one vote per share. Our common stock is described in greater detail in this prospectus
under <i>&#8220;Daxor Corporation Common Stock&#8221;</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus supplement that we may authorize to be provided to you may also add, update or change information contained in this prospectus
or in documents we have incorporated by reference. However, no prospectus supplement will offer a security that is not registered and
described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer shares of common stock (1) directly to one or more purchasers, (2) through agents that we may designate from time to time or
(3) to or through underwriters or dealers. We, and our underwriters or agents, reserve the right to accept or reject all or part of any
proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable prospectus
supplement: (1) the names of those underwriters or agents; (2) applicable fees, discounts and commissions to be paid to them; (3) details
regarding over-allotment options, if any; and (4) the net proceeds to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information that we have provided or incorporated by reference in this prospectus, and any applicable prospectus supplement that we may
authorize to be provided to you. We have not authorized any dealer, salesman or other person to give any information or to make any representation
other than those contained or incorporated by reference in this prospectus, and any applicable prospectus supplement. You must not rely
upon any information or representation not contained or incorporated by reference in this prospectus, and any accompanying prospectus
supplement. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may
give you.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus and any
accompanying supplement to this prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other
than the registered securities to which they relate, nor do this prospectus and any accompanying supplement to this prospectus
constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful
to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and
any applicable prospectus supplement is accurate on any date subsequent to the date set forth on the front of the document or that any
information we have incorporated by reference therein is correct on any date subsequent to the date of the document incorporated by reference,
even though this prospectus and any applicable prospectus supplement is delivered or the applicable securities are sold on a later date.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock has continuously been traded since its initial public offering. The company&#8217;s common stock is traded on Nasdaq under
the symbol DXR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>There
are risks involved in investing in the Daxor Corporation&#8217;s stock. See the &#8220;Risk Factors&#8221; section beginning on page
10 of this prospectus.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus sets forth
concisely the information about Daxor Corporation that a prospective investor ought to know before investing. This prospectus should
be retained for future reference. Additional information about the company, in the form of a Statement of Additional Information, dated
as of the date of this prospectus, is incorporated herein by reference. You may request a free copy of the Statement of Additional Information,
the table of contents of which is on page 27 of this prospectus, or request other information about the company (including our
annual and semi-annual reports) or make shareholder inquiries by calling (888) 774-3268 or by writing us at 107 Meco Lane, Oak Ridge,
TN 37830, Attention Corporate Secretary; or you may obtain a copy (and other information regarding the company) from the SEC&#8217;s
website (www.sec.gov). Free copies of our reports and the SAI will also be available from our website at <span style="text-decoration: underline">www.Daxor.com</span>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may elect to receive shareholder reports and other communications from Daxor or your financial intermediary electronically, by calling
Daxor at 212-330-8500 or by sending an email to Robert J. Michel, CFO at rmichel@daxor.com, or by contacting your financial intermediary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may elect to receive all future reports in paper free of charge. You can inform Daxor that you wish to continue receiving paper copies
of your shareholder reports by calling Daxor at 212-330-8500 or by sending an email to Robert J. Michel, CFO at rmichel@daxor.com. Your
election to receive reports in paper will apply to all funds held with your financial intermediary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The date of this prospectus is July [&#9679;], 2025.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. This Prospectus is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FEE TABLE AND SYNOPSIS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL HIGHLIGHTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SENIOR SECURITIES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SELLING SHAREHOLDER</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GENERAL DESCRIPTION OF DAXOR CORPORATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Objectives and Policies</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Policies</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-Looking Statements Regarding Daxor Corporation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Management</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor Corporation Common Stock</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">21</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#me_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and Executive Officers of Daxor Corporation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">22</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#me_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Information about Daxor Corporation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">24</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#me_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAX MATTERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">24</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#me_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#me_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#me_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRIVACY PRINCIPLES OF THE COMPANY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#me_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#me_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE OF CONTENTS FOR THE STATEMENT OF ADDITIONAL INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You
should rely only on the information included or incorporated by reference in this prospectus. Daxor Corporation has not authorized anyone
to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on
it. You should not assume that the information included in this prospectus is accurate as of any date other than the date on the front
of this prospectus. The company&#8217;s prospects and its business, financial condition and results of operations, each may have changed
since the date on the front of this prospectus.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>FEE
TABLE AND SYNOPSIS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table contains
information about the costs and expenses that shareholders will bear directly or indirectly. The table is based on the capital structure
of the company as of December 31, 2024 (except as noted below). The purpose of the table and the example below is to help you
understand the fees and expenses that you, as a holder of common stock, would bear directly or indirectly.</p>
<p id="xdx_8AD_zdPY1pQv1Kpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000053" name="cef:ShareholderTransactionExpensesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecef--ShareholderTransactionExpensesTableTextBlock_dU_zT4WMUQWE779" summary="xdx: Disclosure - Shareholder Transaction Expenses" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Common Shareholder Transaction Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250723__20250723_zJADkWOTmyuf" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecef--SalesLoadPercent_pid_dp_zGS2n4HJu698" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Sales load paid by you (<span id="xdx_903_ecef--BasisOfTransactionFeesNoteTextBlock_c20250723__20250723_zk8UL3lQNP58"><ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000056" name="cef:BasisOfTransactionFeesNoteTextBlock">as a percentage of offering price</ix:nonNumeric></span>)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0055">-</span></td><td style="width: 1%; text-align: left">%<sup id="xdx_F4F_zKIUasgqN8Fg">(1)</sup></td></tr>
  <tr id="xdx_405_ecef--OtherTransactionExpensesPercent_pid_dp_zNYdcPcOOMp3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Offering expenses borne by shareholders (<span id="xdx_908_ecef--BasisOfTransactionFeesNoteTextBlock_c20250723__20250723_zPzONEUOqUF3"><ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000059" name="cef:BasisOfTransactionFeesNoteTextBlock">as a percentage of offering price</ix:nonNumeric></span>)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0058">-</span></td><td style="text-align: left">%<sup id="xdx_F4A_zV6Rzg1eA8bh">(2)</sup></td></tr>
  </table></ix:nonNumeric>


<p id="xdx_8AD_zAULMHa4uQg5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000061" name="cef:AnnualExpensesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_ecef--AnnualExpensesTableTextBlock_dU_zGGjYGAlBQS2" summary="xdx: Disclosure - Annual Expenses" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_490_20250723__20250723_zKcgspektxmi" style="text-align: center"><span style="font-size: 10pt"><b>Percentage of Net Assets</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt"><b>Annual Expenses</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Attributable to Common
    Shares <sup id="xdx_F5C_zBtX5oFdgtC9">(3)</sup></b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_ecef--ManagementFeesPercent_pid_dpn_zF7WGBV6gQn" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Management Fees<sup id="xdx_F44_zfDLcKvuWFIl">(4)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="cef:ManagementFeesPercent" contextRef="AsOf2025-07-23" id="Fact000063" format="ixt-sec:numwordsen" decimals="INF" scale="-2" unitRef="Ratio">None</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecef--InterestExpensesOnBorrowingsPercent_pid_dp_zu0uOmFZXjD4" style="vertical-align: bottom; background-color: white">
    <td style="width: 80%"><span style="font-size: 10pt">Annualized Interest Payments on Borrowed Funds</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="cef:InterestExpensesOnBorrowingsPercent" contextRef="AsOf2025-07-23" id="Fact000065" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.29</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40C_ecef--OtherAnnualExpensesPercent_pid_dp_z2uqCqgZNZu2" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Annualized Other Expenses <sup id="xdx_F49_z3xWlQMCCGif">(5)</sup></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="cef:OtherAnnualExpensesPercent" contextRef="AsOf2025-07-23" id="Fact000067" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">5.45</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40C_ecef--TotalAnnualExpensesPercent_pid_dp_zNwiwiUE8eMb" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Total Annual Expenses before Taxes</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="cef:TotalAnnualExpensesPercent" contextRef="AsOf2025-07-23" id="Fact000069" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">5.74</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_400_ecef--WaiversAndReimbursementsOfFeesPercent_pid_dp_zr4xTe2PiqAd" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Estimated Annualized Tax Expense</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="cef:WaiversAndReimbursementsOfFeesPercent" contextRef="AsOf2025-07-23" id="Fact000071" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.10</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_401_ecef--NetExpenseOverAssetsPercent_pid_dp_zv8FiPCYvGMg" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total Annual Expenses after Taxes<sup id="xdx_F4A_zObVlKQzkKGa">(6)</sup></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="cef:NetExpenseOverAssetsPercent" contextRef="AsOf2025-07-23" id="Fact000073" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">5.84</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">%</span></td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><sup id="xdx_F0F_zOeaWNu7qOKl">(1)</sup></span></td>
    <td style="text-align: justify"><span id="xdx_F1B_zwGutgVSi1ba" style="font-size: 10pt"><ix:footnote id="Footnote000074" xml:lang="en-US">If shares of Common Stock to which this prospectus
    relates are sold to or through underwriters, the applicable prospectus supplement will set forth any applicable sales load and the
    estimated expenses borne by the Company.</ix:footnote></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><sup id="xdx_F0C_zv4Ug8Rht2C4">(2)</sup></span></td>
    <td style="text-align: justify"><span id="xdx_F13_zFRQucw2MNM1" style="font-size: 10pt"><ix:footnote id="Footnote000075" xml:lang="en-US">The company will bear the costs of the offering
    expenses and the applicable prospectus supplement will set forth the estimated offering costs.</ix:footnote></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><sup id="xdx_F0B_zA8oW7FCrMZ8">(3)</sup></span></td>
    <td style="text-align: justify"><span id="xdx_F11_zhowqlDiR0Ne" style="font-size: 10pt"><ix:footnote id="Footnote000076" xml:lang="en-US">Based upon average monthly net assets applicable
    to shares of Common Stock during the period ended December 31, 2024.</ix:footnote></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><sup id="xdx_F0E_zG51K1jywH71">(4)</sup></span></td>
    <td style="text-align: justify"><span id="xdx_F1C_zNtlFPgICNll" style="font-size: 10pt"><ix:footnote id="Footnote000077" xml:lang="en-US">The company does not pay a management fee.</ix:footnote></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><sup id="xdx_F00_z9Twvh3w3hr9">(5)</sup></span></td>
    <td style="text-align: justify"><span id="xdx_F13_zyG6L1hsLPli" style="font-size: 10pt"><ix:footnote id="Footnote000078" xml:lang="en-US">&#8220;<span id="xdx_90C_ecef--OtherExpensesNoteTextBlock_c20250723__20250723_zzP4gCGPYxFj"><ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000079" name="cef:OtherExpensesNoteTextBlock">Annualized Other Expenses&#8221; are
    based on estimated expense amounts for the current fiscal year.</ix:nonNumeric></span></ix:footnote></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span id="xdx_F0B_zn7NXfXCnAYk" style="font-size: 10pt"><sup>(6)</sup></span></td>
    <td style="text-align: justify"><span id="xdx_F1F_z4kKnfsQJ1V4" style="font-size: 10pt"><ix:footnote id="Footnote000080" xml:lang="en-US">As explained in the company&#8217;s Form
    N-CSR, as filed on March 3, 2025, the company has significant net operating loss and capital loss carry forwards and for the foreseeable
    future no adjustments to tax liabilities or operations is necessary. However, the company is subject to state and local taxes where
    the annualized impact to operations is approximately 0.10%.</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As required by relevant Securities and Exchange
Commission regulations, the following example illustrates the expenses that you would pay on a $1,000 investment in shares of common
stock, assuming (1) &#8220;Total Annual Expenses after Taxes&#8221; of 5.84% of net assets attributable to shares and (2)
a 5% annual return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.75pt">&#160;</p>

<ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000082" name="cef:ExpenseExampleTableTextBlock"><p id="xdx_89C_ecef--ExpenseExampleTableTextBlock_dU_zFvMO11Ttwh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Example should not be considered a representation
of future expenses or returns. Actual expenses may be higher or lower than those assumed. Moreover, the company&#8217;s actual rate of
return may be higher or lower than the hypothetical 5% return shown in the example. </b>The example assumes that all dividends and distributions
are reinvested at net asset value.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>1 Year</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>3 Years</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>5 Years</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>10 Years</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 40%"><span style="font-size: 10pt">Total Expenses paid by Common Shareholders</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_ecef--ExpenseExampleYear01_c20250723__20250723_zwVuYNeE84H1" style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="cef:ExpenseExampleYear01" contextRef="AsOf2025-07-23" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_ecef--ExpenseExampleYears1to3_c20250723__20250723_z00Vvy6yAeL4" style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="cef:ExpenseExampleYears1to3" contextRef="AsOf2025-07-23" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_ecef--ExpenseExampleYears1to5_c20250723__20250723_zl2MiziYbNB8" style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="cef:ExpenseExampleYears1to5" contextRef="AsOf2025-07-23" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_987_ecef--ExpenseExampleYears1to10_c20250723__20250723_zlhIIm8qzgy4" style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="cef:ExpenseExampleYears1to10" contextRef="AsOf2025-07-23" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The example above does not include sales loads
or estimated offering costs. In connection with an offering of shares of common stock, the applicable prospectus supplement will
set forth an Example including sales load and estimated offering costs.</p>
</ix:nonNumeric><p id="xdx_8AA_z9G048f0WWO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_002"></span>Daxor
Corporation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Highlights</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tables below set forth financial data
for weighted average shares of stock outstanding for each year and for one share of capital stock outstanding throughout the years presented.
The total investment return does not reflect sales load. The financial highlights for the five most recent fiscal years are based
on audited financial information. This information has been derived from our audited financial statements. The audited financial statements
for the most recent fiscal year ended December 31, 2024, along with the audit report of Bush &amp; Associates CPA, are included in
<a href="https://www.sec.gov/Archives/edgar/data/27367/000149315225008923/formncsr.htm" style="-sec-extract: exhibit">our Annual Report
on Form N-CSR, as filed with the SEC on March 3, 2025</a>. The Annual Report is available upon request by calling 212-330-8500.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Per share operating performance data is designed
to allow you to trace the operating performance, on a per share of common stock basis, from the beginning net asset value to the ending
net asset value, so that you can understand what&#160;effect the individual items have on your investment, assuming it was held throughout
the period. Generally, the per&#160;share amounts are derived by converting the actual dollar amounts incurred for each item, as disclosed
in the&#160;financial statements, to their equivalent per share of common stock amounts, using average shares of stock outstanding for
each year and for one share of capital stock outstanding throughout the years presented</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Total investment
return measures Daxor&#8217;s performance assuming that&#160;investors purchased shares at market price or&#160;net asset value as of
the beginning of the period,&#160;reinvested all their distributions and then sold their shares at the&#160;closing market price or net
asset value&#160;on the last day of the period. The computations do not reflect&#160;taxes or&#160;any&#160; sales commissions&#160;investors
may incur on distributions or on the sale of&#160;shares.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Year Ended<br/> December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Year Ended<br/> December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; padding-bottom: 1.5pt">Net Asset Value Per Share, Beginning of Year</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">7.08</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">6.75</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">5.24</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income (loss) from operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.32</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.19</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.24</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Net realized and unrealized gain (loss) from investments, options and securities
    borrowed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.02</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net loss and unrealized appreciation (depreciation) of operating division</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.53</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.02</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.40</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total income (loss) from Investment Operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.09</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.87</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Capital share issuances:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Increase in net assets from stock based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.26</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase from sale of treasury stock and exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Increase (decrease) in Net Asset Value Per Share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.85</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.51</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Net Asset Value Per Share, End of Year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"> &#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">&#160;&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Market Price Per Share of Common Stock, Beginning of Year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11.29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Market Price Per Share of Common Stock, End of Year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7.69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9.60</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9.16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Change in Price Per Share of Common Stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.91</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Investment Return</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(19.90</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4.8</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18.87</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Weighted Average Shares Outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,842,476</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,631,255</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,083,847</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Ratios/Supplemental Data</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net assets, End of Year (in 000&#8217;s)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-size: 10pt">&#160; &#160;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">34,010</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">28,969</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ratio of total expenses to average net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,010</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.32</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.86</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ratio of net investment (loss) income after income taxes to average net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.71</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.80</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.73</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Portfolio turnover rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46.07</td><td style="text-align: left">%<sup>(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(1)</td><td>Primarily due to the increase in Daxor shares outstanding in
                                            2024</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Highlights (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Year Ended<br/> December 31, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Year Ended<br/> December 31, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; padding-bottom: 1.5pt">Net Asset Value Per Share, Beginning of Year</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">3.89</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">3.41</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">3.49</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income (loss) from operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.20</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.08</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Net realized and unrealized gain (loss) from investments, options and securities borrowed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.32</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.59</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net loss and unrealized appreciation (depreciation) of operating division</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.69</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total income (loss) from Investment Operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.28</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.13</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Capital share issuances:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Increase in net assets from stock based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.06</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.05</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase from sale of treasury stock and exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Increase (decrease) in Net Asset Value Per Share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1.35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.08</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Net Asset Value Per Share, End of Year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5.24</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.89</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.41</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Market Price Per Share of Common Stock, Beginning of Year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Market Price Per Share of Common Stock, End of Year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11.29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9.40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Change in Price Per Share of Common Stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.21</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.10</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Investment Return</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9.68</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">32.98</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">14.63</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Weighted Average Shares Outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,036,660</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,935,902</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,746,858</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Ratios/Supplemental Data</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net assets, End of Year (in 000&#8217;s)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,766</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ratio of total expenses to average net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.29</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.79</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.26</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ratio of net investment (loss) income after income taxes to average net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.44</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.53</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.12</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Portfolio turnover rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.54</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Daxor Corporation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Financial Highlights (continued)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.2pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Year Ended<br/> December 31, 2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Year Ended<br/> December 31, 2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; padding-bottom: 1.5pt">Net Asset Value Per Share, Beginning of Year</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">3.68</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">4.04</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income (loss) from operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.07</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Net realized and unrealized gain (loss) from investments, options and securities
    borrowed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.23</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net realized and unrealized loss from operating division</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.36</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.62</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Income tax (expense) benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.09</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.05</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.01</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total income (loss) from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.33</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Distributions to shareholders from net investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.03</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Increase (decrease) in Net Asset Value Per Share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.36</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Net Asset Value Per Share, End of Year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.49</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.68</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Market Price Per Share of Common Stock, Beginning of Year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.24</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Market Price Per Share of Common Stock, End of Year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4.57</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Change in Price Per Share of Common Stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.63</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.67</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Investment Return</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">79.43</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(44.54</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Weighted Average Shares Outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,741,954</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,767,756</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Ratios/Supplemental Data</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net assets, End of Year (in 000&#8217;s)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,062</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,758</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ratio of total expenses to average net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.14</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.90</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ratio of net investment income before income taxes to average net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.07</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.89</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ratio of net investment (loss) income after income taxes to average net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.55</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.72</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Portfolio turnover rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.52</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.63</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Daxor Corporation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Financial Highlights (continued)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Year Ended<br/> December 31, 2016</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Year Ended<br/> December 31, 2015</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; padding-bottom: 1.5pt">Net Asset Value Per Share, Beginning of Year</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">3.74</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">6.16</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income (loss) from operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Net realized and unrealized gain (loss) from investments, options and securities
    borrowed</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.12</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net realized and unrealized loss from operating division</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.21</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Income tax (expense) benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.32</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.05</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.05</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total income (loss) from Investment Operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2.36</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Distributions to shareholders from net investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.03</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.04</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Increase (decrease) in Net Asset Value Per Share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2.42</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Net Asset Value Per Share, End of Year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4.04</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.74</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Market Price Per Share of Common Stock, Beginning of Year</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Market Price Per Share of Common Stock, End of Year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8.24</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7.60</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Change in Price Per Share of Common Stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.64</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Investment Return</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">8.42</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11.76</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Weighted Average Shares Outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,825,476</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,921,697</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Ratios/Supplemental Data</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net assets, End of Year (in 000&#8217;s)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,344</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,427</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ratio of total expenses to average net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.44</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.06</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ratio of net investment income before income taxes to average net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.86</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.31</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ratio of net investment (loss) income after income taxes to average net assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.78</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.18</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Portfolio turnover rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.59</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.43</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>PLAN
OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities being offered hereby in one or more of the following ways from time to time:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
    agents to the public or to investors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    underwriters for resale to the public or to investors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">directly
    to investors; or through a combination of any of these methods of sale.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will set forth in a prospectus supplement the terms of that particular offering of securities, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    name or names of any agents or underwriters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    purchase price of the securities being offered and the proceeds we will receive from the sale;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    over-allotment options under which underwriters may purchase additional securities from us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    discounts or concessions allowed or reallowed or paid to dealers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Agents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may designate agents who agree to use their reasonable efforts to solicit purchases of our securities for the period of their appointment
or to sell our securities on a continuing basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underwriters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we use underwriters for
a sale of securities, the underwriters will acquire the securities for their own account. The underwriters may resell the securities
in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the
time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. The underwriters will be obligated to purchase all the securities of the series offered if they purchase any
of the securities of that series. We may change from time to time any initial public offering price and any discounts or concessions
the underwriters allow or reallow or pay to dealers. We may use underwriters with whom we have a material relationship. We will describe
the nature of any such relationship in any prospectus supplement naming any such underwriter. Only underwriters we name in a prospectus
supplement are underwriters of the securities offered by the prospectus supplement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Direct
Sales</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also sell securities directly to one or more purchasers without using underwriters or agents. Underwriters, dealers and agents that
participate in the distribution of the securities may be underwriters as defined in the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities
Act</span>&#8221;), and any discounts or commissions they receive from us and any profit on their resale of the securities may be treated
as underwriting discounts and commissions under the Securities Act. We will identify in the applicable prospectus supplement any underwriters,
dealers or agents and will describe their compensation. We may have agreements with the underwriters, dealers and agents to indemnify
them against specified civil liabilities, including liabilities under the Securities Act. Underwriters, dealers and agents may engage
in transactions with or perform services for us in the ordinary course of their businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stabilization
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation
M under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Overallotment involves sales in excess of the offering
size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing
bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the
distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer
when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities
may cause the price of the securities to be higher than it would otherwise be. The underwriters may discontinue any of these activities,
if commenced, at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Agents, underwriters, or
dealers participating in an offering of Common Shares may be deemed to be underwriters, and any discounts and commission received
by them and any profit realized by them on resale of the offered shares of common stock for whom they act as agent, may be deemed to
be underwriting discounts and commissions under the Securities Act.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer to sell securities either at a fixed price or at prices that may vary, at market prices prevailing at the time of sale, at
prices related to prevailing market prices or at negotiated prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
agreements entered into with us, underwriters and agents may be entitled to indemnification by us against certain civil liabilities,
including liabilities under the Securities Act, or to contribution for payments the underwriters or agents may be required to make.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters, agents, and their affiliates may engage in financial or other business transactions with us in the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a requirement of the Financial Industry Regulatory Authority, or FINRA, the maximum compensation to be received by any FINRA member
or independent broker-dealer may not be greater than eight percent (8%) of the gross proceeds received by us for the sale of any securities
being registered pursuant to Rule 415 under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate offering price specified on the cover of this prospectus relates to the offering of the shares of common stock not yet issued
as of the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent permitted under
the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;), and the rules and regulations promulgated
thereunder, the underwriters may from time to time act as a broker or dealer and receive fees in connection with the execution of portfolio
transactions on behalf of the company after the underwriters have ceased to be underwriters and, subject to certain restrictions, each
may act as a broker while it is an underwriter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A prospectus and any
accompanying prospectus supplement in electronic form may be made available on the websites maintained by underwriters. The underwriters
may agree to allocate a number of shares of common stock for sale to their online brokerage account holders. Such allocations of shares
of common stock for internet distributions will be made on the same basis as other allocations. In addition, shares of common stock may
be sold by the underwriters to securities dealers who resell shares of common stock to online brokerage account holders.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000088" name="cef:SeniorSecuritiesNoteTextBlock"><p id="xdx_802_ecef--SeniorSecuritiesNoteTextBlock_dU_zzTxdxMPdOXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>SENIOR
SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000090" name="cef:SeniorSecuritiesTableTextBlock"><p id="xdx_89F_ecef--SeniorSecuritiesTableTextBlock_dU_zDRJcKUZ5tgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information about our senior securities is
shown in the following table as of the end of the last 10 fiscal years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_480_ecef--SeniorSecuritiesAmt_iI_zxpMPN7mkOwe" style="border-bottom: Black 1pt solid; font-weight: bold">Total Amount Outstanding Exclusive of Treasury Securities</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_48E_ecef--SeniorSecuritiesCvgPerUnit_iI_zxE1f4tGopu8" style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 10pt"><b>Asset Coverage Per<br/>
    $1,000 of Indebtedness<sup id="xdx_F5F_z2oM1gKvzZEg">(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Involuntary<br/> Liquidating<br/> Preferences Per Unit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 10pt"><b>Average Market<br/> Value<sup id="xdx_F58_zbLeoLJFX2ej">(2)</sup></b></span></td></tr>
  <tr id="xdx_41E_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyFourMember_zjxa8QG7Rrid" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Margin Loans 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesAmt" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyFourMember" id="Fact000091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">729,966</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesCvgPerUnit" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyFourMember" id="Fact000092" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">50,033</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%">N/A</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%">N/A<span id="xdx_902_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyFourMember_fKDIp_zQkdhHdNh739" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></span></td></tr>
  <tr id="xdx_41F_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyThreeMember_z1SrotRFAKSd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Margin Loans 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesAmt" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyThreeMember" id="Fact000094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">755,659</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesCvgPerUnit" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyThreeMember" id="Fact000095" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">46,008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>N/A</td><td>&#160;</td>
    <td>N/A<span id="xdx_905_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyThreeMember_fKDIp_zUDlnZTXmPK" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0096">-</span></span></td></tr>
  <tr id="xdx_41E_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyTwoMember_z8AngQ8jFSPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Margin Loans 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesAmt" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyTwoMember" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,229,164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesCvgPerUnit" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyTwoMember" id="Fact000098" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>N/A</td><td>&#160;</td>
    <td>N/A<span id="xdx_901_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyTwoMember_fKDIp_zqPCosFagNqf" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></span></td></tr>
  <tr id="xdx_41C_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyOneMember_zuoXFYn1qGb8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Margin Loans 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesAmt" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyOneMember" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,022,542</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesCvgPerUnit" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyOneMember" id="Fact000101" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7,998</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>N/A</td><td>&#160;</td>
    <td>N/A<span id="xdx_90D_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyOneMember_fKDIp_zz2ond7r8Eng" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0102">-</span></span></td></tr>
  <tr id="xdx_412_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyMember_zlaDbUamBv2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Margin Loans 2020</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesAmt" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyMember" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,689</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesCvgPerUnit" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyMember" id="Fact000104" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">92,835</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>N/A</td><td>&#160;</td>
    <td>N/A<span id="xdx_90D_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyMember_fKDIp_zpB99vxHBn4g" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0105">-</span></span></td></tr>
  <tr id="xdx_41D_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandNineteenMember_zxrrudkDJ6C6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Margin Loans 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesAmt" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandNineteenMember" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,342,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesCvgPerUnit" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandNineteenMember" id="Fact000107" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10,509</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>N/A</td><td>&#160;</td>
    <td>N/A<span id="xdx_903_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandNineteenMember_fKDIp_zqVlXWJhOAO6" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0108">-</span></span></td></tr>
  <tr id="xdx_419_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandEighteenMember_zdr1npg18v2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Margin Loans 2018</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesAmt" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandEighteenMember" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,454,613</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesCvgPerUnit" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandEighteenMember" id="Fact000110" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30,197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>N/A</td><td>&#160;</td>
    <td>N/A<span id="xdx_907_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandEighteenMember_fKDIp_zdqUt3lGjPu8" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0111">-</span></span></td></tr>
  <tr id="xdx_410_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSeventeenMember_zbyb23dKhzQ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Margin Loans 2017</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesAmt" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandSeventeenMember" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,334,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesCvgPerUnit" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandSeventeenMember" id="Fact000113" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,174</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>N/A</td><td>&#160;</td>
    <td>N/A<span id="xdx_906_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSeventeenMember_fKDIp_zyNXOKU897kj" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0114">-</span></span></td></tr>
  <tr id="xdx_418_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSixteenMember_za6OUmVc9kh8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Margin Loans 2016</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesAmt" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandSixteenMember" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,801,732</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesCvgPerUnit" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandSixteenMember" id="Fact000116" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6,477</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>N/A</td><td>&#160;</td>
    <td>N/A<span id="xdx_906_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSixteenMember_fKDIp_zBxZnM4oQtyc" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0117">-</span></span></td></tr>
  <tr id="xdx_416_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFifteenMember_zFP50yZCc94i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Margin Loans 2015</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesAmt" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandFifteenMember" id="Fact000118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,845,112</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesCvgPerUnit" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandFifteenMember" id="Fact000119" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,752</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>N/A</td><td>&#160;</td>
    <td>N/A<span id="xdx_90A_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFifteenMember_fKDIp_zeXC3yO9D2e9" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0120">-</span></span></td></tr>
  <tr id="xdx_414_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFourteenMember_zxRuis4aRwZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Margin Loans 2014</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesAmt" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandFourteenMember" id="Fact000121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,356,338</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cef:SeniorSecuritiesCvgPerUnit" contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandFourteenMember" id="Fact000122" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>N/A</td><td>&#160;</td>
    <td>N/A<span id="xdx_90A_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFourteenMember_fKDIp_z7M63JIQUFm4" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0123">-</span></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span id="xdx_F0C_ztxIzWyKmFa" style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span id="xdx_F13_zqVoC7iFSJSg" style="font-size: 10pt"><ix:footnote id="Footnote000124" xml:lang="en-US">Derivatives transactions entered into in compliance
    with Rule 18f-4 under the Investment Company Act are not considered for purposes of computing asset coverage.</ix:footnote></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span id="xdx_F04_zN4rtX3H9FAd" style="font-size: 10pt">(2)</span></td>
    <td style="font-size: 10pt"><span id="xdx_F16_zkwZ7FBg2cHc" style="font-size: 10pt"><ix:footnote id="Footnote000125" xml:lang="en-US">Not applicable as the senior securities are not registered for public
    trading.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric></ix:nonNumeric><p id="xdx_81E_zWdCy3PLEaYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>SELLING
SHAREHOLDER</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering certain of the shares covered by this prospectus on behalf of the selling shareholder named in the table below (including
its donees, pledgees, transferees or other successors-in-interest who receive any of the shares covered by this prospectus), the Joseph
Feldschuh Estate. We are registering the shares to permit the selling shareholder to offer these shares for resale from time to time.
The selling shareholder may sell all, some or none of the shares covered by this prospectus. All information with respect to beneficial
ownership has been furnished to us by the selling shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estate of Joseph Feldschuh, M.D., controls more than 50% of the company&#8217;s voting power, and shareholders and members of the company&#8217;s
board of directors submit nominees for election to the company&#8217;s board to Mr. Michael Feldschuh, executor of the Joseph Feldschuh
estate, for his consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">NUMBER OF</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"/><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">SHARES</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">NUMBER OF</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">OWNED PRIOR</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">SHARES</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">BEING</p></td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">TO THIS</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">OFFERED</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">SHARES OWNED AFTER</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SELLING SHAREHOLDER</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OFFERING</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">HEREBY</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OFFERING (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NUMBER</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PERCENTAGE (2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left">Joseph Feldschuh Estate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">2,553,230</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">-0-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">2,553,230</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">51.5</td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes
    that the shareholder disposes of all of the shares of common stock covered by this prospectus and does not acquire or dispose of
    any additional shares of common stock. However, the selling shareholder is not representing that any of the shares covered by this
    prospectus will be offered for sale, and the selling shareholder reserves the right to accept or reject, in whole or in part, any
    proposed sale of shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The
                                            percentage of common stock beneficially owned is based on the shares of common stock outstanding
                                            on May 19, 2025. This prospectus also covers any additional shares of common stock
                                            that become issuable in connection with the shares being registered by reason of any stock
                                            dividend, stock split, recapitalization or other similar transaction effected without the
                                            receipt of consideration which results in an increase in the number of outstanding shares
                                            of our common stock.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>USE
OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described in any applicable prospectus supplement in connection with a specific offering, we currently intend to use the net proceeds
from the sale of the securities offered hereby for working capital and other general corporate purposes, including to develop our products,
fund capital expenditures, make investments in or acquisitions of other businesses, solutions or technologies or repay a portion of our
outstanding borrowings. We currently have no plan or proposal to make any particular such investment or acquisition. Pending these uses,
we intend to invest the net proceeds in, interest-bearing, investment-grade securities. Specifically, the interest bearing securities
are preferred stocks with perpetual maturities that are rated investment grade (Baa3/BBB-/BBB- or higher) using the middle rating of
Moody&#8217;s, S&amp;P and Fitch.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling shareholder will receive all of the proceeds from the sale of the common stock offered by this prospectus for the selling shareholder.
We will not receive any of the proceeds from the sale of such common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>GENERAL
DESCRIPTION OF DAXOR CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation is an investment company with medical instrumentation and biotechnology operations. Daxor Corporation was originally incorporated
in New York State as Iatric Corporation in May 1971 for cryobanking services and discontinued these services through its wholly-owned
subsidiary, Scientific Medical Systems in 2017. In October 1971, the name Iatric Corporation was changed to Idant Corporation. In May
1973, the name Idant Corporation was changed to Daxor Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 107 Meco Lane, Oak Ridge, TN 37830.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the company is not primarily engaged in the business of investing, reinvesting, owning, holding or trading in securities, the company
is dependent upon earnings from its investment portfolio to fund operations. While Daxor Corporation is registering as a closed-end investment
company, Daxor Corporation&#8217;s major focus will remain the development of the BVA-100 &#174; Blood Volume Analyzer, an instrument
that rapidly and accurately measures human blood volume. This instrument is used in conjunction with Volumex &#174;, a single-use radiopharmaceutical
diagnostic injection and collection kit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also own the Daxor Oak Ridge Operations (DORO) facility in Oak Ridge, TN, which manufactures, tests, and develops next-generation models
of the BVA-100 &#174;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain an internet website at <span style="text-decoration: underline">www.daxor.com</span>. Except as expressly incorporated herein by reference, the information contained
on the website is not incorporated by reference into this prospectus or into any other document filed by us with the Securities and Exchange
Commission.</span></p>

<ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000127" name="cef:InvestmentObjectivesAndPracticesTextBlock"><p id="xdx_897_ecef--InvestmentObjectivesAndPracticesTextBlock_dU_zSJNKrVzeq9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span><span id="xdx_8B7_zk0pgA4YPtsk">Investment
Objectives and Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
objective is to support and expand our operating businesses, through organic growth (i.e., the rate of business expansion through internal
enhancement of the business and operations as opposed to mergers, acquisitions and takeovers). The company is not primarily engaged in
the business of investing, reinvesting, owning, holding or trading in securities. Funds in excess of the company&#8217;s business needs
are placed in instruments designed to maximize capital preservation and assure liquidity. The foregoing policies may be changed without
a shareholder vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
concentrate our investments in the utility industry and have an investment policy that calls for a minimum of 80% of the company&#8217;s
investment portfolio to consist of electric utility stocks. The Board of Directors has authorized this minimum to be temporarily lowered
to 70% when management deems it to be necessary. At least once a year, the company reviews its investment strategy, and more frequently
as needed, at board meetings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investment portfolio primarily consists of electric utility companies which are publicly traded common and preferred stock. In addition
to receiving income from dividends from the securities held in the investment portfolio, we also have an investment policy of selling
puts on stocks that we are willing to own. Such options usually have a maturity of less than 1 year. The company will also sell covered
calls on securities within its investment portfolio. Covered calls involve stocks, which usually do not exceed 15% of the value of the
company&#8217;s portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will, at times, sell naked or uncovered calls, as well as, engage in short sales as part of an income strategy, and to a lesser extent
a strategy to mitigate risk. Our net short position will usually amount to less than 15% of the company&#8217;s portfolio value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this time, investments in debt instruments and foreign securities are not a principal investment strategy, and we expect any such investments
to be minimal.</span></p>

</ix:nonNumeric><p id="xdx_8A1_z0tXGtagNaJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000129" name="cef:RiskFactorsTableTextBlock"><p id="xdx_80A_ecef--RiskFactorsTableTextBlock_dU_zSiuRGblvSre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span><span id="xdx_82E_zzIGkIWZDIs5">Risk
Factors</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Deregistration as Investment Company</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to file an application
pursuant to Section 8(f) of the Investment Company Act of 1940 seeking an order declaring that Daxor has ceased to be a registered investment
company. Investors in registered investment companies benefit from legal protections imposed for their benefit under the&#160;Investment
Company Act, and those legal protections will no longer apply if we receive the requested order. In addition, if we receive the requested
order, our tax treatment may change, and such a change could have an adverse effect on the value of an investment in Daxor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with deregistering
as an investment company, we will take the appropriate steps to register under the Securities Exchange Act of 1934, as amended, and will
continue to be listed on Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With regard to this registration
statement, if we receive the order declaring that we have ceased to be an investment company, then we will immediately cease any offering
under this registration statement. In such eventuality, we will take the appropriate steps to convert this registration statement to
a registration statement on Form S-1 or Form S-3, as appropriate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investment
Portfolio Risks</span></span></p>

<ix:nonNumeric contextRef="From2025-07-232025-07-23_custom_MarketRisksMember" escape="true" id="Fact000131" name="cef:RiskTextBlock"><p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--MarketRisksMember_dU_zNkxyeHRnqJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B1_zLES2XAyxjF2">Market
Risks</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
of money is a risk of investing in the company. The net asset value of the company can be expected to change daily and you may lose money.
There is no guarantee that the performance of our investment portfolio will be positive over any period of time, either short-term or
long-term. Market risk may affect a single issuer, industry, sector of the economy, or the market as a whole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
and international markets have experienced significant periods of volatility in recent years due to a number of economic, political and
global macro factors, including the impact of the coronavirus (COVID-19) as a global pandemic and related public health issues, growth
concerns in the U.S. and overseas, uncertainties regarding interest rates, trade tensions and the threat of tariffs imposed by the U.S.
and other countries. In particular, the spread of the novel coronavirus worldwide has resulted in disruptions to supply chains and customer
activity, stress on the global healthcare system, rising unemployment claims, quarantines, cancellations, market declines, the closing
of borders, restrictions on travel and widespread concern and uncertainty. Health crises and related political, social and economic disruptions
caused by the spread of the recent coronavirus outbreak may also exacerbate other pre-existing political, social and economic risks in
certain countries. It is not possible to know the extent of these impacts, and they may be short term or may last for an extended period
of time. These developments as well as other events, such as the U.S. presidential election, could result in further market volatility
and negatively affect security prices, the liquidity of certain securities and the normal operations of securities exchanges and other
markets, despite government efforts to address market disruptions.</span></p>

</ix:nonNumeric><p id="xdx_8A2_zj5kLvJ6yADh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-232025-07-23_custom_EquityInvestmentsMember" escape="true" id="Fact000133" name="cef:RiskTextBlock"><p id="xdx_890_ecef--RiskTextBlock_hcef--RiskAxis__custom--EquityInvestmentsMember_dU_zWJ4DwOdPiEk" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B9_zxdsQ7NCzdya">Equity
Investments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we invest in equity securities, fluctuations in the stock market in general, as well as in the value of particular equity securities
held by us, can affect the performance of our investment portfolio. The value of equity securities will fluctuate due to many factors,
including the past and predicted earnings of the issuer, the quality of the issuer&#8217;s management, general market conditions, forecasts
for the issuer&#8217;s industry and the value of the issuer&#8217;s assets.</span></p>

</ix:nonNumeric><p id="xdx_8A2_zVzEjT5FLyjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2025-07-232025-07-23_custom_IndustryConcentrationMember" escape="true" id="Fact000135" name="cef:RiskTextBlock"><p id="xdx_894_ecef--RiskTextBlock_hcef--RiskAxis__custom--IndustryConcentrationMember_dU_zjMqRS3FKFxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B8_zjOj42ECW6b1">Industry
Concentration</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
concentrate our investments within the electric utility industry. Because of its narrow industry focus, the performance of our investment
portfolio is tied closely to and affected by developments in the electric utility industry, such as competition and weather. The electric
utility industry is also sensitive to increased interest rates because of the industry&#8217;s capital intensive nature. Also, an increase
in interest rates could cause some electric utilities to decrease dividends paid to shareholders which would reduce our investment income.
The earnings of electric utility companies could also be negatively affected by power outages. Electric utilities operate in an environment
of federal, state and local regulations, and these regulations may disproportionately affect an individual utility.</span></p>

</ix:nonNumeric><p id="xdx_8A2_zqDmrmH7UdZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2025-07-232025-07-23_custom_ShortSaleRisksMember" escape="true" id="Fact000137" name="cef:RiskTextBlock"><p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--ShortSaleRisksMember_dU_zwQlhTiLokCi" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B3_zraT901Ofvyh">Short
Sale Risks</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investment portfolio will suffer a loss if it sells a security short and the value of the security rises rather than falls. It is possible
that the investment portfolio&#8217;s long positions will decline in value at the same time that the value of its short positions increase,
thereby increasing potential losses to the portfolio. Short sales expose our investment portfolio to the risk that it will be required
to buy the security sold short (also known as &#8220;covering&#8221; the short position) at a time when the security has appreciated
in value, thus resulting in a loss to the portfolio. The investment performance of our investment portfolio will also suffer if it is
required to close out a short position earlier than it had intended. In addition, our investment portfolio may be subject to expenses
related to short sales that are not typically associated with investing in securities directly, such as costs of borrowing. These expenses
may negatively impact the performance of the investment portfolio. Short positions introduce more risk to the investment portfolio than
long positions (purchases) because the maximum sustainable loss on a security purchased (held long) is limited to the amount paid for
the security plus the transaction costs, whereas there is no maximum attainable price of the shorted security. Therefore, in theory,
securities sold short have unlimited risk.</span></p>

</ix:nonNumeric><p id="xdx_8A2_zlBhvSV9QER5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-07-232025-07-23_custom_PutAndCallOptionsRiskMember" escape="true" id="Fact000139" name="cef:RiskTextBlock"><p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--PutAndCallOptionsRiskMember_dU_zrGCDSV3pdqj" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B9_zP5YksLm47P">Put
and Call Options Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of options involves investment strategies and risks different from those associated with ordinary portfolio securities transactions.
If a strategy is applied at an inappropriate time or market conditions or trends are judged incorrectly, the use of options may lower
the return on the investment. There can be no guarantee that the use of options will increase the return or income on an investment.
In addition, there may be an imperfect correlation between the movement in prices of options and the securities underlying them and there
may at times not be a liquid secondary market for various options. An abrupt change in the price of an underlying security could render
an option worthless. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in
the value of the underlying instrument, or in interest or currency exchange rates, including the anticipated volatility of the underlying
instrument (known as implied volatility), which in turn are affected by fiscal and monetary policies and by national and international
political and economic events, as will the performance of the issuer of the underlying instrument. As such, prior to the exercise or
expiration of the option, the Company is exposed to implied volatility risk, meaning the value, as based on implied volatility, of an
option may increase due to market and economic conditions or views based on the sector or industry in which issuers of the underlying
instrument participate, including company-specific factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
writing put options, the Company takes on the risk of declines in the value of the underlying instrument, including the possibility of
a loss up to the entire strike price of each option it sells, but without the corresponding opportunity to benefit from potential increases
in the value of the underlying instrument. When the Company writes a put option, it assumes the risk that it must purchase the underlying
instrument at a strike price that may be higher than the market price of the instrument. If there is a broad market decline and the Company
is not able to close out its written put options, it may result in substantial losses. By writing a call option, the Company may be obligated
to deliver instruments underlying an option at less than the market price. In the case of an uncovered call option, there is a risk of
unlimited loss. When an uncovered call is exercised, the Company must purchase the underlying instrument to meet its call obligations
and the necessary instruments may be unavailable for purchase. When the Company writes a covered call option, it gives up the opportunity
to profit from a price increase in the underlying instrument above the strike price. If a covered call option that the Company has written
is exercised, the Company will experience a gain or loss from the sale of the underlying instrument, depending on the price at which
the Company purchased the instrument and the strike price of the option. The Company will receive a premium from writing options, but
the premium received may not be sufficient to offset any losses sustained from exercised options. In the case of a covered call, the
premium received may be offset by a decline in the market value of the underlying instrument during the option period. If an option that
the Company has purchased is never exercised or closed out, the Company will lose the amount of the premium it paid and the use of those
funds. There were no put or call option positions at December 31, 2024.</span></p>

</ix:nonNumeric><p id="xdx_8A2_zwucELldXWm" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2025-07-232025-07-23_custom_OperatingCompanyRisksMember" escape="true" id="Fact000141" name="cef:RiskTextBlock"><p id="xdx_899_ecef--RiskTextBlock_hcef--RiskAxis__custom--OperatingCompanyRisksMember_dU_zzR8qhUshmU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_8BB_z8vvVCSLFzee">Operating
Company Risks</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is at an early stage of commercial development and we may struggle to generate significant commercial uptake in our products
with our current resources.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is at an early stage of commercial development. We have a base of installed devices or tests run at approximately 80 hospitals
and clinics and approximately 65,000 kits have been sold to clinicians. These sites are covered by a sales, marketing, technical, and
clinical support team of 12 individuals composed of employees and consultants. Investment in expanding these resources will be required
to reach larger target customers at hospitals and clinics across the country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, significant research and clinical studies on the potential benefits of blood volume analysis to guide therapeutic decisions
will be required to gain acceptance into the guidelines of care and for broader clinical adoption. There is no guarantee that these studies
will be successful or completed in a timely or cost-effective manner allowing the company to benefit commercially from their completion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need additional capital to conduct our operations and develop our products, and our ability to obtain the necessary funding is uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have used a significant amount of cash and retained earnings since inception to finance the continued development and testing of our
BVA-100 system, and we expect to need additional capital resources in order to further commercialize the product as well as develop related
products and updates to our existing device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be successful in maintaining operating cash flow, and the timing of our capital expenditures and other expenditures may impede
our commercialization efforts if not sufficient. If financing is not sufficient and additional financing is not available or available
only on terms that are detrimental to our long-term survival, it could have a material adverse effect on our ability to successfully
commercialize our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
financing through strategic collaborations, public or private equity or debt financings or other financing sources may not be available
on acceptable terms for our operating company, or at all. Additional equity financing could result in dilution to our shareholders. Further,
if we obtain additional funds through arrangements with collaborative partners, these arrangements may require us to relinquish rights
to some of our technologies, product or products that we would otherwise seek to develop and commercialize on our own.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
sufficient capital is not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or product
development initiatives, any of which could have an adverse effect on our financial condition or business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
financial reporting reflects our status as a closed-end investment fund with an operating medical device division whose financial performance
is not broken out in detail and reported on a regular basis as is the case with traditional operating companies. As a result, shareholders
could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common
stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
seek detailed financial information in their investments and our reporting structure conforms to that of an investment fund. Investors
may become dissatisfied with the level of reporting detail that our current fund structure maintains and require greater transparency
in the future or lose confidence in the management resulting in a negative impact on the stock price. While the company intends to file
for a change of reporting structure in the future to a traditional operating company with the SEC as revenues from the operating division
increase whether that will be achievable and at what date remains unknown at this point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our efforts to protect our intellectual property related to our technologies are not adequate, we may not be able to compete effectively
in our market and our business would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related
to our technologies. Any disclosure to or misappropriation by third parties of our trade secrets or other confidential information could
assist competitors in duplicating or surpassing our technological achievements, thus eroding the competitive advantage we may derive
from these patents or know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
strength of patents in the medical diagnostic field involves complex legal and scientific questions and can be uncertain. The patent
applications we own may fail to result in issued patents in the United States or in foreign countries and existing patents on parts of
our technology have entered the public domain. Third parties may challenge the validity, enforceability or scope of any issued patents
we own or license or any applications that may issue as patents in the future, which may result in those patents being narrowed, invalidated
or held unenforceable. Even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual
property or prevent others from developing similar products that do not fall within the scope of our patents. If the breadth or strength
of protection provided by the patents we hold or pursue is threatened, our ability to commercialize any product candidates with technology
protected by those patents could be threatened. Since patent applications in the United States and most other countries are confidential
for a period of time after filing, we cannot be certain at the time of filing that we are the first to file any patent application related
to our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect
proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery
platform and drug development processes that involve proprietary know-how, information or technology that is not covered by patents or
not amenable to patent protection. Although we endeavor that all of our employees and certain consultants and advisors to assign inventions
to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information
or technology to enter into confidentiality agreements, our trade secrets and other proprietary information may be disclosed or competitors
may otherwise gain access to such information or independently develop substantially equivalent information. Further, the laws of some
foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result,
we may encounter significant difficulty in protecting and defending our intellectual property both in the United States and abroad. If
we are unable to prevent material disclosure of the trade secret intellectual property related to our technologies to third parties,
we may not be able to establish or maintain the competitive advantage that we believe is provided by such intellectual property, which
could materially adversely affect our market position and business and operational results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be involved in lawsuits to protect or enforce our patent, which could be expensive, time-consuming and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patents. To attempt to stop infringement or unauthorized use, we may need to enforce one or more of our patents, which
can be expensive and time-consuming and distract management. If we pursue any litigation, a court may decide that a patent of ours or
our licensor&#8217;s is not valid or is unenforceable, or may refuse to stop the other party from using the relevant technology on the
grounds that our patents do not cover the technology in question. Further, the legal systems of certain countries, particularly certain
developing countries, do not favor the enforcement of patents, which could reduce the likelihood of success of any infringement proceeding
we pursue in any such jurisdiction. An adverse result in any infringement litigation or defense proceedings could put one or more of
our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of
not issuing, which could limit our ability to exclude competitors from directly competing with us in the applicable jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interference
proceedings provoked by third parties or brought by the U.S. PTO may be necessary to determine the priority of inventions with respect
to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to use it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms, or at all. Litigation or interference proceedings may fail and, even if successful, may
result in substantial costs and distract our management and other employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unsuccessful in obtaining or maintaining patent protection for intellectual property in development, our business and competitive
position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are seeking patent protection for some of our technology and future products. Patent prosecution is a challenging process and is not
assured of success. If we are unable to secure patent protection for our technology and product candidates, our business may be adversely
impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, issued patents and pending international applications require regular maintenance. Failure to maintain our portfolio may result
in loss of rights that may adversely impact our intellectual property rights, for example by rendering issued patents unenforceable or
by prematurely terminating pending international applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how,
technology and other proprietary information, to maintain our competitive position. We currently, and expect in the future to continue
to, seek to protect these trade secrets, in part, by entering into confidentiality agreements with parties who have access to them, such
as our employees, collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality
and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach
the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies
for any such disclosure. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive
and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing
or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor,
we would have no right to prevent them, or those to whom they disclose the trade secrets, from using that technology or information to
compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position
would be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will have to hire additional executive officers and employees to expand our business. If we are unable to hire qualified personnel, we
may not be able to implement our business strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loss of the services of any of our key product or business development employees could delay our product development programs and our
research and development efforts. We do not maintain key person life insurance on any of our officers, employees or consultants. In order
to develop our business in accordance with our business strategy, we will have to hire additional qualified personnel, including in the
areas of sales, physician education, manufacturing, clinical trials management, regulatory affairs, and business development. We will
need to raise sufficient funds to hire the necessary employees and have commenced our search for additional key employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on key personnel for our continued operations and future success, and a loss of certain key personnel could significantly hinder
our ability to move forward with our business plan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the specialized nature of our business, we are highly dependent on our ability to identify, hire, train and retain highly qualified
scientific and technical personnel for the research and development activities we conduct or sponsor. The loss of one or more key executive
officers, or scientific officers, would be significantly detrimental to us. In addition, recruiting and retaining qualified scientific
personnel to perform research and development work is critical to our success. Our anticipated growth and expansion into areas and activities
requiring additional expertise will require the addition of new management personnel and the development of additional expertise by existing
management personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could cause our business to suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
regulations of governmental authorities, such as the FDA or the European Medicines Agency, or EMA, to provide accurate information to
the FDA or EMA, to comply with manufacturing standards we have established, to comply with federal, state and international healthcare
fraud and abuse laws and regulations as they may become applicable to our operations, to report financial information or data accurately
or to disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the
course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to
identify and deter employee misconduct, and the precautions we currently take and the procedures we may establish in the future as our
operations and employee base expand to detect and prevent this type of activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure by our employees
to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves
or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition
of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we experience delays or difficulties in clinical outcome studies or lack the funding to conduct them, receipt of necessary outcome data
could be delayed or prevented.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials using our BVA-100 depend upon the successful funding, enrollment, and initiation of studies in coordination with research institutions
and hospitals. The company does not have sufficient funds to fully sponsor as many outcome studies as may be warranted for adoption of
our diagnostic as a standard of care. As such, the company depends upon a combination of grants and research agreements with sponsoring
institutions for many of the studies that have been conducted with its technology and anticipates continuing to do so for the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
and our suppliers are subject to extensive FDA regulation, which can be costly and time consuming and can subject us to unanticipated
business costs or difficulties. Even though regulatory approval for products may have been granted, those products may still face regulatory
difficulties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our current and potential products, as well as those supplied to Daxor by third parties, processing and manufacturing activities,
are subject to comprehensive regulation by the FDA in the United States and by comparable authorities in other countries. The company
has spent considerable resources and time obtaining FDA and other required regulatory approvals but is still subject to regulatory action
from the FDA if it chooses to revoke or enforce an interpretation of the regulations that would make distribution or manufacture of our
products disallowed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we, or third-party manufacturers we may contract with, violate regulatory requirements at any stage the FDA may take enforcement action(s)
against us, which could include issuing a warning or untitled letter, placing a clinical hold on an ongoing clinical trial, product seizure,
enjoining our operations, refusal to consider our applications for pre-market approval, refusal of an investigational new drug application,
fines, or even civil or criminal liability, any of which could materially harm our reputation and financial results. In addition, if
manufacturing problems occur, regulators may withdraw their approval or demand additional changes in product manufacture or marketing
practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforcement
actions we and our suppliers are subject to include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters or other actions requiring changes in product manufacturing processes or restrictions on product marketing or distribution;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls or seizures or the temporary or permanent withdrawal of a product from the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspending
    any ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">temporary
    or permanent injunctions against our production operations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitution or disgorgement of profits or revenue, the imposition of civil penalties or criminal prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of these actions would likely cause a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
difficulties or failures that we encounter regarding regulatory approval for our products or those of third-party suppliers would likely
have a substantial adverse impact on our ability to generate product sales, and could make any search for a collaborative partner more
difficult.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For
some of our products, we currently lack sufficient manufacturing capabilities to produce our products in-house and rely upon third party
suppliers. Disruption in our manufacturing supply, could negatively impact our ability to meet any future demand for the product.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that we would need to significantly expand our manufacturing capabilities to meet potential demand for our diagnostic devices
and Volumex kits. In addition, we depend upon a single manufacturer for components of our products and a disruption in that supply could
materially impact our business disrupting out ability to meet demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently manufacture our BVA-100 device in a 20,000 square foot facility in Oak Ridge, Tennessee. If our facilities where our products
are currently being manufactured or equipment were significantly damaged or destroyed, or if there were other disruptions, delays or
difficulties affecting manufacturing capacity, including if such facilities are deemed not in compliance with current Good Manufacturing
Practice, or GMP, requirements, future clinical studies and commercial production for our products would likely be significantly disrupted
and delayed. It would be both time-consuming and expensive to replace this capacity with third parties, particularly since any new facility
would need to comply with the regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ultimately,
if we are unable to supply our products to meet commercial demand, whether because of processing constraints or other disruptions, delays
or difficulties that we experience, our production costs could dramatically increase and sales of our products and their long-term commercial
prospects could be significantly damaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
be successful, our diagnostic products must be broadly accepted by the healthcare community, which can be very slow to adopt or unreceptive
to new technologies and products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
products that we manufacture represent substantial departure from more established methods of volume assessment and compete with a number
of more conventional therapies based upon measures of pressure or hemodynamics manufactured and marketed by major medical device companies.
The degree of market acceptance and uptake of our products depends on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    establishment and demonstration to the medical community the clinical efficacy and safety of our proposed products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate that our products are superior to alternatives currently on the market in accuracy and ease of use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish in the medical community the potential advantage of our diagnostic over alternative diagnostic methods; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reimbursement
    policies of government and third-party payers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the healthcare community does not accept our products for any of these reasons, or for any other reason, our business would be materially
harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
competition includes diagnostic companies that have significant advantages over us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for medical diagnostic products is highly competitive. We expect that our most significant competitors will be fully integrated
and more established medical device companies with extensive product lines and distribution networks. These companies may seek to develop
similar products, and they have significantly greater capital resources and research and development, manufacturing, testing, regulatory
compliance, and marketing capabilities. As a result, our competitors may develop more competitive or affordable products, or achieve
earlier patent protection or product commercialization than we are able to achieve. Competitive products may render our products or future
products that we develop obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to litigation that will be costly to defend or pursue and uncertain in its outcome.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business may bring us into conflict with our licensees, licensors or others with whom we have contractual or other business relationships,
or with our competitors or others whose interests differ from ours. If we are unable to resolve those conflicts on terms that are satisfactory
to all parties, we may become involved in litigation brought by or against us. That litigation is likely to be expensive and may require
a significant amount of management&#8217;s time and attention, at the expense of other aspects of our business. The outcome of litigation
is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities,
or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are exposed to the risk of liability claims, for which we may not have adequate insurance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
we participate in the health care industry, we may be subject to liability claims by employees, customers, end users and third parties
for past products and services as well as current or future products. While the company carries liability insurance there can be no assurance
that the liability insurance we carry will be adequate to cover claims asserted against us or that we will be able to maintain such insurance
in the future</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have a marketing and sales force of approximately 12 employees and consultants. If we are unable to establish effective marketing
and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively
market and scale our sales to a significant scale.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have a marketing and sales team for the marketing, sales and distribution of our BVA-100 device and kits. In order to fully
commercialize our products, we must expand our territory-by-territory basis marketing, sales, distribution, managerial and other non-technical
capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
failure or delay in the further development of our internal sales, marketing and distribution capabilities would adversely impact the
commercialization of any of our products that we obtain approval to market. We may choose to collaborate, either globally or on a territory-by-territory
basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and
distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when
needed on acceptable terms or at all this will adversely affect our ability to rapidly scale the sale of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations would suffer in the event of system failures or natural and man-made disasters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to
damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While
we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our operations. For example, a hurricane or severe flood could disrupt
one of our key suppliers disrupting our supply chain for weeks or months causing material losses. If any disruption or security breach
resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability and additional costs despite some insurance products that the company has purchased to mitigate such costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred net operating losses in the past, and may incur them in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred cumulative net operating losses in the past. These losses have mainly resulted from ongoing expenses for marketing and
research and development as the company attempts to build a market for its products. In the past, the company&#8217;s cumulative net
income from investments and other items exceeded the operating losses and provided the necessary funds for its continued research and
development and marketing. It is the opinion of management that the financial health of the company would have been adversely affected
if net income from investments had been substantially less than losses from operations. There is no guarantee that future net income
from investments will continue to completely offset operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
loss of any one customer could have an adverse effect on our consolidated operating business for a short period of time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, the sale of Blood Volume Kits has accounted for a significant portion of the company&#8217;s total consolidated operating revenue,
and a small number of customers (hospitals) has comprised the majority of such sales. Management believes that the loss of any one customer
would have an adverse effect on our consolidated operating business for a short period of time. The company continues to seek new customers,
so that any one hospital will represent a smaller percentage of overall sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
there is a decrease in the market value of our available for sale securities, this could have an adverse effect on our ability to fund
research and development and marketing efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December 31, 2024,
67.2% of the fair market value of Daxor&#8217;s investment in securities consisted of utility stocks, all of which are electric utilities,
whose market price can be sensitive to rising interest rates. The company&#8217;s investment policy calls for a minimum of 80% of the
investment portfolio to consist of electric utility stocks. The Board of Directors has authorized this minimum to be temporarily lowered
to 70% when management deems it to be necessary. Investments in utilities are primarily in electric companies. Investments in non-utility
stocks will generally not exceed 20% of the value of the portfolio of investment securities. Given the current volatility in the market,
management feels this is a temporary situation. Depending on the duration of the current market conditions the Board of Directors will
revisit this investment policy. At December 31, 2024, the fair market value of Daxor&#8217;s investment in securities was 8.36%
of total net assets. The value of the operating division on a standalone basis and other assets and liabilities was the remaining balance
of the portfolio. At December 31, 2024, the company&#8217;s investment portfolio consisted of 8 separate investments in common stocks
and one preferred stock. The top five holdings as of this date in the investment portfolio were Bank of America, Evergy. Avista, Enbridge
and Eversource. These five holdings comprised 92.9% of the value of the investments in our securities portfolio and accounted for 53.9%
of the dividend income for the year ended December 31, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a risk that in an environment of rising interest rates that the market value of these stocks could decline and the utilities could
reduce their dividend payments to compensate for increased interest expense. This could have an adverse effect on Daxor&#8217;s ability
to fund research and development and marketing efforts necessary to build a market for the company&#8217;s products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
absence of patents or the inability to defend patents could negatively impact our ability to compete for and obtain new business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation&#8217;s patents for the BVA 100 expired in 2010. The company filed two additional patent applications for an automated instrument
to measure human blood volume which were granted April 7, 2015. The filings describe innovations which will be or have been incorporated
into the company&#8217;s BVA-100 Blood Volume Analyzer, these patents expanded the capabilities of the analyzer to incorporate total
body albumin measures and error correction software to improve accuracy. In addition, the company filed additional patents on its blood
volume technology in January of 2018, and has several more patents in various stages of development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
blood volume analyzer, however, works most efficiently with the tracer injection kit system which has a separate patent and which expired
in 2016. It is possible that another company could develop another version of the Blood Volume Analyzer which would use a different tracer
injection kit. To the best of the company&#8217;s knowledge, this has not happened yet and management views the development of a competing
tracer injection kit as unlikely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the current manufacturer were to cease filling the Volumex syringes for us for any reason before we had a chance to make alternative
arrangements, this could have a material negative impact on our operating revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of Daxor Corporation&#8217;s orders for Volumex syringes are filled by a single FDA inspected radio pharmaceutical manufacturer. If this
manufacturer were to cease filling the Volumex syringes for the company or were denied permission to do so by FDA for any reason before
the company had a chance to make alternative arrangements, the effect on the company&#8217;s operating revenue could be material. In
January 2007, we purchased two 10,000 square foot buildings in Oak Ridge, Tennessee to expand its research, development, and manufacturing
capabilities.</span></p>

</ix:nonNumeric><p id="xdx_8AF_z7MFihMvJ5O9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><p id="xdx_81F_z6Kmog2NBRW9" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>Other
Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management expects that our investment portfolio will continue to consist primarily of publicly traded common and preferred stocks of
electric utilities. The percentage of investments other than electric utilities is expected to remain at less than 20% of the investment
portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
regard to the non-principal investments for the investment portfolio, we are flexible in how we may allocate our investments. We may
allocate the non-principal investments among the following types of securities, in proportions which reflect the judgment of our management
of the potential returns and risks of such securities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stocks and other equity securities (including common stocks, preferred stocks, convertible preferred stocks, warrants, options and
    American Depository Receipts);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonds
    and other debt securities (including U.S. Treasury Notes and Bonds, investment grade corporate debt securities, convertible debt
    securities and debt securities below investment grade); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money
    market instruments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Forward-Looking
Statements Regarding Daxor Corporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
made by Daxor Corporation in this prospectus that are not historical facts may constitute &#8220;forward-looking statements&#8221; within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21 of the Exchange Act. These forward-looking statements
are necessarily estimates reflecting the judgment of the company&#8217;s senior management based on its current estimates, expectations,
forecasts and projections and include comments that express the company&#8217;s current opinions about trends and factors that may impact
future operating results. Disclosures that use words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221;
&#8220;intend,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;project&#8221; or the negative of these,
as well as similar expressions, are intended to identify forward-looking statements. These statements are not guarantees of future performance,
rely on a number of assumptions concerning future events, many of which are outside of the company&#8217;s control, and involve known
and unknown risks and uncertainties that could cause actual results, performance or achievement, or industry results, to differ materially
from any future results, performance or achievements, expressed or implied by such forward-looking statements. These risks, uncertainties
and other factors which could cause results to differ materially from management&#8217;s expectations are discussed in this prospectus.
Additional information regarding factors that could cause results to differ materially from management&#8217;s expectations is found
in the section entitled &#8220;Risk Factors&#8221;. Any such forward-looking statements, whether made in this report or elsewhere, should
be considered in the context of the various disclosures made by the company about its businesses including, without limitation, the risk
factors discussed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation intends that the forward-looking statements included herein be subject to the above-mentioned statutory safe harbor. Investors
are cautioned not to rely on forward-looking statements. Except as required under the federal securities laws and the rules and regulations
of the SEC, the company does not have any intention or obligation to update publicly any forward-looking statements, whether as a result
of new information, future events, changes in assumptions, or otherwise.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>Investment
Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
responsibility of the Board of Directors is to exercise corporate powers and to oversee management of the business of Daxor Corporation.
The officers of the company are principally responsible for its operations. The company is not primarily engaged in the business of investing,
reinvesting, owning, holding or trading in securities. As such, the company has no investment advisors, administrator, affiliated brokerage,
dividend paying agent, non-resident managers, or portfolio managers. The nature of the instruments in which funds in excess of immediate
capital needs are placed are consistent with capital preservation and liquidity. Subject to the oversight of the Board, the company&#8217;s
Chief Executive Officer, Michael Feldschuh, is the only individual responsible for the day-to-day management of Daxor&#8217;s investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We act as custodian of our
securities in accordance with Section 17(f)(1)(C) and Rule 17f-2 of the Investment Company Act of 1940, and we will deposit our securities
and similar investments in the safekeeping of one or more requested broker-dealers under the Securities Exchange Act of 1934. We will
evidence these arrangements in written contracts (ratified and approved annually by a majority of the board of directors), which will
be filed with the SEC. These contracts require that (1) the securities be physically segregated and marked to show that they are the
property of the company; (2) the securities and other investments must be verified three times annually by an independent accountant;
(3) the broker-dealer not have the ability to hypothecate, pledge or sell the securities, except at the direction of the company and
for its account; and (4) the securities and investments may not be subject to any lien or charge in favor of the broker-dealer. Our current
broker-dealer is UBS Financial Services, Inc., located at 299 Park Avenue, New York, NY 10171.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nature of the instruments in which funds in excess of immediate capital needs are placed are consistent with capital preservation and
liquidity. We are dependent on income from our investment portfolio to support our manufacturing operations and our biotechnology. The
Company&#8217;s Chief Executive Officer, Michael Feldschuh, is primarily responsible for the day-to-day management of any such investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Feldschuh has been president of Daxor since 2017. He earned his bachelor&#8217;s degree in Pre-Med studies at Columbia College, Columbia
University in 1991. Prior to joining Daxor&#8217;s executive team in December of 2014 as Executive Vice President, he served as a member
of the board of directors for one and a half years prior. Mr. Feldschuh headed his own hedge fund, Aristarc Capital, from 2009 to 2013
specializing in quantitative equity strategies. Prior to founding his own fund, Mr. Feldschuh was a Managing Director at Morgan Stanley
Investment Management from 2005 to 2009 and also served as a Managing Director and Portfolio Manager at Millennium Partners in New York
from 1997-2005. Mr. Feldschuh was a proprietary trader for Morgan Stanley &amp; Co. from 1994-1997. Mr. Feldschuh began his career at
D.E. Shaw &amp; Co. in New York, where he worked with Jeffery Bezos prior to Mr. Bezos&#8217;s founding of Amazon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation paid to Mr. Feldschuh is set forth in the following table. There is no &#8220;Fund Complex&#8221; as defined in the 1940
Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">Pension or</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"/><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Aggregate</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">Benefits Accrues</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Compensation</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Compensation</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">as Part of</td><td>&#160;</td>
    <td style="text-align: center">Annual Benefits</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Fund Complex</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Name</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">From Company</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Company Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Upon Retirement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Paid to Director</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 24%; text-align: left">Michael Feldschuh</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%">None</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%">None</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Feldschuh has deliberately elected to draw a salary that is well below what the company believes is the market rate for someone with
his responsibilities and qualifications. It is the belief of the Board of Directors that annual compensation of two or three times what
he is currently earning could easily be justified. The decision to keep his annual compensation at well below market rate has been made
as part of an effort to preserve capital in light of the company&#8217;s ongoing losses from operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the share ownership of Mr. Feldschuh.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">Number of Shares</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">Percent of</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">Beneficially</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">Common</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Name of Beneficial Owner</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Owned</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Stock</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 64%"><span style="font-size: 10pt">Michael Feldschuh, President and Director*</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><span style="font-size: 10pt">232,694</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><span style="font-size: 10pt">4.7</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">%</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*Includes 212,694 shares of common stock
and 20,000 shares of common stock issuable upon the exercise of options issued under the company&#8217;s 2020 Incentive Compensation
Plan. On April 24, 2020, we received an exemptive order that permits us to adopt an incentive compensation plan, and shareholders
approved our incentive compensation plan at our 2020 annual meeting</p>
<ix:nonNumeric contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember" escape="true" id="Fact000143" name="cef:CapitalStockTableTextBlock"><p id="xdx_80A_ecef--CapitalStockTableTextBlock_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_dU_zMjWa7hmbT53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span><span id="xdx_820_zASonCYeWJv7">Daxor
Corporation <span id="xdx_904_ecef--SecurityTitleTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z26bEP0327gb"><ix:nonNumeric contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember" escape="true" id="Fact000144" name="cef:SecurityTitleTextBlock">Common Stock</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecef--SecurityVotingRightsTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUvKC5kqg0w6"><ix:nonNumeric contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember" escape="true" id="Fact000145" name="cef:SecurityVotingRightsTextBlock">The
holders of the common stock have one vote per share for the election of directors, without provisions for cumulative voting, and on all
other matters. Thus, holders of more than 50% of the shares voting for the election of directors can elect all the directors if they
choose to do so.</ix:nonNumeric></span> <span id="xdx_906_ecef--SecurityPreemptiveAndOtherRightsTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zYj6UBnw7bIi"><ix:nonNumeric contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember" escape="true" id="Fact000146" name="cef:SecurityPreemptiveAndOtherRightsTextBlock">The common stock is not redeemable and has no conversion or preemptive rights.</ix:nonNumeric></span> <span id="xdx_903_ecef--SecurityObligationsOfOwnershipTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zorbvrVYVBC2"><ix:nonNumeric contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember" escape="true" id="Fact000147" name="cef:SecurityObligationsOfOwnershipTextBlock">The company qualifies as a &#8220;controlled
company&#8221; under Nasdaq rules, as the estate of Joseph Feldschuh, M.D. controls more than 50% of the company&#8217;s voting power,
as evidenced by the company&#8217;s ownership records.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock has continuously
been traded since its initial public offering. The company&#8217;s common stock is traded on Nasdaq under the symbol DXR. As of May 19,
2025, the company&#8217;s authorized securities consisted of <span id="xdx_903_ecef--OutstandingSecurityAuthorizedShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z7GeZzkdKBx5"><ix:nonFraction name="cef:OutstandingSecurityAuthorizedShares" contextRef="From2025-05-192025-05-19_us-gaap_CommonStockMember" id="Fact000148" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000150" name="cef:OutstandingSecuritiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_886_ecef--OutstandingSecuritiesTableTextBlock_dU_z6yRSkG2s235" summary="xdx: Disclosure - Outstanding Securities of Common Stock" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Amount Held by Company or for</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Title of Class</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount Authorized</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">its Account</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount Outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_983_ecef--OutstandingSecurityTitleTextBlock_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z0AADpTeGQq7" style="width: 46%; text-align: left"><ix:nonNumeric contextRef="From2025-05-192025-05-19_us-gaap_CommonStockMember" escape="true" id="Fact000151" name="cef:OutstandingSecurityTitleTextBlock">Common Stock</ix:nonNumeric></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecef--OutstandingSecurityAuthorizedShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zl4bpCpkTP2" style="width: 14%; text-align: right"><ix:nonFraction name="cef:OutstandingSecurityAuthorizedShares" contextRef="From2025-05-192025-05-19_us-gaap_CommonStockMember" id="Fact000152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecef--OutstandingSecurityHeldShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zH2fO3bqlSg" style="width: 14%; text-align: right"><ix:nonFraction name="cef:OutstandingSecurityHeldShares" contextRef="From2025-05-192025-05-19_us-gaap_CommonStockMember" id="Fact000153" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,437,245</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecef--OutstandingSecurityNotHeldShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zTI0bNIgkuUj" style="width: 14%; text-align: right"><ix:nonFraction name="cef:OutstandingSecurityNotHeldShares" contextRef="From2025-05-192025-05-19_us-gaap_CommonStockMember" id="Fact000154" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,962,245</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8AA_zmsBXGLpU6T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, for each of the periods indicated, the high and low closing market prices for the shares of Common Stock
on Nasdaq, the net asset value per share and the premium or discount to net asset value per share at which the shares were trading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="AsOf2025-07-23" escape="true" id="Fact000156" name="cef:SharePriceTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_886_ecef--SharePriceTableTextBlock_zfEWmwucpTXd" summary="xdx: Disclosure - Price Range of Common Stock" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    Quarter Ended</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_48A_ecef--HighestPriceOrBid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zCcVRfMVHjsl" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">High</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_487_ecef--LowestPriceOrBid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zABdm5KnXz08" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_48A_eus-gaap--NetAssetValuePerShare_iE_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zFBEAhU0kw06" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share<sup id="xdx_F52_zDqFm44X6qlg">(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_486_ecef--HighestPriceOrBidPremiumDiscountToNavPercent_pid_dp_uRatio_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z2PcwxOBcdA9" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">High
    <sup id="xdx_F50_zHF1eUQWbXjj">(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_486_ecef--LowestPriceOrBidPremiumDiscountToNavPercent_pid_dp_uRatio_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSbN2RcS9Lt7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low
    <sup id="xdx_F57_z5ER9VfmcEk8">(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Premium/(Discount) to</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Market</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net Asset Value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net Asset Value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price
    Per Share</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">per
    Common</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">High
    and Low<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    Quarter Ended</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">High</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">High</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_419_20250401__20250630_zPB4cO5DYp4h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-June-25</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000157" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.79</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000159" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.15</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"/><td style="text-align: right"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">36.9</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember" id="Fact000161" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0.7</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_415_20250101__20250331_zULuvPPfu0Wb" style="vertical-align: bottom; background-color: White">
    <td style="width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-25</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.50</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000163" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.05</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.18</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000165" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">18.4</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Ratio">1.8</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr id="xdx_417_20241001__20241231_zlSAp93YOo06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Dec-24</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2024-10-012024-12-31_us-gaap_CommonStockMember" id="Fact000167" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.89</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2024-10-012024-12-31_us-gaap_CommonStockMember" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.63</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000169" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.25</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2024-10-012024-12-31_us-gaap_CommonStockMember" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">36.4</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2024-10-012024-12-31_us-gaap_CommonStockMember" id="Fact000171" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">5.2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_413_20240701__20240930_zl1UpJ62enFk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Sep-24</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.70</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000173" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.86</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.70</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000175" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">44.8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">17.3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_418_20240401__20240630_zBJi3jS1ervh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-June-24</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000177" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.94</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.64</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000179" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.75</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">47.3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">28.0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41F_20240101__20240331_zWGwjOo02Ac2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-24</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000182" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.03</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000183" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.19</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000184" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.89</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000185" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">45.6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000186" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.4</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41D_20231001__20231231_zmnef5EjEIv7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Dec-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" id="Fact000187" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.60</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" id="Fact000188" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.26</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000189" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.08</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" id="Fact000190" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">35.6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">2.5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41D_20230701__20230930_zgPZK4jcAsm7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Sep-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.15</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.03</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.03</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">68.3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">49.8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41B_20230401__20230630_zuTB9wtB1kNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Jun-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact000197" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.03</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact000198" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.51</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000199" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.33</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">105.8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact000201" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">50.2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_415_20230101__20230331_z6ED7KXbAgS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000202" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.23</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000203" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.25</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000204" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.41</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000205" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">75.2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000206" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">28.7</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41F_20221001__20221231_zSukFvs5utV6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Dec-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="Fact000207" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.63</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="Fact000208" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000209" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.75</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="Fact000210" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">101.9</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember" id="Fact000211" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">34.8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41B_20220701__20220930_zzcjV9EH2cId" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Sep-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="Fact000212" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.23</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="Fact000213" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" id="Fact000214" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.52</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="Fact000215" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">214.8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="Fact000216" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">167.7</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41E_20220401__20220630_z9kPiQk7hV78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Jun-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="Fact000217" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.21</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="Fact000218" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.62</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" id="Fact000219" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.85</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">172.4</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="Fact000221" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">119.0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_414_20220101__20220331_zAxliSVE4FRj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="Fact000222" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.52</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="Fact000223" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.51</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" id="Fact000224" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.18</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="Fact000225" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">122.4</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="Fact000226" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">102.9</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_414_20211001__20211231_zKqYCZqGT7c3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Dec-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="Fact000227" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="Fact000228" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.59</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000229" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.24</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="Fact000230" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">119.5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="Fact000231" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">102.1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41F_20210701__20210930_zhP16iq88Vej" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Sep-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.05</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="Fact000233" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.77</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.37</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="Fact000235" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">257.6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="Fact000236" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">160.2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_415_20210401__20210630_zvM7S33BuWU7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Jun-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="Fact000237" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.15</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="Fact000238" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.90</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" id="Fact000239" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.59</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">294.2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="Fact000241" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">147.9</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_413_20210101__20210331_zIuNgCePRq7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBid" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.86</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBid" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="Fact000243" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.02</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetAssetValuePerShare" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" id="Fact000244" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.77</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:HighestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="Fact000245" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">268.0</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="cef:LowestPriceOrBidPremiumDiscountToNavPercent" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="Fact000246" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">192.6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F06_zU2DzSwEVEpf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_z2LATWapOgXc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000247" xml:lang="en-US">As
    we calculate our Net Asset Value at month end, the table reflects the month end net asset value, and the premium/(discount) to net
    asset value is based on the month end net asset value. Percentages are rounded.</ix:footnote></span></td></tr>
  </table>
<p id="xdx_8AF_zmPIdxXqTAt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">The last reported sale price
on June 4, 2025 was $8.59 per share, and the net asset value at May 31, 2025 was $7.18, for a premium of $1.41. Historically,
shares have traded at a premium to net asset value. We cannot predict whether our shares will trade in the future at a premium to
or discount from net asset value, or the level of any premium or discount.</p>
</ix:nonNumeric><p id="xdx_81F_zjmWbREfLBx4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_024"></span>Directors
and Executive Officers of Daxor Corporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the name, age, current and past five years&#8217; business experience, directorships, and positions held with
Daxor Corporation by each person who is a director or executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 20%">&#160;</td>
    <td style="vertical-align: top; width: 2%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 56%"><span style="font-size: 10pt">Principal Occupation and</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 20%; text-align: center"><span style="font-size: 10pt">Director Continuously</span></td></tr>
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; text-align: justify"><span style="font-size: 10pt">Name and Age</span></td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top"><span style="font-size: 10pt">Position with the Company</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt">Since</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Michael Feldschuh, 55</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chairman, President, CEO (1)</p></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2013</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Caleb DesRosiers, 52</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Attorney (2)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2022</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Henry D. Cremisi, MD, 67</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Medical Director, AstraZeneca Pharmaceuticals (3)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2020</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Joy S. Goudie, 68</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Partner, Wissing Miller, LLP patent attorney (4)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2020</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Edward Feuer, 69</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Partner, Feuer &amp; Orlando, LLP (5)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2016</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Jonathan Feldschuh, 60</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Chief Scientific Officer of the Company (6)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2017</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Michael
    Feldschuh </b>has been president of Daxor since 2017. He earned his bachelor&#8217;s degree in Pre-Med studies at Columbia College,
    Columbia University in 1991. Prior to joining Daxor&#8217;s executive team in December of 2014 as Executive Vice President, he served
    as a member of the board of directors for one and a half years prior. Mr. Feldschuh headed his own hedge fund, Aristarc Capital,
    from 2009 to 2013 specializing in quantitative equity strategies. Prior to founding his own fund, Mr. Feldschuh was a Managing Director
    at Morgan Stanley Investment Management from 2005 to 2009 and also served as a Managing Director and Portfolio Manager at Millennium
    Partners in New York from 1997-2005. Mr. Feldschuh was a proprietary trader for Morgan Stanley &amp; Co. from 1994-1997. Mr. Feldschuh
    began his career at D.E. Shaw &amp; Co. in New York, where he worked with Jeffery Bezos prior to Mr. Bezos&#8217;s founding of Amazon.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Caleb
    DesRosiers</b> is currently a Senior Principal at Valuate Healthcare Consultancy, a leading strategic and market access consulting
    firm that is part of Omnicom, a multi-billion communication and consulting public company, and serves on the board of the Health
    Alliance Plan of Michigan, a company of Henry Ford Health System. He also serves on advisory boards of Copilot Provider Support Services,
    Inc. and TruLite Health. Mr. DesRosiers holds a B.A., Master in Public Administration, and law degrees from Suffolk University. He
    began his career in state government working on policy to expand healthcare access and prescription drug benefit to seniors. He served
    as a Special Assistant at the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) in Washington DC where he advised the
    Offices of Regulatory Affairs and Administrator on payment policy and managing the clearance of all regulations within the U.S. Department
    of Health and Human Services, the White House&#8217;s Office of Management and Budget, and the Office of Federal Register. Mr. DesRosiers
    spent five years in the life science industry at Pfizer and Roche supporting brand teams cross-functional payment policy, advocacy,
    managed care and commercial initiatives.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
    Henry D. Cremisi </b>is a Medical Director (Renal) at AstraZeneca Pharmaceuticals with over 32 years of experience in medicine. Prior,
    Dr. Cremisi served as Chairman of Medical Education and a Nephrologist and Hospitalist for Novant Health in Charlotte, North Carolina.
    He is a Fellow of the American College of Physicians and certified by the American Board of Internal Medicine in both internal medicine
    and nephrology. Dr. Cremisi has many scientific and professional memberships including the International Society of Nephrology, American
    Society of Nephrology, Cardiorenal Society of America, Heart Failure Society of America, Society of Hospital Medicine, American College
    of Physicians, Renal Physicians Association and the American Medical Association. Dr. Cremisi graduated from Tufts University School
    of Medicine and did his residency at Emory Healthcare in internal medicine.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Joy
    Goudie, Esq.</b> is currently a partner at Wissing Miller, LLP, following twelve years as Senior Patent Counsel for Revlon leading
    cross-functional teams in the US and Spain. In addition, she served as Vice President managing Revlon&#8217;s global R&amp;D portfolio
    and driving new technologies. A published scientist, Ms. Goudie has worked with patents and R&amp;D teams in the development of new
    antibiotics and small molecules for treatment of solid tumor cancers. Ms. Goudie earned her JD degree from Pace University, has a
    Masters Degree in Chemistry from Long Island University and graduated from Mercy College with a BS in Medical Technology, Behavioral
    Science and Health Service Management.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Edward
    Feuer</b> has over 35 years&#8217; experience as an accountant, and is a member of the AICPA and The New York State Society of Certified
    Public Accountants where he has served on the State and Local Tax Committee and the Continuity of Practice Committee. Mr. Feuer graduated
    from George Washington University and Scarsdale High School. Prior to founding this firm Edward worked at the NYS Department of Taxation
    and Finance, Westvaco Corp., as well as two metropolitan CPA firms. His areas of specialty are professional service companies, broker
    dealers, mutual funds, high net worth individuals, wealth management, financial planning, business management and advisory. He reviews
    all financial statements issued by the firm. Mr. Feuer is proud of the teamwork of the firm and its focus on the success of their
    clients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jonathan
    Feldschuh </b>has been Chief Scientific Officer of Daxor since 2017. Prior to that he served as a scientific consultant to Daxor
    since 1985. He has been involved with developing Daxor&#8217;s technology and is a co-inventor on multiple Daxor patents, including
    the original patent covering the blood volume analyzer (BVA-100). Mr. Feldschuh studied Physics at Harvard University, receiving
    an A.B. degree summa cum laude in 1986. Prior to taking on the role of CSO at Daxor, Jonathan worked extensively in technology and
    quantitative finance. He was the Chief Quantitative Officer at Aristarc Capital, overseeing the research, development, and execution
    of quantitative trading strategies. Prior to Aristarc he worked in quantitative roles at financial firms such as Morgan Stanley,
    Millennium Partners, and American Express.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
(Member of the Audit Committee)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, the named executive officers of Daxor Corporation are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MICHAEL
FELDSCHUH, Chairman of the Board and President, earned his bachelor&#8217;s degree in Pre-Med studies at Columbia College, Columbia University
in 1991. Prior to joining Daxor&#8217;s executive team in December of 2014 he served as a member of the board of directors for one and
a half years prior. Michael headed his own hedge fund, Aristarc Capital, from 2009 to 2013 specializing in quantitative strategies. Prior
to founding his own fund, Michael was a Managing Director at Morgan Stanley from 2005 to 2009 and also served as a Managing Director
and Portfolio Manager at Millennium Partners in New York from 1997-2005. Michael was a proprietary trader for Morgan Stanley &amp; Co.
from 1994-1997. Michael began his career at D.E. Shaw &amp; Co. in New York, where he worked with Jeffery Bezos prior to Bezos&#8217;s
founding of Amazon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JONATHAN
FELDSCHUH, Chief Scientific Officer, has been Chief Scientific Officer of Daxor since 2017. Prior to that he served as a scientific consultant
to Daxor since 1985. He has been involved with developing Daxor&#8217;s technology and is a co-inventor on multiple Daxor patents, including
the original patent covering the blood volume analyzer (BVA-100). Mr. Feldschuh studied Physics at Harvard University, receiving an A.B.
degree summa cum laude in 1986. Prior to taking on the role of CSO at Daxor, Jonathan worked extensively in technology and quantitative
finance. He was the Chief Quantitative Officer at Aristarc Capital, overseeing the research, development, and execution of quantitative
trading strategies. Prior to Aristarc he worked in quantitative roles at financial firms such as Morgan Stanley, Millennium Partners,
and American Express.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROBERT
J. MICHEL, Chief Financial Officer, Chief Compliance Officer and Corporate Secretary has over 30 years&#8217; experience across a wide
array of industries, including serving on the board of a biometric solutions company. In addition, he has public company experience in
accounting and finance for companies specializing in consumer finance, engineering/manufacturing, marketing and the healthcare industry,
both privately held and publicly traded. Prior to joining Daxor he served as CFO of at Sher-Del Transfer and Relocation Services, and
prior spent seven years as CFO of Asta Funding, (Nasdaq: ASFI) a publicly traded diversified financial services company. He is a Certified
Public Accountant and holds a degree in Business Administration from the Villanova School of Business and an MBA from St. John&#8217;s
University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_025"></span>Additional
Information about Daxor Corporation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial information regarding
Daxor Corporation is hereby incorporated by reference from <a href="https://www.sec.gov/Archives/edgar/data/27367/000149315225008923/formncsr.htm" style="-sec-extract: exhibit">our Annual Report on Form N-CSR, as filed with the SEC on March 3, 2025</a>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_026"></span>TAX
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion is a brief summary of certain U.S. federal income tax considerations affecting the company and the purchase, ownership
and disposition of our shares of common stock. A more complete discussion of the tax rules applicable to the company and our shares of
common stock can be found in the SAI that is incorporated by reference into this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary is based upon U.S. federal income tax law as of the date of this prospectus, which is subject to change or differing interpretations,
possibly with retroactive effect. This summary does not discuss all aspects of U.S. federal income taxation that may be important to
particular investors in light of their individual circumstances, including investors subject to special tax rules (e.g., financial institutions,
insurance companies, broker-dealers, partnerships and their partners, tax-exempt organizations (including private foundations), taxpayers
that have elected mark-to-market accounting, S corporations, regulated investment companies, real estate investment trusts, investors
that will hold the common stock as part of a straddle, hedge, conversion, or other integrated transaction for U.S. federal income tax
purposes, former citizens or residents of the United States or investors that have a functional currency other than the U.S. dollar),
all of whom may be subject to tax rules that differ materially from those summarized below. In addition, this summary does not discuss
other U.S. federal tax consequences (e.g., estate or gift tax), any state, local, or non-U.S. tax considerations or the Medicare tax
or alternative minimum tax. In addition, this summary is limited to investors that will hold our securities as &#8220;capital assets&#8221;
(generally, property held for investment) under the Internal Revenue Code of 1986, as amended, (the &#8220;Code&#8221;), and that acquired
the common stock pursuant to this offering. No ruling from the Internal Revenue Service, (the &#8220;IRS&#8221;) has been or will be
sought regarding any matter discussed herein. No assurance can be given that the IRS would not assert, or that a court would not sustain
a position contrary to any of the tax aspects set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this summary, a &#8220;U.S. Holder&#8221; is a beneficial holder of securities who or that, for U.S. federal income tax purposes
is:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    individual who is a United States citizen or resident of the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    corporation, or other entity treated as a corporation for United States federal income tax purposes created in, or organized under
    the laws of, the United States or any state or political subdivision thereof;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    estate, the income of which is includible in gross income for United States federal income tax purposes regardless of its source;
    or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    trust (A) the administration of which is subject to the primary supervision of a United States court and which has one or more United
    States persons (within the meaning of the Code) who have the authority to control all substantial decisions of the trust or (B) that
    has in effect a valid election under applicable Treasury regulations to be treated as a United States person.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds the common stock,
the tax treatment of a partner in such partnership will generally depend upon the status of the partner, the activities of the partnership
and certain determinations made at the partner level. If you are a partner of a partnership holding the common stock, you are urged to
consult your tax advisor regarding the tax consequences of the ownership and disposition of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THIS
DISCUSSION OF U.S. FEDERAL INCOME TAX CONSIDERATIONS IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. WE URGE PROSPECTIVE
HOLDERS TO CONSULT THEIR TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF OWNING AND DISPOSING OF THE COMMON
STOCK, AS WELL AS THE APPLICATION OF ANY, STATE, LOCAL AND NON-U.S. INCOME, ESTATE AND OTHER TAX CONSIDERATIONS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Personal
Holding Company Status</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is subject to
a second level of U.S Federal income tax on a portion of its income as a personal holding company (&#8220;PHC&#8221;) for U.S Federal
income tax purposes. As a PHC in a given year, the Company is subject to an additional PHC tax, currently 20%, on its undistributed PHC
income, which generally includes its taxable income, subject to certain adjustments. Update: For the year ended December 31, 2024,
more than 60% of Daxor&#8217;s adjusted gross income came from items defined as PHC income. The Company incurred no
liability for PHC for the year ended December 31, 2024 due to the net operating losses applied to realized gains incurred during
the year.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxation
of Distributions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I<span id="xdx_906_ecef--SecurityDividendsTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zMtyCbHqdf49"><ix:nonNumeric contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember" escape="true" id="Fact000248" name="cef:SecurityDividendsTextBlock">f
the company pays cash distributions to U.S. Holders of shares of the common stock, such distributions will constitute dividends for U.S.
federal income tax purposes to the extent paid from the company&#8217;s current or accumulated earnings and profits, as determined under
U.S. federal income tax principles. Distributions in excess of current and accumulated earnings and profits will constitute a return
of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in the common stock.
Any remaining excess will be treated as gain realized on the sale or other disposition of the common stock and will be treated as described
under &#8220;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of the Common Stock&#8221; below.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gain
or Loss on Sale, Taxable Exchange or Other Taxable Disposition of the Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder will recognize gain or loss on the sale, taxable exchange or other taxable disposition of the common stock. Any such gain
or loss will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the common
stock so disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1) the
sum of the amount of cash and the fair market value of any property received in such disposition and (2) the U.S. Holder&#8217;s adjusted
tax basis in its common stock so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its common stock will generally equal the U.S.
Holder&#8217;s acquisition cost less any prior distributions treated as a return of capital. The deductibility of capital losses is subject
to limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
Reporting and Backup Withholding</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, information reporting requirements may apply to dividends paid to a U.S. Holder and to the proceeds of the sale or other disposition
of shares of common stock, unless the U.S. Holder is an exempt recipient. Backup withholding may apply to such payments if the U.S. Holder
fails to provide a taxpayer identification number, a certification of exempt status or has been notified by the IRS that it is subject
to backup withholding (and such notification has not been withdrawn). Any amounts withheld under the backup withholding rules will be
allowed as a refund or a credit against a U.S. Holder&#8217;s U.S. federal income tax liability provided the required information is
timely furnished to the IRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_027"></span>LEGAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
legal matters will be passed on for the company by Foley &amp; Lardner LLP, New York, New York, in connection with the offering of the
shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_028"></span>INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bush &amp; Associates
CPA is the independent registered public accounting firm of the company. The company&#8217;s independent registered public accounting
firm is expected to render an opinion annually on the financial statements of the Fund.<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_029"></span>PRIVACY
PRINCIPLES OF THE COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company is committed to maintaining the privacy of its shareholders and to safeguarding their non-public personal information. The following
information is provided to help you understand what personal information the company collects, how the company protects that information
and why, in certain cases, the company may share information with select other parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
the company does not receive any non-public personal information relating to its shareholders, although certain non-public personal information
of its shareholders may become available to the company. The company does not disclose any non-public personal information about its
shareholders or former shareholders to anyone, except as permitted by law or as is necessary in order to service shareholder accounts
(for example, to a transfer agent).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company restricts access to non-public personal information about its shareholders to its employees and its delegates and affiliates
with a legitimate business need for the information. As a result, we do not provide a means for opting out of our limited sharing of
your information. The company maintains physical, electronic and procedural safeguards designed to protect the non-public personal information
of its shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_030"></span>ADDITIONAL
INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation has filed a Registration Statement on Form N-2, including amendments thereto, with the Securities and Exchange Commission,
Washington, D.C. This prospectus does not contain all of the information set forth in the Registration Statement, including any exhibits
and schedules thereto. For further information with respect to the company, reference is made to the Registration Statement. Statements
contained in this prospectus as to the contents of any contract or other document referred to are not necessarily complete and in each
instance reference is made to the copy of such contract or other document filed as an exhibit to the Registration Statement, each such
statement being qualified in all respects by such reference. Copies of the Registration Statement may be inspected without charge at
the Securities and Exchange Commission&#8217;s principal office in Washington, D.C., and copies of all or any part thereof may be obtained
from the Securities and Exchange Commission upon the payment of certain fees prescribed by the Securities and Exchange Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows Daxor Corporation
to &#8220;incorporate by reference&#8221; information into this prospectus and any prospectus supplement, which means that the company
can disclose important information to you by referring you to other documents filed separately with the SEC. The information incorporated
by reference is considered part of this prospectus. The company incorporates by reference into this prospectus and any accompanying
prospectus supplement the document listed below (excluding any portions of such documents that have been &#8220;furnished&#8221;
by not &#8220;filed&#8221; for purposes of the Exchange Act):</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/27367/000149315225008923/formncsr.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Annual Report on Form N-CSR, as filed with the SEC on March 3, 2025</span></a><span style="font-size: 10pt">;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation will provide without charge upon written or oral request to each person, including any beneficial owner, to whom a prospectus
is delivered, a copy of any and all of the documents which are incorporated by reference into this prospectus but not delivered with
this prospectus (other than exhibits unless such exhibits are specifically incorporated by reference in such documents).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may request a copy of these documents by writing or telephoning Daxor Corporation at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Relations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107
Meco Lane</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oak
Ridge, TN 37830</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212)
330-8500</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_031"></span>TABLE
OF CONTENTS FOR THE STATEMENT OF ADDITIONAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_001">HISTORY OF DAXOR CORPORATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_002">INVESTMENT OBJECTIVE AND INVESTMENT RESTRICTIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_003">ADDITIONAL INVESTMENT POLICIES AND RESTRICTIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_004">MANAGEMENT OF THE COMPANY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_005">Directors and Officers</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_006">Board Leadership Structure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_007">Audit Committee</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_008">Board&#8217;s Risk Oversight Role</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_009">Qualifications of the Trustees</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_010">Equity Ownership of Directors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_011">Board Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_012">CONTROL PERSONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_013">INVESTMENT ADVISORY AND OTHER SERVICES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_014">Code of Ethics</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_015">Proxy Voting Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_016">PORTFOLIO TRANSACTIONS AND BROKERAGE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_017">DESCRIPTION OF SHARES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_018">REPURCHASE OF SHARES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_019">NET ASSET VALUE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_020">UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-12</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_021">INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-14</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_022">ADDITIONAL INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-14</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_023">FINANCIAL STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-15</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>SUBJECT
TO COMPLETION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>PRELIMINARY
STATEMENT OF ADDITIONAL INFORMATION DATED JULY 23, 2025</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The information in this Statement of Additional
Information is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities
and Exchange Commission is effective. This Statement of Additional Information is not an offer to sell these securities, and it is not
soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STATEMENT
OF ADDITIONAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Dated [&#9679;], 2025</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DAXOR
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107
Meco Lane</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oak
Ridge, TN 37830</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212)-330-8500</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation is an investment company with medical instrumentation and biotechnology operations. While the company is not primarily engaged
in the business of investing, reinvesting, owning, holding or trading in securities, the company is dependent upon earnings from its
investment portfolio to fund operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>This Statement of Additional
Information (SAI) is not a prospectus and is authorized for distribution to investors only if preceded or accompanied by Daxor Corporation&#8217;s
prospectus dated July [&#9679;], 2025 (the &#8220;Prospectus&#8221;), as supplemented to date, which is incorporated herein by
reference. This SAI should be read in conjunction with the Prospectus, a copy of which may be obtained without charge by contacting your
financial intermediary or by calling the company at (888) 774-3268, by writing to the company at the address above or from the company&#8217;s
website (http://www.Daxor.com). You may also obtain a copy of the Prospectus on the website of the Securities and Exchange Commission
(&#8220;SEC&#8221;), http://www.sec.gov.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in, or that can be accessed through, the Daxor Corporation&#8217;s website is not part of the Prospectus or this
SAI. Capitalized terms used but not defined in this SAI have the meanings ascribed to them in the Prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_001">HISTORY
    OF DAXOR CORPORATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_002">INVESTMENT
    OBJECTIVE AND INVESTMENT RESTRICTIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_003">ADDITIONAL
    INVESTMENT POLICIES AND RESTRICTIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_004">MANAGEMENT
    OF THE COMPANY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_005">Directors
    and Officers</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_006">Board
    Leadership Structure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_007">Audit
    Committee</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_008">Board&#8217;s
    Risk Oversight Role</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_009">Qualifications
    of the Trustees</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_010">Equity
    Ownership of Directors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_011">Board
    Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_012">CONTROL
    PERSONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_013">INVESTMENT
    ADVISORY AND OTHER SERVICES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_014">Code
    of Ethics</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_015">Proxy
    Voting Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_016">PORTFOLIO
    TRANSACTIONS AND BROKERAGE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_017">DESCRIPTION
    OF SHARES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_018">REPURCHASE
    OF SHARES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_019">NET
    ASSET VALUE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_020">UNITED
    STATES FEDERAL INCOME TAX CONSIDERATIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-12</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_021">INDEPENDENT
    REGISTERED PUBLIC ACCOUNTING FIRM</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-14</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_022">ADDITIONAL
    INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-14</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_023">FINANCIAL
    STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-15</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_001"></span>HISTORY
OF DAXOR CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation is an investment company with medical instrumentation and biotechnology operations. The company was originally incorporated
in New York State as Iatric Corporation in May 1971 for cryobanking services and discontinued these services through its wholly-owned
subsidiary, Scientific Medical Systems in 2017. In October 1971, the name Iatric Corporation was changed to Idant Corporation. In May
1973, the name Idant Corporation was changed to Daxor Corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the company is not primarily engaged in the business of investing, reinvesting, owning, holding or trading in securities, the company
is dependent upon earnings from its investment portfolio to fund operations. On March 30, 2012, the company filed a Form N-8A with the
Securities and Exchange Commission to register as a closed-end management investment company under the Investment Company Act of 1940,
as amended (the &#8220;1940 Act&#8221;). The company&#8217;s principal executive offices are located at 109 Meco Lane, Oak Ridge, TN
37830. The &#8220;Investor Relations&#8221; section of the company&#8217;s website currently provides free copies of the company&#8217;s
annual and semi-annual reports on Form N-CSR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the past 21 years, the company&#8217;s major focus has been the creation and development of the BVA-100&#174; Blood Volume Analyzer, an
instrument that rapidly and accurately measures human blood volume. This instrument is used in conjunction with Volumex&#174;, a single-use
radiopharmaceutical diagnostic injection and collection kit. The company also owns the Daxor Oak Ridge Operations (DORO) facility in
Oak Ridge, TN, which manufactures, tests, and develops next-generation models of the BVA-100&#174;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company maintains an internet website at <span style="text-decoration: underline">www.daxor.com</span>. The website for Daxor describe the operation of the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_002"></span>INVESTMENT
OBJECTIVE AND INVESTMENT RESTRICTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation&#8217;s objective is to support and expand its operating business segment through organic growth (i.e., the rate of business
expansion through internal enhancement of the business and operations as opposed to mergers, acquisitions and takeovers). The company
is not primarily engaged in the business of investing, reinvesting, owning, holding or trading in securities. As a result, the company
has no fundamental investment policies or significant investing practices, activities, objectives or techniques, except as set forth
below. Funds in excess of the company&#8217;s immediate capital needs are placed in instruments designed to maximize capital preservation
and assure liquidity. Objectives are achieved by focusing management and employee effort on the company&#8217;s business of manufacturing
medical devices and providing additional biotechnology services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company&#8217;s investment policy calls for a minimum of 80% of the company&#8217;s investment portfolio to consist of electric utility
stocks. The Board of Directors has authorized this minimum to be temporarily lowered to 70% when management deems it to be necessary.
At least once a year, the company reviews its investment strategy, and more frequently as needed, at Board meetings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investment portfolio primarily consists of common stock and preferred stock of publicly traded electric utility companies. In addition
to receiving income from dividends from the securities held in the investment portfolio, the company also has an investment policy of
selling puts on stocks that it is willing to own. Such options usually have a maturity of less than one year. The company will also sell
covered calls on securities within its investment portfolio. Covered calls involve stocks, which usually do not exceed 15% of the value
of the company&#8217;s portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The company may also sell
uncovered calls and may have net short positions in common stock up to 15% of the value of the portfolio. The company&#8217;s net short
position may temporarily rise to 15% of the company&#8217;s portfolio without any specific action because of changes in valuation, but
should not exceed that amount. At December 31, 2024, the Company did not have any short positions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company has adopted the following investment restrictions which are matters of fundamental policy. The company&#8217;s investment restrictions
cannot be changed without approval of the holders of (i) 67% of the company&#8217;s common stock present or represented at a meeting
of shareholders at which the holders of more than 50% of the common stock are present or represented; or (ii) more than 50% of the outstanding
interests of shareholders:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    company may borrow money to the extent permitted under the 1940 Act.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    company may issue senior securities to the extent permitted under the 1940 Act<b>.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    company may not engage in the business of underwriting securities issued by other persons, except to the extent that it may be deemed
    to be an &#8220;underwriter&#8221; within the meaning of the Securities Act of 1933 in the disposition of its investment securities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    company will concentrate its investments in the utility industry.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    company may invest in real estate or commodities to the extent permitted under the 1940 Act.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    company may make loans to other persons to the extent permitted under the 1940 Act.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_003"></span>ADDITIONAL
INVESTMENT POLICIES AND RESTRICTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
investment strategies are described in the Prospectus. The following is a description of the various investment policies in which Daxor
Corporation may be engaged, whether as a primary or secondary strategy, and a summary of certain attendant risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
Stocks</i>. Common stocks generally represent an ownership interest in an issuer, without preference over any other class of securities,
including such issuer&#8217;s debt securities, preferred stock and other senior equity securities. Common stocks are entitled to the
income and increase in the value of the assets and business of the issuer after all its debt obligations and obligations to preferred
shareholders are satisfied. Common stocks generally have voting rights. Common stocks fluctuate in price in response to many factors,
including historical and prospective earnings of the issuer, the value of its assets, general economic conditions, interest rates, investor
perceptions and market liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred
Stocks</i>. Preferred stocks with predominantly equity investment characteristics, like common stocks, represent an equity ownership
in an issuer. Generally, preferred stocks have a priority of claim over common stocks in dividend payments and upon liquidation of the
issuer. Unlike common stocks, preferred stocks do not usually have voting rights. Preferred stocks in some instances are convertible
into common stocks. Although they are equity securities, preferred stocks have certain characteristics of both debt securities and common
stocks. They are debt-like in that their promised income is contractually fixed. They are like common stocks in that they do not have
rights to precipitate bankruptcy proceedings or collection activities in the event of missed payments. Furthermore, they have many of
the key characteristics of equity due to their subordinated position in an issuer&#8217;s capital structure and because their quality
and value are heavily dependent on the profitability of the issuer rather than on any legal claims to specific assets or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to be payable, dividends on preferred stock must be declared by the issuer&#8217;s board of directors. In addition, distributions
on preferred stock may be subject to deferral and thus may not be automatically payable. Income payments on some preferred stocks are
cumulative, causing dividends and distributions to accrue even if not declared by the board of directors or otherwise made payable. Other
preferred stocks are non-cumulative, meaning that skipped dividends and distributions do not continue to accrue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of preferred stock have a liquidation value that generally equals their original purchase price at the date of issuance. The market values
of preferred stocks may be affected by favorable and unfavorable changes impacting the issuers&#8217; industries or sectors. They also
may be affected by actual and anticipated changes or ambiguities in the tax status of the security and by actual and anticipated changes
or ambiguities in tax laws, such as changes in corporate and individual income tax rates or the characterization of dividends as tax-advantaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Put and Call Options</i>. The company may purchase and sell &#8220;call&#8221; and &#8220;put&#8221; options on securities and securities
indices which are listed on a national securities exchange or in the over-the- counter markets as a means of increasing exposure or hedging
the value of the company&#8217;s investment portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&#8220;call&#8221; option is a contract that gives the holder of the option the right to buy from the writer (i.e., the seller) of the
option, in return for a premium paid, the security underlying the option at a specified exercise price at any time during the term of
the option. The writer of the call option has the obligation upon exercise of the option to deliver the underlying security upon payment
of the exercise price during the option period. A &#8220;put&#8221; option is a contract that gives the holder of the option the right
to sell to the writer (i.e., the seller), in return for the premium, the underlying security at a specified price during the term of
the option. The writer of the put option, who receives the premium, has the obligation to buy the underlying security upon exercise,
at the exercise price during the option period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the company has written an option, it may terminate its obligation by effecting a closing purchase transaction. This is accomplished
by purchasing an option of the same series as the option previously written. There can be no assurance that a closing purchase transaction
can be effected when the company so desires. An exchange-traded option may be closed out only on an exchange which provides a secondary
market for an option of the same series.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Short
Sales</i>. A short sale is the sale of a security that the company does not own in anticipation of purchasing the same security at a
later date at a lower price. To make delivery to the counterparty, the company must borrow the security, and the company is obligated
to return the security to the lender, which is accomplished by a later purchase of the security by the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Portfolio Trading and Turnover Rate</i>. Portfolio
trading may be undertaken to accomplish the investment objectives of the company. While the company may engage in portfolio trading when
considered appropriate, short-term trading in the company&#8217;s portfolio will not be used as the primary means of achieving the company&#8217;s
investment objective. The company expects a moderate level of annual portfolio turnover. The turnover rate is not expected to exceed
100% under normal circumstances. However, there are no limits on the rate of portfolio turnover, and investments may be sold without
regard to length of time held when, in the company&#8217;s opinion, investment considerations warrant such action. A higher portfolio
turnover rate results in correspondingly greater brokerage commissions and other transactional expenses that are borne by the company.
The company&#8217;s portfolio turnover rate   for 2023 was 46.07% and for 2024 was 0%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_004"></span>MANAGEMENT
OF THE COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_005"></span>Directors
and Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
management of Daxor Corporation is the responsibility of the Board of Directors. None of the directors who are not &#8220;interested
persons&#8221; of the company (as defined in the 1940 Act) has ever been a director or employee of, or consultant to, the company or
its affiliates. The officers of the company serve annual terms and are elected on an annual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors has an Audit Committee. The Board does not have a standing nominating committee or a charter with respect to the process
for nominating directors for election to the company&#8217;s Board. The company qualifies as a &#8220;controlled company&#8221; under
Nasdaq rules, as the estate of Joseph Feldschuh, M.D controls more than 50% of the company&#8217;s voting power, as evidenced by the
company&#8217;s ownership records. As a result, the Nasdaq continued listing standards do not require the company to have a nominating
and compensation committees or a written charter. Shareholders and members of the Board submit nominees for election to the company&#8217;s
Board to Mr. Michael Feldschuh, Executor of the Joseph Feldschuh estate, for his consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no non-resident directors of the company, nor or there any arrangements or understandings between any director or officer and any
other persons pursuant to which he was selected as a director or officer. As the company has no investment advisers or underwriters,
there is no investment advisory contract that is approved by the directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
names and business addresses of the Directors of the company, their principal occupations and other affiliations during the past five
years, the number of portfolios each oversees and other directorships they hold, or have held during the past five years, are set forth
below. Michael Feldschuh and Jonathan Feldschuh are brothers, and are classified as &#8220;interested persons&#8221; due to their employment
with the company. There is no &#8220;Fund Complex&#8221; as defined in the 1940 Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Name, Address and Age</b></span></td>
    <td style="width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Position(s) Held with<br/>
Company</b></span></td>
    <td style="width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 13%; text-align: center"><span style="font-size: 10pt"><b>Term of Office and Length of<br/>
Time Served</b></span></td>
    <td style="width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 29%; text-align: center"><span style="font-size: 10pt"><b>Principal <br/>
Occupation(s) <br/>
During <br/>
Past Five Years</b></span></td>
    <td style="width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Number of Portfolios Overseen By<br/>
Directors</b></span></td>
    <td style="width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Other Directorships Held (during past five years)<br/>
by Director</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><b>&#8220;Noninterested Persons&#8221;</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Caleb DesRosiers<br/>
109 Meco Lane Oak Ridge, TN 37830</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">One year term,<br/>
Director since 2022</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">Attorney</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">None</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">None</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Age: 52</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Henry D Cremisi, MD<br/>
109 Meco Lane Oak Ridge, TN 37830</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">One year term,<br/>
Director since 2020</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">Medical Director, AstraZeneca Pharmaceuticals</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">None</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">None</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Age: 67</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Edward Feuer<br/>
109 Meco Lane Oak Ridge, TN 37830</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">One year term,<br/>
Director since 2016</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">Managing Partner, Feuer &amp; Orlando</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">None</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">None</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Age: 69</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Joy Goudie, Esq.<br/>
109 Meco Lane Oak Ridge, TN 37830</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">One year term,<br/>
Director since 2020</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">Partner, Wissing Miller, LLP<br/>
Patent Attorney.</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">None</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">None</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Age: 68</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Name, Address and Age</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Position(s) Held with<br/>
Company</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 13%; text-align: center"><span style="font-size: 10pt"><b>Term of Office and Length of<br/>
Time Served</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 29%; text-align: center"><span style="font-size: 10pt"><b>Principal <br/>
Occupation(s) <br/>
During <br/>
Past Five Years</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Number of Portfolios Overseen By<br/>
Directors</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Other Directorships Held (during past five years)<br/>
by Director</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>&#8220;Interested Persons&#8221;</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Michael Feldschuh</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">One year term,</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Executive Vice President Chairman,</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">One</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">None</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">109 Meco Lane Oak Ridge, TN 37830</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director since 2013</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">President, CEO</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Age: 55</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Jonathan Feldschuh</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">One year term,</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Scientific Officer</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">None</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">109 Meco Lane Oak Ridge, TN 37830</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director since 2017</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Age: 60</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_006"></span>Board
Leadership Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors currently comprises six members, four of whom are independent or disinterested persons, which means that they are
not &#8220;interested persons&#8221; of the company as defined in Section 2(a)(19) of the 1940 Act (the &#8220;Independent Directors&#8221;).
The Board has general oversight responsibility with respect to the operation of the company, and has established an Audit Committee to
assist the Board in performing its oversight responsibilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Chairman of the Board, Mr. Feldschuh is the presiding officer at all meetings of the Board of Directors. The company does not have a
lead Independent Director. The company has determined that its leadership structure is appropriate given the size and structure of the
company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_007"></span>Audit
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee operates pursuant to a Charter approved by the Board of Directors, a copy of which is available on the company&#8217;s
website. The Charter sets forth the responsibilities of the Audit Committee. The functions of the Audit Committee include, among others,
to meet with the independent registered public accounting firm of the company to review the scope of the company&#8217;s audit, the company&#8217;s
financial statements and internal accounting controls, and to meet with management concerning these matters, internal audit activities
and other matters. The Audit Committee currently consists of Edward Feuer, Joy Goudie and Caleb DesRosiers, all of whom are considered
independent under the rules promulgated by Nasdaq and, in addition, are not &#8220;interested persons&#8221; of the company as defined
in Section 2(a)(19) of the 1940 Act. Edward Feuer serves as Chairperson of the Audit Committee and has been designated as the audit committee
financial expert under the Sarbanes-Oxley Act. The Audit Committee met four times in fiscal 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_008"></span>Board&#8217;s
Risk Oversight Role</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
day-to-day management of various risks relating to the administration and operation of the company is the responsibility of management
and other service providers retained by the Board of Directors or by management, most of whom employ professional personnel who have
risk management responsibilities. The Board oversees this risk management function consistent with and as part of its oversight duties.
The Board performs this risk management oversight function directly and, with respect to various matters, through its committees. The
Board has been advised that it is not practicable to identify all of the risks that may impact the company or to develop procedures or
controls that are designed to eliminate all such risk exposures, and that applicable securities law regulations do not contemplate that
all such risks be identified and addressed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors has overseen the company&#8217;s development and administration of a compliance program that meets the requirements
of Rule 38a-1 promulgated under the 1940 Act, and the development and administration of a code of ethics program that meets the requirements
of Rule 17j-1 promulgated under the 1940 Act. The Board meets regularly with the company&#8217;s Chief Compliance Officer on all aspects
of the company&#8217;s compliance requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_009"></span>Qualifications
of the Trustees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Feldschuh has been the Chief Executive Officer since 2016 and a director of the company since 2013. His experience and skills in the
company&#8217;s business operations, as well as his familiarity with the company, led to the conclusion that he should serve as a director.
Jonathan Feldschuh has been the Chief Scientific Officer since 2017, and has served as a scientific consultant to the company since 1985.
His experience and knowledge regarding the company&#8217;s products, as well as his scientific background, led to the conclusion that
he should serve as a director. The company believes that the business and industry backgrounds of Caleb DesRosiers, Henry Cremisi, MD,
Joy Goudie Esq., and Edward Feuer have provided them with the experience that will benefit the company and its shareholders. Further,
the company believes Caleb DesRosiers, Dr. Henry Cremisi, Joy Goudie Esq., and Edward Feuer each take a conservative and thoughtful approach
to addressing issues facing the company. This combination of experience and skills led to the conclusion that each of Caleb DesRosiers,
Dr. Henry Cremisi, Joy Goudie Esq., and Edward Feuer should serve as a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_010"></span>Equity
Ownership of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the dollar range of shares of the company beneficially owned by each current director as of December 31, 2024,
which is also the valuation date, using the following ranges: None; $1-$10,000; $10,001 - $50,000; $50,001 - $100,000; and Over $100,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name of Director</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Share Ownership</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; width: 80%">Interested Persons:</td><td style="font-size: 12pt; width: 2%">&#160;</td>
    <td style="font-size: 12pt; text-align: left; width: 1%">&#160;</td><td style="font-size: 12pt; text-align: right; width: 16%">&#160;</td><td style="font-size: 12pt; text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Michael Feldschuh</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">Over $100,000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jonathan Feldschuh</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">Over $100,000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Noninterested Persons:</td><td style="font-size: 12pt">&#160;</td>
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Caleb DesRosiers</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-size: 10pt"> 50,001 - $100,000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Henry D. Cremisi, MD</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">Over $100,000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Edward Feuer</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-size: 10pt"> 50,001 - $100,000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Joy Goudie, Esq.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-size: 10pt"> 50,001 - $100,000</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_011"></span>Board
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2023 the outside
directors who attended the annual meeting were paid $1,000 each for attendance at the annual meeting and a Board meeting which took place
on the same day. The number of directors who attended the annual meeting was five. In addition, every director who attended a
dial-in Board meeting was paid $375 for each meeting which took place respectively in May, October and December 2024. Each
incumbent director attended at least 75% of the aggregate number of meetings of the Board during 2024, with a total number of
four Board meetings being held. Other than the officers identified below, Messrs. Michael Feldschuh, Jonathan Feldschuh and Robert J.
Michel, there are no officers of the Company that had aggregate compensation in excess of $120,000 during the most recently completed
fiscal year.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation paid to current and former directors in 2024 is set forth in the following table. There is no &#8220;Fund Complex&#8221;
as defined in the 1940 Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>Pension or</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Compensation</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Aggregate</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>Benefits Accrues</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Fund Complex</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Compensation</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>as Part of</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>Annual Benefits</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Paid</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>From Company</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Company Expenses</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Upon Retirement</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>to Director</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt"><i>Interested Person:</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 40%"><span style="font-size: 10pt">Michael Feldschuh</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-size: 10pt">None</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-size: 10pt">None</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Jonathan Feldschuh</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">127,920</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">127,920</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt"><i>Noninterested Persons:</i></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Caleb DesRosiers</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1,750</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1,750</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Henry D. Cremisi, MD</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1,750</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1,750</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Edward Feuer</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1,750</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1,750</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Joy Goudie, Esq.</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">750</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">750</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_012"></span>CONTROL
PERSONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 19, 2025, Daxor
Corporation had issued and outstanding 4,962,245 shares of common stock, par value $.01 per share, each of which entitled the
holder to one vote.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;Since the estate of
Dr. Feldschuh owns more than 50% of Daxor stock, and Michael Feldschuh is the executor of the estate, the company is considered a controlled
corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth certain information as of May 19, 2025, concerning the ownership of the common stock by (a) each person who, to the company&#8217;s
knowledge, beneficially owned on that date more than 5% of the outstanding common stock, (b) each of the company&#8217;s then current
directors and the named executive officers and (c) all then current directors and executive officers of the company as a group.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares</span><span style="font-family: Times New Roman, Times, Serif"><br/>
    <span style="font-size: 10pt">Beneficially</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent of<br/>
    Common</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: Black 1pt solid; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Beneficial Owner (a) (b)</span></td>
    <td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Owned(b)</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock(b)</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estate of Joseph Feldschuh(c)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,553,230</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51.5</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Feldschuh, President and Director(d)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">232,694</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan Feldschuh, Director(e)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,574</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert J. Michel, Chief Financial Officer, Chief Compliance
    Officer(f)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,717</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Jefferies, MD, Chief Medical Officer (g)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,615</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Henry Cremisi, MD, Director ( h )</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,666</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joy Goudie, Esq., Director ( i )</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,733</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edward Feuer, Director ( j )</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,433</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caleb DesRosiers ( k )</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,823</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All directors and officers as a Group (7 persons) (l)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,950,484</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59.5</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Indicates less than 1%.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Unless otherwise indicated, the address of each person listed is c/o Daxor Corporation, 109 Meco Lane, Oak Ridge, TN 37830.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Beneficial ownership is determined in accordance with the rules of
    the SEC and generally includes voting or investment power with respect to securities. In accordance with SEC rules, shares of common
    stock issuable upon the exercise of options or warrants which are currently exercisable or which become exercisable within 60 days
    following May 19, 2025 are deemed to be beneficially owned by, and outstanding with respect to, the holder of such option
    or warrant. Except as indicated by footnote, and subject to community property laws where applicable, to the knowledge of the Company,
    each person listed is believed to have sole voting and investment power with respect to all shares of common stock beneficially owned
    by such person.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 2,553,230 shares of common stock.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 212,694 shares of common stock and 20,000 shares
    of common stock issuable upon the exercise of options issued under the Company&#8217;s 2020 Incentive Compensation Plan (the &#8220;2020
    Plan&#8221;).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 35,908 shares of common stock and 16,666 shares
    of common stock issuable upon the exercise of options issued under the 2020 Plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(f)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 17,050 of common stock and 12,667 shares of
    common stock issuable upon the exercise of option issued under the 2020 Plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(g)</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Includes 21,615 shares of common stock
    issuable upon the exercise of options issued under the 2020 Plan.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(h)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 26,666 shares of common stock issuable upon the exercise
    of options issued under the 2020 Plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 300 shares of common stock and 9,433 shares
    of common stock issuable upon the exercise of options issued under the 2020 Plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(j)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 1,000 shares of common stock and 7,433 shares
    of common stock issuable upon the exercise of options issued under the 2020 Plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(k)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 3,157 shares of common stock and 12,666 shares of common
    stock issuable upon exercise of options issued under the 2020 Plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(l)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">See Footnotes (c) through (j).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors currently serving
have options totaling 92,864 shares of common stock exercisable at prices ranging from $7.75 to $14.11 per share. We ceased issuing
options under the 2020 Plan. On April 24, 2020, we received an exemptive order that permits us to adopt an incentive compensation plan,
and our shareholders approved the incentive compensation plan at our 2023 annual meeting. The outstanding options as of May 19, 2025
are provided below:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">Number of Options</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt">Name</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%"><span style="font-size: 10pt">Michael Feldschuh</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><span style="font-size: 10pt">20,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Jonathan Feldschuh</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">16,666</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Henry Cremisi, MD</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">26,666</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Joy Goudie Esq.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9,433</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Edward Feuer</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7,433</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Caleb DesRosiers</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">12,666</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">92,864</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_013"></span>INVESTMENT
ADVISORY AND OTHER SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
responsibility of the Board of Directors is to exercise corporate powers and to oversee management of the business of Daxor Corporation.
The officers of the company are principally responsible for its operations. The company is not primarily engaged in the business of investing,
reinvesting, owning, holding or trading in securities. As such, the company has no investment advisors, administrator, affiliated brokerage,
dividend paying agent, non-resident managers, or active portfolio manager. The nature of the instruments in which funds in excess of
immediate capital needs are placed are consistent with capital preservation and liquidity. The company&#8217;s Chief Executive Officer,
Michael Feldschuh, is primarily responsible for the day-to-day management of any such investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the estate of Dr. Feldschuh owns more than 50% of Daxor stock, and Michael Feldschuh is the executor of the estate, the company is considered
a controlled corporation. In reviewing the salaries of Chief Executive Officers at pharmaceutical and scientific companies, many of these
individuals earn annual salaries from $300,000 to over $1,000,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Feldschuh has deliberately elected to draw a salary that is well below what the company believes is the market rate for someone with
his responsibilities and qualifications. It is the belief of the Board of Directors that annual compensation of two or three times what
he is currently earning could easily be justified. The decision to keep his annual compensation at well below market rate has been made
as part of an effort to preserve capital in light of the company&#8217;s ongoing losses from operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors reviews Mr. Feldschuh&#8217;s compensation each year. The Board votes on his salary at this time. The Board is in
agreement that his annual compensation is well below market rate for someone with his experience and qualifications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_014"></span>Code
of Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 17j-1 of the 1940 Act, the company has adopted a Code of Ethics governing personal trading activities of all directors and officers
of the company and persons who, in connection with their regular functions, play a role in the recommendation of any purchase or sale
of a security by the company or obtain information pertaining to such purchase or sale. The Code of Ethics is intended to prohibit fraud
against the company that may arise from personal trading. Personal trading is permitted by such persons subject to certain restrictions;
however, such persons are generally required to pre-clear many security transactions with the company&#8217;s Chief Compliance Officer
and to report all transactions on a regular basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Code of Ethics is available in the EDGAR Database on the SEC&#8217;s internet website at (<span style="text-decoration: underline">http://www.sec.gov</span>). You may obtain
copies of this information, after paying a duplication fee, by electronic request at the following e-mail address: publicinfo@sec.gov.
A copy of the Code of Ethics is also available for free at <span style="text-decoration: underline">http://www.daxor.com/pdfs/daxor_codeofethics.pdf</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_015"></span>Proxy
Voting Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company is responsible for voting proxies on securities held in its portfolio. When the company receives a proxy, the decision regarding
how to vote such proxy will be made by Mr. Feldschuh in accordance with its proxy voting procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
vote with respect to most routine issues presented in proxy statements is expected to be cast in accordance with the position of the
issuer&#8217;s management, unless it is determined by Mr. Feldschuh or the Board of Directors that supporting management&#8217;s position
would adversely affect the investment merits of owning the issuer&#8217;s security. However, each issue will be considered on its own
merits, and a position of management found not to be in the best interests of the company&#8217;s shareholders will not be supported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxies
solicited by issuers whose securities are held by the company will be voted solely in the interests of the shareholders of the company.
Any conflict of interest will be resolved in the way that will most benefit the company and its shareholders. If the conflict of interest
is determined to be material, the conflict shall be disclosed to the Board of Directors and Mr. Feldschuh will follow the instructions
of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company is required to annually file Form N-PX, which lists the company&#8217;s complete proxy voting record for the most recent 12-month
period ending June 30. The company&#8217;s proxy voting record is available without charge, upon request, by calling the company toll-free
at (888) 774-3268 and on the SEC&#8217;s website at <span style="text-decoration: underline">www.sec.gov</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_016"></span>PORTFOLIO
TRANSACTIONS AND BROKERAGE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the supervision of the Board of Directors, Mr. Feldschuh is responsible for decisions to purchase and sell securities for the company,
the negotiation of the prices to be paid and the allocation of transactions among various dealer firms. Transactions on stock exchanges
involve the payment by the company of brokerage commissions. There generally is no stated commission in the case of securities traded
in the over-the-counter market but the price paid by the company usually includes an undisclosed dealer commission or mark-up. Transactions
in the over-the-counter market can also be placed with broker-dealers who act as agents and charge brokerage commissions for effecting
over-the-counter transactions. The company may place its over-the-counter transactions either directly with principal market makers,
or with broker-dealers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
certain instances, the company may make purchases of underwritten issues at prices that include underwriting fees. Portfolio securities
may be purchased directly from an underwriter or in the over-the-counter market from the principal dealers in such securities, unless
it appears that a better price or execution may be obtained through other means. The company does not direct brokerage transactions to
brokers because of research services provided by such brokers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The company incurred
total commission expense of $6,894 for the three years ended December 31, 2024 as follows: $1,940 in 2024;
$1,185 in 2023; and $3,769 in 2022. The cost basis of securities purchased includes any commissions paid and the
proceeds of securities sold is recorded net of any commissions paid.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_017"></span>DESCRIPTION
OF SHARES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the common stock have one vote per share for the election of directors, without provisions for cumulative voting, and on all
other matters. Thus, holders of more than 50% of the shares voting for the election of directors can elect all the directors if they
choose to do so. The common stock is not redeemable and has no conversion or preemptive rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_018"></span>REPURCHASE
OF SHARES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
do not have the right to cause the company to redeem their shares. The shares trade in the open market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_019"></span>NET
ASSET VALUE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company will determine its net asset value as of the close of regular session trading on the New York Stock Exchange on the last business
day of its semi-annual reporting period and its fiscal year, and will make its net asset value available for publication on those dates.
Net asset value is computed by dividing the value of all of our assets (including accrued interest and distributions and current and
deferred income tax assets), less all of our liabilities (including accrued expenses, distributions payable, current and deferred accrued
income taxes, and any borrowings) and the liquidation value of any outstanding preferred stock, by the total number of shares outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publicly
traded securities with a readily available market price listed on any exchange other than the NASDAQ are valued, except as indicated
below, at the last sale price on the business day as of which such value is being determined. If there has been no sale on such day,
the securities are valued at the mean of the most recent bid and asked prices on such day. Securities admitted to trade on the NASDAQ
are valued at the NASDAQ official closing price. Portfolio securities traded on more than one securities exchange are valued at the last
sale price on the business day as of which such value is being determined at the close of the exchange representing the principal market
for such securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
securities traded in the over-the-counter market, but excluding securities admitted to trading on the NASDAQ, are valued at the closing
bid prices. Debt securities that are considered bonds are valued by using the mean of the bid and ask prices provided by an independent
pricing service. For debt securities that are considered bank loans, the fair market value is determined by using the mean of the bid
and ask prices provided by the agent or syndicate bank or principal market maker. When price quotes are not available, fair market value
will be based on prices of comparable securities. In certain cases, the company may not be able to purchase or sell debt securities at
the quoted prices due to the lack of liquidity for these securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
derivative transaction that the company enters into may, depending on the applicable market environment, have a positive or negative
value for purposes of calculating the net asset value. Exchange-traded options and futures contracts are valued at the last sales price
at the close of trading in the market where such contracts are principally traded or, if there was no sale on the applicable exchange
on such day, at the mean between the quoted bid and ask price as of the close of such exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
any portfolio security held by us for which reliable market quotations are not readily available, valuations are determined in a manner
that most fairly reflects fair value of the security on the valuation date, pursuant to the oversight of the Board of Directors. Due
to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair
value of such investments may fluctuate from period to period. Additionally, the fair value of such investments may differ from the values
that would have been used had a ready market existed for such investments and may differ materially from the values that company may
ultimately realize.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_020"></span>UNITED
STATES FEDERAL INCOME TAX CONSIDERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion is a summary of the U.S. federal income tax considerations generally applicable to the acquisition, ownership and
disposition of the common stock. This summary is based upon U.S. federal income tax law as of the date of this SAI, which is subject
to change or differing interpretations, possibly with retroactive effect. This summary does not discuss all aspects of U.S. federal income
taxation that may be important to particular investors in light of their individual circumstances, including investors subject to special
tax rules (e.g., financial institutions, insurance companies, broker-dealers, partnerships and their partners, tax-exempt organizations
(including private foundations), taxpayers that have elected mark-to-market accounting, S corporations, regulated investment companies,
real estate investment trusts, investors that will hold the common stock as part of a straddle, hedge, conversion, or other integrated
transaction for U.S. federal income tax purposes, former citizens or residents of the United States or investors that have a functional
currency other than the U.S. dollar), all of whom may be subject to tax rules that differ materially from those summarized below. In
addition, this summary does not discuss other U.S. federal tax consequences (e.g., estate or gift tax), any state, local, or non-U.S.
tax considerations or the Medicare tax or alternative minimum tax. In addition, this summary is limited to investors that will hold our
securities as &#8220;capital assets&#8221; (generally, property held for investment) under the Internal Revenue Code of 1986, as amended,
(the &#8220;Code&#8221;), and that acquired the common stock pursuant to this offering. No ruling from the Internal Revenue Service,
(the &#8220;IRS&#8221;) has been or will be sought regarding any matter discussed herein. No assurance can be given that the IRS would
not assert, or that a court would not sustain a position contrary to any of the tax aspects set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this summary, a &#8220;U.S. Holder&#8221; is a beneficial holder of securities who or that, for U.S. federal income tax purposes
is:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    individual who is a United States citizen or resident of the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    corporation, or other entity treated as a corporation for United States federal income tax purposes created in, or organized under
    the laws of, the United States or any state or political subdivision thereof;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    estate, the income of which is includible in gross income for United States federal income tax purposes regardless of its source;
    or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    trust (A) the administration of which is subject to the primary supervision of a United States court and which has one or more United
    States persons (within the meaning of the Code) who have the authority to control all substantial decisions of the trust or (B) that
    has in effect a valid election under applicable Treasury regulations to be treated as a United States person.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds the common stock,
the tax treatment of a partner in such partnership will generally depend upon the status of the partner, the activities of the partnership
and certain determinations made at the partner level. If you are a partner of a partnership holding the common stock, you are urged to
consult your tax advisor regarding the tax consequences of the ownership and disposition of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THIS
DISCUSSION OF U.S. FEDERAL INCOME TAX CONSIDERATIONS IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. WE URGE PROSPECTIVE
HOLDERS TO CONSULT THEIR TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF OWNING AND DISPOSING OF THE COMMON
STOCK, AS WELL AS THE APPLICATION OF ANY, STATE, LOCAL AND NON-U.S. INCOME, ESTATE AND OTHER TAX CONSIDERATIONS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Personal
Holding Company Status</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company would be subject to a second level of U.S. federal income tax on a portion of its income if it is determined to be a personal
holding company, or PHC, for U.S. federal income tax purposes. A U.S. corporation will generally be classified as a PHC for U.S. federal
income tax purposes in a given taxable year if (1) at any time during the last half of such taxable year, five or fewer individuals (without
regard to their citizenship or residency and including as individuals for this purpose certain entities such as certain tax-exempt organizations,
pension funds, and charitable trusts) own or are deemed to own (pursuant to certain constructive ownership rules) more than 50% of the
stock of the corporation by value and (2) at least 60% of the corporation&#8217;s adjusted ordinary gross income, as determined for U.S.
federal income tax purposes, for such taxable year consists of PHC income (which includes, among other things, dividends, interest, certain
royalties, annuities and, under certain circumstances, rents).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that at least 60% of the company&#8217;s adjusted ordinary gross income may consist of PHC income as discussed above. In
addition, depending on the concentration of the common stock in the hands of individuals, it is possible that more than 50% of our stock
will be owned or deemed owned (pursuant to the constructive ownership rules) by such persons during the last half of a taxable year.
Thus, no assurance can be given that the company will not become a PHC following this offering or in the future. If the company is or
were to become a PHC in a given taxable year, the company would be subject to an additional PHC tax, currently 20%, on its undistributed
PHC income, which generally includes its taxable income, subject to certain adjustments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Taxation
of Distributions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the company pays cash distributions to U.S. Holders of shares of the common stock, such distributions will constitute dividends for U.S.
federal income tax purposes to the extent paid from the company&#8217;s current or accumulated earnings and profits, as determined under
U.S. federal income tax principles. Distributions in excess of current and accumulated earnings and profits will constitute a return
of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in the common stock.
Any remaining excess will be treated as gain realized on the sale or other disposition of the common stock and will be treated as described
under &#8220;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of the Common Stock&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
the company pays to a U.S. Holder that is a taxable corporation generally will qualify for the dividends received deduction if the requisite
holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest
deduction limitations), and provided certain holding period requirements are met, dividends the company pays to a non-corporate U.S.
Holder will generally constitute &#8220;qualified dividends&#8221; that will be subject to tax at the maximum tax rate accorded to long-term
capital gains.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gain
or Loss on Sale, Taxable Exchange or Other Taxable Disposition of the Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder will recognize gain or loss on the sale, taxable exchange or other taxable disposition of the common stock. Any such gain
or loss will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the common
stock so disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1) the
sum of the amount of cash and the fair market value of any property received in such disposition and (2) the U.S. Holder&#8217;s adjusted
tax basis in its common stock so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its common stock will generally equal the U.S.
Holder&#8217;s acquisition cost less any prior distributions treated as a return of capital. The deductibility of capital losses is subject
to limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Information
Reporting and Backup Withholding</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, information reporting requirements may apply to dividends paid to a U.S. Holder and to the proceeds of the sale or other disposition
of shares of common stock, unless the U.S. Holder is an exempt recipient. Backup withholding may apply to such payments if the U.S. Holder
fails to provide a taxpayer identification number, a certification of exempt status or has been notified by the IRS that it is subject
to backup withholding (and such notification has not been withdrawn). Any amounts withheld under the backup withholding rules will be
allowed as a refund or a credit against a U.S. Holder&#8217;s U.S. federal income tax liability provided the required information is
timely furnished to the IRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_021"></span>INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bush &amp; Associates
CPA has been appointed as independent registered public accounting firm for the company, providing audit services, tax return preparation,
and assistance and consultation with respect to the preparation of filings with the SEC. Bush &amp; Associates CPA is located
at 179 Gibson Road, Henderson, NV 89014.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_022"></span>ADDITIONAL
INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Daxor Corporation has filed
a Registration Statement on Form N-2, including amendments thereto, with the Securities and Exchange Commission, Washington, D.C. This
SAI and the prospectus do not contain all of the information set forth in the Registration Statement, including any exhibits and schedules
thereto. For further information with respect to the company, reference is made to the Registration Statement. Statements contained in
this SAI as to the contents of any contract or other document referred to are not necessarily complete and in each instance reference
is made to the copy of such contract or other document filed as an exhibit to the Registration Statement, each such statement being qualified
in all respects by such reference. Copies of the Registration Statement may be inspected without charge at the Securities and Exchange
Commission&#8217;s principal office in Washington, D.C., and copies of all or any part thereof may be obtained from the Securities and
Exchange Commission upon the payment of certain fees prescribed by the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Daxor Corporation previously
filed annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any reports, statements
or other information that we file with the SEC <span style="background-color: white">on the EDGAR Database on the SEC&#8217;s Internet
website at http://www.sec.gov. Copies of this information may be obtained, upon payment of a duplicating fee, by electronic request at
the following e-mail address: publicinfo@sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The company incorporates
by reference into this SAI the documents listed below (excluding any portions of such documents that have been &#8220;furnished&#8221;
but not &#8220;filed&#8221; for purposes of the Securities Exchange Act of 1934):</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/27367/000149315225008923/formncsr.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Annual
Report on Form N-CSR, as filed with the SEC on March 3, 2025</span></a><span style="font-size: 10pt">;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may request a copy of these documents by writing or telephoning Daxor Corporation at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Relations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107
Meco Lane</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oak
Ridge, TN 37830</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212)
330-8500</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_023"></span>FINANCIAL
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Daxor Corporation&#8217;s
<a href="https://www.sec.gov/Archives/edgar/data/27367/000149315225008923/formncsr.htm" style="-sec-extract: exhibit">Annual Report on
Form N-CSR, as filed with the SEC on March 3, 2025</a>, which includes the company&#8217;s financial statements for the fiscal
year ended December 31, 2024, is incorporated herein by reference with respect to all information included therein.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
C - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
25. FINANCIAL STATEMENTS AND EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Financial Statements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Incorporated by reference into Part
B of the Registration Statement, as described in the Statement of Additional Information, are:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify">The Registrant&#8217;s
                                            audited financial statements, notes to such financial statements and the report of independent
                                            registered public accounting firm thereon, by reference to the Registrant&#8217;s Annual
                                            Report for the fiscal year ended December 31, 2024, as contained in the Registrant&#8217;s
                                            Form N-CSR filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;)
                                            on March 14, 2025.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Exhibits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exhibit
Index</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; text-align: justify"><span style="font-size: 10pt">(a)</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/27367/000101905612000811/ex_a.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Certificate of Incorporation - Filed as Exhibit (a) to Daxor Corporation&#8217;s Registration Statement on Form N-2, File No. 811-22684, filed on June 28, 2012, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(b)</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/27367/000101905610000373/ex3_2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Bylaws - Filed as Exhibit 3.2 to Daxor Corporation&#8217;s Annual Report on Form 10-K for the year ended December 31, 2009, File No. 001-09999, filed on March 29, 2010, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">(c)</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Not Applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">(d)(1)</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">See Item 25(2)(a).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(d)(2)</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/27367/000101905610000373/ex4_1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Specimen Stock Certificate - Filed as Exhibit 4.1 to Daxor Corporation&#8217;s Annual Report on Form 10-K for the year ended December 31, 2009, File No. 001-09999, filed on March 29, 2010, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">(e)</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Not Applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">(f)</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Not Applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(g)</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Not Applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(h)</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/27367/000149315218015032/ex-h.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Equity Distribution Agreement - Filed as Exhibit (h) to Daxor Corporation&#8217;s Post-Effective Amendment No. 1 to the Form N-2 Registration Statement File No. 333-224509, filed on October 31, 2018, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Not Applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">(j)</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Not Applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(k)(1)</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/27367/000101905610000373/ex10_1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Agreement of Lease Dated as of December 19, 2002 - Filed as Exhibit 10.1 to Daxor Corporation&#8217;s Annual Report on Form 10-K for the year ended December 31, 2009, File No. 001-09999, filed on March 29, 2010, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(k)(2)</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/27367/000149315220010572/formdef14a.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Daxor Corporation 2020 Incentive Compensation Plan - Filed as Appendix A to Daxor Corporation&#8217;s Proxy Statement, File No. 811-22684, filed on June 4, 2020, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(l)</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="exl.htm">Opinion and Consent of Foley &amp; Lardner LLP - Filed herewith.</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">(m)</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Not Applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(n)</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Consent of Bush &amp; Associates CPA &#8211; To be filed by
    amendment. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">(o)</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Not Applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">(p)</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Not Applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">(q)</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Not Applicable.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(r)</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/27367/000101905612000811/ex_r.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Code of Ethics - Filed as Exhibit (r) to Daxor Corporation&#8217;s Registration Statement on Form N-2, File No. 811-22684, filed on June 28, 2012, and incorporated herein by reference.</span></a></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
26. MARKETING ARRANGEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is made to Exhibit (h) to this Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
27. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain estimated expenses to be incurred in connection with the offering described in this Registration Statement:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: left; width: 82%"><span style="font-size: 10pt">SEC Registration Fee</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 14%; text-align: right"><span style="font-size: 10pt">*</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><span style="font-size: 10pt">Nasdaq</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: left"><span style="font-size: 10pt">Printing/Engraving</span><span style="font-size: 10pt"> Expenses</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><span style="font-size: 10pt">Independent Registered Public Accounting Firm Fees</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: left"><span style="font-size: 10pt">Legal Fees</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left"><span style="font-size: 10pt">FINRA Filing Fee</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: left"><span style="font-size: 10pt">Miscellaneous</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
To be filed by amendment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
28. PERSONS CONTROLLED BY OR UNDER COMMON CONTROL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Management of the Company&#8221; and &#8220;Control Persons&#8221; in the Statement of Additional Information contained herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
29. NUMBER OF HOLDERS OF SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of May 19, 2025,
the aggregate number of record holders of the common stock was as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom">Title of Class</td><td style="text-align: left; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom">Number of Record Holders</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Common Stock, par value $0.01 per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 49%; text-align: right">66</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
30. INDEMNIFICATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Certificate of Incorporation and Bylaws of Daxor Corporation provide that Daxor Corporation shall indemnify any person to the full extent
permitted by the New York Business Corporation Law. Reference is hereby made to Sections 722-725 of the New York Business Corporation
Law relating to the indemnification of the officers and directors, which Sections are hereby incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation also has indemnification Agreements with each of its directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
31. BUSINESS AND OTHER CONNECTIONS OF INVESTMENT ADVISER</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
32. LOCATION OF ACCOUNTS AND RECORDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Records
of the Registrant are maintained at its principal business address at 109 Meco Lane, Oak Ridge, TN 37830.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
33. MANAGEMENT SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
34. UNDERTAKINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The Registrant undertakes to suspend the offering of shares until the prospectus is amended if (1) subsequent to the effective date of
its registration statement, the net asset value declines more than ten percent from its net asset value as of the effective date of the
registration statement or (2) the net asset value increases to an amount greater than its net proceeds as stated in the prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Not applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Not applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The Registrant undertakes that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (1) to
include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; (2) to reflect in the prospectus any facts or events
arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually
or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and (3) to include any
material information with respect to the plan of distribution not previously disclosed in the registration statement or any material
change to such information in the registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
that, for the purpose of determining any liability under the 1933 Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of those securities at that time shall be deemed
to be the initial bona fide offering thereof; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
that, for the purpose of determining liability under the 1933 Act to any purchaser, if the Registrant is subject to Rule 430C: Each prospectus
filed pursuant to Rule 497(b), (c), (d) or (e) under the 1933 Act as part of a registration statement relating to an offering, other
than a prospectus filed in reliance on Rule 430A under the 1933 Act, shall be deemed to be part of and included in the registration statement
as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such date of first use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.
that for the purpose of determining liability of the Registrant under the 1933 Act to any purchaser in the initial distribution of securities:
The undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to the purchaser: (1) any preliminary prospectus or prospectus of the undersigned Registrant
relating to the offering required to be filed pursuant to Rule 497 under the 1933 Act; (2) the portion of any advertisement pursuant
to Rule 482 under the 1933 Act relating to the offering containing material information about the undersigned Registrant or its securities
provided by or on behalf of the undersigned Registrant; and (3) any other communication that is an offer in the offering made by the
undersigned Registrant to the purchaser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The Registrant undertakes that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
for the purpose of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part
of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Fund under Rule 497(h) under
the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of the securities at
that time shall be deemed to be the initial bona fide offering thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
The Fund undertakes to send by first class mail or other means designed to ensure equally prompt delivery, within two business days of
receipt of a written or oral request, any Statement of Additional Information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933 and the Investment Company Act of 1940, the Registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, and State of New York, on the 23<sup>rd</sup>
day of July, 2025.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DAXOR
    CORPORATION</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><i>/s/ <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Feldschuh</span></i></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Feldschuh</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Chairman</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 25%; text-align: center"><span style="font-size: 10pt">Signature</span></td>
    <td style="vertical-align: bottom; width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 46%; text-align: center"><span style="font-size: 10pt">Title</span></td>
    <td style="vertical-align: bottom; width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 25%; text-align: center"><span style="font-size: 10pt">Date</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt"><i>/s/ Michael Feldschuh</i></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td><span style="font-size: 10pt">President, Chief Executive Officer and</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td><span style="font-size: 10pt">July 23, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Michael Feldschuh</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chairman (Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt"><i>/s/ Robert J. Michel</i></span></td>
    <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Chief Financial Officer and Chief Compliance Officer (Principal</span></td>
    <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">July 23, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Robert Michel</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Financial and Accounting Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><i>/s/ Joy Goudie, Esq.</i></td>
    <td>&#160;</td>
    <td>Director</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">July 23, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td>Joy Goudie, Esq.</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><i>Caleb DesRosiers </i>+</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><i>Henry Cremisi, MD+</i></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><i>Edward Feuer </i>+</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><i>Johnathan Feldschuh </i>+</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 3%; padding-bottom: 1.5pt"><span style="font-size: 10pt">+By:</span></td>
    <td style="border-bottom: Black 1pt solid; width: 47%"><i>/s/ <span style="font-size: 10pt">Michael Feldschuh</span></i></td>
    <td style="width: 50%; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Michael Feldschuh</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Attorney-in-Fact</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
Page</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJyd0t1ugjAUB/An8B0aro22xU/uNqJmGTrjyLJk2UWnR20GrWmr6CPtLVcgyy6WdAVCQuCcP79DOEHQDRZyzjNQ6PV+k6AU8lPGDKAN7EGB2ILtiB8eI2SvGzhwbRQTprr9CcbSZsBmRj3C7POq88I17CKEx30a9ukQ4TAiA7ReBp2yHkux5zsQhrMMMbFDayVPioNh6la/IWVXKWR+q6QXUJpLESHSw3X5C1FMKFrJCyuk+tQoSeKg062OTrBQ8nyyXbOrAVEm0SyD3HK6Tv+e1TTbszYyj5ZMHbhIJBM6LWR6lGdtR0sLm7vN5VktIf8AZfsxppTgu3KUOoOqkB2JDtBb3fb+X7GJnh4VgA8fuviwNV9IH5y6cNoWfxJeX05cOGmL+8jYJePmcrlqBkB42MS1bqTFus353pceuuhhc/qZX33pkYsetaDhYn+2Jz524ePm+Iwfjr72xGVPmtsrLsDXnrrs6R/7G9Hq+Ms= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>exl.htm
<DESCRIPTION>EX-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
(l)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOLEY
    &amp; LARDNER LLP</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATTORNEYS
    AT LAW</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">777
    East Wisconsin Avenue, Suite 3800</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milwaukee,
    Wisconsin 53202-5306</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">414.271.2400
    TEL</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">414.297.4900
    FAX</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>www.foley.com</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> July
                                            23, 2025 </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WRITER&rsquo;S
    DIRECT LINE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">414.297.5596</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pfetzer@foley.com
    Email</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Via
EDGAR</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350
Fifth Avenue (Empire State Building)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
4740</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10118</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel for Daxor Corporation (the &ldquo;Company&rdquo;), a New York corporation, in connection with the registration
statement on Form N-2 (File No. 811-22684) (the &ldquo;Registration Statement&rdquo;) under the Securities Act of 1933, as amended (the
&ldquo;1933 Act&rdquo;), and under the Investment Company Act of 1940, as amended, relating to the issuance and sale by the Company of
authorized shares of common stock, par value $0.01 per share (the &ldquo;Shares&rdquo;), in the amount designated in the Registration
Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have examined originals and certified copies, or copies otherwise identified to our satisfaction as being true copies, of various corporate
records of the Company and such other instruments, documents and records as we have deemed necessary in order to render this opinion.
We have assumed the genuineness of all signatures, the authenticity of all documents examined by us and the correctness of all statements
of fact contained in those documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing, we are of the opinion that the Shares being registered pursuant to the Registration Statement, when issued in accordance
with the terms described in the Registration Statement, will be legally issued, fully paid, and non-assessable by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion as an exhibit to the Registration Statement, to be filed with the Securities and Exchange
Commission. In giving such consent, however, we do not admit that we are within the category of persons whose consent is required by
Section 7 of the 1933 Act and the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Peter D. Fetzer</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    D. Fetzer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dxr-20250723.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaeO+bP9z5Z8KekhvWBzbbnaXyonnalBXClARW7G8SMK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:DXR="http://daxor.com/20250723" elementFormDefault="qualified" targetNamespace="http://daxor.com/20250723">
    <annotation>
      <appinfo>
        <link:linkbaseRef xlink:type="simple" xlink:href="dxr-20250723_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="dxr-20250723_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="dxr-20250723_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/cef/2025" schemaLocation="https://xbrl.sec.gov/cef/2025/cef-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/cef-pre/2025" schemaLocation="https://xbrl.sec.gov/cef/2025/cef-2025_pre.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="DXR_MarginLoansTwoThousandTwentyFourMember" name="MarginLoansTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_MarginLoansTwoThousandTwentyThreeMember" name="MarginLoansTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_MarginLoansTwoThousandTwentyTwoMember" name="MarginLoansTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_MarginLoansTwoThousandTwentyOneMember" name="MarginLoansTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_MarginLoansTwoThousandTwentyMember" name="MarginLoansTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_MarginLoansTwoThousandNineteenMember" name="MarginLoansTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_MarginLoansTwoThousandEighteenMember" name="MarginLoansTwoThousandEighteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_MarginLoansTwoThousandSeventeenMember" name="MarginLoansTwoThousandSeventeenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_MarginLoansTwoThousandSixteenMember" name="MarginLoansTwoThousandSixteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_MarginLoansTwoThousandFifteenMember" name="MarginLoansTwoThousandFifteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_MarginLoansTwoThousandFourteenMember" name="MarginLoansTwoThousandFourteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_MarketRisksMember" name="MarketRisksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_EquityInvestmentsMember" name="EquityInvestmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_IndustryConcentrationMember" name="IndustryConcentrationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_ShortSaleRisksMember" name="ShortSaleRisksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_PutAndCallOptionsRiskMember" name="PutAndCallOptionsRiskMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="DXR_OperatingCompanyRisksMember" name="OperatingCompanyRisksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>dxr-20250723_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2025/cef-2025.xsd#SecurityOnly" roleURI="http://xbrl.sec.gov/cef/role/SecurityOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2025/cef-2025.xsd#AddressTypeOnly" roleURI="http://xbrl.sec.gov/cef/role/AddressTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2025/cef-2025.xsd#RiskOnly" roleURI="http://xbrl.sec.gov/cef/role/RiskOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/SecurityOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/SecurityOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/SecurityOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyFourMember" xlink:label="loc_DXRMarginLoansTwoThousandTwentyFourMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandTwentyFourMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyThreeMember" xlink:label="loc_DXRMarginLoansTwoThousandTwentyThreeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandTwentyThreeMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyTwoMember" xlink:label="loc_DXRMarginLoansTwoThousandTwentyTwoMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandTwentyTwoMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyOneMember" xlink:label="loc_DXRMarginLoansTwoThousandTwentyOneMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandTwentyOneMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyMember" xlink:label="loc_DXRMarginLoansTwoThousandTwentyMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandTwentyMember" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandNineteenMember" xlink:label="loc_DXRMarginLoansTwoThousandNineteenMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandNineteenMember" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandEighteenMember" xlink:label="loc_DXRMarginLoansTwoThousandEighteenMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandEighteenMember" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandSeventeenMember" xlink:label="loc_DXRMarginLoansTwoThousandSeventeenMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandSeventeenMember" xlink:type="arc" order="70" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandSixteenMember" xlink:label="loc_DXRMarginLoansTwoThousandSixteenMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandSixteenMember" xlink:type="arc" order="80" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandFifteenMember" xlink:label="loc_DXRMarginLoansTwoThousandFifteenMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandFifteenMember" xlink:type="arc" order="90" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandFourteenMember" xlink:label="loc_DXRMarginLoansTwoThousandFourteenMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandFourteenMember" xlink:type="arc" order="100" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/AddressTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/RiskOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2025/cef-2025.xsd#cef_AllRisksMember" xlink:label="loc_cefAllRisksMember" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarketRisksMember" xlink:label="loc_DXRMarketRisksMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXRMarketRisksMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_EquityInvestmentsMember" xlink:label="loc_DXREquityInvestmentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXREquityInvestmentsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_IndustryConcentrationMember" xlink:label="loc_DXRIndustryConcentrationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXRIndustryConcentrationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_ShortSaleRisksMember" xlink:label="loc_DXRShortSaleRisksMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXRShortSaleRisksMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_PutAndCallOptionsRiskMember" xlink:label="loc_DXRPutAndCallOptionsRiskMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXRPutAndCallOptionsRiskMember" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_OperatingCompanyRisksMember" xlink:label="loc_DXROperatingCompanyRisksMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXROperatingCompanyRisksMember" xlink:type="arc" order="50" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>dxr-20250723_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyFourMember" xlink:label="DXR_MarginLoansTwoThousandTwentyFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandTwentyFourMember" xlink:to="DXR_MarginLoansTwoThousandTwentyFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarginLoansTwoThousandTwentyFourMember_lbl" xml:lang="en-US">Margin Loans 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyThreeMember" xlink:label="DXR_MarginLoansTwoThousandTwentyThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandTwentyThreeMember" xlink:to="DXR_MarginLoansTwoThousandTwentyThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarginLoansTwoThousandTwentyThreeMember_lbl" xml:lang="en-US">Margin Loans 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyTwoMember" xlink:label="DXR_MarginLoansTwoThousandTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandTwentyTwoMember" xlink:to="DXR_MarginLoansTwoThousandTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarginLoansTwoThousandTwentyTwoMember_lbl" xml:lang="en-US">Margin Loans 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyOneMember" xlink:label="DXR_MarginLoansTwoThousandTwentyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandTwentyOneMember" xlink:to="DXR_MarginLoansTwoThousandTwentyOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarginLoansTwoThousandTwentyOneMember_lbl" xml:lang="en-US">Margin Loans 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyMember" xlink:label="DXR_MarginLoansTwoThousandTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandTwentyMember" xlink:to="DXR_MarginLoansTwoThousandTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarginLoansTwoThousandTwentyMember_lbl" xml:lang="en-US">Margin Loans 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandNineteenMember" xlink:label="DXR_MarginLoansTwoThousandNineteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandNineteenMember" xlink:to="DXR_MarginLoansTwoThousandNineteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarginLoansTwoThousandNineteenMember_lbl" xml:lang="en-US">Margin Loans 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandEighteenMember" xlink:label="DXR_MarginLoansTwoThousandEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandEighteenMember" xlink:to="DXR_MarginLoansTwoThousandEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarginLoansTwoThousandEighteenMember_lbl" xml:lang="en-US">Margin Loans 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandSeventeenMember" xlink:label="DXR_MarginLoansTwoThousandSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandSeventeenMember" xlink:to="DXR_MarginLoansTwoThousandSeventeenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarginLoansTwoThousandSeventeenMember_lbl" xml:lang="en-US">Margin Loans 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandSixteenMember" xlink:label="DXR_MarginLoansTwoThousandSixteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandSixteenMember" xlink:to="DXR_MarginLoansTwoThousandSixteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarginLoansTwoThousandSixteenMember_lbl" xml:lang="en-US">Margin Loans 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandFifteenMember" xlink:label="DXR_MarginLoansTwoThousandFifteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandFifteenMember" xlink:to="DXR_MarginLoansTwoThousandFifteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarginLoansTwoThousandFifteenMember_lbl" xml:lang="en-US">Margin Loans 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandFourteenMember" xlink:label="DXR_MarginLoansTwoThousandFourteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandFourteenMember" xlink:to="DXR_MarginLoansTwoThousandFourteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarginLoansTwoThousandFourteenMember_lbl" xml:lang="en-US">Margin Loans 2014 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarketRisksMember" xlink:label="DXR_MarketRisksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarketRisksMember" xlink:to="DXR_MarketRisksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_MarketRisksMember_lbl" xml:lang="en-US">Market Risks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_EquityInvestmentsMember" xlink:label="DXR_EquityInvestmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_EquityInvestmentsMember" xlink:to="DXR_EquityInvestmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_EquityInvestmentsMember_lbl" xml:lang="en-US">Equity Investments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_IndustryConcentrationMember" xlink:label="DXR_IndustryConcentrationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_IndustryConcentrationMember" xlink:to="DXR_IndustryConcentrationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_IndustryConcentrationMember_lbl" xml:lang="en-US">Industry Concentration [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_ShortSaleRisksMember" xlink:label="DXR_ShortSaleRisksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_ShortSaleRisksMember" xlink:to="DXR_ShortSaleRisksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_ShortSaleRisksMember_lbl" xml:lang="en-US">Short Sale Risks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_PutAndCallOptionsRiskMember" xlink:label="DXR_PutAndCallOptionsRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_PutAndCallOptionsRiskMember" xlink:to="DXR_PutAndCallOptionsRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_PutAndCallOptionsRiskMember_lbl" xml:lang="en-US">Put And Call Options Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_OperatingCompanyRisksMember" xlink:label="DXR_OperatingCompanyRisksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_OperatingCompanyRisksMember" xlink:to="DXR_OperatingCompanyRisksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="DXR_OperatingCompanyRisksMember_lbl" xml:lang="en-US">Operating Company Risks [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandTwentyFourMember" xlink:to="DXR_MarginLoansTwoThousandTwentyFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="DXR_MarginLoansTwoThousandTwentyFourMember_doc" xml:lang="en-US">Margin Loans 2024 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandTwentyThreeMember" xlink:to="DXR_MarginLoansTwoThousandTwentyThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="DXR_MarginLoansTwoThousandTwentyThreeMember_doc" xml:lang="en-US">Margin Loans 2023 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandTwentyTwoMember" xlink:to="DXR_MarginLoansTwoThousandTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="DXR_MarginLoansTwoThousandTwentyTwoMember_doc" xml:lang="en-US">Margin Loans 2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandTwentyOneMember" xlink:to="DXR_MarginLoansTwoThousandTwentyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="DXR_MarginLoansTwoThousandTwentyOneMember_doc" xml:lang="en-US">Margin Loans 2021 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandTwentyMember" xlink:to="DXR_MarginLoansTwoThousandTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="DXR_MarginLoansTwoThousandTwentyMember_doc" xml:lang="en-US">Margin Loans 2020 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandFourteenMember" xlink:to="DXR_MarginLoansTwoThousandFourteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="DXR_MarginLoansTwoThousandFourteenMember_doc" xml:lang="en-US">Margin Loans 2014 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandFifteenMember" xlink:to="DXR_MarginLoansTwoThousandFifteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="DXR_MarginLoansTwoThousandFifteenMember_doc" xml:lang="en-US">Margin Loans 2015 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandSixteenMember" xlink:to="DXR_MarginLoansTwoThousandSixteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="DXR_MarginLoansTwoThousandSixteenMember_doc" xml:lang="en-US">Margin Loans 2016 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandSeventeenMember" xlink:to="DXR_MarginLoansTwoThousandSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="DXR_MarginLoansTwoThousandSeventeenMember_doc" xml:lang="en-US">Margin Loans 2017 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandEighteenMember" xlink:to="DXR_MarginLoansTwoThousandEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="DXR_MarginLoansTwoThousandEighteenMember_doc" xml:lang="en-US">Margin Loans 2018 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DXR_MarginLoansTwoThousandNineteenMember" xlink:to="DXR_MarginLoansTwoThousandNineteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="DXR_MarginLoansTwoThousandNineteenMember_doc" xml:lang="en-US">Margin Loans 2019 [Member]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>dxr-20250723_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2025/cef-2025.xsd#N2Cover" roleURI="http://xbrl.sec.gov/cef/role/N2Cover" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2025/cef-2025.xsd#N2" roleURI="http://xbrl.sec.gov/cef/role/N2" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/N2" xlink:title="995470 - Disclosure - N-2">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2025/cef-2025.xsd#cef_ProspectusLineItems" xlink:label="loc_cefProspectusLineItems" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/N2">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" order="0" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/N2">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyFourMember" xlink:label="loc_DXRMarginLoansTwoThousandTwentyFourMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandTwentyFourMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyThreeMember" xlink:label="loc_DXRMarginLoansTwoThousandTwentyThreeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandTwentyThreeMember" order="100" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyTwoMember" xlink:label="loc_DXRMarginLoansTwoThousandTwentyTwoMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandTwentyTwoMember" order="200" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyOneMember" xlink:label="loc_DXRMarginLoansTwoThousandTwentyOneMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandTwentyOneMember" order="300" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandTwentyMember" xlink:label="loc_DXRMarginLoansTwoThousandTwentyMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandTwentyMember" order="400" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandNineteenMember" xlink:label="loc_DXRMarginLoansTwoThousandNineteenMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandNineteenMember" order="500" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandEighteenMember" xlink:label="loc_DXRMarginLoansTwoThousandEighteenMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandEighteenMember" order="600" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandSeventeenMember" xlink:label="loc_DXRMarginLoansTwoThousandSeventeenMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandSeventeenMember" order="700" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandSixteenMember" xlink:label="loc_DXRMarginLoansTwoThousandSixteenMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandSixteenMember" order="800" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandFifteenMember" xlink:label="loc_DXRMarginLoansTwoThousandFifteenMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandFifteenMember" order="900" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarginLoansTwoThousandFourteenMember" xlink:label="loc_DXRMarginLoansTwoThousandFourteenMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_DXRMarginLoansTwoThousandFourteenMember" order="1000" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/N2" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/N2">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2025/cef-2025.xsd#cef_AllRisksMember" xlink:label="loc_cefAllRisksMember" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_MarketRisksMember" xlink:label="loc_DXRMarketRisksMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXRMarketRisksMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_EquityInvestmentsMember" xlink:label="loc_DXREquityInvestmentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXREquityInvestmentsMember" order="100" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_IndustryConcentrationMember" xlink:label="loc_DXRIndustryConcentrationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXRIndustryConcentrationMember" order="200" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_ShortSaleRisksMember" xlink:label="loc_DXRShortSaleRisksMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXRShortSaleRisksMember" order="300" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_PutAndCallOptionsRiskMember" xlink:label="loc_DXRPutAndCallOptionsRiskMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXRPutAndCallOptionsRiskMember" order="400" />
      <link:loc xlink:type="locator" xlink:href="dxr-20250723.xsd#DXR_OperatingCompanyRisksMember" xlink:label="loc_DXROperatingCompanyRisksMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cefAllRisksMember" xlink:to="loc_DXROperatingCompanyRisksMember" order="500" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001641172-25-020885-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-020885-xbrl.zip
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M4/]J*0U7TWM8:[$J:#;6OUA*P[_4=!P?&HE7\O\>A$/NYF_[Q<A/4$L#!!0
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M7>Y]_5('IA/]$@>BJX.=F^EP AQGXD^;INS_.Q9=T5_Z=0FU\A-02P,$%
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MVF[-VK1; $\] !C,D&2Z+Q4BPH%#M$F!P</)4E](++$IB#"2<\9AK*#)''/
M#;:A1O?!42&9 W-MB#FZQ1ZDTE^MDE5!(6#3;5,ANM*]UW[ <*BKV(>1EL@E
M EB*U>C'%T:I<5G%M/03R>+GG0?('5@(@ Q /;@7]H0FJ4,X8*=PWF$A599@
M8C!?$0/2\ 45P&OEDFD&3&<1L!%8)*;8*!\D,2%:!APHNS(T!0YSRB*QFC4
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M@#>*%?=!Q\H-)&GL/=R7K!YMEG\1?M@T-&)%/DV_"3RNV&;.?AH3*YIP^/H
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M".744$P.(BSL1RAOVH^0BD=B$&&S?H22YT<HI89B0A"AM(0?H;1I/T(J'LE
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M;,$]7]69W^G:-- [9CL6;OYXYDAOJA&;T'V<.^C89J[DA6^$?H3/682YQZS
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MY2^G>EC?F\V2Y9QJG//UXA]1>A8E2]" +I:Y&FQ0M.7V)WLT#N.P4.+#.)'
M_FOW?5QL 4I> 0A/5H$<-?F_ZK<7)>V?J^L*^M'7 @=5/QS,0=C>,47M,6,
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MLU?4S(F<<^.?EC6V%[1,;BM.(#UR1O=F[A:!_0%^9]ZN/_=4( HTCB/=&3W
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MSU-X3-I$>:!:@V X-LUPA[LZOD 3U6*HB1=M@(F Z5M4X_!2](5?YI&K;K)
M; *#7NG)%U'R&4HW]5#YSEOY<9*G+9FDKV&@P40#83G\)B,;>G(S"87 :C@C
MT$C@=3D4,,,";&G030;/?$'!P=F8M!?(?-S%0%U_\D,,VN@1 A0"@^[Q1=,8
MP;#-B)8LKX 8HWG6$QF7]ABRXX+]LH*D&3#95"VTW4[PB!$$ /ESXEA#X7]
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M(</**[ LC98C8[4RP[1@;G(TY2/HGSRK(DN*.BGA]?(8/K"$K'^!4CH>9EJ
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MI/F'ZB3GD8%=UOF%+9C06>E.@WL'^4]$T1E['R-),]SW9%"E&=Q<ZH-#>7^
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MD"HS:7]%*GAV28VA65@SBI2CZ,M@^=:I_4>48ZL5X)RS6-(MFZH [WODVZ,
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MH:.$.)4!,OE)0B@S7%V^'M1Q5^/R4H1Z9XJ;.J 8CX*UNYA:3@MJL&JPQ#R
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M#1AND8T'4("G,.C!7G8)" "_\T&MP:+!UEWV0#6Q5?0N[J)QRJ<!EZ:3T"C
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MQ&OP::?:.J"U\=SG5_A,==^\5VL-8W@N!MX8),CC:^1*.N1DP,A0%H<.K+!
M?4-LO.[Y>]\0!]MS0S!.2>:B<Y'0[8"*@;V7@V(1C>7!H.Z(,("*U7U>) -T
MP6SV]O3EV>4IQXWA)YTXO**0K67RGBFW@9.-,EBLGY^:^"<.3]X&,H#.#\-W
MO(I)PWC?$ ,S#,"[$=KPE5C]@-]W2:P>76$^J#*-"(;26LWD@W\3<0(JS0K*
MEC3A%=BTJ8_%H\BZ(ZWCJE1PAI8Q91@D3$S>)#)P_.:O*RNFBF.%^9!YKJ^N
M%^"F4073)Y%F8Z\;4W52LX'; C=TB/_-)C%L19;$&)#,T'& ?<"WIE1GBMP
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M_6N I;:[A\V]?_TK_U>6[%R[[@1^J''O3P(W2;K#'AJ)K>]^8CUS0O8C?<.
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M@?9BV/P[[U>@Z@K*)U(@GGJM4N^\A.R"9# "GL=-0V@R=:IF'&:Q:I4R8PD
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M!DN&%RW<QTZDE'>7S#? Q;1 58=EM?$K=/$S'4EL1U-)8S_53WEJ?Y1D$^"
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M.5B6!_II.'(VI5'T34S LI6.*N9(T,SVW"D'5T*# _<#A+H)X:751<=.TY?
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M/#9#%<,-9 S,/1YCQOR,6U\#*P"IX35H:6!UH/+#+W>GI/G/QFF&><HZX3.
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MH1^/;3N>L_Y8YI+RGZ$,5ZTR&#Q/VX 34 5=A6F@VEE@&@HE45!"&I?[Z#1
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MY@9&%?/CHEO".,R788^<_!+JK'#HG?OZ/Q=XU]'QE_&#PU#N^G,M\;\6&3D
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MQ';D=J:.XSPVIIV]+-?/UT05[C#R,L@]B@OC77-X=P43/3B-;@C$JH^G=5%
MS2ZPB B1ZBK[<FCHK#&H1< WS +D(.VK)^X=[=-1.H3I%M/Q\6*WQJ3,7>$"
M('##GV)#O$I:\(2&*6XGA/[++]-DW(4>$$0<T$,67.(:994&#F\XJ,2>H0\8
MJI]\#KE7X%-S@$^%X#F(NB'N)?<#9T*M!@,JU3&&T6F@ 43PBW?T0WI@\JDY
M,Z%LZF(LL^MV-KC;(<=CX%;#DHV%GLFX $5EU@I][LR+:&E-[=9XXVD]#M68
M??0QR<R+'-]'F[GH*R$6Q06JW"$!(";*%D-!]O6ZHC,5SF^A&40B !8(4C&_
MC.Y@^#5<D\=$) ZAPK:'/-Q, K=T1C#^^,IPE*D+=I-U_G8/<QD47BD&O\RW
MK\+IS/?0_EYJW\$[OE9YV2Z+5SXZ2Z6^<5RCP[6X"IW=I_ (>U</=4U&&'Z"
MRU(!&0IA7.AQC#,#3LT@1]RSR^P.*#L@0A$^F\T:UN>PM\^9'(,[7.5)D2VD
MJB.!#F3/V U^C$'W10I/X5DD]NC^A+%,I(IV<T#[ 7_S>H!SO/R!_67PQ'ED
M.#"5<LRW%@(42C"@%Z1_4':C3"<"?'20[Q#*RU+FR/ZJ[9H.T! _*;I%U!%\
MUU5UXH'#V: 4UL9YMV"3YS2H]$\E=* U4%.[(RMJ8COTR*+J*.:6M!Y:!MUB
M;&?*V(3P'\TYQU0%=105F@DP9<9^#H<#'!0Q'A/!)&KF%N6Q1QTPRZA$R7:A
M$$1MGN=9%M5DV _QCB=VC&*9;WQ%B[E=5?TFJ-D'8GQ/(9-'1IF4+Y,3$OB$
M^*ZG/X=+'EVCAX,B^T:U#QJVR;=$2K9J2W29%C?P0*?"RSP$8[()T6P8:<Q!
M$**I8</8VLTG?5S-^YKV<D1 7P:U="R-Z*K,110+?/.AB>@V)H/;LA1;)7?R
M@D=QV#',G4LC>)2J>8*-&'C7)BZV*7XD5N?>AAN2I6+Q.)7(?Q6+<(1[D$[@
MJ:QT+&(AS??CLY.]SGY,W.O"/_(^<WOA_:#I( *1[2;?*PL<\0SU<!F/B3J<
MM +SC"$_TN33HON%/JD@"#2EXSED9 .54[#F<:?&R[H"3)L#I@3/,<CPJ\*X
MV5,,"E M@&(<Z;H' L0'Q*'H/X3DRC&QKS]3:&S$N [2=!\;6(BLHLWF$^6R
M;VW8 (K'WG  Z TNZUV+?3H6]TI_8G-F[..QEN&*9NM@_VN$&?,37S&_9T55
M64-P$ !/=#DP1EQ3TQ$@01(*"#//,C6<(!0#=@K'L8*["'2U+8AHQJ"T*>FZ
M[,0Y>Z]DLX.$)H<QX>R;I.L9S29,"&8\O![ D<?_ 64WU(U71^.4N):12]$.
M>6\@L9@?]XN?]M,12@N<_YX5R_'LF$$)&\G%)E^9QXH-22@7Z.Z?[;WB1PF5
M6LK%T?B5CQ^?LS?/&-&O5:9<&H+O6@>L=4-6(<#*/^(SO 5<)IA"?)D?OK"!
ML*I.@B['II[2B7ZSP,"N00&.&8K#!&<_>LP<PWX>P//*)$+"I*798>,D%L8
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M,>L*SBVO5 G# 3/?9N<,EB@E-C6N_=BWS44AX,XAW%@+F[=GG3&C0>%('8)
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M'M3(OWS5#SNZ/(*_?7.@?O\_4$L! A0#%     @ LXOX6KILP#0I!   $QH
M !               ( !     &1X<BTR,#(U,#<R,RYX<V102P$"% ,4
M" "SB_A:^QD[X5X$  !Q)P  %               @ %7!   9'AR+3(P,C4P
M-S(S7V1E9BYX;6Q02P$"% ,4    " "SB_A:D(:3 4L%   L0@  %
M        @ 'G"   9'AR+3(P,C4P-S(S7VQA8BYX;6Q02P$"% ,4    " "S
MB_A:80VKV04$  !_(P  %               @ %D#@  9'AR+3(P,C4P-S(S
M7W!R92YX;6Q02P$"% ,4    " "SB_A:L29QB_@&  #V.0  !P
M    @ &;$@  97AL+FAT;5!+ 0(4 Q0    ( +.+^%K#L<-48E@! ,9_#  ,
M              "  ;@9  !F;W)M;BTR82YH=&U02P4&      8 !@!S 0
&1'(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>formn-2a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:DXR="http://daxor.com/20250723"
  xmlns:cef="http://xbrl.sec.gov/cef/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dxr-20250723.xsd" xlink:type="simple"/>
    <context id="AsOf2025-07-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="AsOf2025-07-23_custom_MarginLoansTwoThousandNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="AsOf2025-07-23_custom_MarginLoansTwoThousandEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="AsOf2025-07-23_custom_MarginLoansTwoThousandSeventeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="AsOf2025-07-23_custom_MarginLoansTwoThousandSixteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="AsOf2025-07-23_custom_MarginLoansTwoThousandFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="AsOf2025-07-23_custom_MarginLoansTwoThousandFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-23</instant>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarketRisksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:MarketRisksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-05-192025-05-19_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-19</startDate>
            <endDate>2025-05-19</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandSeventeenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandSixteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandFifteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_MarginLoansTwoThousandFourteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">DXR:MarginLoansTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_EquityInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:EquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_IndustryConcentrationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:IndustryConcentrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_ShortSaleRisksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:ShortSaleRisksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_PutAndCallOptionsRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:PutAndCallOptionsRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-07-232025-07-23_custom_OperatingCompanyRisksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cef:RiskAxis">DXR:OperatingCompanyRisksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-10-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000027367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-07-23" id="Fact000003">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-07-23" id="Fact000004">0000027367</dei:EntityCentralIndexKey>
    <dei:EntityWellKnownSeasonedIssuer contextRef="AsOf2025-07-23" id="xdx2ixbrl0049">No</dei:EntityWellKnownSeasonedIssuer>
    <cef:SalesLoadPercent
      contextRef="AsOf2025-07-23"
      id="xdx2ixbrl0055"
      unitRef="Ratio"
      xsi:nil="true"/>
    <cef:OtherTransactionExpensesPercent
      contextRef="AsOf2025-07-23"
      id="xdx2ixbrl0058"
      unitRef="Ratio"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyFourMember"
      id="xdx2ixbrl0093"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyThreeMember"
      id="xdx2ixbrl0096"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyTwoMember"
      id="xdx2ixbrl0099"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyOneMember"
      id="xdx2ixbrl0102"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandTwentyMember"
      id="xdx2ixbrl0105"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandNineteenMember"
      id="xdx2ixbrl0108"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandEighteenMember"
      id="xdx2ixbrl0111"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandSeventeenMember"
      id="xdx2ixbrl0114"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandSixteenMember"
      id="xdx2ixbrl0117"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandFifteenMember"
      id="xdx2ixbrl0120"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <cef:SeniorSecuritiesAverageMarketValuePerUnit
      contextRef="From2025-07-232025-07-23_custom_MarginLoansTwoThousandFourteenMember"
      id="xdx2ixbrl0123"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:EntityFileNumber contextRef="AsOf2025-07-23" id="Fact000010">333-281622</dei:EntityFileNumber>
    <dei:InvestmentCompanyActFileNumber contextRef="AsOf2025-07-23" id="Fact000011">811-22684</dei:InvestmentCompanyActFileNumber>
    <dei:DocumentType contextRef="AsOf2025-07-23" id="Fact000012">N-2/A</dei:DocumentType>
    <dei:EntityInvCompanyType contextRef="AsOf2025-07-23" id="Fact000013">N-2</dei:EntityInvCompanyType>
    <dei:DocumentRegistrationStatement contextRef="AsOf2025-07-23" id="Fact000014">true</dei:DocumentRegistrationStatement>
    <dei:PreEffectiveAmendmentNumber contextRef="AsOf2025-07-23" id="Fact000015">1</dei:PreEffectiveAmendmentNumber>
    <dei:PreEffectiveAmendment contextRef="AsOf2025-07-23" id="Fact000016">true</dei:PreEffectiveAmendment>
    <dei:PostEffectiveAmendment contextRef="AsOf2025-07-23" id="Fact000017">false</dei:PostEffectiveAmendment>
    <dei:InvestmentCompanyActRegistration contextRef="AsOf2025-07-23" id="Fact000018">true</dei:InvestmentCompanyActRegistration>
    <dei:AmendmentDescription contextRef="AsOf2025-07-23" id="Fact000019">Amendment
    No. 1</dei:AmendmentDescription>
    <dei:InvestmentCompanyRegistrationAmendmentNumber contextRef="AsOf2025-07-23" id="Fact000020">1</dei:InvestmentCompanyRegistrationAmendmentNumber>
    <dei:InvestmentCompanyRegistrationAmendment contextRef="AsOf2025-07-23" id="Fact000021">true</dei:InvestmentCompanyRegistrationAmendment>
    <dei:EntityRegistrantName contextRef="AsOf2025-07-23" id="Fact000022">DAXOR CORPORATION</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-07-23" id="Fact000023">107     Meco Lane</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-07-23" id="Fact000024">Oak     Ridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-07-23" id="Fact000025">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-07-23" id="Fact000026">37830</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode
      contextRef="From2025-07-232025-07-23_dei_BusinessContactMember"
      id="Fact000027">37830</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-07-23" id="Fact000028">(212)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-07-23" id="Fact000029">330-8500</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="From2025-07-232025-07-23_dei_BusinessContactMember"
      id="Fact000030">Michael     Feldschuh</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2025-07-232025-07-23_dei_BusinessContactMember"
      id="Fact000031">107     Meco Lane</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="From2025-07-232025-07-23_dei_BusinessContactMember"
      id="Fact000032">Oak     Ridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From2025-07-232025-07-23_dei_BusinessContactMember"
      id="Fact000033">TN</dei:EntityAddressStateOrProvince>
    <dei:ApproximateDateOfCommencementOfProposedSaleToThePublic contextRef="AsOf2025-07-23" id="Fact000034">From time to time after the effective date of this Registration Statement.</dei:ApproximateDateOfCommencementOfProposedSaleToThePublic>
    <dei:DividendOrInterestReinvestmentPlanOnly contextRef="AsOf2025-07-23" id="Fact000035">false</dei:DividendOrInterestReinvestmentPlanOnly>
    <dei:DelayedOrContinuousOffering contextRef="AsOf2025-07-23" id="Fact000036">true</dei:DelayedOrContinuousOffering>
    <cef:PrimaryShelfFlag contextRef="AsOf2025-07-23" id="Fact000037">false</cef:PrimaryShelfFlag>
    <dei:EffectiveUponFiling462e contextRef="AsOf2025-07-23" id="Fact000038">false</dei:EffectiveUponFiling462e>
    <dei:AdditionalSecuritiesEffective413b contextRef="AsOf2025-07-23" id="Fact000039">false</dei:AdditionalSecuritiesEffective413b>
    <dei:EffectiveWhenDeclaredSection8c contextRef="AsOf2025-07-23" id="Fact000040">false</dei:EffectiveWhenDeclaredSection8c>
    <dei:NewEffectiveDateForPreviousFiling contextRef="AsOf2025-07-23" id="Fact000041">false</dei:NewEffectiveDateForPreviousFiling>
    <dei:AdditionalSecurities462b contextRef="AsOf2025-07-23" id="Fact000042">false</dei:AdditionalSecurities462b>
    <dei:NoSubstantiveChanges462c contextRef="AsOf2025-07-23" id="Fact000043">false</dei:NoSubstantiveChanges462c>
    <dei:ExhibitsOnly462d contextRef="AsOf2025-07-23" id="Fact000044">false</dei:ExhibitsOnly462d>
    <cef:RegisteredClosedEndFundFlag contextRef="AsOf2025-07-23" id="Fact000045">true</cef:RegisteredClosedEndFundFlag>
    <cef:BusinessDevelopmentCompanyFlag contextRef="AsOf2025-07-23" id="Fact000046">false</cef:BusinessDevelopmentCompanyFlag>
    <cef:IntervalFundFlag contextRef="AsOf2025-07-23" id="Fact000047">false</cef:IntervalFundFlag>
    <cef:PrimaryShelfQualifiedFlag contextRef="AsOf2025-07-23" id="Fact000048">false</cef:PrimaryShelfQualifiedFlag>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-07-23" id="Fact000050">false</dei:EntityEmergingGrowthCompany>
    <cef:NewCefOrBdcRegistrantFlag contextRef="AsOf2025-07-23" id="Fact000051">false</cef:NewCefOrBdcRegistrantFlag>
    <cef:ShareholderTransactionExpensesTableTextBlock contextRef="AsOf2025-07-23" id="Fact000053">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecef--ShareholderTransactionExpensesTableTextBlock_dU_zT4WMUQWE779" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Shareholder Transaction Expenses"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Common Shareholder Transaction Expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250723__20250723_zJADkWOTmyuf" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecef--SalesLoadPercent_pid_dp_zGS2n4HJu698" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Sales load paid by you (&lt;span id="xdx_903_ecef--BasisOfTransactionFeesNoteTextBlock_c20250723__20250723_zk8UL3lQNP58"&gt;as a percentage of offering price&lt;/span&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;sup id="xdx_F4F_zKIUasgqN8Fg"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecef--OtherTransactionExpensesPercent_pid_dp_zNYdcPcOOMp3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Offering expenses borne by shareholders (&lt;span id="xdx_908_ecef--BasisOfTransactionFeesNoteTextBlock_c20250723__20250723_zPzONEUOqUF3"&gt;as a percentage of offering price&lt;/span&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0058"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;sup id="xdx_F4A_zV6Rzg1eA8bh"&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cef:ShareholderTransactionExpensesTableTextBlock>
    <cef:BasisOfTransactionFeesNoteTextBlock contextRef="AsOf2025-07-23" id="Fact000056">as a percentage of offering price</cef:BasisOfTransactionFeesNoteTextBlock>
    <cef:BasisOfTransactionFeesNoteTextBlock contextRef="AsOf2025-07-23" id="Fact000059">as a percentage of offering price</cef:BasisOfTransactionFeesNoteTextBlock>
    <cef:AnnualExpensesTableTextBlock contextRef="AsOf2025-07-23" id="Fact000061">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_ecef--AnnualExpensesTableTextBlock_dU_zGGjYGAlBQS2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Annual Expenses"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250723__20250723_zKcgspektxmi" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Percentage of Net Assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Annual Expenses&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Attributable to Common
    &lt;span style="-sec-ix-redline: true"&gt;Shares&lt;/span&gt; &lt;sup id="xdx_F5C_zBtX5oFdgtC9"&gt;(3)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecef--ManagementFeesPercent_pid_dpn_zF7WGBV6gQn" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Management Fees&lt;sup id="xdx_F44_zfDLcKvuWFIl"&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;None&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecef--InterestExpensesOnBorrowingsPercent_pid_dp_zu0uOmFZXjD4" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 80%"&gt;&lt;span style="font-size: 10pt"&gt;Annualized Interest Payments on Borrowed Funds&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;0.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecef--OtherAnnualExpensesPercent_pid_dp_z2uqCqgZNZu2" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Annualized Other Expenses &lt;sup id="xdx_F49_z3xWlQMCCGif"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;5.45&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecef--TotalAnnualExpensesPercent_pid_dp_zNwiwiUE8eMb" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Total Annual Expenses before Taxes&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;5.74&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecef--WaiversAndReimbursementsOfFeesPercent_pid_dp_zr4xTe2PiqAd" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Estimated Annualized Tax Expense&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;0.10&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecef--NetExpenseOverAssetsPercent_pid_dp_zv8FiPCYvGMg" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Total Annual Expenses after Taxes&lt;sup id="xdx_F4A_zObVlKQzkKGa"&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;5.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cef:AnnualExpensesTableTextBlock>
    <cef:ManagementFeesPercent
      contextRef="AsOf2025-07-23"
      decimals="INF"
      id="Fact000063"
      unitRef="Ratio">0</cef:ManagementFeesPercent>
    <cef:InterestExpensesOnBorrowingsPercent
      contextRef="AsOf2025-07-23"
      decimals="INF"
      id="Fact000065"
      unitRef="Ratio">0.0029</cef:InterestExpensesOnBorrowingsPercent>
    <cef:OtherAnnualExpensesPercent
      contextRef="AsOf2025-07-23"
      decimals="INF"
      id="Fact000067"
      unitRef="Ratio">0.0545</cef:OtherAnnualExpensesPercent>
    <cef:TotalAnnualExpensesPercent
      contextRef="AsOf2025-07-23"
      decimals="INF"
      id="Fact000069"
      unitRef="Ratio">0.0574</cef:TotalAnnualExpensesPercent>
    <cef:WaiversAndReimbursementsOfFeesPercent
      contextRef="AsOf2025-07-23"
      decimals="INF"
      id="Fact000071"
      unitRef="Ratio">0.0010</cef:WaiversAndReimbursementsOfFeesPercent>
    <cef:NetExpenseOverAssetsPercent
      contextRef="AsOf2025-07-23"
      decimals="INF"
      id="Fact000073"
      unitRef="Ratio">0.0584</cef:NetExpenseOverAssetsPercent>
    <cef:OtherExpensesNoteTextBlock contextRef="AsOf2025-07-23" id="Fact000079">Annualized Other Expenses&#x201d; are
    based on estimated expense amounts for the current fiscal year.</cef:OtherExpensesNoteTextBlock>
    <cef:ExpenseExampleTableTextBlock contextRef="AsOf2025-07-23" id="Fact000082">&lt;p id="xdx_89C_ecef--ExpenseExampleTableTextBlock_dU_zFvMO11Ttwh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;The Example should not be considered a representation
of future expenses or returns. Actual expenses may be higher or lower than those assumed. Moreover, the company&#x2019;s actual rate of
return may be higher or lower than the hypothetical 5% return shown in the example. &lt;/b&gt;The example assumes that all dividends and distributions
are reinvested at net asset value.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;1 Year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;3 Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;5 Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;10 Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 40%"&gt;&lt;span style="font-size: 10pt"&gt;Total Expenses paid by Common Shareholders&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecef--ExpenseExampleYear01_c20250723__20250723_zwVuYNeE84H1" style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;210&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_ecef--ExpenseExampleYears1to3_c20250723__20250723_z00Vvy6yAeL4" style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;294&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecef--ExpenseExampleYears1to5_c20250723__20250723_zl2MiziYbNB8" style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;379&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecef--ExpenseExampleYears1to10_c20250723__20250723_zlhIIm8qzgy4" style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;588&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;The example above does not include sales loads
or estimated offering costs. In connection with an offering of shares of common stock, the &lt;span style="-sec-ix-redline: true"&gt;applicable&lt;/span&gt; prospectus supplement will
set forth an Example including sales load and estimated offering costs.&lt;/p&gt;
</cef:ExpenseExampleTableTextBlock>
    <cef:ExpenseExampleYear01
      contextRef="AsOf2025-07-23"
      decimals="0"
      id="Fact000083"
      unitRef="USD">210</cef:ExpenseExampleYear01>
    <cef:ExpenseExampleYears1to3
      contextRef="AsOf2025-07-23"
      decimals="0"
      id="Fact000084"
      unitRef="USD">294</cef:ExpenseExampleYears1to3>
    <cef:ExpenseExampleYears1to5
      contextRef="AsOf2025-07-23"
      decimals="0"
      id="Fact000085"
      unitRef="USD">379</cef:ExpenseExampleYears1to5>
    <cef:ExpenseExampleYears1to10
      contextRef="AsOf2025-07-23"
      decimals="0"
      id="Fact000086"
      unitRef="USD">588</cef:ExpenseExampleYears1to10>
    <cef:SeniorSecuritiesNoteTextBlock contextRef="AsOf2025-07-23" id="Fact000088">&lt;p id="xdx_802_ecef--SeniorSecuritiesNoteTextBlock_dU_zzTxdxMPdOXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="a_004"&gt;&lt;/span&gt;SENIOR
SECURITIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecef--SeniorSecuritiesTableTextBlock_dU_zDRJcKUZ5tgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Information about our senior securities is
shown in the following table as of the end of the last 10 fiscal years.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_480_ecef--SeniorSecuritiesAmt_iI_zxpMPN7mkOwe" style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total Amount Outstanding Exclusive of Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48E_ecef--SeniorSecuritiesCvgPerUnit_iI_zxE1f4tGopu8" style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Asset Coverage Per&lt;br/&gt;
    $1,000 of Indebtedness&lt;sup id="xdx_F5F_z2oM1gKvzZEg"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Involuntary&lt;br/&gt; Liquidating&lt;br/&gt; Preferences Per Unit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Average Market&lt;br/&gt; Value&lt;sup id="xdx_F58_zbLeoLJFX2ej"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyFourMember_zjxa8QG7Rrid" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;729,966&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;50,033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%"&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%"&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_902_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyFourMember_fKDIp_zQkdhHdNh739" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0093"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyThreeMember_z1SrotRFAKSd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;755,659&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;46,008&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_905_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyThreeMember_fKDIp_zUDlnZTXmPK" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0096"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyTwoMember_z8AngQ8jFSPf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,229,164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;24,568&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_901_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyTwoMember_fKDIp_zqPCosFagNqf" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0099"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyOneMember_zuoXFYn1qGb8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,022,542&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;7,998&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_90D_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyOneMember_fKDIp_zz2ond7r8Eng" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0102"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyMember_zlaDbUamBv2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;170,689&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;92,835&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_90D_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyMember_fKDIp_zpB99vxHBn4g" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0105"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandNineteenMember_zxrrudkDJ6C6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2019&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,342,550&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;10,509&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_903_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandNineteenMember_fKDIp_zqVlXWJhOAO6" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0108"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandEighteenMember_zdr1npg18v2g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2018&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,454,613&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;30,197&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_907_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandEighteenMember_fKDIp_zdqUt3lGjPu8" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0111"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_410_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSeventeenMember_zbyb23dKhzQ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,334,552&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,174&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_906_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSeventeenMember_fKDIp_zyNXOKU897kj" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0114"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_418_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSixteenMember_za6OUmVc9kh8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2016&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2,801,732&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;6,477&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_906_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSixteenMember_fKDIp_zBxZnM4oQtyc" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0117"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFifteenMember_zFP50yZCc94i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2015&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,845,112&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,752&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_90A_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFifteenMember_fKDIp_zeXC3yO9D2e9" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0120"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFourteenMember_zxRuis4aRwZf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2014&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;21,356,338&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2,146&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_90A_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFourteenMember_fKDIp_z7M63JIQUFm4" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0123"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F0C_ztxIzWyKmFa" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F13_zqVoC7iFSJSg" style="font-size: 10pt"&gt;Derivatives transactions entered into in compliance
    with Rule 18f-4 under the Investment Company Act are not considered for purposes of computing asset coverage.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F04_zN4rtX3H9FAd" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F16_zkwZ7FBg2cHc" style="font-size: 10pt"&gt;Not applicable as the senior securities are not registered for public
    trading.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</cef:SeniorSecuritiesNoteTextBlock>
    <cef:SeniorSecuritiesTableTextBlock contextRef="AsOf2025-07-23" id="Fact000090">&lt;p id="xdx_89F_ecef--SeniorSecuritiesTableTextBlock_dU_zDRJcKUZ5tgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;Information about our senior securities is
shown in the following table as of the end of the last 10 fiscal years.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_480_ecef--SeniorSecuritiesAmt_iI_zxpMPN7mkOwe" style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Total Amount Outstanding Exclusive of Treasury Securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48E_ecef--SeniorSecuritiesCvgPerUnit_iI_zxE1f4tGopu8" style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Asset Coverage Per&lt;br/&gt;
    $1,000 of Indebtedness&lt;sup id="xdx_F5F_z2oM1gKvzZEg"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;Involuntary&lt;br/&gt; Liquidating&lt;br/&gt; Preferences Per Unit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Average Market&lt;br/&gt; Value&lt;sup id="xdx_F58_zbLeoLJFX2ej"&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyFourMember_zjxa8QG7Rrid" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;729,966&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;50,033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%"&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 14%"&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_902_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyFourMember_fKDIp_zQkdhHdNh739" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0093"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyThreeMember_z1SrotRFAKSd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;755,659&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;46,008&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_905_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyThreeMember_fKDIp_zUDlnZTXmPK" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0096"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyTwoMember_z8AngQ8jFSPf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,229,164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;24,568&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_901_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyTwoMember_fKDIp_zqPCosFagNqf" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0099"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyOneMember_zuoXFYn1qGb8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2021&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,022,542&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;7,998&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_90D_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyOneMember_fKDIp_zz2ond7r8Eng" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0102"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_412_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyMember_zlaDbUamBv2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2020&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;170,689&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;92,835&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_90D_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyMember_fKDIp_zpB99vxHBn4g" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0105"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandNineteenMember_zxrrudkDJ6C6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2019&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;1,342,550&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;10,509&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_903_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandNineteenMember_fKDIp_zqVlXWJhOAO6" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0108"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandEighteenMember_zdr1npg18v2g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2018&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,454,613&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;30,197&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_907_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandEighteenMember_fKDIp_zdqUt3lGjPu8" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0111"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_410_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSeventeenMember_zbyb23dKhzQ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,334,552&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,174&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_906_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSeventeenMember_fKDIp_zyNXOKU897kj" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0114"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_418_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSixteenMember_za6OUmVc9kh8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2016&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2,801,732&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;6,477&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_906_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSixteenMember_fKDIp_zBxZnM4oQtyc" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0117"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_416_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFifteenMember_zFP50yZCc94i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2015&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;3,845,112&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,752&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_90A_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFifteenMember_fKDIp_zeXC3yO9D2e9" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0120"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFourteenMember_zxRuis4aRwZf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;Margin Loans 2014&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;21,356,338&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;2,146&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;N/A&lt;/span&gt;&lt;span id="xdx_90A_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFourteenMember_fKDIp_z7M63JIQUFm4" style="display: none"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0123"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F0C_ztxIzWyKmFa" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F13_zqVoC7iFSJSg" style="font-size: 10pt"&gt;Derivatives transactions entered into in compliance
    with Rule 18f-4 under the Investment Company Act are not considered for purposes of computing asset coverage.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F04_zN4rtX3H9FAd" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span id="xdx_F16_zkwZ7FBg2cHc" style="font-size: 10pt"&gt;Not applicable as the senior securities are not registered for public
    trading.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</cef:SeniorSecuritiesTableTextBlock>
    <cef:SeniorSecuritiesAmt
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyFourMember"
      decimals="0"
      id="Fact000091"
      unitRef="USD">729966</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyFourMember"
      decimals="INF"
      id="Fact000092"
      unitRef="USDPShares">50033</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesAmt
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyThreeMember"
      decimals="0"
      id="Fact000094"
      unitRef="USD">755659</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyThreeMember"
      decimals="INF"
      id="Fact000095"
      unitRef="USDPShares">46008</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesAmt
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyTwoMember"
      decimals="0"
      id="Fact000097"
      unitRef="USD">1229164</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyTwoMember"
      decimals="INF"
      id="Fact000098"
      unitRef="USDPShares">24568</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesAmt
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyOneMember"
      decimals="0"
      id="Fact000100"
      unitRef="USD">3022542</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyOneMember"
      decimals="INF"
      id="Fact000101"
      unitRef="USDPShares">7998</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesAmt
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyMember"
      decimals="0"
      id="Fact000103"
      unitRef="USD">170689</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandTwentyMember"
      decimals="INF"
      id="Fact000104"
      unitRef="USDPShares">92835</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesAmt
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandNineteenMember"
      decimals="0"
      id="Fact000106"
      unitRef="USD">1342550</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandNineteenMember"
      decimals="INF"
      id="Fact000107"
      unitRef="USDPShares">10509</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesAmt
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandEighteenMember"
      decimals="0"
      id="Fact000109"
      unitRef="USD">4454613</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandEighteenMember"
      decimals="INF"
      id="Fact000110"
      unitRef="USDPShares">30197</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesAmt
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandSeventeenMember"
      decimals="0"
      id="Fact000112"
      unitRef="USD">4334552</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandSeventeenMember"
      decimals="INF"
      id="Fact000113"
      unitRef="USDPShares">4174</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesAmt
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandSixteenMember"
      decimals="0"
      id="Fact000115"
      unitRef="USD">2801732</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandSixteenMember"
      decimals="INF"
      id="Fact000116"
      unitRef="USDPShares">6477</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesAmt
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandFifteenMember"
      decimals="0"
      id="Fact000118"
      unitRef="USD">3845112</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandFifteenMember"
      decimals="INF"
      id="Fact000119"
      unitRef="USDPShares">4752</cef:SeniorSecuritiesCvgPerUnit>
    <cef:SeniorSecuritiesAmt
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandFourteenMember"
      decimals="0"
      id="Fact000121"
      unitRef="USD">21356338</cef:SeniorSecuritiesAmt>
    <cef:SeniorSecuritiesCvgPerUnit
      contextRef="AsOf2025-07-23_custom_MarginLoansTwoThousandFourteenMember"
      decimals="INF"
      id="Fact000122"
      unitRef="USDPShares">2146</cef:SeniorSecuritiesCvgPerUnit>
    <cef:InvestmentObjectivesAndPracticesTextBlock contextRef="AsOf2025-07-23" id="Fact000127">&lt;p id="xdx_897_ecef--InvestmentObjectivesAndPracticesTextBlock_dU_zSJNKrVzeq9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="a_009"&gt;&lt;/span&gt;&lt;span id="xdx_8B7_zk0pgA4YPtsk"&gt;Investment
Objectives and Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
objective is to support and expand our operating businesses, through organic growth (i.e., the rate of business expansion through internal
enhancement of the business and operations as opposed to mergers, acquisitions and takeovers). The company is not primarily engaged in
the business of investing, reinvesting, owning, holding or trading in securities. Funds in excess of the company&#x2019;s business needs
are placed in instruments designed to maximize capital preservation and assure liquidity. The foregoing policies may be changed without
a shareholder vote.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
concentrate our investments in the utility industry and have an investment policy that calls for a minimum of 80% of the company&#x2019;s
investment portfolio to consist of electric utility stocks. The Board of Directors has authorized this minimum to be temporarily lowered
to 70% when management deems it to be necessary. At least once a year, the company reviews its investment strategy, and more frequently
as needed, at board meetings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
investment portfolio primarily consists of electric utility companies which are publicly traded common and preferred stock. In addition
to receiving income from dividends from the securities held in the investment portfolio, we also have an investment policy of selling
puts on stocks that we are willing to own. Such options usually have a maturity of less than 1 year. The company will also sell covered
calls on securities within its investment portfolio. Covered calls involve stocks, which usually do not exceed 15% of the value of the
company&#x2019;s portfolio.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
will, at times, sell naked or uncovered calls, as well as, engage in short sales as part of an income strategy, and to a lesser extent
a strategy to mitigate risk. Our net short position will usually amount to less than 15% of the company&#x2019;s portfolio value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
this time, investments in debt instruments and foreign securities are not a principal investment strategy, and we expect any such investments
to be minimal.&lt;/span&gt;&lt;/p&gt;

</cef:InvestmentObjectivesAndPracticesTextBlock>
    <cef:RiskFactorsTableTextBlock contextRef="AsOf2025-07-23" id="Fact000129">&lt;p id="xdx_80A_ecef--RiskFactorsTableTextBlock_dU_zSiuRGblvSre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="a_010"&gt;&lt;/span&gt;&lt;span id="xdx_82E_zzIGkIWZDIs5"&gt;Risk
Factors&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="text-decoration: underline"&gt;Deregistration as Investment Company&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline: true"&gt;We intend to file an application
pursuant to Section 8(f) of the Investment Company Act of 1940 seeking an order declaring that Daxor has ceased to be a registered investment
company. Investors in registered investment companies benefit from legal protections imposed for their benefit under the&#160;Investment
Company Act, and those legal protections will no longer apply if we receive the requested order. In addition, if we receive the requested
order, our tax treatment may change, and such a change could have an adverse effect on the value of an investment in Daxor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline: true"&gt;In connection with deregistering
as an investment company, we will take the appropriate steps to register under the Securities Exchange Act of 1934, as amended, and will
continue to be listed on Nasdaq.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline: true"&gt;With regard to this registration
statement, if we receive the order declaring that we have ceased to be an investment company, then we will immediately cease any offering
under this registration statement. In such eventuality, we will take the appropriate steps to convert this registration statement to
a registration statement on Form S-1 or Form S-3, as appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Investment
Portfolio Risks&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--MarketRisksMember_dU_zNkxyeHRnqJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8B1_zLES2XAyxjF2"&gt;Market
Risks&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
of money is a risk of investing in the company. The net asset value of the company can be expected to change daily and you may lose money.
There is no guarantee that the performance of our investment portfolio will be positive over any period of time, either short-term or
long-term. Market risk may affect a single issuer, industry, sector of the economy, or the market as a whole.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.
and international markets have experienced significant periods of volatility in recent years due to a number of economic, political and
global macro factors, including the impact of the coronavirus (COVID-19) as a global pandemic and related public health issues, growth
concerns in the U.S. and overseas, uncertainties regarding interest rates, trade tensions and the threat of tariffs imposed by the U.S.
and other countries. In particular, the spread of the novel coronavirus worldwide has resulted in disruptions to supply chains and customer
activity, stress on the global healthcare system, rising unemployment claims, quarantines, cancellations, market declines, the closing
of borders, restrictions on travel and widespread concern and uncertainty. Health crises and related political, social and economic disruptions
caused by the spread of the recent coronavirus outbreak may also exacerbate other pre-existing political, social and economic risks in
certain countries. It is not possible to know the extent of these impacts, and they may be short term or may last for an extended period
of time. These developments as well as other events, such as the U.S. presidential election, could result in further market volatility
and negatively affect security prices, the liquidity of certain securities and the normal operations of securities exchanges and other
markets, despite government efforts to address market disruptions.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A2_zj5kLvJ6yADh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_ecef--RiskTextBlock_hcef--RiskAxis__custom--EquityInvestmentsMember_dU_zWJ4DwOdPiEk" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8B9_zxdsQ7NCzdya"&gt;Equity
Investments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Because
we invest in equity securities, fluctuations in the stock market in general, as well as in the value of particular equity securities
held by us, can affect the performance of our investment portfolio. The value of equity securities will fluctuate due to many factors,
including the past and predicted earnings of the issuer, the quality of the issuer&#x2019;s management, general market conditions, forecasts
for the issuer&#x2019;s industry and the value of the issuer&#x2019;s assets.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A2_zVzEjT5FLyjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p id="xdx_894_ecef--RiskTextBlock_hcef--RiskAxis__custom--IndustryConcentrationMember_dU_zjMqRS3FKFxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8B8_zjOj42ECW6b1"&gt;Industry
Concentration&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
concentrate our investments within the electric utility industry. Because of its narrow industry focus, the performance of our investment
portfolio is tied closely to and affected by developments in the electric utility industry, such as competition and weather. The electric
utility industry is also sensitive to increased interest rates because of the industry&#x2019;s capital intensive nature. Also, an increase
in interest rates could cause some electric utilities to decrease dividends paid to shareholders which would reduce our investment income.
The earnings of electric utility companies could also be negatively affected by power outages. Electric utilities operate in an environment
of federal, state and local regulations, and these regulations may disproportionately affect an individual utility.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A2_zqDmrmH7UdZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--ShortSaleRisksMember_dU_zwQlhTiLokCi" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8B3_zraT901Ofvyh"&gt;Short
Sale Risks&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
investment portfolio will suffer a loss if it sells a security short and the value of the security rises rather than falls. It is possible
that the investment portfolio&#x2019;s long positions will decline in value at the same time that the value of its short positions increase,
thereby increasing potential losses to the portfolio. Short sales expose our investment portfolio to the risk that it will be required
to buy the security sold short (also known as &#x201c;covering&#x201d; the short position) at a time when the security has appreciated
in value, thus resulting in a loss to the portfolio. The investment performance of our investment portfolio will also suffer if it is
required to close out a short position earlier than it had intended. In addition, our investment portfolio may be subject to expenses
related to short sales that are not typically associated with investing in securities directly, such as costs of borrowing. These expenses
may negatively impact the performance of the investment portfolio. Short positions introduce more risk to the investment portfolio than
long positions (purchases) because the maximum sustainable loss on a security purchased (held long) is limited to the amount paid for
the security plus the transaction costs, whereas there is no maximum attainable price of the shorted security. Therefore, in theory,
securities sold short have unlimited risk.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A2_zlBhvSV9QER5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--PutAndCallOptionsRiskMember_dU_zrGCDSV3pdqj" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8B9_zP5YksLm47P"&gt;Put
and Call Options Risk&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
use of options involves investment strategies and risks different from those associated with ordinary portfolio securities transactions.
If a strategy is applied at an inappropriate time or market conditions or trends are judged incorrectly, the use of options may lower
the return on the investment. There can be no guarantee that the use of options will increase the return or income on an investment.
In addition, there may be an imperfect correlation between the movement in prices of options and the securities underlying them and there
may at times not be a liquid secondary market for various options. An abrupt change in the price of an underlying security could render
an option worthless. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in
the value of the underlying instrument, or in interest or currency exchange rates, including the anticipated volatility of the underlying
instrument (known as implied volatility), which in turn are affected by fiscal and monetary policies and by national and international
political and economic events, as will the performance of the issuer of the underlying instrument. As such, prior to the exercise or
expiration of the option, the Company is exposed to implied volatility risk, meaning the value, as based on implied volatility, of an
option may increase due to market and economic conditions or views based on the sector or industry in which issuers of the underlying
instrument participate, including company-specific factors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;By
writing put options, the Company takes on the risk of declines in the value of the underlying instrument, including the possibility of
a loss up to the entire strike price of each option it sells, but without the corresponding opportunity to benefit from potential increases
in the value of the underlying instrument. When the Company writes a put option, it assumes the risk that it must purchase the underlying
instrument at a strike price that may be higher than the market price of the instrument. If there is a broad market decline and the Company
is not able to close out its written put options, it may result in substantial losses. By writing a call option, the Company may be obligated
to deliver instruments underlying an option at less than the market price. In the case of an uncovered call option, there is a risk of
unlimited loss. When an uncovered call is exercised, the Company must purchase the underlying instrument to meet its call obligations
and the necessary instruments may be unavailable for purchase. When the Company writes a covered call option, it gives up the opportunity
to profit from a price increase in the underlying instrument above the strike price. If a covered call option that the Company has written
is exercised, the Company will experience a gain or loss from the sale of the underlying instrument, depending on the price at which
the Company purchased the instrument and the strike price of the option. The Company will receive a premium from writing options, but
the premium received may not be sufficient to offset any losses sustained from exercised options. In the case of a covered call, the
premium received may be offset by a decline in the market value of the underlying instrument during the option period. If an option that
the Company has purchased is never exercised or closed out, the Company will lose the amount of the premium it paid and the use of those
funds. There were no put or call option positions at December 31, &lt;span style="-sec-ix-redline: true"&gt;2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A2_zwucELldXWm" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p id="xdx_899_ecef--RiskTextBlock_hcef--RiskAxis__custom--OperatingCompanyRisksMember_dU_zzR8qhUshmU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8BB_z8vvVCSLFzee"&gt;Operating
Company Risks&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Our
business is at an early stage of commercial development and we may struggle to generate significant commercial uptake in our products
with our current resources.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
business is at an early stage of commercial development. We have a base of installed devices or tests run at approximately 80 hospitals
and clinics and approximately 65,000 kits have been sold to clinicians. These sites are covered by a sales, marketing, technical, and
clinical support team of 12 individuals composed of employees and consultants. Investment in expanding these resources will be required
to reach larger target customers at hospitals and clinics across the country.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, significant research and clinical studies on the potential benefits of blood volume analysis to guide therapeutic decisions
will be required to gain acceptance into the guidelines of care and for broader clinical adoption. There is no guarantee that these studies
will be successful or completed in a timely or cost-effective manner allowing the company to benefit commercially from their completion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
will need additional capital to conduct our operations and develop our products, and our ability to obtain the necessary funding is uncertain.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have used a significant amount of cash and retained earnings since inception to finance the continued development and testing of our
BVA-100 system, and we expect to need additional capital resources in order to further commercialize the product as well as develop related
products and updates to our existing device.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
may not be successful in maintaining operating cash flow, and the timing of our capital expenditures and other expenditures may impede
our commercialization efforts if not sufficient. If financing is not sufficient and additional financing is not available or available
only on terms that are detrimental to our long-term survival, it could have a material adverse effect on our ability to successfully
commercialize our technology.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additional
financing through strategic collaborations, public or private equity or debt financings or other financing sources may not be available
on acceptable terms for our operating company, or at all. Additional equity financing could result in dilution to our shareholders. Further,
if we obtain additional funds through arrangements with collaborative partners, these arrangements may require us to relinquish rights
to some of our technologies, product or products that we would otherwise seek to develop and commercialize on our own.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
sufficient capital is not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or product
development initiatives, any of which could have an adverse effect on our financial condition or business prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Our
financial reporting reflects our status as a closed-end investment fund with an operating medical device division whose financial performance
is not broken out in detail and reported on a regular basis as is the case with traditional operating companies. As a result, shareholders
could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common
stock.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholders
seek detailed financial information in their investments and our reporting structure conforms to that of an investment fund. Investors
may become dissatisfied with the level of reporting detail that our current fund structure maintains and require greater transparency
in the future or lose confidence in the management resulting in a negative impact on the stock price. While the company intends to file
for a change of reporting structure in the future to a traditional operating company with the SEC as revenues from the operating division
increase whether that will be achievable and at what date remains unknown at this point in time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
our efforts to protect our intellectual property related to our technologies are not adequate, we may not be able to compete effectively
in our market and our business would be harmed.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related
to our technologies. Any disclosure to or misappropriation by third parties of our trade secrets or other confidential information could
assist competitors in duplicating or surpassing our technological achievements, thus eroding the competitive advantage we may derive
from these patents or know-how.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
strength of patents in the medical diagnostic field involves complex legal and scientific questions and can be uncertain. The patent
applications we own may fail to result in issued patents in the United States or in foreign countries and existing patents on parts of
our technology have entered the public domain. Third parties may challenge the validity, enforceability or scope of any issued patents
we own or license or any applications that may issue as patents in the future, which may result in those patents being narrowed, invalidated
or held unenforceable. Even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual
property or prevent others from developing similar products that do not fall within the scope of our patents. If the breadth or strength
of protection provided by the patents we hold or pursue is threatened, our ability to commercialize any product candidates with technology
protected by those patents could be threatened. Since patent applications in the United States and most other countries are confidential
for a period of time after filing, we cannot be certain at the time of filing that we are the first to file any patent application related
to our technology.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect
proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery
platform and drug development processes that involve proprietary know-how, information or technology that is not covered by patents or
not amenable to patent protection. Although we endeavor that all of our employees and certain consultants and advisors to assign inventions
to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information
or technology to enter into confidentiality agreements, our trade secrets and other proprietary information may be disclosed or competitors
may otherwise gain access to such information or independently develop substantially equivalent information. Further, the laws of some
foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result,
we may encounter significant difficulty in protecting and defending our intellectual property both in the United States and abroad. If
we are unable to prevent material disclosure of the trade secret intellectual property related to our technologies to third parties,
we may not be able to establish or maintain the competitive advantage that we believe is provided by such intellectual property, which
could materially adversely affect our market position and business and operational results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
may be involved in lawsuits to protect or enforce our patent, which could be expensive, time-consuming and unsuccessful.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Competitors
may infringe our patents. To attempt to stop infringement or unauthorized use, we may need to enforce one or more of our patents, which
can be expensive and time-consuming and distract management. If we pursue any litigation, a court may decide that a patent of ours or
our licensor&#x2019;s is not valid or is unenforceable, or may refuse to stop the other party from using the relevant technology on the
grounds that our patents do not cover the technology in question. Further, the legal systems of certain countries, particularly certain
developing countries, do not favor the enforcement of patents, which could reduce the likelihood of success of any infringement proceeding
we pursue in any such jurisdiction. An adverse result in any infringement litigation or defense proceedings could put one or more of
our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of
not issuing, which could limit our ability to exclude competitors from directly competing with us in the applicable jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interference
proceedings provoked by third parties or brought by the U.S. PTO may be necessary to determine the priority of inventions with respect
to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to use it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms, or at all. Litigation or interference proceedings may fail and, even if successful, may
result in substantial costs and distract our management and other employees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
we are unsuccessful in obtaining or maintaining patent protection for intellectual property in development, our business and competitive
position would be harmed.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are seeking patent protection for some of our technology and future products. Patent prosecution is a challenging process and is not
assured of success. If we are unable to secure patent protection for our technology and product candidates, our business may be adversely
impacted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, issued patents and pending international applications require regular maintenance. Failure to maintain our portfolio may result
in loss of rights that may adversely impact our intellectual property rights, for example by rendering issued patents unenforceable or
by prematurely terminating pending international applications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how,
technology and other proprietary information, to maintain our competitive position. We currently, and expect in the future to continue
to, seek to protect these trade secrets, in part, by entering into confidentiality agreements with parties who have access to them, such
as our employees, collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality
and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach
the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies
for any such disclosure. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive
and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing
or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor,
we would have no right to prevent them, or those to whom they disclose the trade secrets, from using that technology or information to
compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position
would be harmed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
will have to hire additional executive officers and employees to expand our business. If we are unable to hire qualified personnel, we
may not be able to implement our business strategy.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
loss of the services of any of our key product or business development employees could delay our product development programs and our
research and development efforts. We do not maintain key person life insurance on any of our officers, employees or consultants. In order
to develop our business in accordance with our business strategy, we will have to hire additional qualified personnel, including in the
areas of sales, physician education, manufacturing, clinical trials management, regulatory affairs, and business development. We will
need to raise sufficient funds to hire the necessary employees and have commenced our search for additional key employees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
depend on key personnel for our continued operations and future success, and a loss of certain key personnel could significantly hinder
our ability to move forward with our business plan.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Because
of the specialized nature of our business, we are highly dependent on our ability to identify, hire, train and retain highly qualified
scientific and technical personnel for the research and development activities we conduct or sponsor. The loss of one or more key executive
officers, or scientific officers, would be significantly detrimental to us. In addition, recruiting and retaining qualified scientific
personnel to perform research and development work is critical to our success. Our anticipated growth and expansion into areas and activities
requiring additional expertise will require the addition of new management personnel and the development of additional expertise by existing
management personnel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could cause our business to suffer.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
regulations of governmental authorities, such as the FDA or the European Medicines Agency, or EMA, to provide accurate information to
the FDA or EMA, to comply with manufacturing standards we have established, to comply with federal, state and international healthcare
fraud and abuse laws and regulations as they may become applicable to our operations, to report financial information or data accurately
or to disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the
course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to
identify and deter employee misconduct, and the precautions we currently take and the procedures we may establish in the future as our
operations and employee base expand to detect and prevent this type of activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure by our employees
to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves
or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition
of significant fines or other sanctions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
we experience delays or difficulties in clinical outcome studies or lack the funding to conduct them, receipt of necessary outcome data
could be delayed or prevented.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
trials using our BVA-100 depend upon the successful funding, enrollment, and initiation of studies in coordination with research institutions
and hospitals. The company does not have sufficient funds to fully sponsor as many outcome studies as may be warranted for adoption of
our diagnostic as a standard of care. As such, the company depends upon a combination of grants and research agreements with sponsoring
institutions for many of the studies that have been conducted with its technology and anticipates continuing to do so for the foreseeable
future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
and our suppliers are subject to extensive FDA regulation, which can be costly and time consuming and can subject us to unanticipated
business costs or difficulties. Even though regulatory approval for products may have been granted, those products may still face regulatory
difficulties.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of our current and potential products, as well as those supplied to Daxor by third parties, processing and manufacturing activities,
are subject to comprehensive regulation by the FDA in the United States and by comparable authorities in other countries. The company
has spent considerable resources and time obtaining FDA and other required regulatory approvals but is still subject to regulatory action
from the FDA if it chooses to revoke or enforce an interpretation of the regulations that would make distribution or manufacture of our
products disallowed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
we, or third-party manufacturers we may contract with, violate regulatory requirements at any stage the FDA may take enforcement action(s)
against us, which could include issuing a warning or untitled letter, placing a clinical hold on an ongoing clinical trial, product seizure,
enjoining our operations, refusal to consider our applications for pre-market approval, refusal of an investigational new drug application,
fines, or even civil or criminal liability, any of which could materially harm our reputation and financial results. In addition, if
manufacturing problems occur, regulators may withdraw their approval or demand additional changes in product manufacture or marketing
practices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Enforcement
actions we and our suppliers are subject to include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warning
    letters or other actions requiring changes in product manufacturing processes or restrictions on product marketing or distribution;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;product
    recalls or seizures or the temporary or permanent withdrawal of a product from the market;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;suspending
    any ongoing clinical trials;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;temporary
    or permanent injunctions against our production operations; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;fines,
    restitution or disgorgement of profits or revenue, the imposition of civil penalties or criminal prosecution.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
occurrence of any of these actions would likely cause a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
difficulties or failures that we encounter regarding regulatory approval for our products or those of third-party suppliers would likely
have a substantial adverse impact on our ability to generate product sales, and could make any search for a collaborative partner more
difficult.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;For
some of our products, we currently lack sufficient manufacturing capabilities to produce our products in-house and rely upon third party
suppliers. Disruption in our manufacturing supply, could negatively impact our ability to meet any future demand for the product.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
expect that we would need to significantly expand our manufacturing capabilities to meet potential demand for our diagnostic devices
and Volumex kits. In addition, we depend upon a single manufacturer for components of our products and a disruption in that supply could
materially impact our business disrupting out ability to meet demand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
currently manufacture our BVA-100 device in a 20,000 square foot facility in Oak Ridge, Tennessee. If our facilities where our products
are currently being manufactured or equipment were significantly damaged or destroyed, or if there were other disruptions, delays or
difficulties affecting manufacturing capacity, including if such facilities are deemed not in compliance with current Good Manufacturing
Practice, or GMP, requirements, future clinical studies and commercial production for our products would likely be significantly disrupted
and delayed. It would be both time-consuming and expensive to replace this capacity with third parties, particularly since any new facility
would need to comply with the regulatory requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ultimately,
if we are unable to supply our products to meet commercial demand, whether because of processing constraints or other disruptions, delays
or difficulties that we experience, our production costs could dramatically increase and sales of our products and their long-term commercial
prospects could be significantly damaged.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;To
be successful, our diagnostic products must be broadly accepted by the healthcare community, which can be very slow to adopt or unreceptive
to new technologies and products.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
products that we manufacture represent substantial departure from more established methods of volume assessment and compete with a number
of more conventional therapies based upon measures of pressure or hemodynamics manufactured and marketed by major medical device companies.
The degree of market acceptance and uptake of our products depends on a number of factors, including:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    establishment and demonstration to the medical community the clinical efficacy and safety of our proposed products;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to demonstrate that our products are superior to alternatives currently on the market in accuracy and ease of use;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to establish in the medical community the potential advantage of our diagnostic over alternative diagnostic methods; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reimbursement
    policies of government and third-party payers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the healthcare community does not accept our products for any of these reasons, or for any other reason, our business would be materially
harmed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Our
competition includes diagnostic companies that have significant advantages over us.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
market for medical diagnostic products is highly competitive. We expect that our most significant competitors will be fully integrated
and more established medical device companies with extensive product lines and distribution networks. These companies may seek to develop
similar products, and they have significantly greater capital resources and research and development, manufacturing, testing, regulatory
compliance, and marketing capabilities. As a result, our competitors may develop more competitive or affordable products, or achieve
earlier patent protection or product commercialization than we are able to achieve. Competitive products may render our products or future
products that we develop obsolete.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
may be subject to litigation that will be costly to defend or pursue and uncertain in its outcome.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
business may bring us into conflict with our licensees, licensors or others with whom we have contractual or other business relationships,
or with our competitors or others whose interests differ from ours. If we are unable to resolve those conflicts on terms that are satisfactory
to all parties, we may become involved in litigation brought by or against us. That litigation is likely to be expensive and may require
a significant amount of management&#x2019;s time and attention, at the expense of other aspects of our business. The outcome of litigation
is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities,
or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
are exposed to the risk of liability claims, for which we may not have adequate insurance.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
we participate in the health care industry, we may be subject to liability claims by employees, customers, end users and third parties
for past products and services as well as current or future products. While the company carries liability insurance there can be no assurance
that the liability insurance we carry will be adequate to cover claims asserted against us or that we will be able to maintain such insurance
in the future&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
currently have a marketing and sales force of approximately 12 employees and consultants. If we are unable to establish effective marketing
and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively
market and scale our sales to a significant scale.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
currently have a marketing and sales team for the marketing, sales and distribution of our BVA-100 device and kits. In order to fully
commercialize our products, we must expand our territory-by-territory basis marketing, sales, distribution, managerial and other non-technical
capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
failure or delay in the further development of our internal sales, marketing and distribution capabilities would adversely impact the
commercialization of any of our products that we obtain approval to market. We may choose to collaborate, either globally or on a territory-by-territory
basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and
distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when
needed on acceptable terms or at all this will adversely affect our ability to rapidly scale the sale of our products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Our
business and operations would suffer in the event of system failures or natural and man-made disasters.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Despite
the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to
damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While
we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our operations. For example, a hurricane or severe flood could disrupt
one of our key suppliers disrupting our supply chain for weeks or months causing material losses. If any disruption or security breach
resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability and additional costs despite some insurance products that the company has purchased to mitigate such costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
have incurred net operating losses in the past, and may incur them in the future.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have incurred cumulative net operating losses in the past. These losses have mainly resulted from ongoing expenses for marketing and
research and development as the company attempts to build a market for its products. In the past, the company&#x2019;s cumulative net
income from investments and other items exceeded the operating losses and provided the necessary funds for its continued research and
development and marketing. It is the opinion of management that the financial health of the company would have been adversely affected
if net income from investments had been substantially less than losses from operations. There is no guarantee that future net income
from investments will continue to completely offset operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;The
loss of any one customer could have an adverse effect on our consolidated operating business for a short period of time.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the past, the sale of Blood Volume Kits has accounted for a significant portion of the company&#x2019;s total consolidated operating revenue,
and a small number of customers (hospitals) has comprised the majority of such sales. Management believes that the loss of any one customer
would have an adverse effect on our consolidated operating business for a short period of time. The company continues to seek new customers,
so that any one hospital will represent a smaller percentage of overall sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
there is a decrease in the market value of our available for sale securities, this could have an adverse effect on our ability to fund
research and development and marketing efforts.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At December 31, &lt;span style="-sec-ix-redline: true"&gt;2024,
67.2%&lt;/span&gt; of the fair market value of Daxor&#x2019;s investment in securities consisted of utility stocks, all of which are electric utilities,
whose market price can be sensitive to rising interest rates. The company&#x2019;s investment policy calls for a minimum of 80% of the
investment portfolio to consist of electric utility stocks. The Board of Directors has authorized this minimum to be temporarily lowered
to 70% when management deems it to be necessary. Investments in utilities are primarily in electric companies. Investments in non-utility
stocks will generally not exceed 20% of the value of the portfolio of investment securities. Given the current volatility in the market,
management feels this is a temporary situation. Depending on the duration of the current market conditions the Board of Directors will
revisit this investment policy. At December 31, &lt;span style="-sec-ix-redline: true"&gt;2024,&lt;/span&gt; the fair market value of Daxor&#x2019;s investment in securities was 8.36%
of total net assets. The value of the operating division on a standalone basis and other assets and liabilities was the remaining balance
of the portfolio. &lt;span style="-sec-ix-redline: true"&gt;At December 31, 2024, the company&#x2019;s investment portfolio consisted of 8 separate investments in common stocks
and one preferred stock. The top five holdings as of this date in the investment portfolio were Bank of America, Evergy. Avista, Enbridge
and Eversource. These five holdings comprised 92.9% of the value of the investments in our securities portfolio and accounted for 53.9%
of the dividend income for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
is a risk that in an environment of rising interest rates that the market value of these stocks could decline and the utilities could
reduce their dividend payments to compensate for increased interest expense. This could have an adverse effect on Daxor&#x2019;s ability
to fund research and development and marketing efforts necessary to build a market for the company&#x2019;s products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;The
absence of patents or the inability to defend patents could negatively impact our ability to compete for and obtain new business.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Daxor
Corporation&#x2019;s patents for the BVA 100 expired in 2010. The company filed two additional patent applications for an automated instrument
to measure human blood volume which were granted April 7, 2015. The filings describe innovations which will be or have been incorporated
into the company&#x2019;s BVA-100 Blood Volume Analyzer, these patents expanded the capabilities of the analyzer to incorporate total
body albumin measures and error correction software to improve accuracy. In addition, the company filed additional patents on its blood
volume technology in January of 2018, and has several more patents in various stages of development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
blood volume analyzer, however, works most efficiently with the tracer injection kit system which has a separate patent and which expired
in 2016. It is possible that another company could develop another version of the Blood Volume Analyzer which would use a different tracer
injection kit. To the best of the company&#x2019;s knowledge, this has not happened yet and management views the development of a competing
tracer injection kit as unlikely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
the current manufacturer were to cease filling the Volumex syringes for us for any reason before we had a chance to make alternative
arrangements, this could have a material negative impact on our operating revenue.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of Daxor Corporation&#x2019;s orders for Volumex syringes are filled by a single FDA inspected radio pharmaceutical manufacturer. If this
manufacturer were to cease filling the Volumex syringes for the company or were denied permission to do so by FDA for any reason before
the company had a chance to make alternative arrangements, the effect on the company&#x2019;s operating revenue could be material. In
January 2007, we purchased two 10,000 square foot buildings in Oak Ridge, Tennessee to expand its research, development, and manufacturing
capabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AF_z7MFihMvJ5O9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</cef:RiskFactorsTableTextBlock>
    <cef:RiskTextBlock
      contextRef="From2025-07-232025-07-23_custom_MarketRisksMember"
      id="Fact000131">&lt;p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--MarketRisksMember_dU_zNkxyeHRnqJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8B1_zLES2XAyxjF2"&gt;Market
Risks&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
of money is a risk of investing in the company. The net asset value of the company can be expected to change daily and you may lose money.
There is no guarantee that the performance of our investment portfolio will be positive over any period of time, either short-term or
long-term. Market risk may affect a single issuer, industry, sector of the economy, or the market as a whole.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.
and international markets have experienced significant periods of volatility in recent years due to a number of economic, political and
global macro factors, including the impact of the coronavirus (COVID-19) as a global pandemic and related public health issues, growth
concerns in the U.S. and overseas, uncertainties regarding interest rates, trade tensions and the threat of tariffs imposed by the U.S.
and other countries. In particular, the spread of the novel coronavirus worldwide has resulted in disruptions to supply chains and customer
activity, stress on the global healthcare system, rising unemployment claims, quarantines, cancellations, market declines, the closing
of borders, restrictions on travel and widespread concern and uncertainty. Health crises and related political, social and economic disruptions
caused by the spread of the recent coronavirus outbreak may also exacerbate other pre-existing political, social and economic risks in
certain countries. It is not possible to know the extent of these impacts, and they may be short term or may last for an extended period
of time. These developments as well as other events, such as the U.S. presidential election, could result in further market volatility
and negatively affect security prices, the liquidity of certain securities and the normal operations of securities exchanges and other
markets, despite government efforts to address market disruptions.&lt;/span&gt;&lt;/p&gt;

</cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="From2025-07-232025-07-23_custom_EquityInvestmentsMember"
      id="Fact000133">&lt;p id="xdx_890_ecef--RiskTextBlock_hcef--RiskAxis__custom--EquityInvestmentsMember_dU_zWJ4DwOdPiEk" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8B9_zxdsQ7NCzdya"&gt;Equity
Investments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Because
we invest in equity securities, fluctuations in the stock market in general, as well as in the value of particular equity securities
held by us, can affect the performance of our investment portfolio. The value of equity securities will fluctuate due to many factors,
including the past and predicted earnings of the issuer, the quality of the issuer&#x2019;s management, general market conditions, forecasts
for the issuer&#x2019;s industry and the value of the issuer&#x2019;s assets.&lt;/span&gt;&lt;/p&gt;

</cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="From2025-07-232025-07-23_custom_IndustryConcentrationMember"
      id="Fact000135">&lt;p id="xdx_894_ecef--RiskTextBlock_hcef--RiskAxis__custom--IndustryConcentrationMember_dU_zjMqRS3FKFxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8B8_zjOj42ECW6b1"&gt;Industry
Concentration&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
concentrate our investments within the electric utility industry. Because of its narrow industry focus, the performance of our investment
portfolio is tied closely to and affected by developments in the electric utility industry, such as competition and weather. The electric
utility industry is also sensitive to increased interest rates because of the industry&#x2019;s capital intensive nature. Also, an increase
in interest rates could cause some electric utilities to decrease dividends paid to shareholders which would reduce our investment income.
The earnings of electric utility companies could also be negatively affected by power outages. Electric utilities operate in an environment
of federal, state and local regulations, and these regulations may disproportionately affect an individual utility.&lt;/span&gt;&lt;/p&gt;

</cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="From2025-07-232025-07-23_custom_ShortSaleRisksMember"
      id="Fact000137">&lt;p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--ShortSaleRisksMember_dU_zwQlhTiLokCi" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8B3_zraT901Ofvyh"&gt;Short
Sale Risks&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
investment portfolio will suffer a loss if it sells a security short and the value of the security rises rather than falls. It is possible
that the investment portfolio&#x2019;s long positions will decline in value at the same time that the value of its short positions increase,
thereby increasing potential losses to the portfolio. Short sales expose our investment portfolio to the risk that it will be required
to buy the security sold short (also known as &#x201c;covering&#x201d; the short position) at a time when the security has appreciated
in value, thus resulting in a loss to the portfolio. The investment performance of our investment portfolio will also suffer if it is
required to close out a short position earlier than it had intended. In addition, our investment portfolio may be subject to expenses
related to short sales that are not typically associated with investing in securities directly, such as costs of borrowing. These expenses
may negatively impact the performance of the investment portfolio. Short positions introduce more risk to the investment portfolio than
long positions (purchases) because the maximum sustainable loss on a security purchased (held long) is limited to the amount paid for
the security plus the transaction costs, whereas there is no maximum attainable price of the shorted security. Therefore, in theory,
securities sold short have unlimited risk.&lt;/span&gt;&lt;/p&gt;

</cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="From2025-07-232025-07-23_custom_PutAndCallOptionsRiskMember"
      id="Fact000139">&lt;p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--PutAndCallOptionsRiskMember_dU_zrGCDSV3pdqj" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8B9_zP5YksLm47P"&gt;Put
and Call Options Risk&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
use of options involves investment strategies and risks different from those associated with ordinary portfolio securities transactions.
If a strategy is applied at an inappropriate time or market conditions or trends are judged incorrectly, the use of options may lower
the return on the investment. There can be no guarantee that the use of options will increase the return or income on an investment.
In addition, there may be an imperfect correlation between the movement in prices of options and the securities underlying them and there
may at times not be a liquid secondary market for various options. An abrupt change in the price of an underlying security could render
an option worthless. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in
the value of the underlying instrument, or in interest or currency exchange rates, including the anticipated volatility of the underlying
instrument (known as implied volatility), which in turn are affected by fiscal and monetary policies and by national and international
political and economic events, as will the performance of the issuer of the underlying instrument. As such, prior to the exercise or
expiration of the option, the Company is exposed to implied volatility risk, meaning the value, as based on implied volatility, of an
option may increase due to market and economic conditions or views based on the sector or industry in which issuers of the underlying
instrument participate, including company-specific factors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;By
writing put options, the Company takes on the risk of declines in the value of the underlying instrument, including the possibility of
a loss up to the entire strike price of each option it sells, but without the corresponding opportunity to benefit from potential increases
in the value of the underlying instrument. When the Company writes a put option, it assumes the risk that it must purchase the underlying
instrument at a strike price that may be higher than the market price of the instrument. If there is a broad market decline and the Company
is not able to close out its written put options, it may result in substantial losses. By writing a call option, the Company may be obligated
to deliver instruments underlying an option at less than the market price. In the case of an uncovered call option, there is a risk of
unlimited loss. When an uncovered call is exercised, the Company must purchase the underlying instrument to meet its call obligations
and the necessary instruments may be unavailable for purchase. When the Company writes a covered call option, it gives up the opportunity
to profit from a price increase in the underlying instrument above the strike price. If a covered call option that the Company has written
is exercised, the Company will experience a gain or loss from the sale of the underlying instrument, depending on the price at which
the Company purchased the instrument and the strike price of the option. The Company will receive a premium from writing options, but
the premium received may not be sufficient to offset any losses sustained from exercised options. In the case of a covered call, the
premium received may be offset by a decline in the market value of the underlying instrument during the option period. If an option that
the Company has purchased is never exercised or closed out, the Company will lose the amount of the premium it paid and the use of those
funds. There were no put or call option positions at December 31, &lt;span style="-sec-ix-redline: true"&gt;2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</cef:RiskTextBlock>
    <cef:RiskTextBlock
      contextRef="From2025-07-232025-07-23_custom_OperatingCompanyRisksMember"
      id="Fact000141">&lt;p id="xdx_899_ecef--RiskTextBlock_hcef--RiskAxis__custom--OperatingCompanyRisksMember_dU_zzR8qhUshmU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_8BB_z8vvVCSLFzee"&gt;Operating
Company Risks&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Our
business is at an early stage of commercial development and we may struggle to generate significant commercial uptake in our products
with our current resources.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
business is at an early stage of commercial development. We have a base of installed devices or tests run at approximately 80 hospitals
and clinics and approximately 65,000 kits have been sold to clinicians. These sites are covered by a sales, marketing, technical, and
clinical support team of 12 individuals composed of employees and consultants. Investment in expanding these resources will be required
to reach larger target customers at hospitals and clinics across the country.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, significant research and clinical studies on the potential benefits of blood volume analysis to guide therapeutic decisions
will be required to gain acceptance into the guidelines of care and for broader clinical adoption. There is no guarantee that these studies
will be successful or completed in a timely or cost-effective manner allowing the company to benefit commercially from their completion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
will need additional capital to conduct our operations and develop our products, and our ability to obtain the necessary funding is uncertain.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have used a significant amount of cash and retained earnings since inception to finance the continued development and testing of our
BVA-100 system, and we expect to need additional capital resources in order to further commercialize the product as well as develop related
products and updates to our existing device.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
may not be successful in maintaining operating cash flow, and the timing of our capital expenditures and other expenditures may impede
our commercialization efforts if not sufficient. If financing is not sufficient and additional financing is not available or available
only on terms that are detrimental to our long-term survival, it could have a material adverse effect on our ability to successfully
commercialize our technology.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additional
financing through strategic collaborations, public or private equity or debt financings or other financing sources may not be available
on acceptable terms for our operating company, or at all. Additional equity financing could result in dilution to our shareholders. Further,
if we obtain additional funds through arrangements with collaborative partners, these arrangements may require us to relinquish rights
to some of our technologies, product or products that we would otherwise seek to develop and commercialize on our own.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
sufficient capital is not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or product
development initiatives, any of which could have an adverse effect on our financial condition or business prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Our
financial reporting reflects our status as a closed-end investment fund with an operating medical device division whose financial performance
is not broken out in detail and reported on a regular basis as is the case with traditional operating companies. As a result, shareholders
could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common
stock.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholders
seek detailed financial information in their investments and our reporting structure conforms to that of an investment fund. Investors
may become dissatisfied with the level of reporting detail that our current fund structure maintains and require greater transparency
in the future or lose confidence in the management resulting in a negative impact on the stock price. While the company intends to file
for a change of reporting structure in the future to a traditional operating company with the SEC as revenues from the operating division
increase whether that will be achievable and at what date remains unknown at this point in time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
our efforts to protect our intellectual property related to our technologies are not adequate, we may not be able to compete effectively
in our market and our business would be harmed.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related
to our technologies. Any disclosure to or misappropriation by third parties of our trade secrets or other confidential information could
assist competitors in duplicating or surpassing our technological achievements, thus eroding the competitive advantage we may derive
from these patents or know-how.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
strength of patents in the medical diagnostic field involves complex legal and scientific questions and can be uncertain. The patent
applications we own may fail to result in issued patents in the United States or in foreign countries and existing patents on parts of
our technology have entered the public domain. Third parties may challenge the validity, enforceability or scope of any issued patents
we own or license or any applications that may issue as patents in the future, which may result in those patents being narrowed, invalidated
or held unenforceable. Even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual
property or prevent others from developing similar products that do not fall within the scope of our patents. If the breadth or strength
of protection provided by the patents we hold or pursue is threatened, our ability to commercialize any product candidates with technology
protected by those patents could be threatened. Since patent applications in the United States and most other countries are confidential
for a period of time after filing, we cannot be certain at the time of filing that we are the first to file any patent application related
to our technology.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect
proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery
platform and drug development processes that involve proprietary know-how, information or technology that is not covered by patents or
not amenable to patent protection. Although we endeavor that all of our employees and certain consultants and advisors to assign inventions
to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information
or technology to enter into confidentiality agreements, our trade secrets and other proprietary information may be disclosed or competitors
may otherwise gain access to such information or independently develop substantially equivalent information. Further, the laws of some
foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result,
we may encounter significant difficulty in protecting and defending our intellectual property both in the United States and abroad. If
we are unable to prevent material disclosure of the trade secret intellectual property related to our technologies to third parties,
we may not be able to establish or maintain the competitive advantage that we believe is provided by such intellectual property, which
could materially adversely affect our market position and business and operational results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
may be involved in lawsuits to protect or enforce our patent, which could be expensive, time-consuming and unsuccessful.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Competitors
may infringe our patents. To attempt to stop infringement or unauthorized use, we may need to enforce one or more of our patents, which
can be expensive and time-consuming and distract management. If we pursue any litigation, a court may decide that a patent of ours or
our licensor&#x2019;s is not valid or is unenforceable, or may refuse to stop the other party from using the relevant technology on the
grounds that our patents do not cover the technology in question. Further, the legal systems of certain countries, particularly certain
developing countries, do not favor the enforcement of patents, which could reduce the likelihood of success of any infringement proceeding
we pursue in any such jurisdiction. An adverse result in any infringement litigation or defense proceedings could put one or more of
our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of
not issuing, which could limit our ability to exclude competitors from directly competing with us in the applicable jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interference
proceedings provoked by third parties or brought by the U.S. PTO may be necessary to determine the priority of inventions with respect
to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to use it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms, or at all. Litigation or interference proceedings may fail and, even if successful, may
result in substantial costs and distract our management and other employees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
we are unsuccessful in obtaining or maintaining patent protection for intellectual property in development, our business and competitive
position would be harmed.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are seeking patent protection for some of our technology and future products. Patent prosecution is a challenging process and is not
assured of success. If we are unable to secure patent protection for our technology and product candidates, our business may be adversely
impacted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, issued patents and pending international applications require regular maintenance. Failure to maintain our portfolio may result
in loss of rights that may adversely impact our intellectual property rights, for example by rendering issued patents unenforceable or
by prematurely terminating pending international applications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how,
technology and other proprietary information, to maintain our competitive position. We currently, and expect in the future to continue
to, seek to protect these trade secrets, in part, by entering into confidentiality agreements with parties who have access to them, such
as our employees, collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality
and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach
the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies
for any such disclosure. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive
and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing
or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor,
we would have no right to prevent them, or those to whom they disclose the trade secrets, from using that technology or information to
compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position
would be harmed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
will have to hire additional executive officers and employees to expand our business. If we are unable to hire qualified personnel, we
may not be able to implement our business strategy.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
loss of the services of any of our key product or business development employees could delay our product development programs and our
research and development efforts. We do not maintain key person life insurance on any of our officers, employees or consultants. In order
to develop our business in accordance with our business strategy, we will have to hire additional qualified personnel, including in the
areas of sales, physician education, manufacturing, clinical trials management, regulatory affairs, and business development. We will
need to raise sufficient funds to hire the necessary employees and have commenced our search for additional key employees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
depend on key personnel for our continued operations and future success, and a loss of certain key personnel could significantly hinder
our ability to move forward with our business plan.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Because
of the specialized nature of our business, we are highly dependent on our ability to identify, hire, train and retain highly qualified
scientific and technical personnel for the research and development activities we conduct or sponsor. The loss of one or more key executive
officers, or scientific officers, would be significantly detrimental to us. In addition, recruiting and retaining qualified scientific
personnel to perform research and development work is critical to our success. Our anticipated growth and expansion into areas and activities
requiring additional expertise will require the addition of new management personnel and the development of additional expertise by existing
management personnel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could cause our business to suffer.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
regulations of governmental authorities, such as the FDA or the European Medicines Agency, or EMA, to provide accurate information to
the FDA or EMA, to comply with manufacturing standards we have established, to comply with federal, state and international healthcare
fraud and abuse laws and regulations as they may become applicable to our operations, to report financial information or data accurately
or to disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the
course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to
identify and deter employee misconduct, and the precautions we currently take and the procedures we may establish in the future as our
operations and employee base expand to detect and prevent this type of activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure by our employees
to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves
or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition
of significant fines or other sanctions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
we experience delays or difficulties in clinical outcome studies or lack the funding to conduct them, receipt of necessary outcome data
could be delayed or prevented.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
trials using our BVA-100 depend upon the successful funding, enrollment, and initiation of studies in coordination with research institutions
and hospitals. The company does not have sufficient funds to fully sponsor as many outcome studies as may be warranted for adoption of
our diagnostic as a standard of care. As such, the company depends upon a combination of grants and research agreements with sponsoring
institutions for many of the studies that have been conducted with its technology and anticipates continuing to do so for the foreseeable
future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
and our suppliers are subject to extensive FDA regulation, which can be costly and time consuming and can subject us to unanticipated
business costs or difficulties. Even though regulatory approval for products may have been granted, those products may still face regulatory
difficulties.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of our current and potential products, as well as those supplied to Daxor by third parties, processing and manufacturing activities,
are subject to comprehensive regulation by the FDA in the United States and by comparable authorities in other countries. The company
has spent considerable resources and time obtaining FDA and other required regulatory approvals but is still subject to regulatory action
from the FDA if it chooses to revoke or enforce an interpretation of the regulations that would make distribution or manufacture of our
products disallowed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
we, or third-party manufacturers we may contract with, violate regulatory requirements at any stage the FDA may take enforcement action(s)
against us, which could include issuing a warning or untitled letter, placing a clinical hold on an ongoing clinical trial, product seizure,
enjoining our operations, refusal to consider our applications for pre-market approval, refusal of an investigational new drug application,
fines, or even civil or criminal liability, any of which could materially harm our reputation and financial results. In addition, if
manufacturing problems occur, regulators may withdraw their approval or demand additional changes in product manufacture or marketing
practices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Enforcement
actions we and our suppliers are subject to include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warning
    letters or other actions requiring changes in product manufacturing processes or restrictions on product marketing or distribution;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;product
    recalls or seizures or the temporary or permanent withdrawal of a product from the market;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;suspending
    any ongoing clinical trials;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;temporary
    or permanent injunctions against our production operations; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;fines,
    restitution or disgorgement of profits or revenue, the imposition of civil penalties or criminal prosecution.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
occurrence of any of these actions would likely cause a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
difficulties or failures that we encounter regarding regulatory approval for our products or those of third-party suppliers would likely
have a substantial adverse impact on our ability to generate product sales, and could make any search for a collaborative partner more
difficult.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;For
some of our products, we currently lack sufficient manufacturing capabilities to produce our products in-house and rely upon third party
suppliers. Disruption in our manufacturing supply, could negatively impact our ability to meet any future demand for the product.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
expect that we would need to significantly expand our manufacturing capabilities to meet potential demand for our diagnostic devices
and Volumex kits. In addition, we depend upon a single manufacturer for components of our products and a disruption in that supply could
materially impact our business disrupting out ability to meet demand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
currently manufacture our BVA-100 device in a 20,000 square foot facility in Oak Ridge, Tennessee. If our facilities where our products
are currently being manufactured or equipment were significantly damaged or destroyed, or if there were other disruptions, delays or
difficulties affecting manufacturing capacity, including if such facilities are deemed not in compliance with current Good Manufacturing
Practice, or GMP, requirements, future clinical studies and commercial production for our products would likely be significantly disrupted
and delayed. It would be both time-consuming and expensive to replace this capacity with third parties, particularly since any new facility
would need to comply with the regulatory requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ultimately,
if we are unable to supply our products to meet commercial demand, whether because of processing constraints or other disruptions, delays
or difficulties that we experience, our production costs could dramatically increase and sales of our products and their long-term commercial
prospects could be significantly damaged.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;To
be successful, our diagnostic products must be broadly accepted by the healthcare community, which can be very slow to adopt or unreceptive
to new technologies and products.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
products that we manufacture represent substantial departure from more established methods of volume assessment and compete with a number
of more conventional therapies based upon measures of pressure or hemodynamics manufactured and marketed by major medical device companies.
The degree of market acceptance and uptake of our products depends on a number of factors, including:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    establishment and demonstration to the medical community the clinical efficacy and safety of our proposed products;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to demonstrate that our products are superior to alternatives currently on the market in accuracy and ease of use;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to establish in the medical community the potential advantage of our diagnostic over alternative diagnostic methods; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;reimbursement
    policies of government and third-party payers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the healthcare community does not accept our products for any of these reasons, or for any other reason, our business would be materially
harmed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Our
competition includes diagnostic companies that have significant advantages over us.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
market for medical diagnostic products is highly competitive. We expect that our most significant competitors will be fully integrated
and more established medical device companies with extensive product lines and distribution networks. These companies may seek to develop
similar products, and they have significantly greater capital resources and research and development, manufacturing, testing, regulatory
compliance, and marketing capabilities. As a result, our competitors may develop more competitive or affordable products, or achieve
earlier patent protection or product commercialization than we are able to achieve. Competitive products may render our products or future
products that we develop obsolete.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
may be subject to litigation that will be costly to defend or pursue and uncertain in its outcome.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
business may bring us into conflict with our licensees, licensors or others with whom we have contractual or other business relationships,
or with our competitors or others whose interests differ from ours. If we are unable to resolve those conflicts on terms that are satisfactory
to all parties, we may become involved in litigation brought by or against us. That litigation is likely to be expensive and may require
a significant amount of management&#x2019;s time and attention, at the expense of other aspects of our business. The outcome of litigation
is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities,
or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
are exposed to the risk of liability claims, for which we may not have adequate insurance.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
we participate in the health care industry, we may be subject to liability claims by employees, customers, end users and third parties
for past products and services as well as current or future products. While the company carries liability insurance there can be no assurance
that the liability insurance we carry will be adequate to cover claims asserted against us or that we will be able to maintain such insurance
in the future&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
currently have a marketing and sales force of approximately 12 employees and consultants. If we are unable to establish effective marketing
and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively
market and scale our sales to a significant scale.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
currently have a marketing and sales team for the marketing, sales and distribution of our BVA-100 device and kits. In order to fully
commercialize our products, we must expand our territory-by-territory basis marketing, sales, distribution, managerial and other non-technical
capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
failure or delay in the further development of our internal sales, marketing and distribution capabilities would adversely impact the
commercialization of any of our products that we obtain approval to market. We may choose to collaborate, either globally or on a territory-by-territory
basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and
distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when
needed on acceptable terms or at all this will adversely affect our ability to rapidly scale the sale of our products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Our
business and operations would suffer in the event of system failures or natural and man-made disasters.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Despite
the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to
damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While
we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our operations. For example, a hurricane or severe flood could disrupt
one of our key suppliers disrupting our supply chain for weeks or months causing material losses. If any disruption or security breach
resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability and additional costs despite some insurance products that the company has purchased to mitigate such costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;We
have incurred net operating losses in the past, and may incur them in the future.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have incurred cumulative net operating losses in the past. These losses have mainly resulted from ongoing expenses for marketing and
research and development as the company attempts to build a market for its products. In the past, the company&#x2019;s cumulative net
income from investments and other items exceeded the operating losses and provided the necessary funds for its continued research and
development and marketing. It is the opinion of management that the financial health of the company would have been adversely affected
if net income from investments had been substantially less than losses from operations. There is no guarantee that future net income
from investments will continue to completely offset operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;The
loss of any one customer could have an adverse effect on our consolidated operating business for a short period of time.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the past, the sale of Blood Volume Kits has accounted for a significant portion of the company&#x2019;s total consolidated operating revenue,
and a small number of customers (hospitals) has comprised the majority of such sales. Management believes that the loss of any one customer
would have an adverse effect on our consolidated operating business for a short period of time. The company continues to seek new customers,
so that any one hospital will represent a smaller percentage of overall sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
there is a decrease in the market value of our available for sale securities, this could have an adverse effect on our ability to fund
research and development and marketing efforts.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At December 31, &lt;span style="-sec-ix-redline: true"&gt;2024,
67.2%&lt;/span&gt; of the fair market value of Daxor&#x2019;s investment in securities consisted of utility stocks, all of which are electric utilities,
whose market price can be sensitive to rising interest rates. The company&#x2019;s investment policy calls for a minimum of 80% of the
investment portfolio to consist of electric utility stocks. The Board of Directors has authorized this minimum to be temporarily lowered
to 70% when management deems it to be necessary. Investments in utilities are primarily in electric companies. Investments in non-utility
stocks will generally not exceed 20% of the value of the portfolio of investment securities. Given the current volatility in the market,
management feels this is a temporary situation. Depending on the duration of the current market conditions the Board of Directors will
revisit this investment policy. At December 31, &lt;span style="-sec-ix-redline: true"&gt;2024,&lt;/span&gt; the fair market value of Daxor&#x2019;s investment in securities was 8.36%
of total net assets. The value of the operating division on a standalone basis and other assets and liabilities was the remaining balance
of the portfolio. &lt;span style="-sec-ix-redline: true"&gt;At December 31, 2024, the company&#x2019;s investment portfolio consisted of 8 separate investments in common stocks
and one preferred stock. The top five holdings as of this date in the investment portfolio were Bank of America, Evergy. Avista, Enbridge
and Eversource. These five holdings comprised 92.9% of the value of the investments in our securities portfolio and accounted for 53.9%
of the dividend income for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
is a risk that in an environment of rising interest rates that the market value of these stocks could decline and the utilities could
reduce their dividend payments to compensate for increased interest expense. This could have an adverse effect on Daxor&#x2019;s ability
to fund research and development and marketing efforts necessary to build a market for the company&#x2019;s products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;The
absence of patents or the inability to defend patents could negatively impact our ability to compete for and obtain new business.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Daxor
Corporation&#x2019;s patents for the BVA 100 expired in 2010. The company filed two additional patent applications for an automated instrument
to measure human blood volume which were granted April 7, 2015. The filings describe innovations which will be or have been incorporated
into the company&#x2019;s BVA-100 Blood Volume Analyzer, these patents expanded the capabilities of the analyzer to incorporate total
body albumin measures and error correction software to improve accuracy. In addition, the company filed additional patents on its blood
volume technology in January of 2018, and has several more patents in various stages of development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
blood volume analyzer, however, works most efficiently with the tracer injection kit system which has a separate patent and which expired
in 2016. It is possible that another company could develop another version of the Blood Volume Analyzer which would use a different tracer
injection kit. To the best of the company&#x2019;s knowledge, this has not happened yet and management views the development of a competing
tracer injection kit as unlikely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;If
the current manufacturer were to cease filling the Volumex syringes for us for any reason before we had a chance to make alternative
arrangements, this could have a material negative impact on our operating revenue.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
of Daxor Corporation&#x2019;s orders for Volumex syringes are filled by a single FDA inspected radio pharmaceutical manufacturer. If this
manufacturer were to cease filling the Volumex syringes for the company or were denied permission to do so by FDA for any reason before
the company had a chance to make alternative arrangements, the effect on the company&#x2019;s operating revenue could be material. In
January 2007, we purchased two 10,000 square foot buildings in Oak Ridge, Tennessee to expand its research, development, and manufacturing
capabilities.&lt;/span&gt;&lt;/p&gt;

</cef:RiskTextBlock>
    <cef:CapitalStockTableTextBlock
      contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember"
      id="Fact000143">&lt;p id="xdx_80A_ecef--CapitalStockTableTextBlock_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_dU_zMjWa7hmbT53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="a_014"&gt;&lt;/span&gt;&lt;span id="xdx_820_zASonCYeWJv7"&gt;Daxor
Corporation &lt;span id="xdx_904_ecef--SecurityTitleTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z26bEP0327gb"&gt;Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecef--SecurityVotingRightsTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUvKC5kqg0w6"&gt;The
holders of the common stock have one vote per share for the election of directors, without provisions for cumulative voting, and on all
other matters. Thus, holders of more than 50% of the shares voting for the election of directors can elect all the directors if they
choose to do so.&lt;/span&gt; &lt;span id="xdx_906_ecef--SecurityPreemptiveAndOtherRightsTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zYj6UBnw7bIi"&gt;The common stock is not redeemable and has no conversion or preemptive rights.&lt;/span&gt; &lt;span id="xdx_903_ecef--SecurityObligationsOfOwnershipTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zorbvrVYVBC2"&gt;The company qualifies as a &#x201c;controlled
company&#x201d; under Nasdaq rules, as the estate of Joseph Feldschuh, M.D. controls more than 50% of the company&#x2019;s voting power,
as evidenced by the company&#x2019;s ownership records.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our common stock has continuously
been traded since its initial public offering. The company&#x2019;s common stock is traded on Nasdaq under the symbol DXR. As of May &lt;span style="-sec-ix-redline: true"&gt;19,
2025,&lt;/span&gt; the company&#x2019;s authorized securities consisted of &lt;span id="xdx_903_ecef--OutstandingSecurityAuthorizedShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z7GeZzkdKBx5"&gt;10,000,000&lt;/span&gt; shares of common stock.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecef--OutstandingSecuritiesTableTextBlock_dU_z6yRSkG2s235" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Outstanding Securities of Common Stock"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Amount Held by Company or for&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;Title of Class&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Amount Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;its Account&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Amount Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_983_ecef--OutstandingSecurityTitleTextBlock_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z0AADpTeGQq7" style="width: 46%; text-align: left"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecef--OutstandingSecurityAuthorizedShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zl4bpCpkTP2" style="width: 14%; text-align: right"&gt;10,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecef--OutstandingSecurityHeldShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zH2fO3bqlSg" style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;5,437,245&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecef--OutstandingSecurityNotHeldShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zTI0bNIgkuUj" style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,962,245&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zmsBXGLpU6T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth, for each of the periods indicated, the high and low closing market prices for the shares of Common Stock
on Nasdaq, the net asset value per share and the premium or discount to net asset value per share at which the shares were trading.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecef--SharePriceTableTextBlock_zfEWmwucpTXd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Price Range of Common Stock"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_ecef--HighestPriceOrBid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zCcVRfMVHjsl" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;High&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_487_ecef--LowestPriceOrBid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zABdm5KnXz08" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Low&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--NetAssetValuePerShare_iE_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zFBEAhU0kw06" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share&lt;sup id="xdx_F52_zDqFm44X6qlg"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_486_ecef--HighestPriceOrBidPremiumDiscountToNavPercent_pid_dp_uRatio_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z2PcwxOBcdA9" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;High
    &lt;sup id="xdx_F50_zHF1eUQWbXjj"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_486_ecef--LowestPriceOrBidPremiumDiscountToNavPercent_pid_dp_uRatio_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSbN2RcS9Lt7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Low
    &lt;sup id="xdx_F57_z5ER9VfmcEk8"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Premium/(Discount) to&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Market&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price
    Per Share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;per
    Common&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;High
    and Low&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;High&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Low&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;High&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Low&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20250401__20250630_zPB4cO5DYp4h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-June-25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.79&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;7.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;36.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_415_20250101__20250331_zULuvPPfu0Wb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Mar-25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_417_20241001__20241231_zlSAp93YOo06" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Dec-24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.89&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20240701__20240930_zl1UpJ62enFk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Sep-24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.86&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_418_20240401__20240630_zBJi3jS1ervh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-June-24&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.94&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20240101__20240331_zWGwjOo02Ac2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Mar-24&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20231001__20231231_zmnef5EjEIv7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Dec-23&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.26&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20230701__20230930_zgPZK4jcAsm7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Sep-23&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;68.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20230401__20230630_zuTB9wtB1kNd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Jun-23&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_415_20230101__20230331_z6ED7KXbAgS3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Mar-23&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20221001__20221231_zSukFvs5utV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Dec-22&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20220701__20220930_zzcjV9EH2cId" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Sep-22&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12.10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;214.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;167.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20220401__20220630_z9kPiQk7hV78" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Jun-22&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.21&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.85&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;172.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;119.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20220101__20220331_zAxliSVE4FRj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Mar-22&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;122.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20211001__20211231_zKqYCZqGT7c3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Dec-21&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;119.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20210701__20210930_zhP16iq88Vej" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Sep-21&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;257.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;160.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_415_20210401__20210630_zvM7S33BuWU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Jun-21&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;294.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;147.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20210101__20210331_zIuNgCePRq7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Mar-21&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;268.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F06_zU2DzSwEVEpf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_z2LATWapOgXc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    we calculate our Net Asset Value at month end, the table reflects the month end net asset value, and the premium/(discount) to net
    asset value is based on the month end net asset value. Percentages are rounded.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zmPIdxXqTAt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"&gt;The last reported sale price
on &lt;span style="-sec-ix-redline: true"&gt;June 4, 2025&lt;/span&gt; was &lt;span style="-sec-ix-redline: true"&gt;$8.59&lt;/span&gt; per &lt;span style="-sec-ix-redline: true"&gt;share, and the net asset value at May 31, 2025 was $7.18, for a premium of $1.41. Historically,
shares have traded at a premium to net asset value.&lt;/span&gt; We cannot predict whether our shares will trade in the future at a premium to
or discount from net asset value, or the level of any premium or discount.&lt;/p&gt;
</cef:CapitalStockTableTextBlock>
    <cef:SecurityTitleTextBlock
      contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember"
      id="Fact000144">Common Stock</cef:SecurityTitleTextBlock>
    <cef:SecurityVotingRightsTextBlock
      contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember"
      id="Fact000145">The
holders of the common stock have one vote per share for the election of directors, without provisions for cumulative voting, and on all
other matters. Thus, holders of more than 50% of the shares voting for the election of directors can elect all the directors if they
choose to do so.</cef:SecurityVotingRightsTextBlock>
    <cef:SecurityPreemptiveAndOtherRightsTextBlock
      contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember"
      id="Fact000146">The common stock is not redeemable and has no conversion or preemptive rights.</cef:SecurityPreemptiveAndOtherRightsTextBlock>
    <cef:SecurityObligationsOfOwnershipTextBlock
      contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember"
      id="Fact000147">The company qualifies as a &#x201c;controlled
company&#x201d; under Nasdaq rules, as the estate of Joseph Feldschuh, M.D. controls more than 50% of the company&#x2019;s voting power,
as evidenced by the company&#x2019;s ownership records.</cef:SecurityObligationsOfOwnershipTextBlock>
    <cef:OutstandingSecurityAuthorizedShares
      contextRef="From2025-05-192025-05-19_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000148"
      unitRef="Shares">10000000</cef:OutstandingSecurityAuthorizedShares>
    <cef:OutstandingSecuritiesTableTextBlock contextRef="AsOf2025-07-23" id="Fact000150">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecef--OutstandingSecuritiesTableTextBlock_dU_z6yRSkG2s235" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Outstanding Securities of Common Stock"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Amount Held by Company or for&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;Title of Class&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Amount Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;its Account&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Amount Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_983_ecef--OutstandingSecurityTitleTextBlock_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z0AADpTeGQq7" style="width: 46%; text-align: left"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecef--OutstandingSecurityAuthorizedShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zl4bpCpkTP2" style="width: 14%; text-align: right"&gt;10,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecef--OutstandingSecurityHeldShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zH2fO3bqlSg" style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;5,437,245&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecef--OutstandingSecurityNotHeldShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zTI0bNIgkuUj" style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;4,962,245&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cef:OutstandingSecuritiesTableTextBlock>
    <cef:OutstandingSecurityTitleTextBlock
      contextRef="From2025-05-192025-05-19_us-gaap_CommonStockMember"
      id="Fact000151">Common Stock</cef:OutstandingSecurityTitleTextBlock>
    <cef:OutstandingSecurityAuthorizedShares
      contextRef="From2025-05-192025-05-19_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000152"
      unitRef="Shares">10000000</cef:OutstandingSecurityAuthorizedShares>
    <cef:OutstandingSecurityHeldShares
      contextRef="From2025-05-192025-05-19_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">5437245</cef:OutstandingSecurityHeldShares>
    <cef:OutstandingSecurityNotHeldShares
      contextRef="From2025-05-192025-05-19_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000154"
      unitRef="Shares">4962245</cef:OutstandingSecurityNotHeldShares>
    <cef:SharePriceTableTextBlock contextRef="AsOf2025-07-23" id="Fact000156">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecef--SharePriceTableTextBlock_zfEWmwucpTXd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Price Range of Common Stock"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_ecef--HighestPriceOrBid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zCcVRfMVHjsl" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;High&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_487_ecef--LowestPriceOrBid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zABdm5KnXz08" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Low&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_48A_eus-gaap--NetAssetValuePerShare_iE_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zFBEAhU0kw06" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share&lt;sup id="xdx_F52_zDqFm44X6qlg"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_486_ecef--HighestPriceOrBidPremiumDiscountToNavPercent_pid_dp_uRatio_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z2PcwxOBcdA9" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;High
    &lt;sup id="xdx_F50_zHF1eUQWbXjj"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_486_ecef--LowestPriceOrBidPremiumDiscountToNavPercent_pid_dp_uRatio_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSbN2RcS9Lt7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Low
    &lt;sup id="xdx_F57_z5ER9VfmcEk8"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Premium/(Discount) to&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Market&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price
    Per Share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;per
    Common&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;High
    and Low&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During
    Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;High&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Low&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;High&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Low&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_419_20250401__20250630_zPB4cO5DYp4h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-June-25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.79&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;7.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;36.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_415_20250101__20250331_zULuvPPfu0Wb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Mar-25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_417_20241001__20241231_zlSAp93YOo06" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Dec-24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.89&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20240701__20240930_zl1UpJ62enFk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Sep-24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.86&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline: true"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_418_20240401__20240630_zBJi3jS1ervh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-June-24&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.94&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20240101__20240331_zWGwjOo02Ac2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Mar-24&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20231001__20231231_zmnef5EjEIv7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Dec-23&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.26&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41D_20230701__20230930_zgPZK4jcAsm7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Sep-23&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;68.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20230401__20230630_zuTB9wtB1kNd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Jun-23&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_415_20230101__20230331_z6ED7KXbAgS3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Mar-23&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20221001__20221231_zSukFvs5utV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Dec-22&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41B_20220701__20220930_zzcjV9EH2cId" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Sep-22&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12.10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;214.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;167.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41E_20220401__20220630_z9kPiQk7hV78" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Jun-22&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.21&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.85&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;172.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;119.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20220101__20220331_zAxliSVE4FRj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Mar-22&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.51&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;122.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_414_20211001__20211231_zKqYCZqGT7c3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Dec-21&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;119.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41F_20210701__20210930_zhP16iq88Vej" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Sep-21&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;257.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;160.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_415_20210401__20210630_zvM7S33BuWU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30-Jun-21&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;294.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;147.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_413_20210101__20210331_zIuNgCePRq7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31-Mar-21&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;268.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;192.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cef:SharePriceTableTextBlock>
    <cef:HighestPriceOrBid
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000157"
      unitRef="USDPShares">9.79</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000158"
      unitRef="USDPShares">7.20</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000159"
      unitRef="USDPShares">7.15</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000160"
      unitRef="Ratio">0.369</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2025-04-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000161"
      unitRef="Ratio">0.007</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000162"
      unitRef="USDPShares">8.50</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000163"
      unitRef="USDPShares">7.05</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000164"
      unitRef="USDPShares">7.18</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000165"
      unitRef="Ratio">0.184</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000166"
      unitRef="Ratio">-0.018</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2024-10-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000167"
      unitRef="USDPShares">9.89</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2024-10-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000168"
      unitRef="USDPShares">7.63</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000169"
      unitRef="USDPShares">7.25</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2024-10-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000170"
      unitRef="Ratio">0.364</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2024-10-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000171"
      unitRef="Ratio">0.052</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000172"
      unitRef="USDPShares">9.70</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000173"
      unitRef="USDPShares">7.86</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000174"
      unitRef="USDPShares">6.70</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000175"
      unitRef="Ratio">0.448</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000176"
      unitRef="Ratio">0.173</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000177"
      unitRef="USDPShares">9.94</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000178"
      unitRef="USDPShares">8.64</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000179"
      unitRef="USDPShares">6.75</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000180"
      unitRef="Ratio">0.473</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000181"
      unitRef="Ratio">0.280</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000182"
      unitRef="USDPShares">10.03</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000183"
      unitRef="USDPShares">7.19</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000184"
      unitRef="USDPShares">6.89</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000185"
      unitRef="Ratio">0.456</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000186"
      unitRef="Ratio">0.044</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000187"
      unitRef="USDPShares">9.60</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000188"
      unitRef="USDPShares">7.26</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000189"
      unitRef="USDPShares">7.08</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000190"
      unitRef="Ratio">0.356</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2023-10-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000191"
      unitRef="Ratio">0.025</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000192"
      unitRef="USDPShares">10.15</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000193"
      unitRef="USDPShares">9.03</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000194"
      unitRef="USDPShares">6.03</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000195"
      unitRef="Ratio">0.683</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000196"
      unitRef="Ratio">0.498</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000197"
      unitRef="USDPShares">13.03</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000198"
      unitRef="USDPShares">9.51</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000199"
      unitRef="USDPShares">6.33</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000200"
      unitRef="Ratio">1.058</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000201"
      unitRef="Ratio">0.502</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000202"
      unitRef="USDPShares">11.23</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000203"
      unitRef="USDPShares">8.25</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000204"
      unitRef="USDPShares">6.41</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000205"
      unitRef="Ratio">0.752</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000206"
      unitRef="Ratio">0.287</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000207"
      unitRef="USDPShares">13.63</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000208"
      unitRef="USDPShares">9.10</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000209"
      unitRef="USDPShares">6.75</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000210"
      unitRef="Ratio">1.019</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2022-10-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000211"
      unitRef="Ratio">0.348</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000212"
      unitRef="USDPShares">14.23</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000213"
      unitRef="USDPShares">12.10</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000214"
      unitRef="USDPShares">4.52</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000215"
      unitRef="Ratio">2.148</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000216"
      unitRef="Ratio">1.677</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000217"
      unitRef="USDPShares">13.21</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000218"
      unitRef="USDPShares">10.62</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000219"
      unitRef="USDPShares">4.85</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000220"
      unitRef="Ratio">1.724</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000221"
      unitRef="Ratio">1.190</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000222"
      unitRef="USDPShares">11.52</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000223"
      unitRef="USDPShares">10.51</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000224"
      unitRef="USDPShares">5.18</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000225"
      unitRef="Ratio">1.224</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000226"
      unitRef="Ratio">1.029</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000227"
      unitRef="USDPShares">11.50</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000228"
      unitRef="USDPShares">10.59</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000229"
      unitRef="USDPShares">5.24</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000230"
      unitRef="Ratio">1.195</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000231"
      unitRef="Ratio">1.021</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000232"
      unitRef="USDPShares">12.05</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000233"
      unitRef="USDPShares">8.77</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000234"
      unitRef="USDPShares">3.37</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000235"
      unitRef="Ratio">2.576</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000236"
      unitRef="Ratio">1.602</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000237"
      unitRef="USDPShares">14.15</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000238"
      unitRef="USDPShares">8.90</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000239"
      unitRef="USDPShares">3.59</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000240"
      unitRef="Ratio">2.942</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000241"
      unitRef="Ratio">1.479</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:HighestPriceOrBid
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000242"
      unitRef="USDPShares">13.86</cef:HighestPriceOrBid>
    <cef:LowestPriceOrBid
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000243"
      unitRef="USDPShares">11.02</cef:LowestPriceOrBid>
    <us-gaap:NetAssetValuePerShare
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000244"
      unitRef="USDPShares">3.77</us-gaap:NetAssetValuePerShare>
    <cef:HighestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000245"
      unitRef="Ratio">2.680</cef:HighestPriceOrBidPremiumDiscountToNavPercent>
    <cef:LowestPriceOrBidPremiumDiscountToNavPercent
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000246"
      unitRef="Ratio">1.926</cef:LowestPriceOrBidPremiumDiscountToNavPercent>
    <cef:SecurityDividendsTextBlock
      contextRef="From2025-07-232025-07-23_us-gaap_CommonStockMember"
      id="Fact000248">f
the company pays cash distributions to U.S. Holders of shares of the common stock, such distributions will constitute dividends for U.S.
federal income tax purposes to the extent paid from the company&#x2019;s current or accumulated earnings and profits, as determined under
U.S. federal income tax principles. Distributions in excess of current and accumulated earnings and profits will constitute a return
of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#x2019;s adjusted tax basis in the common stock.
Any remaining excess will be treated as gain realized on the sale or other disposition of the common stock and will be treated as described
under &#x201c;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of the Common Stock&#x201d; below.</cef:SecurityDividendsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#xdx2ixbrl0055"
          xlink:label="xdx2ixbrl0055"
          xlink:type="locator"/>
        <link:footnote id="Footnote000074" xlink:label="Footnote000074" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">If shares of Common Stock to which this prospectus
    relates are sold to or through underwriters, the applicable prospectus supplement will set forth any applicable sales load and the
    estimated expenses borne by the Company.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0055"
          xlink:to="Footnote000074"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0058"
          xlink:label="xdx2ixbrl0058"
          xlink:type="locator"/>
        <link:footnote id="Footnote000075" xlink:label="Footnote000075" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The company will bear the costs of the offering
    expenses and the applicable prospectus supplement will set forth the estimated offering costs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0058"
          xlink:to="Footnote000075"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000063"
          xlink:label="Fact000063"
          xlink:type="locator"/>
        <link:footnote id="Footnote000076" xlink:label="Footnote000076" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based upon average monthly net assets applicable
    to shares of Common Stock during the period ended December 31, 2024.</link:footnote>
        <link:footnote id="Footnote000077" xlink:label="Footnote000077" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The company does not pay a management fee.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000063"
          xlink:to="Footnote000076"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000063"
          xlink:to="Footnote000077"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000065"
          xlink:label="Fact000065"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000065"
          xlink:to="Footnote000076"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000067"
          xlink:label="Fact000067"
          xlink:type="locator"/>
        <link:footnote id="Footnote000078" xlink:label="Footnote000078" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">&#x201c;<xhtml:span id="xdx_90C_ecef--OtherExpensesNoteTextBlock_c20250723__20250723_zzP4gCGPYxFj">Annualized Other Expenses&#x201d; are
    based on estimated expense amounts for the current fiscal year.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000067"
          xlink:to="Footnote000078"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000067"
          xlink:to="Footnote000076"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000069"
          xlink:label="Fact000069"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000069"
          xlink:to="Footnote000076"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000071"
          xlink:label="Fact000071"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000071"
          xlink:to="Footnote000076"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000073"
          xlink:label="Fact000073"
          xlink:type="locator"/>
        <link:footnote id="Footnote000080" xlink:label="Footnote000080" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As explained in the company&#x2019;s Form
    N-CSR, as filed on March 3, 2025, the company has significant net operating loss and capital loss carry forwards and for the foreseeable
    future no adjustments to tax liabilities or operations is necessary. However, the company is subject to state and local taxes where
    the annualized impact to operations is approximately 0.10%.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000073"
          xlink:to="Footnote000080"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000073"
          xlink:to="Footnote000076"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000092"
          xlink:label="Fact000092"
          xlink:type="locator"/>
        <link:footnote id="Footnote000124" xlink:label="Footnote000124" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Derivatives transactions entered into in compliance
    with Rule 18f-4 under the Investment Company Act are not considered for purposes of computing asset coverage.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000092"
          xlink:to="Footnote000124"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000095"
          xlink:label="Fact000095"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000095"
          xlink:to="Footnote000124"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000098"
          xlink:label="Fact000098"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000098"
          xlink:to="Footnote000124"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000101"
          xlink:label="Fact000101"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000101"
          xlink:to="Footnote000124"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000104"
          xlink:label="Fact000104"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000104"
          xlink:to="Footnote000124"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000107"
          xlink:label="Fact000107"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000107"
          xlink:to="Footnote000124"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000110"
          xlink:label="Fact000110"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000110"
          xlink:to="Footnote000124"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000113"
          xlink:label="Fact000113"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000113"
          xlink:to="Footnote000124"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000116"
          xlink:label="Fact000116"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000116"
          xlink:to="Footnote000124"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000119"
          xlink:label="Fact000119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000119"
          xlink:to="Footnote000124"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000122"
          xlink:label="Fact000122"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000122"
          xlink:to="Footnote000124"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0093"
          xlink:label="xdx2ixbrl0093"
          xlink:type="locator"/>
        <link:footnote id="Footnote000125" xlink:label="Footnote000125" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Not applicable as the senior securities are not registered for public
    trading.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0093"
          xlink:to="Footnote000125"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0096"
          xlink:label="xdx2ixbrl0096"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0096"
          xlink:to="Footnote000125"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0099"
          xlink:label="xdx2ixbrl0099"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0099"
          xlink:to="Footnote000125"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0102"
          xlink:label="xdx2ixbrl0102"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0102"
          xlink:to="Footnote000125"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0105"
          xlink:label="xdx2ixbrl0105"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0105"
          xlink:to="Footnote000125"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0108"
          xlink:label="xdx2ixbrl0108"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0108"
          xlink:to="Footnote000125"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0111"
          xlink:label="xdx2ixbrl0111"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0111"
          xlink:to="Footnote000125"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0114"
          xlink:label="xdx2ixbrl0114"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0114"
          xlink:to="Footnote000125"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0117"
          xlink:label="xdx2ixbrl0117"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0117"
          xlink:to="Footnote000125"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0120"
          xlink:label="xdx2ixbrl0120"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0120"
          xlink:to="Footnote000125"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0123"
          xlink:label="xdx2ixbrl0123"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0123"
          xlink:to="Footnote000125"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000159"
          xlink:label="Fact000159"
          xlink:type="locator"/>
        <link:footnote id="Footnote000247" xlink:label="Footnote000247" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As
    we calculate our Net Asset Value at month end, the table reflects the month end net asset value, and the premium/(discount) to net
    asset value is based on the month end net asset value. Percentages are rounded.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000159"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000160"
          xlink:label="Fact000160"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000160"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000161"
          xlink:label="Fact000161"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000161"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000164"
          xlink:label="Fact000164"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000164"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000165"
          xlink:label="Fact000165"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000165"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000166"
          xlink:label="Fact000166"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000166"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000169"
          xlink:label="Fact000169"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000169"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000170"
          xlink:label="Fact000170"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000170"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000171"
          xlink:label="Fact000171"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000171"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000174"
          xlink:label="Fact000174"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000174"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000175"
          xlink:label="Fact000175"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000175"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000176"
          xlink:label="Fact000176"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000176"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000179"
          xlink:label="Fact000179"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000179"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000180"
          xlink:label="Fact000180"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000180"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000181"
          xlink:label="Fact000181"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000181"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000184"
          xlink:label="Fact000184"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000184"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000185"
          xlink:label="Fact000185"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000185"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000186"
          xlink:label="Fact000186"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000186"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000189"
          xlink:label="Fact000189"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000189"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000190"
          xlink:label="Fact000190"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000190"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000191"
          xlink:label="Fact000191"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000191"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000194"
          xlink:label="Fact000194"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000194"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000195"
          xlink:label="Fact000195"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000195"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000196"
          xlink:label="Fact000196"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000196"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000199"
          xlink:label="Fact000199"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000199"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000200"
          xlink:label="Fact000200"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000200"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000201"
          xlink:label="Fact000201"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000201"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000204"
          xlink:label="Fact000204"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000204"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000205"
          xlink:label="Fact000205"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000205"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000206"
          xlink:label="Fact000206"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000206"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000209"
          xlink:label="Fact000209"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000209"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000210"
          xlink:label="Fact000210"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000210"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000211"
          xlink:label="Fact000211"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000211"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000214"
          xlink:label="Fact000214"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000214"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000215"
          xlink:label="Fact000215"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000215"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000216"
          xlink:label="Fact000216"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000216"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000219"
          xlink:label="Fact000219"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000219"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000220"
          xlink:label="Fact000220"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000220"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000221"
          xlink:label="Fact000221"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000221"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000224"
          xlink:label="Fact000224"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000224"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000225"
          xlink:label="Fact000225"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000225"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000226"
          xlink:label="Fact000226"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000226"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000229"
          xlink:label="Fact000229"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000229"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000230"
          xlink:label="Fact000230"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000230"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000231"
          xlink:label="Fact000231"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000231"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000234"
          xlink:label="Fact000234"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000234"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000235"
          xlink:label="Fact000235"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000235"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000236"
          xlink:label="Fact000236"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000236"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000239"
          xlink:label="Fact000239"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000239"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000240"
          xlink:label="Fact000240"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000240"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000241"
          xlink:label="Fact000241"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000241"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000244"
          xlink:label="Fact000244"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000244"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000245"
          xlink:label="Fact000245"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000245"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000246"
          xlink:label="Fact000246"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000246"
          xlink:to="Footnote000247"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>N-2 - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="18">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 23, 2025</div></th>
<th class="th"><div>May 19, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">0000027367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Amendment
    No. 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInvCompanyType', window );">Entity Inv Company Type</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">N-2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">333-281622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_InvestmentCompanyActFileNumber', window );">Investment Company Act File Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">811-22684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">N-2/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreEffectiveAmendment', window );">Pre-Effective Amendment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreEffectiveAmendmentNumber', window );">Pre-Effective Amendment Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PostEffectiveAmendment', window );">Post-Effective Amendment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_InvestmentCompanyActRegistration', window );">Investment Company Act Registration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_InvestmentCompanyRegistrationAmendment', window );">Investment Company Registration Amendment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_InvestmentCompanyRegistrationAmendmentNumber', window );">Investment Company Registration Amendment Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">DAXOR
CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">107
    Meco Lane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Oak
    Ridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">37830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">(212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">330-8500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ApproximateDateOfCommencementOfProposedSaleToThePublic', window );">Approximate Date of Commencement of Proposed Sale to Public</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">From time to time after the effective date of this Registration Statement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DividendOrInterestReinvestmentPlanOnly', window );">Dividend or Interest Reinvestment Plan Only</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DelayedOrContinuousOffering', window );">Delayed or Continuous Offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_PrimaryShelfFlag', window );">Primary Shelf [Flag]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EffectiveUponFiling462e', window );">Effective Upon Filing, 462(e)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AdditionalSecuritiesEffective413b', window );">Additional Securities Effective, 413(b)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EffectiveWhenDeclaredSection8c', window );">Effective when Declared, Section 8(c)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_NewEffectiveDateForPreviousFiling', window );">New Effective Date for Previous Filing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AdditionalSecurities462b', window );">Additional Securities. 462(b)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_NoSubstantiveChanges462c', window );">No Substantive Changes, 462(c)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ExhibitsOnly462d', window );">Exhibits Only, 462(d)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RegisteredClosedEndFundFlag', window );">Registered Closed-End Fund [Flag]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_BusinessDevelopmentCompanyFlag', window );">Business Development Company [Flag]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_IntervalFundFlag', window );">Interval Fund [Flag]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_PrimaryShelfQualifiedFlag', window );">Primary Shelf Qualified [Flag]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_NewCefOrBdcRegistrantFlag', window );">New CEF or BDC Registrant [Flag]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FeeTableAbstract', window );"><strong>Fee Table [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_ShareholderTransactionExpensesTableTextBlock', window );">Shareholder Transaction Expenses [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecef--ShareholderTransactionExpensesTableTextBlock_dU_zT4WMUQWE779" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Shareholder Transaction Expenses">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Common Shareholder Transaction Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250723__20250723_zJADkWOTmyuf" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecef--SalesLoadPercent_pid_dp_zGS2n4HJu698" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Sales load paid by you (<span id="xdx_903_ecef--BasisOfTransactionFeesNoteTextBlock_c20250723__20250723_zk8UL3lQNP58">as a percentage of offering price</span>)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0055">-</span></td><td style="width: 1%; text-align: left">%<sup id="xdx_F4F_zKIUasgqN8Fg">(1)</sup></td></tr>
  <tr id="xdx_405_ecef--OtherTransactionExpensesPercent_pid_dp_zNYdcPcOOMp3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Offering expenses borne by shareholders (<span id="xdx_908_ecef--BasisOfTransactionFeesNoteTextBlock_c20250723__20250723_zPzONEUOqUF3">as a percentage of offering price</span>)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0058">-</span></td><td style="text-align: left">%<sup id="xdx_F4A_zV6Rzg1eA8bh">(2)</sup></td></tr>
  </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SalesLoadPercent', window );">Sales Load [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_OtherTransactionExpensesAbstract', window );"><strong>Other Transaction Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_OtherTransactionExpensesPercent', window );">Other Transaction Expenses [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_AnnualExpensesTableTextBlock', window );">Annual Expenses [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_ecef--AnnualExpensesTableTextBlock_dU_zGGjYGAlBQS2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Annual Expenses">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_490_20250723__20250723_zKcgspektxmi" style="text-align: center"><span style="font-size: 10pt"><b>Percentage of Net Assets</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 10pt"><b>Annual Expenses</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Attributable to Common
    <span style="-sec-ix-redline: true">Shares</span> <sup id="xdx_F5C_zBtX5oFdgtC9">(3)</sup></b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_ecef--ManagementFeesPercent_pid_dpn_zF7WGBV6gQn" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Management Fees<sup id="xdx_F44_zfDLcKvuWFIl">(4)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">None</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecef--InterestExpensesOnBorrowingsPercent_pid_dp_zu0uOmFZXjD4" style="vertical-align: bottom; background-color: white">
    <td style="width: 80%"><span style="font-size: 10pt">Annualized Interest Payments on Borrowed Funds</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-size: 10pt">0.29</span></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40C_ecef--OtherAnnualExpensesPercent_pid_dp_z2uqCqgZNZu2" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Annualized Other Expenses <sup id="xdx_F49_z3xWlQMCCGif">(5)</sup></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true"><span style="font-size: 10pt">5.45</span></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40C_ecef--TotalAnnualExpensesPercent_pid_dp_zNwiwiUE8eMb" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Total Annual Expenses before Taxes</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-redline: true"><span style="font-size: 10pt">5.74</span></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_400_ecef--WaiversAndReimbursementsOfFeesPercent_pid_dp_zr4xTe2PiqAd" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Estimated Annualized Tax Expense</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">0.10</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">%</span></td></tr>
  <tr id="xdx_401_ecef--NetExpenseOverAssetsPercent_pid_dp_zv8FiPCYvGMg" style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total Annual Expenses after Taxes<sup id="xdx_F4A_zObVlKQzkKGa">(6)</sup></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-redline: true"><span style="font-size: 10pt">5.84</span></span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">%</span></td></tr>
  </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_ManagementFeesPercent', window );">Management Fees [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_InterestExpensesOnBorrowingsPercent', window );">Interest Expenses on Borrowings [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_OtherAnnualExpensesAbstract', window );"><strong>Other Annual Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_OtherAnnualExpensesPercent', window );">Other Annual Expenses [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[5]</sup></td>
<td class="nump">5.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_TotalAnnualExpensesPercent', window );">Total Annual Expenses [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">5.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_WaiversAndReimbursementsOfFeesPercent', window );">Waivers and Reimbursements of Fees [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_NetExpenseOverAssetsPercent', window );">Net Expense over Assets [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[6]</sup></td>
<td class="nump">5.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_ExpenseExampleTableTextBlock', window );">Expense Example [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_89C_ecef--ExpenseExampleTableTextBlock_dU_zFvMO11Ttwh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Example should not be considered a representation
of future expenses or returns. Actual expenses may be higher or lower than those assumed. Moreover, the company&#8217;s actual rate of
return may be higher or lower than the hypothetical 5% return shown in the example. </b>The example assumes that all dividends and distributions
are reinvested at net asset value.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>1 Year</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>3 Years</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>5 Years</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>10 Years</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 40%"><span style="font-size: 10pt">Total Expenses paid by Common Shareholders</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98C_ecef--ExpenseExampleYear01_c20250723__20250723_zwVuYNeE84H1" style="width: 11%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-size: 10pt">210</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_ecef--ExpenseExampleYears1to3_c20250723__20250723_z00Vvy6yAeL4" style="width: 11%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-size: 10pt">294</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98B_ecef--ExpenseExampleYears1to5_c20250723__20250723_zl2MiziYbNB8" style="width: 11%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-size: 10pt">379</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_987_ecef--ExpenseExampleYears1to10_c20250723__20250723_zlhIIm8qzgy4" style="width: 11%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-size: 10pt">588</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The example above does not include sales loads
or estimated offering costs. In connection with an offering of shares of common stock, the <span style="-sec-ix-redline: true">applicable</span> prospectus supplement will
set forth an Example including sales load and estimated offering costs.</p>
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_ExpenseExampleYear01', window );">Expense Example, Year 01</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_ExpenseExampleYears1to3', window );">Expense Example, Years 1 to 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_ExpenseExampleYears1to5', window );">Expense Example, Years 1 to 5</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_ExpenseExampleYears1to10', window );">Expense Example, Years 1 to 10</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_BasisOfTransactionFeesNoteTextBlock', window );">Basis of Transaction Fees, Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">as a percentage of offering price<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_OtherExpensesNoteTextBlock', window );">Other Expenses, Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Annualized Other Expenses&#8221; are
    based on estimated expense amounts for the current fiscal year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesTableTextBlock', window );">Senior Securities [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_89F_ecef--SeniorSecuritiesTableTextBlock_dU_zDRJcKUZ5tgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline: true">Information about our senior securities is
shown in the following table as of the end of the last 10 fiscal years.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="-sec-ix-redline: true">Year</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_480_ecef--SeniorSecuritiesAmt_iI_zxpMPN7mkOwe" style="border-bottom: Black 1pt solid; font-weight: bold"><span style="-sec-ix-redline: true">Total Amount Outstanding Exclusive of Treasury Securities</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_48E_ecef--SeniorSecuritiesCvgPerUnit_iI_zxE1f4tGopu8" style="border-bottom: Black 1pt solid; font-weight: bold"><span style="-sec-ix-redline: true"><span style="font-size: 10pt"><b>Asset Coverage Per<br/>
    $1,000 of Indebtedness<sup id="xdx_F5F_z2oM1gKvzZEg">(1)</sup></b></span></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="-sec-ix-redline: true">Involuntary<br/> Liquidating<br/> Preferences Per Unit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="-sec-ix-redline: true"><span style="font-size: 10pt"><b>Average Market<br/> Value<sup id="xdx_F58_zbLeoLJFX2ej">(2)</sup></b></span></span></td></tr>
  <tr id="xdx_41E_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyFourMember_zjxa8QG7Rrid" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2024</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true">729,966</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true">50,033</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 14%"><span style="-sec-ix-redline: true">N/A</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 14%"><span style="-sec-ix-redline: true">N/A</span><span id="xdx_902_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyFourMember_fKDIp_zQkdhHdNh739" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></span></td></tr>
  <tr id="xdx_41F_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyThreeMember_z1SrotRFAKSd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2023</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">755,659</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">46,008</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_905_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyThreeMember_fKDIp_zUDlnZTXmPK" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0096">-</span></span></td></tr>
  <tr id="xdx_41E_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyTwoMember_z8AngQ8jFSPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2022</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">1,229,164</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">24,568</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_901_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyTwoMember_fKDIp_zqPCosFagNqf" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></span></td></tr>
  <tr id="xdx_41C_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyOneMember_zuoXFYn1qGb8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2021</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">3,022,542</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">7,998</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_90D_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyOneMember_fKDIp_zz2ond7r8Eng" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0102">-</span></span></td></tr>
  <tr id="xdx_412_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyMember_zlaDbUamBv2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2020</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">170,689</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">92,835</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_90D_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyMember_fKDIp_zpB99vxHBn4g" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0105">-</span></span></td></tr>
  <tr id="xdx_41D_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandNineteenMember_zxrrudkDJ6C6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2019</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">1,342,550</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">10,509</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_903_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandNineteenMember_fKDIp_zqVlXWJhOAO6" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0108">-</span></span></td></tr>
  <tr id="xdx_419_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandEighteenMember_zdr1npg18v2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2018</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">4,454,613</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">30,197</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_907_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandEighteenMember_fKDIp_zdqUt3lGjPu8" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0111">-</span></span></td></tr>
  <tr id="xdx_410_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSeventeenMember_zbyb23dKhzQ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2017</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">4,334,552</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">4,174</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_906_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSeventeenMember_fKDIp_zyNXOKU897kj" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0114">-</span></span></td></tr>
  <tr id="xdx_418_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSixteenMember_za6OUmVc9kh8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2016</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2,801,732</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">6,477</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_906_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSixteenMember_fKDIp_zBxZnM4oQtyc" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0117">-</span></span></td></tr>
  <tr id="xdx_416_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFifteenMember_zFP50yZCc94i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2015</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">3,845,112</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">4,752</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_90A_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFifteenMember_fKDIp_zeXC3yO9D2e9" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0120">-</span></span></td></tr>
  <tr id="xdx_414_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFourteenMember_zxRuis4aRwZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2014</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">21,356,338</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2,146</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_90A_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFourteenMember_fKDIp_z7M63JIQUFm4" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0123">-</span></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="-sec-ix-redline: true">&#160;</span></div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline: true"><span id="xdx_F0C_ztxIzWyKmFa" style="font-size: 10pt">(1)</span></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline: true"><span id="xdx_F13_zqVoC7iFSJSg" style="font-size: 10pt">Derivatives transactions entered into in compliance
    with Rule 18f-4 under the Investment Company Act are not considered for purposes of computing asset coverage.</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="-sec-ix-redline: true"><span id="xdx_F04_zN4rtX3H9FAd" style="font-size: 10pt">(2)</span></span></td>
    <td style="font-size: 10pt"><span style="-sec-ix-redline: true"><span id="xdx_F16_zkwZ7FBg2cHc" style="font-size: 10pt">Not applicable as the senior securities are not registered for public
    trading.</span></span></td></tr>
  </table>
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesNoteTextBlock', window );">Senior Securities, Note [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_802_ecef--SeniorSecuritiesNoteTextBlock_dU_zzTxdxMPdOXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>SENIOR
SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_89F_ecef--SeniorSecuritiesTableTextBlock_dU_zDRJcKUZ5tgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline: true">Information about our senior securities is
shown in the following table as of the end of the last 10 fiscal years.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="-sec-ix-redline: true">Year</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_480_ecef--SeniorSecuritiesAmt_iI_zxpMPN7mkOwe" style="border-bottom: Black 1pt solid; font-weight: bold"><span style="-sec-ix-redline: true">Total Amount Outstanding Exclusive of Treasury Securities</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td colspan="2" id="xdx_48E_ecef--SeniorSecuritiesCvgPerUnit_iI_zxE1f4tGopu8" style="border-bottom: Black 1pt solid; font-weight: bold"><span style="-sec-ix-redline: true"><span style="font-size: 10pt"><b>Asset Coverage Per<br/>
    $1,000 of Indebtedness<sup id="xdx_F5F_z2oM1gKvzZEg">(1)</sup></b></span></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="-sec-ix-redline: true">Involuntary<br/> Liquidating<br/> Preferences Per Unit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="-sec-ix-redline: true"><span style="font-size: 10pt"><b>Average Market<br/> Value<sup id="xdx_F58_zbLeoLJFX2ej">(2)</sup></b></span></span></td></tr>
  <tr id="xdx_41E_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyFourMember_zjxa8QG7Rrid" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2024</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true">729,966</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true">50,033</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 14%"><span style="-sec-ix-redline: true">N/A</span></td><td style="width: 2%"><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="width: 14%"><span style="-sec-ix-redline: true">N/A</span><span id="xdx_902_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyFourMember_fKDIp_zQkdhHdNh739" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></span></td></tr>
  <tr id="xdx_41F_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyThreeMember_z1SrotRFAKSd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2023</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">755,659</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">46,008</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_905_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyThreeMember_fKDIp_zUDlnZTXmPK" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0096">-</span></span></td></tr>
  <tr id="xdx_41E_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyTwoMember_z8AngQ8jFSPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2022</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">1,229,164</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">24,568</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_901_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyTwoMember_fKDIp_zqPCosFagNqf" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></span></td></tr>
  <tr id="xdx_41C_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyOneMember_zuoXFYn1qGb8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2021</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">3,022,542</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">7,998</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_90D_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyOneMember_fKDIp_zz2ond7r8Eng" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0102">-</span></span></td></tr>
  <tr id="xdx_412_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyMember_zlaDbUamBv2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2020</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">170,689</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">92,835</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_90D_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandTwentyMember_fKDIp_zpB99vxHBn4g" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0105">-</span></span></td></tr>
  <tr id="xdx_41D_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandNineteenMember_zxrrudkDJ6C6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2019</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">1,342,550</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">10,509</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_903_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandNineteenMember_fKDIp_zqVlXWJhOAO6" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0108">-</span></span></td></tr>
  <tr id="xdx_419_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandEighteenMember_zdr1npg18v2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2018</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">4,454,613</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">30,197</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_907_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandEighteenMember_fKDIp_zdqUt3lGjPu8" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0111">-</span></span></td></tr>
  <tr id="xdx_410_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSeventeenMember_zbyb23dKhzQ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2017</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">4,334,552</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">4,174</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_906_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSeventeenMember_fKDIp_zyNXOKU897kj" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0114">-</span></span></td></tr>
  <tr id="xdx_418_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSixteenMember_za6OUmVc9kh8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2016</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2,801,732</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">6,477</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_906_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandSixteenMember_fKDIp_zBxZnM4oQtyc" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0117">-</span></span></td></tr>
  <tr id="xdx_416_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFifteenMember_zFP50yZCc94i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2015</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">3,845,112</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">4,752</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_90A_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFifteenMember_fKDIp_zeXC3yO9D2e9" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0120">-</span></span></td></tr>
  <tr id="xdx_414_20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFourteenMember_zxRuis4aRwZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline: true">Margin Loans 2014</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">21,356,338</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline: true">2,146</span></td><td style="text-align: left"><span style="-sec-ix-redline: true">&#160;</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span></td><td><span style="-sec-ix-redline: true">&#160;</span></td>
    <td><span style="-sec-ix-redline: true">N/A</span><span id="xdx_90A_ecef--SeniorSecuritiesAverageMarketValuePerUnit_c20250723__20250723__us-gaap--DebtInstrumentAxis__custom--MarginLoansTwoThousandFourteenMember_fKDIp_z7M63JIQUFm4" style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0123">-</span></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"><span style="-sec-ix-redline: true">&#160;</span></div></div>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline: true"><span id="xdx_F0C_ztxIzWyKmFa" style="font-size: 10pt">(1)</span></span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline: true"><span id="xdx_F13_zqVoC7iFSJSg" style="font-size: 10pt">Derivatives transactions entered into in compliance
    with Rule 18f-4 under the Investment Company Act are not considered for purposes of computing asset coverage.</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="-sec-ix-redline: true"><span id="xdx_F04_zN4rtX3H9FAd" style="font-size: 10pt">(2)</span></span></td>
    <td style="font-size: 10pt"><span style="-sec-ix-redline: true"><span id="xdx_F16_zkwZ7FBg2cHc" style="font-size: 10pt">Not applicable as the senior securities are not registered for public
    trading.</span></span></td></tr>
  </table>
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_InvestmentObjectivesAndPracticesTextBlock', window );">Investment Objectives and Practices [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_897_ecef--InvestmentObjectivesAndPracticesTextBlock_dU_zSJNKrVzeq9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span><span id="xdx_8B7_zk0pgA4YPtsk">Investment
Objectives and Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
objective is to support and expand our operating businesses, through organic growth (i.e., the rate of business expansion through internal
enhancement of the business and operations as opposed to mergers, acquisitions and takeovers). The company is not primarily engaged in
the business of investing, reinvesting, owning, holding or trading in securities. Funds in excess of the company&#8217;s business needs
are placed in instruments designed to maximize capital preservation and assure liquidity. The foregoing policies may be changed without
a shareholder vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
concentrate our investments in the utility industry and have an investment policy that calls for a minimum of 80% of the company&#8217;s
investment portfolio to consist of electric utility stocks. The Board of Directors has authorized this minimum to be temporarily lowered
to 70% when management deems it to be necessary. At least once a year, the company reviews its investment strategy, and more frequently
as needed, at board meetings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investment portfolio primarily consists of electric utility companies which are publicly traded common and preferred stock. In addition
to receiving income from dividends from the securities held in the investment portfolio, we also have an investment policy of selling
puts on stocks that we are willing to own. Such options usually have a maturity of less than 1 year. The company will also sell covered
calls on securities within its investment portfolio. Covered calls involve stocks, which usually do not exceed 15% of the value of the
company&#8217;s portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will, at times, sell naked or uncovered calls, as well as, engage in short sales as part of an income strategy, and to a lesser extent
a strategy to mitigate risk. Our net short position will usually amount to less than 15% of the company&#8217;s portfolio value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this time, investments in debt instruments and foreign securities are not a principal investment strategy, and we expect any such investments
to be minimal.</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskFactorsTableTextBlock', window );">Risk Factors [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_80A_ecef--RiskFactorsTableTextBlock_dU_zSiuRGblvSre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span><span id="xdx_82E_zzIGkIWZDIs5">Risk
Factors</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline: true"><span style="text-decoration: underline">Deregistration as Investment Company</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true">We intend to file an application
pursuant to Section 8(f) of the Investment Company Act of 1940 seeking an order declaring that Daxor has ceased to be a registered investment
company. Investors in registered investment companies benefit from legal protections imposed for their benefit under the&#160;Investment
Company Act, and those legal protections will no longer apply if we receive the requested order. In addition, if we receive the requested
order, our tax treatment may change, and such a change could have an adverse effect on the value of an investment in Daxor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true">In connection with deregistering
as an investment company, we will take the appropriate steps to register under the Securities Exchange Act of 1934, as amended, and will
continue to be listed on Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline: true">With regard to this registration
statement, if we receive the order declaring that we have ceased to be an investment company, then we will immediately cease any offering
under this registration statement. In such eventuality, we will take the appropriate steps to convert this registration statement to
a registration statement on Form S-1 or Form S-3, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Investment
Portfolio Risks</span></span></p>

<p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--MarketRisksMember_dU_zNkxyeHRnqJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B1_zLES2XAyxjF2">Market
Risks</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
of money is a risk of investing in the company. The net asset value of the company can be expected to change daily and you may lose money.
There is no guarantee that the performance of our investment portfolio will be positive over any period of time, either short-term or
long-term. Market risk may affect a single issuer, industry, sector of the economy, or the market as a whole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
and international markets have experienced significant periods of volatility in recent years due to a number of economic, political and
global macro factors, including the impact of the coronavirus (COVID-19) as a global pandemic and related public health issues, growth
concerns in the U.S. and overseas, uncertainties regarding interest rates, trade tensions and the threat of tariffs imposed by the U.S.
and other countries. In particular, the spread of the novel coronavirus worldwide has resulted in disruptions to supply chains and customer
activity, stress on the global healthcare system, rising unemployment claims, quarantines, cancellations, market declines, the closing
of borders, restrictions on travel and widespread concern and uncertainty. Health crises and related political, social and economic disruptions
caused by the spread of the recent coronavirus outbreak may also exacerbate other pre-existing political, social and economic risks in
certain countries. It is not possible to know the extent of these impacts, and they may be short term or may last for an extended period
of time. These developments as well as other events, such as the U.S. presidential election, could result in further market volatility
and negatively affect security prices, the liquidity of certain securities and the normal operations of securities exchanges and other
markets, despite government efforts to address market disruptions.</span></p>

<p id="xdx_8A2_zj5kLvJ6yADh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_890_ecef--RiskTextBlock_hcef--RiskAxis__custom--EquityInvestmentsMember_dU_zWJ4DwOdPiEk" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B9_zxdsQ7NCzdya">Equity
Investments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we invest in equity securities, fluctuations in the stock market in general, as well as in the value of particular equity securities
held by us, can affect the performance of our investment portfolio. The value of equity securities will fluctuate due to many factors,
including the past and predicted earnings of the issuer, the quality of the issuer&#8217;s management, general market conditions, forecasts
for the issuer&#8217;s industry and the value of the issuer&#8217;s assets.</span></p>

<p id="xdx_8A2_zVzEjT5FLyjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p id="xdx_894_ecef--RiskTextBlock_hcef--RiskAxis__custom--IndustryConcentrationMember_dU_zjMqRS3FKFxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B8_zjOj42ECW6b1">Industry
Concentration</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
concentrate our investments within the electric utility industry. Because of its narrow industry focus, the performance of our investment
portfolio is tied closely to and affected by developments in the electric utility industry, such as competition and weather. The electric
utility industry is also sensitive to increased interest rates because of the industry&#8217;s capital intensive nature. Also, an increase
in interest rates could cause some electric utilities to decrease dividends paid to shareholders which would reduce our investment income.
The earnings of electric utility companies could also be negatively affected by power outages. Electric utilities operate in an environment
of federal, state and local regulations, and these regulations may disproportionately affect an individual utility.</span></p>

<p id="xdx_8A2_zqDmrmH7UdZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--ShortSaleRisksMember_dU_zwQlhTiLokCi" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B3_zraT901Ofvyh">Short
Sale Risks</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investment portfolio will suffer a loss if it sells a security short and the value of the security rises rather than falls. It is possible
that the investment portfolio&#8217;s long positions will decline in value at the same time that the value of its short positions increase,
thereby increasing potential losses to the portfolio. Short sales expose our investment portfolio to the risk that it will be required
to buy the security sold short (also known as &#8220;covering&#8221; the short position) at a time when the security has appreciated
in value, thus resulting in a loss to the portfolio. The investment performance of our investment portfolio will also suffer if it is
required to close out a short position earlier than it had intended. In addition, our investment portfolio may be subject to expenses
related to short sales that are not typically associated with investing in securities directly, such as costs of borrowing. These expenses
may negatively impact the performance of the investment portfolio. Short positions introduce more risk to the investment portfolio than
long positions (purchases) because the maximum sustainable loss on a security purchased (held long) is limited to the amount paid for
the security plus the transaction costs, whereas there is no maximum attainable price of the shorted security. Therefore, in theory,
securities sold short have unlimited risk.</span></p>

<p id="xdx_8A2_zlBhvSV9QER5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--PutAndCallOptionsRiskMember_dU_zrGCDSV3pdqj" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B9_zP5YksLm47P">Put
and Call Options Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of options involves investment strategies and risks different from those associated with ordinary portfolio securities transactions.
If a strategy is applied at an inappropriate time or market conditions or trends are judged incorrectly, the use of options may lower
the return on the investment. There can be no guarantee that the use of options will increase the return or income on an investment.
In addition, there may be an imperfect correlation between the movement in prices of options and the securities underlying them and there
may at times not be a liquid secondary market for various options. An abrupt change in the price of an underlying security could render
an option worthless. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in
the value of the underlying instrument, or in interest or currency exchange rates, including the anticipated volatility of the underlying
instrument (known as implied volatility), which in turn are affected by fiscal and monetary policies and by national and international
political and economic events, as will the performance of the issuer of the underlying instrument. As such, prior to the exercise or
expiration of the option, the Company is exposed to implied volatility risk, meaning the value, as based on implied volatility, of an
option may increase due to market and economic conditions or views based on the sector or industry in which issuers of the underlying
instrument participate, including company-specific factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
writing put options, the Company takes on the risk of declines in the value of the underlying instrument, including the possibility of
a loss up to the entire strike price of each option it sells, but without the corresponding opportunity to benefit from potential increases
in the value of the underlying instrument. When the Company writes a put option, it assumes the risk that it must purchase the underlying
instrument at a strike price that may be higher than the market price of the instrument. If there is a broad market decline and the Company
is not able to close out its written put options, it may result in substantial losses. By writing a call option, the Company may be obligated
to deliver instruments underlying an option at less than the market price. In the case of an uncovered call option, there is a risk of
unlimited loss. When an uncovered call is exercised, the Company must purchase the underlying instrument to meet its call obligations
and the necessary instruments may be unavailable for purchase. When the Company writes a covered call option, it gives up the opportunity
to profit from a price increase in the underlying instrument above the strike price. If a covered call option that the Company has written
is exercised, the Company will experience a gain or loss from the sale of the underlying instrument, depending on the price at which
the Company purchased the instrument and the strike price of the option. The Company will receive a premium from writing options, but
the premium received may not be sufficient to offset any losses sustained from exercised options. In the case of a covered call, the
premium received may be offset by a decline in the market value of the underlying instrument during the option period. If an option that
the Company has purchased is never exercised or closed out, the Company will lose the amount of the premium it paid and the use of those
funds. There were no put or call option positions at December 31, <span style="-sec-ix-redline: true">2024.</span></span></p>

<p id="xdx_8A2_zwucELldXWm" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p id="xdx_899_ecef--RiskTextBlock_hcef--RiskAxis__custom--OperatingCompanyRisksMember_dU_zzR8qhUshmU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_8BB_z8vvVCSLFzee">Operating
Company Risks</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is at an early stage of commercial development and we may struggle to generate significant commercial uptake in our products
with our current resources.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is at an early stage of commercial development. We have a base of installed devices or tests run at approximately 80 hospitals
and clinics and approximately 65,000 kits have been sold to clinicians. These sites are covered by a sales, marketing, technical, and
clinical support team of 12 individuals composed of employees and consultants. Investment in expanding these resources will be required
to reach larger target customers at hospitals and clinics across the country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, significant research and clinical studies on the potential benefits of blood volume analysis to guide therapeutic decisions
will be required to gain acceptance into the guidelines of care and for broader clinical adoption. There is no guarantee that these studies
will be successful or completed in a timely or cost-effective manner allowing the company to benefit commercially from their completion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need additional capital to conduct our operations and develop our products, and our ability to obtain the necessary funding is uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have used a significant amount of cash and retained earnings since inception to finance the continued development and testing of our
BVA-100 system, and we expect to need additional capital resources in order to further commercialize the product as well as develop related
products and updates to our existing device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be successful in maintaining operating cash flow, and the timing of our capital expenditures and other expenditures may impede
our commercialization efforts if not sufficient. If financing is not sufficient and additional financing is not available or available
only on terms that are detrimental to our long-term survival, it could have a material adverse effect on our ability to successfully
commercialize our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
financing through strategic collaborations, public or private equity or debt financings or other financing sources may not be available
on acceptable terms for our operating company, or at all. Additional equity financing could result in dilution to our shareholders. Further,
if we obtain additional funds through arrangements with collaborative partners, these arrangements may require us to relinquish rights
to some of our technologies, product or products that we would otherwise seek to develop and commercialize on our own.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
sufficient capital is not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or product
development initiatives, any of which could have an adverse effect on our financial condition or business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
financial reporting reflects our status as a closed-end investment fund with an operating medical device division whose financial performance
is not broken out in detail and reported on a regular basis as is the case with traditional operating companies. As a result, shareholders
could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common
stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
seek detailed financial information in their investments and our reporting structure conforms to that of an investment fund. Investors
may become dissatisfied with the level of reporting detail that our current fund structure maintains and require greater transparency
in the future or lose confidence in the management resulting in a negative impact on the stock price. While the company intends to file
for a change of reporting structure in the future to a traditional operating company with the SEC as revenues from the operating division
increase whether that will be achievable and at what date remains unknown at this point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our efforts to protect our intellectual property related to our technologies are not adequate, we may not be able to compete effectively
in our market and our business would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related
to our technologies. Any disclosure to or misappropriation by third parties of our trade secrets or other confidential information could
assist competitors in duplicating or surpassing our technological achievements, thus eroding the competitive advantage we may derive
from these patents or know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
strength of patents in the medical diagnostic field involves complex legal and scientific questions and can be uncertain. The patent
applications we own may fail to result in issued patents in the United States or in foreign countries and existing patents on parts of
our technology have entered the public domain. Third parties may challenge the validity, enforceability or scope of any issued patents
we own or license or any applications that may issue as patents in the future, which may result in those patents being narrowed, invalidated
or held unenforceable. Even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual
property or prevent others from developing similar products that do not fall within the scope of our patents. If the breadth or strength
of protection provided by the patents we hold or pursue is threatened, our ability to commercialize any product candidates with technology
protected by those patents could be threatened. Since patent applications in the United States and most other countries are confidential
for a period of time after filing, we cannot be certain at the time of filing that we are the first to file any patent application related
to our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect
proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery
platform and drug development processes that involve proprietary know-how, information or technology that is not covered by patents or
not amenable to patent protection. Although we endeavor that all of our employees and certain consultants and advisors to assign inventions
to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information
or technology to enter into confidentiality agreements, our trade secrets and other proprietary information may be disclosed or competitors
may otherwise gain access to such information or independently develop substantially equivalent information. Further, the laws of some
foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result,
we may encounter significant difficulty in protecting and defending our intellectual property both in the United States and abroad. If
we are unable to prevent material disclosure of the trade secret intellectual property related to our technologies to third parties,
we may not be able to establish or maintain the competitive advantage that we believe is provided by such intellectual property, which
could materially adversely affect our market position and business and operational results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be involved in lawsuits to protect or enforce our patent, which could be expensive, time-consuming and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patents. To attempt to stop infringement or unauthorized use, we may need to enforce one or more of our patents, which
can be expensive and time-consuming and distract management. If we pursue any litigation, a court may decide that a patent of ours or
our licensor&#8217;s is not valid or is unenforceable, or may refuse to stop the other party from using the relevant technology on the
grounds that our patents do not cover the technology in question. Further, the legal systems of certain countries, particularly certain
developing countries, do not favor the enforcement of patents, which could reduce the likelihood of success of any infringement proceeding
we pursue in any such jurisdiction. An adverse result in any infringement litigation or defense proceedings could put one or more of
our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of
not issuing, which could limit our ability to exclude competitors from directly competing with us in the applicable jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interference
proceedings provoked by third parties or brought by the U.S. PTO may be necessary to determine the priority of inventions with respect
to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to use it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms, or at all. Litigation or interference proceedings may fail and, even if successful, may
result in substantial costs and distract our management and other employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unsuccessful in obtaining or maintaining patent protection for intellectual property in development, our business and competitive
position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are seeking patent protection for some of our technology and future products. Patent prosecution is a challenging process and is not
assured of success. If we are unable to secure patent protection for our technology and product candidates, our business may be adversely
impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, issued patents and pending international applications require regular maintenance. Failure to maintain our portfolio may result
in loss of rights that may adversely impact our intellectual property rights, for example by rendering issued patents unenforceable or
by prematurely terminating pending international applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how,
technology and other proprietary information, to maintain our competitive position. We currently, and expect in the future to continue
to, seek to protect these trade secrets, in part, by entering into confidentiality agreements with parties who have access to them, such
as our employees, collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality
and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach
the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies
for any such disclosure. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive
and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing
or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor,
we would have no right to prevent them, or those to whom they disclose the trade secrets, from using that technology or information to
compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position
would be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will have to hire additional executive officers and employees to expand our business. If we are unable to hire qualified personnel, we
may not be able to implement our business strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loss of the services of any of our key product or business development employees could delay our product development programs and our
research and development efforts. We do not maintain key person life insurance on any of our officers, employees or consultants. In order
to develop our business in accordance with our business strategy, we will have to hire additional qualified personnel, including in the
areas of sales, physician education, manufacturing, clinical trials management, regulatory affairs, and business development. We will
need to raise sufficient funds to hire the necessary employees and have commenced our search for additional key employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on key personnel for our continued operations and future success, and a loss of certain key personnel could significantly hinder
our ability to move forward with our business plan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the specialized nature of our business, we are highly dependent on our ability to identify, hire, train and retain highly qualified
scientific and technical personnel for the research and development activities we conduct or sponsor. The loss of one or more key executive
officers, or scientific officers, would be significantly detrimental to us. In addition, recruiting and retaining qualified scientific
personnel to perform research and development work is critical to our success. Our anticipated growth and expansion into areas and activities
requiring additional expertise will require the addition of new management personnel and the development of additional expertise by existing
management personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could cause our business to suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
regulations of governmental authorities, such as the FDA or the European Medicines Agency, or EMA, to provide accurate information to
the FDA or EMA, to comply with manufacturing standards we have established, to comply with federal, state and international healthcare
fraud and abuse laws and regulations as they may become applicable to our operations, to report financial information or data accurately
or to disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the
course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to
identify and deter employee misconduct, and the precautions we currently take and the procedures we may establish in the future as our
operations and employee base expand to detect and prevent this type of activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure by our employees
to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves
or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition
of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we experience delays or difficulties in clinical outcome studies or lack the funding to conduct them, receipt of necessary outcome data
could be delayed or prevented.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials using our BVA-100 depend upon the successful funding, enrollment, and initiation of studies in coordination with research institutions
and hospitals. The company does not have sufficient funds to fully sponsor as many outcome studies as may be warranted for adoption of
our diagnostic as a standard of care. As such, the company depends upon a combination of grants and research agreements with sponsoring
institutions for many of the studies that have been conducted with its technology and anticipates continuing to do so for the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
and our suppliers are subject to extensive FDA regulation, which can be costly and time consuming and can subject us to unanticipated
business costs or difficulties. Even though regulatory approval for products may have been granted, those products may still face regulatory
difficulties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our current and potential products, as well as those supplied to Daxor by third parties, processing and manufacturing activities,
are subject to comprehensive regulation by the FDA in the United States and by comparable authorities in other countries. The company
has spent considerable resources and time obtaining FDA and other required regulatory approvals but is still subject to regulatory action
from the FDA if it chooses to revoke or enforce an interpretation of the regulations that would make distribution or manufacture of our
products disallowed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we, or third-party manufacturers we may contract with, violate regulatory requirements at any stage the FDA may take enforcement action(s)
against us, which could include issuing a warning or untitled letter, placing a clinical hold on an ongoing clinical trial, product seizure,
enjoining our operations, refusal to consider our applications for pre-market approval, refusal of an investigational new drug application,
fines, or even civil or criminal liability, any of which could materially harm our reputation and financial results. In addition, if
manufacturing problems occur, regulators may withdraw their approval or demand additional changes in product manufacture or marketing
practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforcement
actions we and our suppliers are subject to include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters or other actions requiring changes in product manufacturing processes or restrictions on product marketing or distribution;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls or seizures or the temporary or permanent withdrawal of a product from the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspending
    any ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">temporary
    or permanent injunctions against our production operations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitution or disgorgement of profits or revenue, the imposition of civil penalties or criminal prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of these actions would likely cause a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
difficulties or failures that we encounter regarding regulatory approval for our products or those of third-party suppliers would likely
have a substantial adverse impact on our ability to generate product sales, and could make any search for a collaborative partner more
difficult.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For
some of our products, we currently lack sufficient manufacturing capabilities to produce our products in-house and rely upon third party
suppliers. Disruption in our manufacturing supply, could negatively impact our ability to meet any future demand for the product.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that we would need to significantly expand our manufacturing capabilities to meet potential demand for our diagnostic devices
and Volumex kits. In addition, we depend upon a single manufacturer for components of our products and a disruption in that supply could
materially impact our business disrupting out ability to meet demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently manufacture our BVA-100 device in a 20,000 square foot facility in Oak Ridge, Tennessee. If our facilities where our products
are currently being manufactured or equipment were significantly damaged or destroyed, or if there were other disruptions, delays or
difficulties affecting manufacturing capacity, including if such facilities are deemed not in compliance with current Good Manufacturing
Practice, or GMP, requirements, future clinical studies and commercial production for our products would likely be significantly disrupted
and delayed. It would be both time-consuming and expensive to replace this capacity with third parties, particularly since any new facility
would need to comply with the regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ultimately,
if we are unable to supply our products to meet commercial demand, whether because of processing constraints or other disruptions, delays
or difficulties that we experience, our production costs could dramatically increase and sales of our products and their long-term commercial
prospects could be significantly damaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
be successful, our diagnostic products must be broadly accepted by the healthcare community, which can be very slow to adopt or unreceptive
to new technologies and products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
products that we manufacture represent substantial departure from more established methods of volume assessment and compete with a number
of more conventional therapies based upon measures of pressure or hemodynamics manufactured and marketed by major medical device companies.
The degree of market acceptance and uptake of our products depends on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    establishment and demonstration to the medical community the clinical efficacy and safety of our proposed products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate that our products are superior to alternatives currently on the market in accuracy and ease of use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish in the medical community the potential advantage of our diagnostic over alternative diagnostic methods; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reimbursement
    policies of government and third-party payers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the healthcare community does not accept our products for any of these reasons, or for any other reason, our business would be materially
harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
competition includes diagnostic companies that have significant advantages over us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for medical diagnostic products is highly competitive. We expect that our most significant competitors will be fully integrated
and more established medical device companies with extensive product lines and distribution networks. These companies may seek to develop
similar products, and they have significantly greater capital resources and research and development, manufacturing, testing, regulatory
compliance, and marketing capabilities. As a result, our competitors may develop more competitive or affordable products, or achieve
earlier patent protection or product commercialization than we are able to achieve. Competitive products may render our products or future
products that we develop obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to litigation that will be costly to defend or pursue and uncertain in its outcome.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business may bring us into conflict with our licensees, licensors or others with whom we have contractual or other business relationships,
or with our competitors or others whose interests differ from ours. If we are unable to resolve those conflicts on terms that are satisfactory
to all parties, we may become involved in litigation brought by or against us. That litigation is likely to be expensive and may require
a significant amount of management&#8217;s time and attention, at the expense of other aspects of our business. The outcome of litigation
is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities,
or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are exposed to the risk of liability claims, for which we may not have adequate insurance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
we participate in the health care industry, we may be subject to liability claims by employees, customers, end users and third parties
for past products and services as well as current or future products. While the company carries liability insurance there can be no assurance
that the liability insurance we carry will be adequate to cover claims asserted against us or that we will be able to maintain such insurance
in the future</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have a marketing and sales force of approximately 12 employees and consultants. If we are unable to establish effective marketing
and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively
market and scale our sales to a significant scale.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have a marketing and sales team for the marketing, sales and distribution of our BVA-100 device and kits. In order to fully
commercialize our products, we must expand our territory-by-territory basis marketing, sales, distribution, managerial and other non-technical
capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
failure or delay in the further development of our internal sales, marketing and distribution capabilities would adversely impact the
commercialization of any of our products that we obtain approval to market. We may choose to collaborate, either globally or on a territory-by-territory
basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and
distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when
needed on acceptable terms or at all this will adversely affect our ability to rapidly scale the sale of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations would suffer in the event of system failures or natural and man-made disasters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to
damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While
we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our operations. For example, a hurricane or severe flood could disrupt
one of our key suppliers disrupting our supply chain for weeks or months causing material losses. If any disruption or security breach
resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability and additional costs despite some insurance products that the company has purchased to mitigate such costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred net operating losses in the past, and may incur them in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred cumulative net operating losses in the past. These losses have mainly resulted from ongoing expenses for marketing and
research and development as the company attempts to build a market for its products. In the past, the company&#8217;s cumulative net
income from investments and other items exceeded the operating losses and provided the necessary funds for its continued research and
development and marketing. It is the opinion of management that the financial health of the company would have been adversely affected
if net income from investments had been substantially less than losses from operations. There is no guarantee that future net income
from investments will continue to completely offset operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
loss of any one customer could have an adverse effect on our consolidated operating business for a short period of time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, the sale of Blood Volume Kits has accounted for a significant portion of the company&#8217;s total consolidated operating revenue,
and a small number of customers (hospitals) has comprised the majority of such sales. Management believes that the loss of any one customer
would have an adverse effect on our consolidated operating business for a short period of time. The company continues to seek new customers,
so that any one hospital will represent a smaller percentage of overall sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
there is a decrease in the market value of our available for sale securities, this could have an adverse effect on our ability to fund
research and development and marketing efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December 31, <span style="-sec-ix-redline: true">2024,
67.2%</span> of the fair market value of Daxor&#8217;s investment in securities consisted of utility stocks, all of which are electric utilities,
whose market price can be sensitive to rising interest rates. The company&#8217;s investment policy calls for a minimum of 80% of the
investment portfolio to consist of electric utility stocks. The Board of Directors has authorized this minimum to be temporarily lowered
to 70% when management deems it to be necessary. Investments in utilities are primarily in electric companies. Investments in non-utility
stocks will generally not exceed 20% of the value of the portfolio of investment securities. Given the current volatility in the market,
management feels this is a temporary situation. Depending on the duration of the current market conditions the Board of Directors will
revisit this investment policy. At December 31, <span style="-sec-ix-redline: true">2024,</span> the fair market value of Daxor&#8217;s investment in securities was 8.36%
of total net assets. The value of the operating division on a standalone basis and other assets and liabilities was the remaining balance
of the portfolio. <span style="-sec-ix-redline: true">At December 31, 2024, the company&#8217;s investment portfolio consisted of 8 separate investments in common stocks
and one preferred stock. The top five holdings as of this date in the investment portfolio were Bank of America, Evergy. Avista, Enbridge
and Eversource. These five holdings comprised 92.9% of the value of the investments in our securities portfolio and accounted for 53.9%
of the dividend income for the year ended December 31, 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a risk that in an environment of rising interest rates that the market value of these stocks could decline and the utilities could
reduce their dividend payments to compensate for increased interest expense. This could have an adverse effect on Daxor&#8217;s ability
to fund research and development and marketing efforts necessary to build a market for the company&#8217;s products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
absence of patents or the inability to defend patents could negatively impact our ability to compete for and obtain new business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation&#8217;s patents for the BVA 100 expired in 2010. The company filed two additional patent applications for an automated instrument
to measure human blood volume which were granted April 7, 2015. The filings describe innovations which will be or have been incorporated
into the company&#8217;s BVA-100 Blood Volume Analyzer, these patents expanded the capabilities of the analyzer to incorporate total
body albumin measures and error correction software to improve accuracy. In addition, the company filed additional patents on its blood
volume technology in January of 2018, and has several more patents in various stages of development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
blood volume analyzer, however, works most efficiently with the tracer injection kit system which has a separate patent and which expired
in 2016. It is possible that another company could develop another version of the Blood Volume Analyzer which would use a different tracer
injection kit. To the best of the company&#8217;s knowledge, this has not happened yet and management views the development of a competing
tracer injection kit as unlikely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the current manufacturer were to cease filling the Volumex syringes for us for any reason before we had a chance to make alternative
arrangements, this could have a material negative impact on our operating revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of Daxor Corporation&#8217;s orders for Volumex syringes are filled by a single FDA inspected radio pharmaceutical manufacturer. If this
manufacturer were to cease filling the Volumex syringes for the company or were denied permission to do so by FDA for any reason before
the company had a chance to make alternative arrangements, the effect on the company&#8217;s operating revenue could be material. In
January 2007, we purchased two 10,000 square foot buildings in Oak Ridge, Tennessee to expand its research, development, and manufacturing
capabilities.</span></p>

<p id="xdx_8AF_z7MFihMvJ5O9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SharePriceTableTextBlock', window );">Share Price [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_ecef--SharePriceTableTextBlock_zfEWmwucpTXd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Price Range of Common Stock">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    Quarter Ended</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_48A_ecef--HighestPriceOrBid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zCcVRfMVHjsl" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">High</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_487_ecef--LowestPriceOrBid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zABdm5KnXz08" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_48A_eus-gaap--NetAssetValuePerShare_iE_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zFBEAhU0kw06" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share<sup id="xdx_F52_zDqFm44X6qlg">(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_486_ecef--HighestPriceOrBidPremiumDiscountToNavPercent_pid_dp_uRatio_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z2PcwxOBcdA9" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">High
    <sup id="xdx_F50_zHF1eUQWbXjj">(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_486_ecef--LowestPriceOrBidPremiumDiscountToNavPercent_pid_dp_uRatio_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSbN2RcS9Lt7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low
    <sup id="xdx_F57_z5ER9VfmcEk8">(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Premium/(Discount) to</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Market</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net Asset Value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net Asset Value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price
    Per Share</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">per
    Common</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">High
    and Low<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    Quarter Ended</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">High</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">High</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_419_20250401__20250630_zPB4cO5DYp4h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">30-June-25</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">9.79</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.20</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true">7.15</span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"></td><td style="text-align: right"><span style="-sec-ix-redline: true">36.9</span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true">0.7</span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td></tr>
  <tr id="xdx_415_20250101__20250331_zULuvPPfu0Wb" style="vertical-align: bottom; background-color: White">
    <td style="width: 20%; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">31-Mar-25</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">8.50</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">7.05</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">7.18</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">18.4</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">(1.8</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">)%</span></span></td></tr>
  <tr id="xdx_417_20241001__20241231_zlSAp93YOo06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">31-Dec-24</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">9.89</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">7.63</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">7.25</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">36.4</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">5.2</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td></tr>
  <tr id="xdx_413_20240701__20240930_zl1UpJ62enFk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">30-Sep-24</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">9.70</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">7.86</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">6.70</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">44.8</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">17.3</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td></tr>
  <tr id="xdx_418_20240401__20240630_zBJi3jS1ervh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-June-24</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.94</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.64</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">47.3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41F_20240101__20240331_zWGwjOo02Ac2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-24</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.89</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45.6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41D_20231001__20231231_zmnef5EjEIv7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Dec-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.26</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.08</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">35.6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41D_20230701__20230930_zgPZK4jcAsm7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Sep-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">68.3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49.8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41B_20230401__20230630_zuTB9wtB1kNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Jun-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">105.8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">50.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_415_20230101__20230331_z6ED7KXbAgS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.25</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">75.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28.7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41F_20221001__20221231_zSukFvs5utV6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Dec-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">101.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34.8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41B_20220701__20220930_zzcjV9EH2cId" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Sep-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14.23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12.10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.52</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">214.8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">167.7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41E_20220401__20220630_z9kPiQk7hV78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Jun-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.62</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.85</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">172.4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">119.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_414_20220101__20220331_zAxliSVE4FRj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.52</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.18</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">122.4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_414_20211001__20211231_zKqYCZqGT7c3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Dec-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.59</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.24</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">119.5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41F_20210701__20210930_zhP16iq88Vej" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Sep-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12.05</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">257.6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">160.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_415_20210401__20210630_zvM7S33BuWU7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Jun-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14.15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.90</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.59</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">294.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">147.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_413_20210101__20210331_zIuNgCePRq7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.86</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">268.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">192.6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_OutstandingSecuritiesTableTextBlock', window );">Outstanding Securities [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_ecef--OutstandingSecuritiesTableTextBlock_dU_z6yRSkG2s235" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Outstanding Securities of Common Stock">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Amount Held by Company or for</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Title of Class</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount Authorized</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">its Account</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount Outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_983_ecef--OutstandingSecurityTitleTextBlock_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z0AADpTeGQq7" style="width: 46%; text-align: left">Common Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecef--OutstandingSecurityAuthorizedShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zl4bpCpkTP2" style="width: 14%; text-align: right">10,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecef--OutstandingSecurityHeldShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zH2fO3bqlSg" style="width: 14%; text-align: right"><span style="-sec-ix-redline: true">5,437,245</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecef--OutstandingSecurityNotHeldShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zTI0bNIgkuUj" style="width: 14%; text-align: right"><span style="-sec-ix-redline: true">4,962,245</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskAxis=DXR_MarketRisksMember', window );">Market Risks [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--MarketRisksMember_dU_zNkxyeHRnqJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B1_zLES2XAyxjF2">Market
Risks</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
of money is a risk of investing in the company. The net asset value of the company can be expected to change daily and you may lose money.
There is no guarantee that the performance of our investment portfolio will be positive over any period of time, either short-term or
long-term. Market risk may affect a single issuer, industry, sector of the economy, or the market as a whole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
and international markets have experienced significant periods of volatility in recent years due to a number of economic, political and
global macro factors, including the impact of the coronavirus (COVID-19) as a global pandemic and related public health issues, growth
concerns in the U.S. and overseas, uncertainties regarding interest rates, trade tensions and the threat of tariffs imposed by the U.S.
and other countries. In particular, the spread of the novel coronavirus worldwide has resulted in disruptions to supply chains and customer
activity, stress on the global healthcare system, rising unemployment claims, quarantines, cancellations, market declines, the closing
of borders, restrictions on travel and widespread concern and uncertainty. Health crises and related political, social and economic disruptions
caused by the spread of the recent coronavirus outbreak may also exacerbate other pre-existing political, social and economic risks in
certain countries. It is not possible to know the extent of these impacts, and they may be short term or may last for an extended period
of time. These developments as well as other events, such as the U.S. presidential election, could result in further market volatility
and negatively affect security prices, the liquidity of certain securities and the normal operations of securities exchanges and other
markets, despite government efforts to address market disruptions.</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskAxis=DXR_EquityInvestmentsMember', window );">Equity Investments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_890_ecef--RiskTextBlock_hcef--RiskAxis__custom--EquityInvestmentsMember_dU_zWJ4DwOdPiEk" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B9_zxdsQ7NCzdya">Equity
Investments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we invest in equity securities, fluctuations in the stock market in general, as well as in the value of particular equity securities
held by us, can affect the performance of our investment portfolio. The value of equity securities will fluctuate due to many factors,
including the past and predicted earnings of the issuer, the quality of the issuer&#8217;s management, general market conditions, forecasts
for the issuer&#8217;s industry and the value of the issuer&#8217;s assets.</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskAxis=DXR_IndustryConcentrationMember', window );">Industry Concentration [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_894_ecef--RiskTextBlock_hcef--RiskAxis__custom--IndustryConcentrationMember_dU_zjMqRS3FKFxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B8_zjOj42ECW6b1">Industry
Concentration</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
concentrate our investments within the electric utility industry. Because of its narrow industry focus, the performance of our investment
portfolio is tied closely to and affected by developments in the electric utility industry, such as competition and weather. The electric
utility industry is also sensitive to increased interest rates because of the industry&#8217;s capital intensive nature. Also, an increase
in interest rates could cause some electric utilities to decrease dividends paid to shareholders which would reduce our investment income.
The earnings of electric utility companies could also be negatively affected by power outages. Electric utilities operate in an environment
of federal, state and local regulations, and these regulations may disproportionately affect an individual utility.</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskAxis=DXR_ShortSaleRisksMember', window );">Short Sale Risks [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--ShortSaleRisksMember_dU_zwQlhTiLokCi" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B3_zraT901Ofvyh">Short
Sale Risks</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investment portfolio will suffer a loss if it sells a security short and the value of the security rises rather than falls. It is possible
that the investment portfolio&#8217;s long positions will decline in value at the same time that the value of its short positions increase,
thereby increasing potential losses to the portfolio. Short sales expose our investment portfolio to the risk that it will be required
to buy the security sold short (also known as &#8220;covering&#8221; the short position) at a time when the security has appreciated
in value, thus resulting in a loss to the portfolio. The investment performance of our investment portfolio will also suffer if it is
required to close out a short position earlier than it had intended. In addition, our investment portfolio may be subject to expenses
related to short sales that are not typically associated with investing in securities directly, such as costs of borrowing. These expenses
may negatively impact the performance of the investment portfolio. Short positions introduce more risk to the investment portfolio than
long positions (purchases) because the maximum sustainable loss on a security purchased (held long) is limited to the amount paid for
the security plus the transaction costs, whereas there is no maximum attainable price of the shorted security. Therefore, in theory,
securities sold short have unlimited risk.</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskAxis=DXR_PutAndCallOptionsRiskMember', window );">Put And Call Options Risk [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_89D_ecef--RiskTextBlock_hcef--RiskAxis__custom--PutAndCallOptionsRiskMember_dU_zrGCDSV3pdqj" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_8B9_zP5YksLm47P">Put
and Call Options Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of options involves investment strategies and risks different from those associated with ordinary portfolio securities transactions.
If a strategy is applied at an inappropriate time or market conditions or trends are judged incorrectly, the use of options may lower
the return on the investment. There can be no guarantee that the use of options will increase the return or income on an investment.
In addition, there may be an imperfect correlation between the movement in prices of options and the securities underlying them and there
may at times not be a liquid secondary market for various options. An abrupt change in the price of an underlying security could render
an option worthless. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in
the value of the underlying instrument, or in interest or currency exchange rates, including the anticipated volatility of the underlying
instrument (known as implied volatility), which in turn are affected by fiscal and monetary policies and by national and international
political and economic events, as will the performance of the issuer of the underlying instrument. As such, prior to the exercise or
expiration of the option, the Company is exposed to implied volatility risk, meaning the value, as based on implied volatility, of an
option may increase due to market and economic conditions or views based on the sector or industry in which issuers of the underlying
instrument participate, including company-specific factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
writing put options, the Company takes on the risk of declines in the value of the underlying instrument, including the possibility of
a loss up to the entire strike price of each option it sells, but without the corresponding opportunity to benefit from potential increases
in the value of the underlying instrument. When the Company writes a put option, it assumes the risk that it must purchase the underlying
instrument at a strike price that may be higher than the market price of the instrument. If there is a broad market decline and the Company
is not able to close out its written put options, it may result in substantial losses. By writing a call option, the Company may be obligated
to deliver instruments underlying an option at less than the market price. In the case of an uncovered call option, there is a risk of
unlimited loss. When an uncovered call is exercised, the Company must purchase the underlying instrument to meet its call obligations
and the necessary instruments may be unavailable for purchase. When the Company writes a covered call option, it gives up the opportunity
to profit from a price increase in the underlying instrument above the strike price. If a covered call option that the Company has written
is exercised, the Company will experience a gain or loss from the sale of the underlying instrument, depending on the price at which
the Company purchased the instrument and the strike price of the option. The Company will receive a premium from writing options, but
the premium received may not be sufficient to offset any losses sustained from exercised options. In the case of a covered call, the
premium received may be offset by a decline in the market value of the underlying instrument during the option period. If an option that
the Company has purchased is never exercised or closed out, the Company will lose the amount of the premium it paid and the use of those
funds. There were no put or call option positions at December 31, <span style="-sec-ix-redline: true">2024.</span></span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskAxis=DXR_OperatingCompanyRisksMember', window );">Operating Company Risks [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_RiskTextBlock', window );">Risk [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_899_ecef--RiskTextBlock_hcef--RiskAxis__custom--OperatingCompanyRisksMember_dU_zzR8qhUshmU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_8BB_z8vvVCSLFzee">Operating
Company Risks</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is at an early stage of commercial development and we may struggle to generate significant commercial uptake in our products
with our current resources.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is at an early stage of commercial development. We have a base of installed devices or tests run at approximately 80 hospitals
and clinics and approximately 65,000 kits have been sold to clinicians. These sites are covered by a sales, marketing, technical, and
clinical support team of 12 individuals composed of employees and consultants. Investment in expanding these resources will be required
to reach larger target customers at hospitals and clinics across the country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, significant research and clinical studies on the potential benefits of blood volume analysis to guide therapeutic decisions
will be required to gain acceptance into the guidelines of care and for broader clinical adoption. There is no guarantee that these studies
will be successful or completed in a timely or cost-effective manner allowing the company to benefit commercially from their completion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need additional capital to conduct our operations and develop our products, and our ability to obtain the necessary funding is uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have used a significant amount of cash and retained earnings since inception to finance the continued development and testing of our
BVA-100 system, and we expect to need additional capital resources in order to further commercialize the product as well as develop related
products and updates to our existing device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be successful in maintaining operating cash flow, and the timing of our capital expenditures and other expenditures may impede
our commercialization efforts if not sufficient. If financing is not sufficient and additional financing is not available or available
only on terms that are detrimental to our long-term survival, it could have a material adverse effect on our ability to successfully
commercialize our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
financing through strategic collaborations, public or private equity or debt financings or other financing sources may not be available
on acceptable terms for our operating company, or at all. Additional equity financing could result in dilution to our shareholders. Further,
if we obtain additional funds through arrangements with collaborative partners, these arrangements may require us to relinquish rights
to some of our technologies, product or products that we would otherwise seek to develop and commercialize on our own.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
sufficient capital is not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or product
development initiatives, any of which could have an adverse effect on our financial condition or business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
financial reporting reflects our status as a closed-end investment fund with an operating medical device division whose financial performance
is not broken out in detail and reported on a regular basis as is the case with traditional operating companies. As a result, shareholders
could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common
stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
seek detailed financial information in their investments and our reporting structure conforms to that of an investment fund. Investors
may become dissatisfied with the level of reporting detail that our current fund structure maintains and require greater transparency
in the future or lose confidence in the management resulting in a negative impact on the stock price. While the company intends to file
for a change of reporting structure in the future to a traditional operating company with the SEC as revenues from the operating division
increase whether that will be achievable and at what date remains unknown at this point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our efforts to protect our intellectual property related to our technologies are not adequate, we may not be able to compete effectively
in our market and our business would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related
to our technologies. Any disclosure to or misappropriation by third parties of our trade secrets or other confidential information could
assist competitors in duplicating or surpassing our technological achievements, thus eroding the competitive advantage we may derive
from these patents or know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
strength of patents in the medical diagnostic field involves complex legal and scientific questions and can be uncertain. The patent
applications we own may fail to result in issued patents in the United States or in foreign countries and existing patents on parts of
our technology have entered the public domain. Third parties may challenge the validity, enforceability or scope of any issued patents
we own or license or any applications that may issue as patents in the future, which may result in those patents being narrowed, invalidated
or held unenforceable. Even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual
property or prevent others from developing similar products that do not fall within the scope of our patents. If the breadth or strength
of protection provided by the patents we hold or pursue is threatened, our ability to commercialize any product candidates with technology
protected by those patents could be threatened. Since patent applications in the United States and most other countries are confidential
for a period of time after filing, we cannot be certain at the time of filing that we are the first to file any patent application related
to our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect
proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery
platform and drug development processes that involve proprietary know-how, information or technology that is not covered by patents or
not amenable to patent protection. Although we endeavor that all of our employees and certain consultants and advisors to assign inventions
to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information
or technology to enter into confidentiality agreements, our trade secrets and other proprietary information may be disclosed or competitors
may otherwise gain access to such information or independently develop substantially equivalent information. Further, the laws of some
foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result,
we may encounter significant difficulty in protecting and defending our intellectual property both in the United States and abroad. If
we are unable to prevent material disclosure of the trade secret intellectual property related to our technologies to third parties,
we may not be able to establish or maintain the competitive advantage that we believe is provided by such intellectual property, which
could materially adversely affect our market position and business and operational results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be involved in lawsuits to protect or enforce our patent, which could be expensive, time-consuming and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patents. To attempt to stop infringement or unauthorized use, we may need to enforce one or more of our patents, which
can be expensive and time-consuming and distract management. If we pursue any litigation, a court may decide that a patent of ours or
our licensor&#8217;s is not valid or is unenforceable, or may refuse to stop the other party from using the relevant technology on the
grounds that our patents do not cover the technology in question. Further, the legal systems of certain countries, particularly certain
developing countries, do not favor the enforcement of patents, which could reduce the likelihood of success of any infringement proceeding
we pursue in any such jurisdiction. An adverse result in any infringement litigation or defense proceedings could put one or more of
our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of
not issuing, which could limit our ability to exclude competitors from directly competing with us in the applicable jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interference
proceedings provoked by third parties or brought by the U.S. PTO may be necessary to determine the priority of inventions with respect
to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to use it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms, or at all. Litigation or interference proceedings may fail and, even if successful, may
result in substantial costs and distract our management and other employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unsuccessful in obtaining or maintaining patent protection for intellectual property in development, our business and competitive
position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are seeking patent protection for some of our technology and future products. Patent prosecution is a challenging process and is not
assured of success. If we are unable to secure patent protection for our technology and product candidates, our business may be adversely
impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, issued patents and pending international applications require regular maintenance. Failure to maintain our portfolio may result
in loss of rights that may adversely impact our intellectual property rights, for example by rendering issued patents unenforceable or
by prematurely terminating pending international applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how,
technology and other proprietary information, to maintain our competitive position. We currently, and expect in the future to continue
to, seek to protect these trade secrets, in part, by entering into confidentiality agreements with parties who have access to them, such
as our employees, collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality
and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach
the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies
for any such disclosure. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive
and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing
or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor,
we would have no right to prevent them, or those to whom they disclose the trade secrets, from using that technology or information to
compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position
would be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will have to hire additional executive officers and employees to expand our business. If we are unable to hire qualified personnel, we
may not be able to implement our business strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loss of the services of any of our key product or business development employees could delay our product development programs and our
research and development efforts. We do not maintain key person life insurance on any of our officers, employees or consultants. In order
to develop our business in accordance with our business strategy, we will have to hire additional qualified personnel, including in the
areas of sales, physician education, manufacturing, clinical trials management, regulatory affairs, and business development. We will
need to raise sufficient funds to hire the necessary employees and have commenced our search for additional key employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on key personnel for our continued operations and future success, and a loss of certain key personnel could significantly hinder
our ability to move forward with our business plan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the specialized nature of our business, we are highly dependent on our ability to identify, hire, train and retain highly qualified
scientific and technical personnel for the research and development activities we conduct or sponsor. The loss of one or more key executive
officers, or scientific officers, would be significantly detrimental to us. In addition, recruiting and retaining qualified scientific
personnel to perform research and development work is critical to our success. Our anticipated growth and expansion into areas and activities
requiring additional expertise will require the addition of new management personnel and the development of additional expertise by existing
management personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could cause our business to suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
regulations of governmental authorities, such as the FDA or the European Medicines Agency, or EMA, to provide accurate information to
the FDA or EMA, to comply with manufacturing standards we have established, to comply with federal, state and international healthcare
fraud and abuse laws and regulations as they may become applicable to our operations, to report financial information or data accurately
or to disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the
course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to
identify and deter employee misconduct, and the precautions we currently take and the procedures we may establish in the future as our
operations and employee base expand to detect and prevent this type of activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure by our employees
to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves
or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition
of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we experience delays or difficulties in clinical outcome studies or lack the funding to conduct them, receipt of necessary outcome data
could be delayed or prevented.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials using our BVA-100 depend upon the successful funding, enrollment, and initiation of studies in coordination with research institutions
and hospitals. The company does not have sufficient funds to fully sponsor as many outcome studies as may be warranted for adoption of
our diagnostic as a standard of care. As such, the company depends upon a combination of grants and research agreements with sponsoring
institutions for many of the studies that have been conducted with its technology and anticipates continuing to do so for the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
and our suppliers are subject to extensive FDA regulation, which can be costly and time consuming and can subject us to unanticipated
business costs or difficulties. Even though regulatory approval for products may have been granted, those products may still face regulatory
difficulties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our current and potential products, as well as those supplied to Daxor by third parties, processing and manufacturing activities,
are subject to comprehensive regulation by the FDA in the United States and by comparable authorities in other countries. The company
has spent considerable resources and time obtaining FDA and other required regulatory approvals but is still subject to regulatory action
from the FDA if it chooses to revoke or enforce an interpretation of the regulations that would make distribution or manufacture of our
products disallowed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we, or third-party manufacturers we may contract with, violate regulatory requirements at any stage the FDA may take enforcement action(s)
against us, which could include issuing a warning or untitled letter, placing a clinical hold on an ongoing clinical trial, product seizure,
enjoining our operations, refusal to consider our applications for pre-market approval, refusal of an investigational new drug application,
fines, or even civil or criminal liability, any of which could materially harm our reputation and financial results. In addition, if
manufacturing problems occur, regulators may withdraw their approval or demand additional changes in product manufacture or marketing
practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforcement
actions we and our suppliers are subject to include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters or other actions requiring changes in product manufacturing processes or restrictions on product marketing or distribution;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls or seizures or the temporary or permanent withdrawal of a product from the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspending
    any ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">temporary
    or permanent injunctions against our production operations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitution or disgorgement of profits or revenue, the imposition of civil penalties or criminal prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of these actions would likely cause a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
difficulties or failures that we encounter regarding regulatory approval for our products or those of third-party suppliers would likely
have a substantial adverse impact on our ability to generate product sales, and could make any search for a collaborative partner more
difficult.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For
some of our products, we currently lack sufficient manufacturing capabilities to produce our products in-house and rely upon third party
suppliers. Disruption in our manufacturing supply, could negatively impact our ability to meet any future demand for the product.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that we would need to significantly expand our manufacturing capabilities to meet potential demand for our diagnostic devices
and Volumex kits. In addition, we depend upon a single manufacturer for components of our products and a disruption in that supply could
materially impact our business disrupting out ability to meet demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently manufacture our BVA-100 device in a 20,000 square foot facility in Oak Ridge, Tennessee. If our facilities where our products
are currently being manufactured or equipment were significantly damaged or destroyed, or if there were other disruptions, delays or
difficulties affecting manufacturing capacity, including if such facilities are deemed not in compliance with current Good Manufacturing
Practice, or GMP, requirements, future clinical studies and commercial production for our products would likely be significantly disrupted
and delayed. It would be both time-consuming and expensive to replace this capacity with third parties, particularly since any new facility
would need to comply with the regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ultimately,
if we are unable to supply our products to meet commercial demand, whether because of processing constraints or other disruptions, delays
or difficulties that we experience, our production costs could dramatically increase and sales of our products and their long-term commercial
prospects could be significantly damaged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
be successful, our diagnostic products must be broadly accepted by the healthcare community, which can be very slow to adopt or unreceptive
to new technologies and products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
products that we manufacture represent substantial departure from more established methods of volume assessment and compete with a number
of more conventional therapies based upon measures of pressure or hemodynamics manufactured and marketed by major medical device companies.
The degree of market acceptance and uptake of our products depends on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    establishment and demonstration to the medical community the clinical efficacy and safety of our proposed products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate that our products are superior to alternatives currently on the market in accuracy and ease of use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish in the medical community the potential advantage of our diagnostic over alternative diagnostic methods; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reimbursement
    policies of government and third-party payers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the healthcare community does not accept our products for any of these reasons, or for any other reason, our business would be materially
harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
competition includes diagnostic companies that have significant advantages over us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for medical diagnostic products is highly competitive. We expect that our most significant competitors will be fully integrated
and more established medical device companies with extensive product lines and distribution networks. These companies may seek to develop
similar products, and they have significantly greater capital resources and research and development, manufacturing, testing, regulatory
compliance, and marketing capabilities. As a result, our competitors may develop more competitive or affordable products, or achieve
earlier patent protection or product commercialization than we are able to achieve. Competitive products may render our products or future
products that we develop obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to litigation that will be costly to defend or pursue and uncertain in its outcome.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business may bring us into conflict with our licensees, licensors or others with whom we have contractual or other business relationships,
or with our competitors or others whose interests differ from ours. If we are unable to resolve those conflicts on terms that are satisfactory
to all parties, we may become involved in litigation brought by or against us. That litigation is likely to be expensive and may require
a significant amount of management&#8217;s time and attention, at the expense of other aspects of our business. The outcome of litigation
is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities,
or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are exposed to the risk of liability claims, for which we may not have adequate insurance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
we participate in the health care industry, we may be subject to liability claims by employees, customers, end users and third parties
for past products and services as well as current or future products. While the company carries liability insurance there can be no assurance
that the liability insurance we carry will be adequate to cover claims asserted against us or that we will be able to maintain such insurance
in the future</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have a marketing and sales force of approximately 12 employees and consultants. If we are unable to establish effective marketing
and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively
market and scale our sales to a significant scale.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have a marketing and sales team for the marketing, sales and distribution of our BVA-100 device and kits. In order to fully
commercialize our products, we must expand our territory-by-territory basis marketing, sales, distribution, managerial and other non-technical
capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
failure or delay in the further development of our internal sales, marketing and distribution capabilities would adversely impact the
commercialization of any of our products that we obtain approval to market. We may choose to collaborate, either globally or on a territory-by-territory
basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and
distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when
needed on acceptable terms or at all this will adversely affect our ability to rapidly scale the sale of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations would suffer in the event of system failures or natural and man-made disasters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to
damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While
we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our operations. For example, a hurricane or severe flood could disrupt
one of our key suppliers disrupting our supply chain for weeks or months causing material losses. If any disruption or security breach
resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability and additional costs despite some insurance products that the company has purchased to mitigate such costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred net operating losses in the past, and may incur them in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred cumulative net operating losses in the past. These losses have mainly resulted from ongoing expenses for marketing and
research and development as the company attempts to build a market for its products. In the past, the company&#8217;s cumulative net
income from investments and other items exceeded the operating losses and provided the necessary funds for its continued research and
development and marketing. It is the opinion of management that the financial health of the company would have been adversely affected
if net income from investments had been substantially less than losses from operations. There is no guarantee that future net income
from investments will continue to completely offset operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
loss of any one customer could have an adverse effect on our consolidated operating business for a short period of time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, the sale of Blood Volume Kits has accounted for a significant portion of the company&#8217;s total consolidated operating revenue,
and a small number of customers (hospitals) has comprised the majority of such sales. Management believes that the loss of any one customer
would have an adverse effect on our consolidated operating business for a short period of time. The company continues to seek new customers,
so that any one hospital will represent a smaller percentage of overall sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
there is a decrease in the market value of our available for sale securities, this could have an adverse effect on our ability to fund
research and development and marketing efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December 31, <span style="-sec-ix-redline: true">2024,
67.2%</span> of the fair market value of Daxor&#8217;s investment in securities consisted of utility stocks, all of which are electric utilities,
whose market price can be sensitive to rising interest rates. The company&#8217;s investment policy calls for a minimum of 80% of the
investment portfolio to consist of electric utility stocks. The Board of Directors has authorized this minimum to be temporarily lowered
to 70% when management deems it to be necessary. Investments in utilities are primarily in electric companies. Investments in non-utility
stocks will generally not exceed 20% of the value of the portfolio of investment securities. Given the current volatility in the market,
management feels this is a temporary situation. Depending on the duration of the current market conditions the Board of Directors will
revisit this investment policy. At December 31, <span style="-sec-ix-redline: true">2024,</span> the fair market value of Daxor&#8217;s investment in securities was 8.36%
of total net assets. The value of the operating division on a standalone basis and other assets and liabilities was the remaining balance
of the portfolio. <span style="-sec-ix-redline: true">At December 31, 2024, the company&#8217;s investment portfolio consisted of 8 separate investments in common stocks
and one preferred stock. The top five holdings as of this date in the investment portfolio were Bank of America, Evergy. Avista, Enbridge
and Eversource. These five holdings comprised 92.9% of the value of the investments in our securities portfolio and accounted for 53.9%
of the dividend income for the year ended December 31, 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a risk that in an environment of rising interest rates that the market value of these stocks could decline and the utilities could
reduce their dividend payments to compensate for increased interest expense. This could have an adverse effect on Daxor&#8217;s ability
to fund research and development and marketing efforts necessary to build a market for the company&#8217;s products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
absence of patents or the inability to defend patents could negatively impact our ability to compete for and obtain new business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daxor
Corporation&#8217;s patents for the BVA 100 expired in 2010. The company filed two additional patent applications for an automated instrument
to measure human blood volume which were granted April 7, 2015. The filings describe innovations which will be or have been incorporated
into the company&#8217;s BVA-100 Blood Volume Analyzer, these patents expanded the capabilities of the analyzer to incorporate total
body albumin measures and error correction software to improve accuracy. In addition, the company filed additional patents on its blood
volume technology in January of 2018, and has several more patents in various stages of development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
blood volume analyzer, however, works most efficiently with the tracer injection kit system which has a separate patent and which expired
in 2016. It is possible that another company could develop another version of the Blood Volume Analyzer which would use a different tracer
injection kit. To the best of the company&#8217;s knowledge, this has not happened yet and management views the development of a competing
tracer injection kit as unlikely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the current manufacturer were to cease filling the Volumex syringes for us for any reason before we had a chance to make alternative
arrangements, this could have a material negative impact on our operating revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of Daxor Corporation&#8217;s orders for Volumex syringes are filled by a single FDA inspected radio pharmaceutical manufacturer. If this
manufacturer were to cease filling the Volumex syringes for the company or were denied permission to do so by FDA for any reason before
the company had a chance to make alternative arrangements, the effect on the company&#8217;s operating revenue could be material. In
January 2007, we purchased two 10,000 square foot buildings in Oak Ridge, Tennessee to expand its research, development, and manufacturing
capabilities.</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">107
    Meco Lane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Oak
    Ridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">37830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Michael
    Feldschuh<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyFourMember', window );">Margin Loans 2024 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 729,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 50,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyThreeMember', window );">Margin Loans 2023 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 755,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 46,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyTwoMember', window );">Margin Loans 2022 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,229,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 24,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyOneMember', window );">Margin Loans 2021 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,022,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 7,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyMember', window );">Margin Loans 2020 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 170,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 92,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandNineteenMember', window );">Margin Loans 2019 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,342,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 10,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandEighteenMember', window );">Margin Loans 2018 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,454,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 30,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandSeventeenMember', window );">Margin Loans 2017 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,334,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 4,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandSixteenMember', window );">Margin Loans 2016 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,801,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 6,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandFifteenMember', window );">Margin Loans 2015 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,845,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 4,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandFourteenMember', window );">Margin Loans 2014 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_FinancialHighlightsAbstract', window );"><strong>Financial Highlights [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAmt', window );">Senior Securities Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21,356,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesCvgPerUnit', window );">Senior Securities Coverage per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 2,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SeniorSecuritiesAverageMarketValuePerUnit', window );">Senior Securities Average Market Value per Unit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_GeneralDescriptionOfRegistrantAbstract', window );"><strong>General Description of Registrant [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_LowestPriceOrBid', window );">Lowest Price or Bid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="nump">$ 7.63<span></span>
</td>
<td class="nump">$ 7.86<span></span>
</td>
<td class="nump">$ 8.64<span></span>
</td>
<td class="nump">$ 7.19<span></span>
</td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="nump">$ 9.03<span></span>
</td>
<td class="nump">$ 9.51<span></span>
</td>
<td class="nump">$ 8.25<span></span>
</td>
<td class="nump">$ 9.10<span></span>
</td>
<td class="nump">$ 12.10<span></span>
</td>
<td class="nump">$ 10.62<span></span>
</td>
<td class="nump">$ 10.51<span></span>
</td>
<td class="nump">$ 10.59<span></span>
</td>
<td class="nump">$ 8.77<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
<td class="nump">$ 11.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_HighestPriceOrBid', window );">Highest Price or Bid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.79<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="nump">$ 9.89<span></span>
</td>
<td class="nump">$ 9.70<span></span>
</td>
<td class="nump">$ 9.94<span></span>
</td>
<td class="nump">$ 10.03<span></span>
</td>
<td class="nump">$ 9.60<span></span>
</td>
<td class="nump">$ 10.15<span></span>
</td>
<td class="nump">$ 13.03<span></span>
</td>
<td class="nump">$ 11.23<span></span>
</td>
<td class="nump">$ 13.63<span></span>
</td>
<td class="nump">$ 14.23<span></span>
</td>
<td class="nump">$ 13.21<span></span>
</td>
<td class="nump">$ 11.52<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="nump">$ 12.05<span></span>
</td>
<td class="nump">$ 14.15<span></span>
</td>
<td class="nump">$ 13.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_HighestPriceOrBidPremiumDiscountToNavPercent', window );">Highest Price or Bid, Premium (Discount) to NAV [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.90%<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
<td class="nump">36.40%<span></span>
</td>
<td class="nump">44.80%<span></span>
</td>
<td class="nump">47.30%<span></span>
</td>
<td class="nump">45.60%<span></span>
</td>
<td class="nump">35.60%<span></span>
</td>
<td class="nump">68.30%<span></span>
</td>
<td class="nump">105.80%<span></span>
</td>
<td class="nump">75.20%<span></span>
</td>
<td class="nump">101.90%<span></span>
</td>
<td class="nump">214.80%<span></span>
</td>
<td class="nump">172.40%<span></span>
</td>
<td class="nump">122.40%<span></span>
</td>
<td class="nump">119.50%<span></span>
</td>
<td class="nump">257.60%<span></span>
</td>
<td class="nump">294.20%<span></span>
</td>
<td class="nump">268.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_LowestPriceOrBidPremiumDiscountToNavPercent', window );">Lowest Price or Bid, Premium (Discount) to NAV [Percent]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">17.30%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">49.80%<span></span>
</td>
<td class="nump">50.20%<span></span>
</td>
<td class="nump">28.70%<span></span>
</td>
<td class="nump">34.80%<span></span>
</td>
<td class="nump">167.70%<span></span>
</td>
<td class="nump">119.00%<span></span>
</td>
<td class="nump">102.90%<span></span>
</td>
<td class="nump">102.10%<span></span>
</td>
<td class="nump">160.20%<span></span>
</td>
<td class="nump">147.90%<span></span>
</td>
<td class="nump">192.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetAssetValuePerShare', window );">NAV Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
<td class="nump">$ 7.18<span></span>
</td>
<td class="nump">$ 7.25<span></span>
</td>
<td class="nump">$ 6.70<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="nump">$ 6.89<span></span>
</td>
<td class="nump">$ 7.08<span></span>
</td>
<td class="nump">$ 6.03<span></span>
</td>
<td class="nump">$ 6.33<span></span>
</td>
<td class="nump">$ 6.41<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="nump">$ 4.52<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="nump">$ 5.18<span></span>
</td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="nump">$ 3.37<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">$ 3.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract', window );"><strong>Capital Stock, Long-Term Debt, and Other Securities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_CapitalStockTableTextBlock', window );">Capital Stock [Table Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_80A_ecef--CapitalStockTableTextBlock_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_dU_zMjWa7hmbT53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span><span id="xdx_820_zASonCYeWJv7">Daxor
Corporation <span id="xdx_904_ecef--SecurityTitleTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z26bEP0327gb">Common Stock</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecef--SecurityVotingRightsTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zUvKC5kqg0w6">The
holders of the common stock have one vote per share for the election of directors, without provisions for cumulative voting, and on all
other matters. Thus, holders of more than 50% of the shares voting for the election of directors can elect all the directors if they
choose to do so.</span> <span id="xdx_906_ecef--SecurityPreemptiveAndOtherRightsTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zYj6UBnw7bIi">The common stock is not redeemable and has no conversion or preemptive rights.</span> <span id="xdx_903_ecef--SecurityObligationsOfOwnershipTextBlock_c20250723__20250723__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zorbvrVYVBC2">The company qualifies as a &#8220;controlled
company&#8221; under Nasdaq rules, as the estate of Joseph Feldschuh, M.D. controls more than 50% of the company&#8217;s voting power,
as evidenced by the company&#8217;s ownership records.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock has continuously
been traded since its initial public offering. The company&#8217;s common stock is traded on Nasdaq under the symbol DXR. As of May <span style="-sec-ix-redline: true">19,
2025,</span> the company&#8217;s authorized securities consisted of <span id="xdx_903_ecef--OutstandingSecurityAuthorizedShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z7GeZzkdKBx5">10,000,000</span> shares of common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_886_ecef--OutstandingSecuritiesTableTextBlock_dU_z6yRSkG2s235" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Outstanding Securities of Common Stock">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Amount Held by Company or for</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Title of Class</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount Authorized</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">its Account</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount Outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_983_ecef--OutstandingSecurityTitleTextBlock_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z0AADpTeGQq7" style="width: 46%; text-align: left">Common Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecef--OutstandingSecurityAuthorizedShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zl4bpCpkTP2" style="width: 14%; text-align: right">10,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecef--OutstandingSecurityHeldShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zH2fO3bqlSg" style="width: 14%; text-align: right"><span style="-sec-ix-redline: true">5,437,245</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecef--OutstandingSecurityNotHeldShares_c20250519__20250519__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zTI0bNIgkuUj" style="width: 14%; text-align: right"><span style="-sec-ix-redline: true">4,962,245</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zmsBXGLpU6T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, for each of the periods indicated, the high and low closing market prices for the shares of Common Stock
on Nasdaq, the net asset value per share and the premium or discount to net asset value per share at which the shares were trading.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_886_ecef--SharePriceTableTextBlock_zfEWmwucpTXd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Price Range of Common Stock">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    Quarter Ended</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_48A_ecef--HighestPriceOrBid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zCcVRfMVHjsl" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">High</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_487_ecef--LowestPriceOrBid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zABdm5KnXz08" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_48A_eus-gaap--NetAssetValuePerShare_iE_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zFBEAhU0kw06" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share<sup id="xdx_F52_zDqFm44X6qlg">(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_486_ecef--HighestPriceOrBidPremiumDiscountToNavPercent_pid_dp_uRatio_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z2PcwxOBcdA9" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">High
    <sup id="xdx_F50_zHF1eUQWbXjj">(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_486_ecef--LowestPriceOrBidPremiumDiscountToNavPercent_pid_dp_uRatio_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSbN2RcS9Lt7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low
    <sup id="xdx_F57_z5ER9VfmcEk8">(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Premium/(Discount) to</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Market</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net Asset Value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net Asset Value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price
    Per Share</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">per
    Common</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">High
    and Low<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    Quarter Ended</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">High</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">High</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Low</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_419_20250401__20250630_zPB4cO5DYp4h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">30-June-25</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">9.79</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.20</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true">7.15</span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"></td><td style="text-align: right"><span style="-sec-ix-redline: true">36.9</span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true">0.7</span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td></tr>
  <tr id="xdx_415_20250101__20250331_zULuvPPfu0Wb" style="vertical-align: bottom; background-color: White">
    <td style="width: 20%; text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">31-Mar-25</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">8.50</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">7.05</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">7.18</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">18.4</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td><td style="width: 2%"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">(1.8</span></span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">)%</span></span></td></tr>
  <tr id="xdx_417_20241001__20241231_zlSAp93YOo06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">31-Dec-24</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">9.89</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">7.63</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">7.25</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">36.4</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">5.2</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td></tr>
  <tr id="xdx_413_20240701__20240930_zl1UpJ62enFk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">30-Sep-24</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">9.70</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">7.86</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">$</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">6.70</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">44.8</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td><td><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td><td style="text-align: right"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">17.3</span></span></td><td style="text-align: left"><span style="-sec-ix-redline: true"><span style="font-family: Times New Roman, Times, Serif">%</span></span></td></tr>
  <tr id="xdx_418_20240401__20240630_zBJi3jS1ervh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-June-24</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.94</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.64</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">47.3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41F_20240101__20240331_zWGwjOo02Ac2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-24</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.89</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45.6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41D_20231001__20231231_zmnef5EjEIv7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Dec-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.60</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.26</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.08</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">35.6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41D_20230701__20230930_zgPZK4jcAsm7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Sep-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">68.3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49.8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41B_20230401__20230630_zuTB9wtB1kNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Jun-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.03</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">105.8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">50.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_415_20230101__20230331_z6ED7KXbAgS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-23</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.25</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">75.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28.7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41F_20221001__20221231_zSukFvs5utV6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Dec-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">101.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34.8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41B_20220701__20220930_zzcjV9EH2cId" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Sep-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14.23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12.10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.52</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">214.8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">167.7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41E_20220401__20220630_z9kPiQk7hV78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Jun-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.62</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.85</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">172.4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">119.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_414_20220101__20220331_zAxliSVE4FRj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-22</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.52</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.18</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">122.4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_414_20211001__20211231_zKqYCZqGT7c3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Dec-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.59</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.24</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">119.5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_41F_20210701__20210930_zhP16iq88Vej" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Sep-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12.05</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">257.6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">160.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_415_20210401__20210630_zvM7S33BuWU7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">30-Jun-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14.15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.90</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.59</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">294.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">147.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr id="xdx_413_20210101__20210331_zIuNgCePRq7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">31-Mar-21</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.86</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">268.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">192.6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F06_zU2DzSwEVEpf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_z2LATWapOgXc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    we calculate our Net Asset Value at month end, the table reflects the month end net asset value, and the premium/(discount) to net
    asset value is based on the month end net asset value. Percentages are rounded.</span></td></tr>
  </table>
<p id="xdx_8AF_zmPIdxXqTAt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">The last reported sale price
on <span style="-sec-ix-redline: true">June 4, 2025</span> was <span style="-sec-ix-redline: true">$8.59</span> per <span style="-sec-ix-redline: true">share, and the net asset value at May 31, 2025 was $7.18, for a premium of $1.41. Historically,
shares have traded at a premium to net asset value.</span> We cannot predict whether our shares will trade in the future at a premium to
or discount from net asset value, or the level of any premium or discount.</p>
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SecurityTitleTextBlock', window );">Security Title [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SecurityDividendsTextBlock', window );">Security Dividends [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">f
the company pays cash distributions to U.S. Holders of shares of the common stock, such distributions will constitute dividends for U.S.
federal income tax purposes to the extent paid from the company&#8217;s current or accumulated earnings and profits, as determined under
U.S. federal income tax principles. Distributions in excess of current and accumulated earnings and profits will constitute a return
of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in the common stock.
Any remaining excess will be treated as gain realized on the sale or other disposition of the common stock and will be treated as described
under &#8220;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of the Common Stock&#8221; below.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SecurityVotingRightsTextBlock', window );">Security Voting Rights [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">The
holders of the common stock have one vote per share for the election of directors, without provisions for cumulative voting, and on all
other matters. Thus, holders of more than 50% of the shares voting for the election of directors can elect all the directors if they
choose to do so.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SecurityPreemptiveAndOtherRightsTextBlock', window );">Security Preemptive and Other Rights [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">The common stock is not redeemable and has no conversion or preemptive rights.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_SecurityObligationsOfOwnershipTextBlock', window );">Security Obligations of Ownership [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">The company qualifies as a &#8220;controlled
company&#8221; under Nasdaq rules, as the estate of Joseph Feldschuh, M.D. controls more than 50% of the company&#8217;s voting power,
as evidenced by the company&#8217;s ownership records.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_OutstandingSecurityTitleTextBlock', window );">Outstanding Security, Title [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_OutstandingSecurityAuthorizedShares', window );">Outstanding Security, Authorized [Shares]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_OutstandingSecurityHeldShares', window );">Outstanding Security, Held [Shares]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,437,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cef_OutstandingSecurityNotHeldShares', window );">Outstanding Security, Not Held [Shares]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,962,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="21"></td></tr>
<tr><td colspan="21"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">If shares of Common Stock to which this prospectus
    relates are sold to or through underwriters, the applicable prospectus supplement will set forth any applicable sales load and the
    estimated expenses borne by the Company.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The company will bear the costs of the offering
    expenses and the applicable prospectus supplement will set forth the estimated offering costs.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Based upon average monthly net assets applicable
    to shares of Common Stock during the period ended December 31, 2024.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The company does not pay a management fee.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">&#8220;<span id="xdx_90C_ecef--OtherExpensesNoteTextBlock_c20250723__20250723_zzP4gCGPYxFj">Annualized Other Expenses&#8221; are
    based on estimated expense amounts for the current fiscal year.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">As explained in the company&#8217;s Form
    N-CSR, as filed on March 3, 2025, the company has significant net operating loss and capital loss carry forwards and for the foreseeable
    future no adjustments to tax liabilities or operations is necessary. However, the company is subject to state and local taxes where
    the annualized impact to operations is approximately 0.10%.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Derivatives transactions entered into in compliance
    with Rule 18f-4 under the Investment Company Act are not considered for purposes of computing asset coverage.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">Not applicable as the senior securities are not registered for public
    trading.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top">As
    we calculate our Net Asset Value at month end, the table reflects the month end net asset value, and the premium/(discount) to net
    asset value is based on the month end net asset value. Percentages are rounded.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_AnnualExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_AnnualExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_BasisOfTransactionFeesNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_BasisOfTransactionFeesNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_BusinessDevelopmentCompanyFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_BusinessDevelopmentCompanyFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_CapitalStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_CapitalStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYear01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYear01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYears1to10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYears1to10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYears1to3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYears1to3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ExpenseExampleYears1to5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ExpenseExampleYears1to5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_FeeTableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_FeeTableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_FinancialHighlightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_FinancialHighlightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_GeneralDescriptionOfRegistrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_GeneralDescriptionOfRegistrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_HighestPriceOrBid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_HighestPriceOrBid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_HighestPriceOrBidPremiumDiscountToNavPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br> -Subparagraph Instructions 4, 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_HighestPriceOrBidPremiumDiscountToNavPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_InterestExpensesOnBorrowingsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_InterestExpensesOnBorrowingsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_IntervalFundFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_IntervalFundFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_InvestmentObjectivesAndPracticesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 2<br> -Paragraph b, d<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_InvestmentObjectivesAndPracticesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_LowestPriceOrBid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_LowestPriceOrBid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_LowestPriceOrBidPremiumDiscountToNavPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br> -Subparagraph Instructions 4, 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_LowestPriceOrBidPremiumDiscountToNavPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ManagementFeesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 7<br> -Subparagraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ManagementFeesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_NetExpenseOverAssetsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_NetExpenseOverAssetsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_NewCefOrBdcRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_NewCefOrBdcRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherAnnualExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherAnnualExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherAnnualExpensesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherAnnualExpensesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherExpensesNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherExpensesNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherTransactionExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherTransactionExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OtherTransactionExpensesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OtherTransactionExpensesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OutstandingSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OutstandingSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OutstandingSecurityAuthorizedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 5<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OutstandingSecurityAuthorizedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OutstandingSecurityHeldShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 5<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OutstandingSecurityHeldShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OutstandingSecurityNotHeldShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 5<br> -Paragraph 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OutstandingSecurityNotHeldShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_OutstandingSecurityTitleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 5<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_OutstandingSecurityTitleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_PrimaryShelfFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_PrimaryShelfFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_PrimaryShelfQualifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_PrimaryShelfQualifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RegisteredClosedEndFundFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RegisteredClosedEndFundFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskFactorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskFactorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 3<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SalesLoadPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SalesLoadPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SecurityDividendsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br> -Subparagraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SecurityDividendsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SecurityObligationsOfOwnershipTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br> -Subparagraph 6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SecurityObligationsOfOwnershipTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SecurityPreemptiveAndOtherRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br> -Subparagraph 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SecurityPreemptiveAndOtherRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SecurityTitleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SecurityTitleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SecurityVotingRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 10<br> -Subsection 1<br> -Paragraph a<br> -Subparagraph 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SecurityVotingRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesAverageMarketValuePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesAverageMarketValuePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesCvgPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph 3<br> -Subparagraph Instruction 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesCvgPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br> -Paragraph Instruction 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 1<br> -Paragraph Instruction 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SeniorSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 4<br> -Subsection 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SeniorSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_SharePriceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 8<br> -Subsection 5<br> -Paragraph b<br> -Subparagraph 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_SharePriceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_ShareholderTransactionExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_ShareholderTransactionExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_TotalAnnualExpensesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_TotalAnnualExpensesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_WaiversAndReimbursementsOfFeesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br> -Section Item 3<br> -Subsection 1<br> -Paragraph Instruction 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_WaiversAndReimbursementsOfFeesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AdditionalSecurities462b">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 462<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AdditionalSecurities462b</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AdditionalSecuritiesEffective413b">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 413<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AdditionalSecuritiesEffective413b</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ApproximateDateOfCommencementOfProposedSaleToThePublic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ApproximateDateOfCommencementOfProposedSaleToThePublic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:dateOrAsapItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DelayedOrContinuousOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form S-3<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form F-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DelayedOrContinuousOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DividendOrInterestReinvestmentPlanOnly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form S-3<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form F-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DividendOrInterestReinvestmentPlanOnly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EffectiveUponFiling462e">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 462<br> -Subsection e<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EffectiveUponFiling462e</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EffectiveWhenDeclaredSection8c">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Section 8<br> -Subsection c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EffectiveWhenDeclaredSection8c</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInvCompanyType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInvCompanyType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:invCompanyType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ExhibitsOnly462d">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 462<br> -Subsection d<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ExhibitsOnly462d</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_InvestmentCompanyActFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-3<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-4<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_InvestmentCompanyActFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_InvestmentCompanyActRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Investment Company Act<br> -Number 270<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_InvestmentCompanyActRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_InvestmentCompanyRegistrationAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Investment Company Act<br> -Number 270<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_InvestmentCompanyRegistrationAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_InvestmentCompanyRegistrationAmendmentNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Investment Company Act<br> -Number 270<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_InvestmentCompanyRegistrationAmendmentNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NewEffectiveDateForPreviousFiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-3<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-4<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NewEffectiveDateForPreviousFiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoSubstantiveChanges462c">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 462<br> -Subsection c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoSubstantiveChanges462c</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PostEffectiveAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PostEffectiveAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreEffectiveAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreEffectiveAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreEffectiveAmendmentNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreEffectiveAmendmentNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAssetValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAssetValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=DXR_MarketRisksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=DXR_MarketRisksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=DXR_EquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=DXR_EquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=DXR_IndustryConcentrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=DXR_IndustryConcentrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=DXR_ShortSaleRisksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=DXR_ShortSaleRisksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=DXR_PutAndCallOptionsRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=DXR_PutAndCallOptionsRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cef_RiskAxis=DXR_OperatingCompanyRisksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cef_RiskAxis=DXR_OperatingCompanyRisksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=DXR_MarginLoansTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>68</ContextCount>
  <ElementCount>82</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>19</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="formn-2a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995470 - Disclosure - N-2</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cef/role/N2</Role>
      <ShortName>N-2</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dxr-20250723.xsd</File>
    <File>dxr-20250723_def.xml</File>
    <File>dxr-20250723_lab.xml</File>
    <File>dxr-20250723_pre.xml</File>
    <File doctype="N-2/A" isN2Prospectus="true" isUsgaap="true" original="formn-2a.htm">formn-2a.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="18">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="152">http://xbrl.sec.gov/cef/2025</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>22
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "formn-2a.htm": {
   "nsprefix": "DXR",
   "nsuri": "http://daxor.com/20250723",
   "dts": {
    "schema": {
     "local": [
      "dxr-20250723.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/2006/xbrldi-2006.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/cef/2025/cef-2025.xsd",
      "https://xbrl.sec.gov/cef/2025/cef-2025_pre.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "dxr-20250723_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "dxr-20250723_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dxr-20250723_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "formn-2a.htm"
     ]
    }
   },
   "keyStandard": 82,
   "keyCustom": 0,
   "axisStandard": 4,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 17,
   "hidden": {
    "total": 16,
    "http://xbrl.sec.gov/cef/2025": 13,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 68,
   "entityCount": 1,
   "segmentCount": 19,
   "elementCount": 212,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/cef/2025": 152,
    "http://xbrl.sec.gov/dei/2025": 38,
    "http://fasb.org/us-gaap/2025": 18
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/cef/role/N2",
     "longName": "995470 - Disclosure - N-2",
     "shortName": "N-2",
     "isDefault": "true",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-07-23",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formn-2a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-07-23",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formn-2a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "cef_AcquiredFundFeesAndExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AcquiredFundFeesAndExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "cef_AcquiredFundFeesAndExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AcquiredFundFeesAndExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "cef_AcquiredFundFeesEstimatedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AcquiredFundFeesEstimatedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees Estimated, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "cef_AcquiredFundIncentiveAllocationNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AcquiredFundIncentiveAllocationNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Incentive Allocation, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Total Annual Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "cef_AllCoregistrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AllCoregistrantsMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Coregistrants [Member]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "cef_AllRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AllRisksMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Risks:"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualCoverageReturnRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AnnualCoverageReturnRatePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Coverage Return Rate [Percent]"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "cef_AnnualDividendPayment": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AnnualDividendPayment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "cef_AnnualDividendPaymentCurrent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AnnualDividendPaymentCurrent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Current"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "cef_AnnualDividendPaymentInitial": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AnnualDividendPaymentInitial",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Initial"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "cef_AnnualExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AnnualExpensesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "cef_AnnualInterestRateCurrentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AnnualInterestRateCurrentPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Current [Percent]"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "cef_AnnualInterestRateInitialPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AnnualInterestRateInitialPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Initial [Percent]"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "cef_AnnualInterestRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "AnnualInterestRatePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate [Percent]"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "cef_BasisOfTransactionFeesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "BasisOfTransactionFeesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Transaction Fees, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "cef_BdcFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "BdcFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BDC File Number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98"
     ]
    },
    "cef_BusinessDevelopmentCompanyFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "BusinessDevelopmentCompanyFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Development Company [Flag]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "cef_CapitalStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "CapitalStockTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r182",
      "r185",
      "r187",
      "r192"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r189",
      "r190",
      "r191",
      "r197",
      "r201",
      "r202"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "cef_CoregistrantAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "CoregistrantAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coregistrant [Axis]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r3",
      "r4",
      "r6",
      "r7",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r183",
      "r184",
      "r186",
      "r188",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r200"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r183",
      "r184",
      "r186",
      "r188",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r200"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r169"
     ]
    },
    "cef_DistributionServicingFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "DistributionServicingFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution/Servicing Fees [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "cef_DistributionsMayReducePrincipalTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "DistributionsMayReducePrincipalTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributions May Reduce Principal [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "cef_DividendAndInterestExpensesOnShortSalesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "DividendAndInterestExpensesOnShortSalesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend and Interest Expenses on Short Sales [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "cef_DividendExpenseOnPreferredSharesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "DividendExpenseOnPreferredSharesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Expenses on Preferred Shares [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r169"
     ]
    },
    "cef_DividendReinvestmentAndCashPurchaseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "DividendReinvestmentAndCashPurchaseFees",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Reinvestment and Cash Purchase Fees"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "cef_EffectsOfLeveragePurposeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "EffectsOfLeveragePurposeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage, Purpose [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "cef_EffectsOfLeverageTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "EffectsOfLeverageTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "cef_EffectsOfLeverageTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "EffectsOfLeverageTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "DXR_EquityInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "EquityInvestmentsMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Investments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "cef_ExpenseExampleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ExpenseExampleTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "cef_ExpenseExampleYear01": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ExpenseExampleYear01",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Year 01"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "cef_ExpenseExampleYears1to10": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ExpenseExampleYears1to10",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 10"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "cef_ExpenseExampleYears1to3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ExpenseExampleYears1to3",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 3"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "cef_ExpenseExampleYears1to5": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ExpenseExampleYears1to5",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 5"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "cef_FeeTableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "FeeTableAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Table [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "cef_FinancialHighlightsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "FinancialHighlightsAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Highlights [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "cef_GeneralDescriptionOfRegistrantAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "GeneralDescriptionOfRegistrantAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Description of Registrant [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "cef_HighestPriceOrBid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "HighestPriceOrBid",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "cef_HighestPriceOrBidNav": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "HighestPriceOrBidNav",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, NAV"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "cef_HighestPriceOrBidPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "HighestPriceOrBidPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "cef_IncentiveAllocationMaximumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "IncentiveAllocationMaximumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Maximum [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "cef_IncentiveAllocationMinimumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "IncentiveAllocationMinimumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Minimum [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "cef_IncentiveAllocationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "IncentiveAllocationPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation [Percent]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "cef_IncentiveFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "IncentiveFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Fees [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "DXR_IndustryConcentrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "IndustryConcentrationMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Industry Concentration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_InterestExpensesOnBorrowingsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "InterestExpensesOnBorrowingsPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expenses on Borrowings [Percent]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_InterestRateRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestRateRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Rate Risk [Member]",
        "documentation": "The risk associated with changes in interest rates that effect the value of an interest-bearing asset or liability, and a servicing asset or liability."
       }
      }
     },
     "auth_ref": []
    },
    "cef_IntervalFundFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "IntervalFundFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interval Fund [Flag]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r100",
      "r166",
      "r167",
      "r168"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "cef_InvestmentObjectivesAndPracticesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "InvestmentObjectivesAndPracticesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Objectives and Practices [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "cef_LatestPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LatestPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "cef_LoanServicingFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LoanServicingFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Servicing Fees [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtDividendsAndCovenantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LongTermDebtDividendsAndCovenantsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Dividends and Covenants [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Issuance and Substitution [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "cef_LongTermDebtPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LongTermDebtPrincipal",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Principal"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "cef_LongTermDebtStructuringTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LongTermDebtStructuringTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Structuring [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "cef_LongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LongTermDebtTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "cef_LongTermDebtTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LongTermDebtTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Title [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "cef_LowestPriceOrBid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LowestPriceOrBid",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "cef_LowestPriceOrBidNav": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LowestPriceOrBidNav",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, NAV"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "cef_LowestPriceOrBidPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "LowestPriceOrBidPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fee not based on Net Assets, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "cef_ManagementFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ManagementFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fees [Percent]"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "DXR_MarginLoansTwoThousandEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarginLoansTwoThousandEighteenMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Margin Loans 2018 [Member]",
        "documentation": "Margin Loans 2018 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "DXR_MarginLoansTwoThousandFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarginLoansTwoThousandFifteenMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Margin Loans 2015 [Member]",
        "documentation": "Margin Loans 2015 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "DXR_MarginLoansTwoThousandFourteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarginLoansTwoThousandFourteenMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Margin Loans 2014 [Member]",
        "documentation": "Margin Loans 2014 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "DXR_MarginLoansTwoThousandNineteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarginLoansTwoThousandNineteenMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Margin Loans 2019 [Member]",
        "documentation": "Margin Loans 2019 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "DXR_MarginLoansTwoThousandSeventeenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarginLoansTwoThousandSeventeenMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Margin Loans 2017 [Member]",
        "documentation": "Margin Loans 2017 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "DXR_MarginLoansTwoThousandSixteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarginLoansTwoThousandSixteenMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Margin Loans 2016 [Member]",
        "documentation": "Margin Loans 2016 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "DXR_MarginLoansTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarginLoansTwoThousandTwentyFourMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Margin Loans 2024 [Member]",
        "documentation": "Margin Loans 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "DXR_MarginLoansTwoThousandTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarginLoansTwoThousandTwentyMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Margin Loans 2020 [Member]",
        "documentation": "Margin Loans 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "DXR_MarginLoansTwoThousandTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarginLoansTwoThousandTwentyOneMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Margin Loans 2021 [Member]",
        "documentation": "Margin Loans 2021 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "DXR_MarginLoansTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarginLoansTwoThousandTwentyThreeMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Margin Loans 2023 [Member]",
        "documentation": "Margin Loans 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "DXR_MarginLoansTwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarginLoansTwoThousandTwentyTwoMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Margin Loans 2022 [Member]",
        "documentation": "Margin Loans 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "DXR_MarketRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "MarketRisksMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market Risks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetAssetValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetAssetValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NAV Per Share",
        "documentation": "Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r69",
      "r70",
      "r72",
      "r73",
      "r76",
      "r94"
     ]
    },
    "cef_NetExpenseOverAssetsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "NetExpenseOverAssetsPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Expense over Assets [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "cef_NewCefOrBdcRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "NewCefOrBdcRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New CEF or BDC Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r100",
      "r166",
      "r167",
      "r168"
     ]
    },
    "cef_NoPublicTradingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "NoPublicTradingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Public Trading [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "cef_NoTradingHistoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "NoTradingHistoryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading History [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "DXR_OperatingCompanyRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "OperatingCompanyRisksMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Company Risks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpense1Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherAnnualExpense1Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 1 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "cef_OtherAnnualExpense2Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherAnnualExpense2Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 2 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "cef_OtherAnnualExpense3Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherAnnualExpense3Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 3 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "cef_OtherAnnualExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherAnnualExpensesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "cef_OtherAnnualExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherAnnualExpensesPercent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "cef_OtherExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "cef_OtherFeederFundExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherFeederFundExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Feeder Fund Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "cef_OtherMasterFundExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherMasterFundExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Master Fund Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "cef_OtherSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "cef_OtherSecurityDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherSecurityDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "cef_OtherSecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherSecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Title [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "cef_OtherTransactionExpense1Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherTransactionExpense1Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 1 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "cef_OtherTransactionExpense2Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherTransactionExpense2Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 2 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "cef_OtherTransactionExpense3Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherTransactionExpense3Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 3 [Percent]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "cef_OtherTransactionExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherTransactionExpensesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "cef_OtherTransactionExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherTransactionExpensesPercent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "cef_OtherTransactionFeesBasisMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherTransactionFeesBasisMaximum",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "cef_OtherTransactionFeesBasisMaximumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherTransactionFeesBasisMaximumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum [Percent]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "cef_OtherTransactionFeesBasisNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherTransactionFeesBasisNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "cef_OtherTransactionFeesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OtherTransactionFeesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "cef_OutstandingSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OutstandingSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "cef_OutstandingSecurityAuthorizedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OutstandingSecurityAuthorizedShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Authorized [Shares]"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "cef_OutstandingSecurityHeldShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OutstandingSecurityHeldShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Held [Shares]"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "cef_OutstandingSecurityNotHeldShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OutstandingSecurityNotHeldShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Not Held [Shares]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "cef_OutstandingSecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "OutstandingSecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Title [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Liquidating Preference",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r5",
      "r183",
      "r185",
      "r196"
     ]
    },
    "cef_PreferredStockRestrictionsArrearageTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "PreferredStockRestrictionsArrearageTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Arrearage [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "cef_PreferredStockRestrictionsOtherTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "PreferredStockRestrictionsOtherTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Other [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "cef_PrimaryShelfFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "PrimaryShelfFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf [Flag]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "cef_PrimaryShelfQualifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "PrimaryShelfQualifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf Qualified [Flag]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "cef_ProspectusLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ProspectusLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "cef_ProspectusTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ProspectusTable",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "cef_PurposeOfFeeTableNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "PurposeOfFeeTableNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purpose of Fee Table , Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "DXR_PutAndCallOptionsRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "PutAndCallOptionsRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put And Call Options Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RegisteredClosedEndFundFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "RegisteredClosedEndFundFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Closed-End Fund [Flag]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "cef_ReturnAtMinusFivePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ReturnAtMinusFivePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Five [Percent]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "cef_ReturnAtMinusTenPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ReturnAtMinusTenPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Ten [Percent]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "cef_ReturnAtPlusFivePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ReturnAtPlusFivePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Five [Percent]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "cef_ReturnAtPlusTenPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ReturnAtPlusTenPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Ten [Percent]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "cef_ReturnAtZeroPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ReturnAtZeroPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Zero [Percent]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "cef_RightsLimitedByOtherSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "RightsLimitedByOtherSecuritiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Subject to Other than Majority Vote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "cef_RiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "RiskAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Axis]"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "cef_RiskFactorsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "RiskFactorsTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Factors [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "cef_RiskTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "RiskTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "cef_SalesLoadPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SalesLoadPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Load [Percent]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "cef_SecurityDividendsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SecurityDividendsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Dividends [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "cef_SecurityLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SecurityLiabilitiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liabilities [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "cef_SecurityLiquidationRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SecurityLiquidationRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liquidation Rights [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "cef_SecurityObligationsOfOwnershipTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SecurityObligationsOfOwnershipTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Obligations of Ownership [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "cef_SecurityPreemptiveAndOtherRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SecurityPreemptiveAndOtherRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Preemptive and Other Rights [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "cef_SecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Title [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "cef_SecurityVotingRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SecurityVotingRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Voting Rights [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "cef_SeniorSecuritiesAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SeniorSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "cef_SeniorSecuritiesAverageMarketValuePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SeniorSecuritiesAverageMarketValuePerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Average Market Value per Unit"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Averaging Method, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "cef_SeniorSecuritiesCvgPerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SeniorSecuritiesCvgPerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "cef_SeniorSecuritiesHeadingsNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SeniorSecuritiesHeadingsNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Headings, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Annualized, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r148"
     ]
    },
    "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Audited, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r148"
     ]
    },
    "cef_SeniorSecuritiesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SeniorSecuritiesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities, Note [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r148"
     ]
    },
    "cef_SeniorSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SeniorSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "cef_SharePriceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SharePriceTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "cef_SharePricesNotActualTransactionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "SharePricesNotActualTransactionsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Prices Not Actual Transactions [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "cef_ShareholderTransactionExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "ShareholderTransactionExpensesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Transaction Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "DXR_ShortSaleRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://daxor.com/20250723",
     "localname": "ShortSaleRisksMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Sale Risks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r182",
      "r185",
      "r187",
      "r192"
     ]
    },
    "cef_TotalAnnualExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "TotalAnnualExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Annual Expenses [Percent]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "cef_UnderwritersCompensationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "UnderwritersCompensationPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters Compensation [Percent]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "cef_WaiversAndReimbursementsOfFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "WaiversAndReimbursementsOfFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Waivers and Reimbursements of Fees [Percent]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "cef_WarrantsOrRightsCalledAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "WarrantsOrRightsCalledAmount",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Amount"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "cef_WarrantsOrRightsCalledPeriodDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "WarrantsOrRightsCalledPeriodDate",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Period [Date]"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "cef_WarrantsOrRightsCalledTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "WarrantsOrRightsCalledTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Title"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "cef_WarrantsOrRightsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2025",
     "localname": "WarrantsOrRightsExercisePrice",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "4"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "5"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "a",
   "Subparagraph": "Instruction 2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "b",
   "Subparagraph": "1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "b",
   "Subparagraph": "2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "c"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "1",
   "Paragraph": "d"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "2"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "2",
   "Paragraph": "a"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "2",
   "Paragraph": "b"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "2",
   "Paragraph": "c"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "2",
   "Paragraph": "e"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "3"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "5"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "5",
   "Paragraph": "1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "5",
   "Paragraph": "2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "5",
   "Paragraph": "3"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 10",
   "Subsection": "5",
   "Paragraph": "4"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 10",
   "Subparagraph": "a"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 10",
   "Subparagraph": "a, g, h"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 10",
   "Subparagraph": "f"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 10",
   "Subparagraph": "g"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 10",
   "Subparagraph": "i"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 11"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 4"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 7",
   "Subparagraph": "a"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 7",
   "Subparagraph": "b"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 8"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 3",
   "Subsection": "1",
   "Paragraph": "Instruction 9"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "1",
   "Paragraph": "Instruction 2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "1",
   "Paragraph": "Instruction 3"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "1",
   "Paragraph": "Instruction 8"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "3",
   "Subparagraph": "Instruction 2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "5"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "Instruction 1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "Instruction 4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 4",
   "Subsection": "3",
   "Paragraph": "Instruction 5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "2",
   "Paragraph": "b, d"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "3",
   "Paragraph": "a"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "3",
   "Paragraph": "b"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "3",
   "Paragraph": "b",
   "Subparagraph": "1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "3",
   "Paragraph": "b",
   "Subparagraph": "2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "3",
   "Paragraph": "b",
   "Subparagraph": "3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b",
   "Subparagraph": "4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b",
   "Subparagraph": "Instruction 2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b",
   "Subparagraph": "Instruction 3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b",
   "Subparagraph": "Instruction 4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "b",
   "Subparagraph": "Instructions 4, 5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "c"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2",
   "Section": "Item 8",
   "Subsection": "5",
   "Paragraph": "e"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
